Note: Descriptions are shown in the official language in which they were submitted.
CA 02348824 2001-04-27
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE OE CETTE DEMANDE OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME / DE
NOTE: ~ Pour tes tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECT10N OF THE APPL1CAT10NlPATENT CONTAINS MORE
'THAN ONE VOLUME
THIS IS VOLUME / OF
NOTE: For additional volumes please contact the Canadian Patent Offica
CA 02348824 2001-04-27
WO 00/29435
12 Human Secreted Proteins
Field of the Invention
PCT/US99/25031
This invention relates to newly identified polynucleotides and the
polypeptides
encoded by these polynucleotides, uses of such polynucleotides and
polypeptides, and
their production.
Background of the Invention
Unlike bacterium, which exist as a single compartment surrounded by a
membrane, human cells and other eucaryotes are subdivided by membranes into
many
functionally distinct compartments. Each membrane-bounded compartment, or
1_5 organelle, contains different proteins essential for the function of the
organelle. The cell
uses "sorting signals," which are amino acid motifs located within the
protein, to target
proteins to particular cellular organelles.
One type of sorting signal, called a signal sequence, a signal peptide, or a
leader
sequence, directs a class of proteins to an organelle called the endoplasmic
reticulum
(ER). The ER separates the membrane-bounded proteins from all other types of
proteins.
Once localized to the ER, both groups of proteins can be further directed to
another
organelle called the Golgi apparatus. Here, the Golgi distributes the proteins
to vesicles,
including secretory vesicles, the cell membrane, lysosomes, and the other
organelles.
Proteins targeted to the ER by a signal sequence can be released into the
extracellular space as a secreted protein. For example, vesicles containing
secreted
SUBSTITUTE SHEET (RULE Z6)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
2
proteins can fuse with the cell membrane and release their contents into the
extracellular
space - a process called exocytosis. Exocytosis can occur constitutively or
after receipt
of a triggering signal. In the latter case, the proteins are stored in
secretory vesicles (or
secretory granules) until exocytosis is triggered. Similarly, proteins
residing on the cell
membrane can also be secreted into the extracellular space by proteolytic
cleavage of a
"linker" holding the protein to the membrane.
Despite the great progress made in recent years, only a small number of genes
encoding human secreted proteins have been identified. 'these secreted
proteins include
the commercially valuable human insulin, interferon, Factor VIII, human growth
hormone, tissue plasminogen activator, and erythropoeitin. Thus, in light of
the
pervasive role of secreted proteins in human physiology, a need exists for
identifying and
characterizing novel human secreted proteins and the genes that encode them.
This
knowledge will allow one to detect, to treat, and to prevent medical disorders
by using
secreted proteins or the genes that encode them.
Summary of the Invention
The present invention relates to novel polynucleotides and the encoded
polypeptides. Moreover, the present invention relates to vectors, host cells,
antibodies,
and recombinant and synthetic methods for producing the polypeptides and
polynucleotides. Also provided are diagnostic methods for detecting disorders
and
conditions related to the polypeptides and polynucleotides, and therapeutic
methods for
treating such disorders and conditions. The invention further relates to
screening
methods for identifying binding partners of the polypeptides.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
3
Detailed Description
The following definitions are provided to facilitate understanding of certain
terms
S used throughout this specification.
In the present invention, "isolated" refers to matez-ial removed from its
original
environment (e.g., the natural environment if it is naturally occurring), and
thus is altered
"by the hand of man" from its natural state. For example, an isolated
polynucleotide
could be part of a vector or a composition of matter, or could be contained
within a cell,
and still be "isolated" because that vector, composition of matter, or
particular cell is not
the original environment of the polynucleotide. The term "isolated" does not
refer to
genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA
preparations (including those separated by electrophoresis and transferred
onto blots),
sheared whole cell genomic DNA preparations or other compositions where the
art
demonstrates no distinguishing features of the polynucleotide/sequences of the
present
invention.
In the present invention, a "secreted" protein refers to those proteins
capable of
being directed to the ER, secretory vesicles, or the extracellular space as a
result of a
signal sequence, as well as those proteins released into the extracellular
space without
necessarily containing a signal sequence. If the secreted protein is released
into the
extracellular space, the secreted protein can undergo extracellular processing
to produce
a "mature" protein. Release into the extracellular space can occur by many
mechanisms,
including exocytosis and proteolytic cleavage.
In specific embodiments, the polynucleotides of the invention are at least 15,
at
least 30, at least 50, at least 100, at least 125, at least 500, or at least
1000 continuous
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
4
nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15
kb, 10 kb, 7.5
kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment,
polynucleotides of
the invention comprise a portion of the coding sequences, as disclosed herein,
but do not
comprise all or a portion of any intron. In another embodiment, the
polynucleotides
comprising coding sequences do not contain coding sequences of a genomic
flanking
gene (i.e., _S' or 3' to the gene of interest in the genome). In other
embodiments, the
polynucleotides of the invention do not contain the coding sequence of more
than 1000,
500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
As used herein, a "polynucleotide" refers to a molecule having a nucleic acid
sequence contained in SEQ ID NO:X or the cDNA contained within the clone
deposited
with the ATCC. For example, the polynucleotide can contain the nucleotide
sequence of
the full length cDNA sequence, including the _5' and 3' untranslated
sequences, the coding
region, with or without the signal sequence, the secreted protein coding
region, as well as
fragments, epitopes, domains, and variants of the nucleic acid sequence.
Moreover, as
used herein, a "polypeptide" refers to a molecule having the translated amino
acid
sequence generated from the poiynucleotide as broadly defined.
In the present invention, the full length sequence identified as SEQ ID NO:X
was
often generated by overlapping sequences contained in multiple clones (contig
analysis).
A representative clone containing all or most of the sequence for SEQ ID NO:X
was
deposited with the American Type Culture Collection ("ATCC"). As shown in
Table
XIII, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC
Deposit
Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia
20110-2209, USA. The ATCC deposit was made pursuant to the terms of the
Budapest
Treaty on the international recognition of the deposit of microorganisms for
purposes of
patent procedure.
A "polynucleotide" of the present invention also includes those
polynucleotides
capable of hybridizing, under stringent hybridization conditions, to sequences
contained
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
_S
in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited
with
the ATCC. "Stringent hybridization conditions" refers to an overnight
incubation at 42
degree C in a solution comprising SO% formamide, Sx SSC (7S0 mM NaCI, 7S mM
trisodium citrate), SO mM sodium phosphate (pH 7.6), Sx Denhardt's solution,
10%
S dextran sulfate, and 20 ,ug/ml denatured, sheared salmon sperm DNA, followed
by
washing the filters in O.lx SSC at about 6S degree C.
Also contemplated are nucleic acid molecules that hybridize to the
polynucleotides of the present invention at lower stringency hybridization
conditions.
Changes in the stringency of hybridization and signal detection are primarily
accomplished through the manipulation of formamide concentration (lower
percentages
of foimamide result in lowered stringency); salt conditions, or temperature.
For
example, lower stringency conditions include an overnight incubation at 37
degree C in a
solution comprising 6X SSPE (20X SSPE = 3M NaCI; 0.2M NaH,POa; 0.02M EDTA,
pH 7.4), O.S% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA;
followed
1 S by washes at SO degree C with 1 XSSPE, 0.1 % SDS. In addition, to achieve
even lower
stringency, washes performed following stringent hybridization can be done at
higher
salt concentrations (e.g. SX SSC).
Note that variations in the above conditions may be accomplished through the
inclusion and/or substitution of alternate blocking reagents used to suppress
background
in hybridization experiments. Typical blocking reagents include Denhardt's
reagent,
BLOTTO, heparin, denatured salmon sperm DNA, and commercially available
proprietary formulations. The inclusion of specific blocking reagents may
require
modification of the hybridization conditions described above, due to problems
with
compatibility.
Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as
any 3' terminal polyA+ tract of° a cDNA shown in the sequence listing),
or to a
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
6
complementary stretch of T (or U) residues, would not be included in the
definition of
"polynucleotide," since such a polynucleotide would hybridize to any nucleic
acid
molecule containing a poly (A) stretch or the complement thereof (e.g.,
practically any
double-stranded cDNA clone generated using oligo dT as a primer).
The polynucleotide of the present invention can be composed of any
polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or
DNA
or modified RNA or DNA. For example, polynucleotides can be composed of single-
and double-stranded DNA, DNA that is a mixture of single- and double-stranded
regions,
single- and double-stranded RNA, and RNA that is mixture of single- and doubke-
stranded regions, hybrid molecules comprising DNA and RNA that may be single-
stranded or, more typically, double-stranded or a mixture of single- and
double-stranded
regions. In addition, the polynucleotide can be composed of triple-stranded
regions
comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain
one or more modified bases or DNA or RNA backbones modified for stability or
for
other reasons. "Modified" bases include, for example, tritylated bases and
unusual bases
such as inosine. A variety of modifications can be made to DNA and RNA; thus,
"polynucleotide" embraces chemically, enzymatically, or metabolically modified
forms.
The pokypeptide of the present invention can be composed of amino acids joined
to each other by peptide bonds or modified peptide bonds, i.e., peptide
isosteres, and may
contain amino acids other than the 20 gene-encoded amino acids. The
polypeptides may
be modified by either natural processes, such as posttranslational processing,
or by
chemical modification techniques which are well known in the art. Such
modifications
are well described in basic texts and in more detailed monographs, as well as
in a
voluminous research literature. Modifications can occur anywhere in a
polypeptide,
including the peptide backbone, the amino acid side-chains and the amino or
carboxyl
termini. It will be appreciated that the same type of modification may be
present in the
same or varying degrees at several sites in a given polypeptide. Also, a given
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
7
polypeptide may contain many types of modifications. Polypeptides may be
branched ,
for example, as a result of ubiquitination, and they may be cyclic, with or
without
branching. Cyclic, branched, and branched cyclic polypeptides may result from
posttranslation natural processes or may be made by synthetic methods.
Modifications
include acetylation, acylation, ADP-ribosylation, amidation, covalent
attachment of
flavin, covalent attachment of a heme moiety, covalent attachment of a
nucleotide or
nucleotide derivative, covalent attachment of a lipid or lipid derivative,
covalent
attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond
formation,
demethylation, formation of covalent cross-links, formation of cysteine,
formation of
pyroglutamate, formylation, gamma-carboxylation, glycosylation> GPI anchor
formation,
hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation,
proteolytic
processing, phosphorylation, prenylation, racemization, selenoylation,
sulfation, transfer-
RNA mediated addition of amino acids to proteins such as arginylation, and
ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR
PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York
(1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B.
C. Johnson, Ed., Academic Press, New York, pgs. I-12 (1983); Seifter et al.,
Meth
Enzymol 182:626-646 ( 1990); Rattan et al., Ann NY Acad Sci 663:48-62 (
1992).)
"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y"
refers to a polypeptide sequence, both sequences identified by an integer
specified in
Table XIII.
"A polypeptide having biological activity" refers to polypeptides exhibiting
activity similar, but not necessarily identical to, an activity of a
polypeptide of the
present invention, including mature forms, as measured in a particular
biological assay,
with or without dose dependency. In the case where dose dependency does exist,
it need
not be identical to that of the polypeptide, but rather substantially similar
to the dose-
dependence in a given activity as compared to the polypeptide of the present
invention
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
(i.e., the candidate polypeptide will exhibit greater activity or not more
than about 25-
fold less and, preferably, not more than about tenfold less activity, and most
preferably,
not more than about three-fold less activity relative to the polypeptide of
the present
invention.)
Polynucleotides and Poly~eatides of the Invention
FEATURES OF PROTEIN ENCODED BY GENE NO: 1
The translation product of this gene shares sequence homology with a protein
from Xenopus laevis that is described as upregulated in response to thyroid
hormone in
tadpoles, and is thought to be important in .the tail resorption process
during Xenopus
laevis metamorphosis (See Proc. Natl. Acad. Sci. USA (1996 Mar. 5):93(5):1924-
9,
which is herein incorporated by reference). In addition, translation product
of this gene
shares sequence homology with a recently described group of proteins, called
hedgehog
interacting proteins (HIPs) (See International Publication No. W098/12326,
which is
herein incorporated by reference). These proteins bind to hedgehog
polypeptides such as
Shh and Dhh with high affinity (Kd approx. I nM). HIPs exhibit spatiallyand
temporally
restricted expression domains indicative of important roles in hedgehog-
mediated
induction. They regulate differentiation of neuronal cells, regulate survival
of
differentiated neuronal cells, proliferation of chondrocytes, proliferation of
testicular
germ line cells and/or expression of patched or hedgehog genes. The biological
activity
of this polypeptide is assayed by techniques known in the art, otherwise
disclosed herein
and as described in International Publication No. W098/12326, which is herein
incorporated by reference.
Preferred polypeptides of the invention comprise the following amino acid
sequence:
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
9
MLRTSTPNLCGGLHCRAPWLSSGILCLCLIFLLGQVGLLQGHPQCLDYGPPFQPP
LHLEFCSDYESFGCCDQHKDRRIAARYWDIMEYFDLKRHELCGDYIKDILCQEC
SPYAAHLYDAENTQTPLRNLPGLCSDYCSAFHSNCHSAISLLTNDRGLQESHGRD
GTRFCHLLDLPDKDYCFPNVLRNDYLNRHLGMVAQDPQGCLQLCLSEVANGLR
NPVSMVHAGDGTHRFFVAEQVGVVWVYLPDGSRLEQPFLDLKNIVLTTPWIGD
ERGFLGLAFHPKFRHNRKFYIYYSCLDKKKVEKIRISEMKVSRADPNKADLKSER
VILEIEEPASNHNGGQLLFGLDGYMYIFTGDGGQAGDPFGLFGNAQNKSSLLGK
VLRIDVNRAGSHGKRYRVPSDNPFVSEPGAHPAIYAYGIRNMWRCAVDRGDPIT
RQGRGRIFCGDVGQNRFEEVDLILKGGNYGWRAKEGFACYDKKLCHNASLDDV
LPIYAYGHAVGKSVTGGYVYRGCESPNLNGLYIFGDFMSGRLMALQEDRKNKK
WKKQDLCLGSTTSCAFPGLISTHSKFIISFAEDEAGELYFLATSYPSAYAPRGSIYK
FVDPSRRAPPGKCKYKPVPVRTKSKRIPFRPLAKTVLDLLKEQSEKAARKSSSAT
LASGPAQGLSEKGSSKKLASPTSSKNTLRGPGTKKKARVGPHVRQGKRRKSLKS
HSGRMRPSAEQKRAGRSLP (SEQ ID NO: 47). Also preferred are polypeptides
comprising the mature polypeptide which is predicted to consist of residues 42-
724 of the
foregoing sequence, and biologically active fragments of the mature
polypeptide.
Figures lA-C show the nucleotide (SEQ ID NO:11) and deduced amino acid
sequence (SEQ ID N0:29) of this protein.
Figure 2 shows the regions of similarity between the amino acid sequences of
SEQ ID N0:29, the Xenopus laevis tail resoiption protein (gi~1234787) (SEQ ID
N0:48), and the Hedgehog Interacting Protein ("HiP"; gi~AAD31172.1 ) (SEQ ID
N0:49).
Figure 3 shows an analysis of the amino acid sequence of SEQ ID NO: 29.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic
regions; flexible regions; antigenic index and surface probability are shown.
Northern analysis indicates that a 2.5-3.0 kb transcript of this gene is
expressed
primarily in testes tissue and A549 lung carcinoma tissue, but interestingly
is absent from
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
normal lung tissue. This gene is also expressed in osteoarthritis tissue and
human fetal
tissues.
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the polypeptide having the amino acid sequence shown
in
5 Figures lA-C (SEQ ID N0:29), which was determined by sequencing a cloned
cDNA.
The nucleotide sequence shown in Figures lA-C (SEQ ID NO:11) was obtained by
sequencing a cloned cDNA, which was deposited on Nov. 17, 1998 at the American
Type Culture Collection, and given Accession Number 203484. The deposited gene
is
inserted in the pSport plasmid (Life Technologies, Rockville, MD) using the
SaII/NotI
10 restriction endonuclease cleavage sites.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
NO:11 is intended DNA fragments at least about l5nt, and more preferably at
least about
20 nt, still more preferably at least about 30 nt, and even more preferably,
at least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
course, larger fragments 50-1500 nt in length are also useful according to the
present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ 1D NO:11. By a fragment at least 20
nt in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
shown in SEQ ID NO:11. In this context "about" includes the particularly
recited size,
larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either
terminus or at both
termini. Representative examples of polynucleotide fragments of the invention
include,
for example, fragments that comprise, or alternatively, consist of, a sequence
from about
nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about
150, from
about 151 to about 200, from about 201 to about 250, from about 251 to about
300, from
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
11
about 301 to about 350, from about 351 to about 400, from about 401 to about
450, from
about 451 to about 500, and from about 501 to about 550, and from about 551 to
about
570 of SEQ ID NO:11, or the complementary strand thereto, or the cDNA
contained in
the deposited gene. In this context "about" includes the particularly recited
ranges, larger
or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at
both termini. In
additional embodiments, the polynucleotides of the invention encode functional
attributes of the corresponding protein.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions. The data
representing
the structural or functional attributes of the protein set forth in Figure 3
and/or Table I, as
described above, was generated using the various modules and algorithms of the
DNA*STAR set on default parameters. In a preferred embodiment, the data
presented in
columns VIII, IX, XIII, and XIV of Table I can be used to determine regions of
the
protein which exhibit a high degree of potential for antigenicity. Regions of
high
antigenicity are determined from the data presented in columns VIII, IX, XIII,
and/or
XIV by choosing values which represent regions of the polypeptide which are
likely to
be exposed on the surface of the polypeptide in an environment in which
antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 3, but may,
as
shown in Table I, be represented or identified by using tabular
representations of the data
presented in Figure 3. The DNA*STAR computer algorithm used to generate Figure
3
(set on the original default parameters) was used to present the data in
Figure 3 in a
tabular format (See Table I). The tabular format of the data in Figure 3 is
used to easily
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
12
determine specific boundaries of a preferred region. The above-mentioned
preferred
regions set out in Figure 3 and in Table I include, but are not limited to,
regions of the
aforementioned types identified by analysis of the amino acid sequence set out
in Figures
1 A-C (SEQ ID N0:29). As set out in Figure 3 and in Table I, such preferred
regions
include Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-
regions,
Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic
regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-
amphipathic
regions, Karpius-Schulz flexible regions, Jameson-Wolf regions of high
antigenic index
and Emini surface-forming regions. Even if deletion of ane or more amino acids
from the
N-terminus of a protein results in modification of loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities, ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened muteins to
induce and/or bind to antibodies which recognize the complete or mature forms
of the
polypeptides generally will be retained when less than the majority of the
residues of the
complete or mature polypeptide are removed from the N-terminus. Whether a
particular
polypeptide lacking N-terminal residues of a complete polypeptide retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the amino acid sequence shown
in
Figures lA-C, up to the alanine residue at position number 524 and
polynucleotides
encoding such polypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-524 of Figures lA-C, where
nl is an
integer from 1 to 524 corresponding to the position of the amino acid residue
in Figures
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
13
lA-C {which is identical to the sequence shown as SEQ ID NO:29). N-terminal
deletions
of the polypeptide of the invention shown as SEQ ID N0:29 include polypeptides
comprising the amino acid sequence of residues: V-2 to P-529; A-3 to P-529; Q-
4 to P-
529; D-5 to P-529; P-6 to P-529; Q-7 to P-529; G-8 to P-529; C-9 to P-529; L-
10 to P-
529; Q-11 to P-529; L-12 to I'-529; C-13 to P-529; L-14 to P-529; S-15 to P-
529; E-16 to
P-529; V-17 to P-529; A-18 to P-_529; N-19 to P-529; G-20 to P-529; L-21 to P-
529; R-
22 to P-529; N-23 to P-529; P-24 to P-529; V-25 to P-529; S-26 to P-529; M-27
to P-
529; V-28 to P-529; H-29 to P-529; A-30 to P-529; G-31 to P-529; D-32 to P-
529; G-33
to P-529; T-34 to P-529; H-35 to P-529: R-36 to P-529; F-37 to P-529; F-38 to
P-529; V-
39 to P-529; A-40 to P-529; E-41 to P-529; Q-42 to P-529; V-43 to P-529; G-44
to P-
529; V-45 to P-529; V-46 to P-529; W-47 to P-529; V-48 to P-529; Y-49 to P-
529; L-50
to P-529; P-51 to P-529; D-_52 to P-529; G-53 to P-529; S-54 to P-529; R-55 to
P-529; L-
56 to P-529; E-57 to P-529; Q-58 to P-529; P-S9 to P-529; F-60 to P-529; L-61
to P-529;
D-62 to P-529; L-63 to P-529; K-64 to P-529; N-65 to P-529; I-66 to P-529; V-
67 to P-
529; L-68 to P-529; T-69 to P-529; T-70 to P-529; P-71 to P-529; W-72 to P-
529; I-73 to
P-529; G-74 to P-529; D-75 to P-529; E-76 to P-529; R-77 to P-529; G-78 to P-
529; F-
79 to P-529; L-80 to P-529; G-81 to P-529; L-82 to P-529; A-83 to P-529; F-84
to P-529;
H-85 to P-529; P-86 to P-529; K-87 to P-529; F-88 to P-529; R-89 to P-529; H-
90 to P-
529; N-91 to P-529; R-92 to P-529; K-93 to P-529; F-94 to P-529; Y-95 to P-
529; I-96 to
P-529; Y-97 to P-529; Y-98 to P-529; S-99 to P-529; C-100 to P-529; L-101 to P-
529;
D-102 to P-529; K-103 to P-529; K-104 to P-529; K-105 to P-529; V-106 to P-
529; E-
107 to P-529; K-108 to P-529; I-109 to P-529; R-110 to P-529; I-111 to P-529;
S-112 to
P-529; E-113 to P-529; M-114 to P-529; K-1 IS to P-529; V-116 to P-529; S-117
to P-
529; R-118 to P-529; A-119 to P-529; D-120 to P-529; P-121 to P-529; N-122 to
P-529;
K-123 to P-529; A-124 to P-529; D-125 to P-529; L-126 to P-529; K-127 to P-
529; S-
128 to P-529; E-129 to P-529; R-130 to P-529; V-131 to P-529; I-132 to P-529;
L-133 to
P-529; E-134 to P-529; I-135 to P-529; E-136 to P-529; E-137 to P-529; P-138
to P-529;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
14
A-139 to P-529; S-140 to P-529; N-141 to P-529; H-142 to P-529; N-143 to P-
529; 6-
144 to P-529; G-145 to P-529; Q-146 to P-529; L-147 to P-529; L-148 to P-529;
F-149
to P-529; G-150 to P-529; L-151 to P-529; D-152 to P-529; G-153 to P-529; Y-
154 to P-
529; M-155 to P-529; Y-156 t.o P-529; I-157 to P-529; F-158 to P-529; T-159 to
P-529;
_5 G-160 to P-529; D-161 to P-529; G-162 to P-.529; G-163 to P-529; Q-164 to P-
529; A-
165 to P-529; G-166 to P-529; D-167 to P-529; P-168 to P-529; F-169 to P-529;
G-170
to P-529; L-171 to P-529; F-172 to P-529; G-173 to P-529; N-174 to P-529; A-
17_5 to P-
529; Q-176 to P-529; N-177 to P-529; K-178 to P-529; S-179 to P-529; S-180 to
P-529;
L-181 to P-529; L-182 to P-529; G-183 to P-529; K-184 to P-529; V-185 to P-
529; L-
186 to P-529; R-187 to P-529; I-188 to P-529; D-189 to P-529; V-190 to P-529;
N-191 to
P-529; R-192 to P-529; A-193 to P-529; G-194 to P-529; S-195 to P-529; H-19G
to P-
529; G-197 to P-529; K-198 to P-529; R-199 to P-529; Y-200 to P-529; R-201 to
P-529:
V-202 to P-529; P-203 to P-529; S-204 to P-529; D-205 to P-529; N-206 to P-
529; P-207
to P-529; F-208 to P-529; V-209 to P-529; S-210 to P-529; E-211 to P-529; P-
212 to P-
529; G-213 to P-529; A-214 to P-529; H-2I S to P-529; P-216 to P-529; A-217 to
P-529;
I-218 to P-529; Y-219 to P-529; A-220 to P-529; Y-221 to P-529; G-222 to P-
529; I-223
to P-529; R-224 to P-529; N-225 to P-529; M-226 to P-529; W-227 to P-529; R-
228 to
P-529; C-229 to P-529; A-230 to P-529; V-231 to P-529; D-232 to P-529; R-233
to P-
529; G-234 to P-529; D-235 to P-529; P-236 to P-529; I-237 to P-529; T-238 to
P-529;
R-239 to P-529; Q-240 to P-529; G-241 to P-529; R-242 to P-529; G-243 to P-
529; R-
244 to P-529; I-245 to P-529; F-246 to P-529; C-247 to P-529; G-248 to P-529;
D-249 to
P-529; V-250 to P-529; G-251 to P-529; Q-252 to P-529; N-253 to P-529; R-254
to P-
529; F-255 to P-529; E-256 to P-529; E-257 to P-529; V-258 to P-529; D-259 to
P-529;
L-260 to P-529; I-261 to P-529; L-262 to P-529; K-263 to P-529; G-264 to P-
529; G-265
to P-529; N-266 to P-529; Y-267 to P-529; G-268 to P-529; W-269 to P-529; R-
270 to P-
529; A-271 to P-529; K-272 to P-529; E-273 to P-529; G-274 to P-529; F-275 to
P-529;
A-276 to P-529; C-277 to P-529; Y-278 to P-529; D-279 to P-529; K-280 to P-
529; K-
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
281 to P-529; L-282 to P-529; C-283 to P-529; H-284 to P-529; N-285 to P-529;
A-286
to P-529; S-287 to P-529; L-288 to P-529; D-289 to P-529; D-290 to P-529; V-
291 to P-
529; L-292 to P-529; P-293 to P-529; I-294 to P-529; Y-295 to P-529; A-296 to
P-529;
Y-297 to P-529; G-298 to P-529; H-299 to P-529; A-300 to P-529; V-301 to P-
529; G-
5 302 to P-529; K-303 to P-529; S-304 to P-529; V-305 to P-529; T-306 to P-
.529; G-307
to P-529; G-308 to P-529; Y-309 to P-529; V-310 to P-529; Y-311 to P-529; R-
312 to P-
529; G-313 to P-529; C-314 to P-529; E-315 to P-529; S-3i6 to P-529; P-317 to
P-529;
N-318 to P-529; L-319 to P-529; N-320 to P-529; G-321 to P-529; L-322 to P-
529; Y-
323 to P-529; I-324 to P-529; F-325 to P-529; G-326 to P-529; D-327 to P-529;
F-328 to
10 P-529; M-329 to P-529; S-330 to P-529; G-331 to P-529; R-332 to P-529: L-
333 to P-
529; M-334 to P-529; A-335 to P-529; L-336 to P-529; Q-337 to P-529; E-338 to
P-529;
D-339 to P-529; R-340 to P-529; K-341 to P-529; N-342 to P-529; K-343 to P-
529; K-
344 to P-529; W-345 to P-529; K-346 to P-529; K-347 to P-529; Q-348 to P-529:
D-349
to P-529; L-350 to P-529; C-351 to P-529; L-352 to P-529; G-353 to P-529; S-
354 to P-
15 529; T-355 to P-529; T-356 to P-529; S-357 to P-529; C-358 to P-529; A-359
to P-529;
F-360 to P-529; P-361 to P-529; G-362 to P-529; L-363 to P-529; I-364 to P-
_529; S-365
to P-529; T-366 to P-529; H-367 to P-529; S-368 to P-529; K-369 to P-529; F-
370 to P-
529; I-371 to P-529; I-372 to P-529; S-373 to P-529; F-374 to P-529; A-375 to
P-529; E-
376 to P-529; D-377 to P-529; E-378 to P-529; A-379 to P-529; G-380 to P-529;
E-381
to P-529; L-382 to P-529; Y-383 to P-529; F-384 to P-529; L-385 to P-529; A-
386 to P-
529; T-387 to P-_529; S-388 to P-529; Y-389 to P-529; P-390 to P-529; S-391 to
P-529;
A-392 to P-529; Y-393 to P-529; A-394 to P-529; P-395 to P-529; R-396 to P-
529; 6-
397 to P-529; S-398 to P-529; I-399 to P-529; Y-400 to P-529; K-401 to P-529;
F-402 to
P-529; V-403 to P-529; D-404 to P-529; P-405 to P-529; S-406 to P-529; R-407
to P-
529; R-408 to P-529; A-409 to P-529; P-410 to P-529; P-411 to P-529; G-412 to
P-529;
K-413 to P-529; C-414 to P-529; K-415 to P-529; Y-416 to P-529; K-417 to P-
529; P-
418 to P-529; V-419 to P-529; P-420 to P-529; V-421 to P-529; R-422 to P-529;
T-423
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
16
to P-529; K-424 to P-529; S-425 to P-529; K-426 to P-529; R-427 to P-529; I-
428 to P-
529; P-429 to P-529; F-430 to P-529; R-431 to P-529; P-432 to P-529; L-433 to
P-529;
A-434 to P-529; K-435 to P-529; T-436 to P-529; V-437 to P-529; L-438 to P-
529; D-
439 to P-529; L-440 to P-529; L-441 to P-529; K-442 to P-529; E-443 to P-529;
Q-444
to P-529; S-445 to P-529; E-446 to P-529; K-447 to P-529; A-448 to P-529; A-
449 to P-
529; R-450 to P-529; K-451 to P-529; S-452 to P-529; S-453 to P-529; S-454 to
P-529;
A-455 to P-529; T-456 to P-529; L-457 to P-529; A-458 to P-529; S-459 to P-
529; 6-
460 to P-529; P-461 to P-_529; A-462 to P-529; Q-463 to P-529; G-464 to P-529;
L-465
to P-529; S-466 to P-529; E-467 to P-529; K-468 to P-529; G-469 to P-529: S-
470 to P
529; S-471 to P-529; K-472 to P-529; K-473 to P-529; L-474 to P-529; A-475 to
P-529;
S-476 to P-529; P-477 to P-529; T-478 to P-529; S-479 to P-529; S-480 to P-
529; K-481
to P-529; N-482 to P-529; T-483 to P-529; L-484 to P-529; R-485 to P-529; G-
486 to P-
529: P-487 to P-529; G-488 to P-529; T-489 to P-529; K-490 to P-529; K-491 to
P-529;
K-492 to P-529; A-493 to P-529; R-494 to P-529; V-495 to P-_529; G-496 to P-
529; P-
497 to P-529; H-498 to P-529; V-499 to P-529; R-500 to P-529; Q-501 to P-529;
G-502
to P-529; K-503 to P-529; R-504 to P-529; R-505 to P-529; K-506 to P-529; S-
507 to P-
529; L-508 to P-529; K-509 to P-529; S-510 to P-529; H-511 to P-529; S-512 to
P-529;
G-513 to P-529; R-514 to P-529; M-515 to P-529; R-516 to P-529; P-517 to P-
529; S-
518 to P-529; A-519 to P-529; E-520 to P-529; Q-521 to P-529; K-522 to P-529;
R-523
to P-529; A-524 to P-529; of SEQ ID N0:29. Polypeptides encoded by these
polynucleotides are also encompassed by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities (e.g., ability
to illicit mitogenic activity, induce differentiation of normai or malignant
cells, bind to
EGF receptors, etc.)), may still be retained. For example the ability to
induce and/or bind
to antibodies which recognize the complete or mature forms of the polypeptide
generally
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
17
will be retained when less than the majority of the residues of the complete
or mature
polypeptide are removed from the C-terminus. Whether a particular polypeptide
lacking
C-terminal residues of a complete polypeptide retains such immunologic
activities can
readily be determined by routine methods described herein and otherwise known
in the
art. It is not unlikely that a mutein with a large number of deleted C-
terminal amino acid
residues may retain some biological or immunogenic activities. In fact,
peptides
composed of as few as six amino acid residues may often evoke an immune
response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
polypeptide shown in Figures lA-C, up to the glutamine residue at position
number 7,
and polynucleotides encoding such polypeptides. In particular, the present
invention
provides polypeptides comprising the amino acid sequence of residues 1-ml of
Figures
IA-C, where ml is an integer from 7 to 528 corresponding to the position of
the amino
acid residue in Figures IA-C. Moreover, the invention provides polynucleotides
encoding polypeptides comprising, or alternatively consisting of, the amino
acid
sequence of C-terminal deletions of the polypeptide of the invention shown as
SEQ ID
N0:29 include polypeptides comprising the amino acid sequence of residues: M-1
to L-
528; M-1 to S-527; M-1 to R-526; M-1 to G-525; M-1 to A-524; M-1 to R-523; M-1
to
K-522; M-1 to Q-521; M-1 to E-520; M-1 to A-519; M-1 to S-518; M-1 to P-517; M-
1 to
R-516; M-1 to M-515; M-1 to R-514; M-1 to G-513; M-I to S-512; M-1 to H-511; M-
I
to S-510; M-1 to K-509; M-1 to L-508; M-1 to S-507; M-1 to K-506; M-1 to R-
505; M-1
to R-504; M-1 to K-503; M-1 to G-502; M-1 to Q-501; M-1 to R-500; M-1 to V-
499; M-
1 to H-498; M-1 to P-497; M-1 to G-496; M-I to V-495; M-1 to R-494; M-1 to A-
493;
M-1 to K-492; M-1 to K-491; M-1 to K-490; M-1 to T-489; M-1 to G-488; M- I to
P-
487; M-1 to G-486; M-I to R-485; M-1 to L-484; M-1 to T-483; M-1 to N-482; M-1
to
K-481; M-1 to S-480; M-1 to S-479; M-1 to T-478; M-1 to P-477; M-I to S-476; M-
I to
A-475; M-I to L-474; M-1 to K-473; M-I to K-472; M-1 to S-471; M-1 to S-470; M-
1 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/L3S99/25031
18
G-469; M-1 to K-468; M-1 to E-467; M-1 to S-466; M-1 to L-465; M-1 to G-464; M-
1
to Q-463; M-1 to A-462; M-I to P-461; M-I to G-460; M-1 to S-459; M-1 to A-
458; M-
1 to L-457; M-1 to T-456; M-1 to A-455; M-I to S-454; M-1 to S-453; M-I to S-
452; M-
1 to K-451; M-1 to R-450; M-1 to A-449; M-1 to A-448; M- I to K-447; M-1 to E-
446;
M-1 to S-445; M-I to Q-444; M-I to E-443; M-I to K-442; M-1 to L-441; M-1 to L-
440;
M-I to D-439; M-1 to L-438; M-1 to V-437; M-1 to T-436; M-1 to K-435; M-1 to A-
434; M-I to L-433; M-I to P-432; M-I to R-431; M-I to F-430; M-1 to P-429; M-1
to I-
428; M-1 to R-427; M-1 to K-426; M-1 to S-425; M-1 to K-424; M-I to T-423; M-1
to
R-422; M-1 to V-421; M-1 to P-420; M-I to V-419; M-1 to P-418; M-1 to K-417; M-
1
to Y-416; M-1 to K-415; M-1 to C-414; M-1 to K-413; M-1 to G-412; M-I to P-
411; M-
1 to P-410; M-I to A-409; M-1 to R-408; M-I to R-407; M-1 to S-406; M-1 to P-
405;
M-1 to D-404; M-1 to V-403; M-1 to F-402; M-1 to K-401; M-1 to Y-400; M-1 to I-
399;
M-1 to S-398; M-1 to G-397; M-1 to R-396; M-1 to P-395; M-1 to A-394; M-1 to Y-
393; M-1 to A-392; M-1 to S-391; M-1 to P-390; M-I to Y-389; M-1 to S-388; M-1
to
T-387; M-1 to A-386; M-1 to L-385; M-1 to F-384; M-1 to Y-383; M-1 to L-382; M-
1 to
E-381; M-1 to G-380; M-1 to A-379; M-1 to E-378; M-1 to D-377; M-1 to E-376; M-
1
to A-375; M-1 to F-374; M-1 to S-373; M-1 to I-372; M-1 to I-371; M-1 to F-
370; M-1
to K-369; M-1 to S-368; M-1 to H-367; M-1 to T-366; M-1 to S-365; M-1 to I-
364; M-I
to L-363; M-1 to G-362; M-1 to P-361; M-1 to F-360; M-1 to A-359; M-1 to C-
358; M-1
to S-357; M-I to T-356; M-1 to T-355; M-1 to S-354; M-1 to G-353; M-1 to L-
352; M-1
to C-351; M- I to L-350; M-1 to D-349; M-1 to Q-348; M- I to K-347; M- I to K-
346; M-
1 to W-345; M-1 to K-344; M-1 to K-343; M- I to N-342; M-1 to K-341; M-1 to R-
340;
M-1 to D-339; M-1 to E-338; M-1 to Q-337; M-1 to L-336; M-1 to A-335; M-1 to M-
334; M-1 to L-333; M-1 to R-332; M-I to G-33I; M-1 to S-330; M-1 to M-329; M-1
to
F-328; M-1 to D-327; M-1 to C~-326; M-I to F-325; M-1 to I-324; M-1 to Y-323;
M-1 to
L-322; M-1 to G-321; M-1 to N-320; M-1 to L-319; M-1 to N-318; M-1 to P-317; M-
1
to S-316; M-1 to E-315 ; M-1 to C-314; M-1 to G-313 ; M-1 to R-312; M-1 to Y-3
I 1; M-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
19
1 to V-310; M-1 to Y-309; M-1 to G-308; M-1 to G-307; M-I to T-306; M-I to V-
305;
M-1 to S-304; M-1 to K-303; M-1 to G-302; M-1 to V-301; M-1 to A-300; M-1 to H-
299; M-1 to G-298; M-I to Y-297; M-1 to A-296; M-1 to Y-295; M-1 to I-294; M-1
to
P-293; M-1 to L-292; M-1 to V-291; M-1 to D-290; M-1 to D-289; M-I to L-288; M-
1
S to S-287; M-1 to A-286; M-1 to N-285; M-1 to H-284; M-1 to C-283; M-I to L-
282; M-
I to K-281; M-1 to K-280; M-1 to D-279; M-1 to Y-278; M-1 to C-277; M-1 to A-
276;
M-1 to F-275; M-1 to G-274; M-1 to E-273; M-I to K-272; M-I to A-271; M-1 to 8-
270; M-I to W-269; M-1 to G-268; M-1 to Y-267; M-1 to N-266; M-1 to G-265; M-I
to
G-264; M-I to K-263; M-1 to L-262; M-1 to I-261; M-1 to L-260; M-1 to D-259; M-
1 to
V-258; M-1 to E-257; M-I to E-256; M-I to F-255; M-1 to R-254; M-1 to N-253; M-
1 to
Q-252; M-1 to G-251; M-1 to V-250; M-1 to D-249; M-1 to G-248; M-1 to C-247; M-
1
to F-246; M-I to I-245; M-1 to R-244; M-1 to G-243; M-1 to R-242; M-I to G-
241; M-1
to Q-240; M-1 to R-239; M-1 to T-238; M-1 to I-237; M-1 to P-236; M-I to D-
235; M-I
to G-234; M-I to R-233; M-1 to D-232; M-1 to V-231; M-I to A-230; M-1 to C-
229; M-
1 to R-228; M-I to W-227; M-1 to M-226; M-1 to N-225; M-1 to R-224; M-1 to I-
223;
M-1 to G-222; M-1 to Y-221; M-1 to A-220; M-1 to Y-219; M-1 to I-218; M-1 to A-
217; M-1 to P-216; M-1 to H-215; M-1 to A-214; M-1 to G-213; M-I to P-212; M-I
to
E-211; M-I to S-210; M-1 to V-209; M-1 to F-208; M-1 to P-207; M-1 to N-206; M-
1 to
D-205; M-1 to S-204; M-1 to P-203; M-1 to V-202; M-1 to R-201; M-1 to Y-200; M-
I
to R-199; M-1 to K-198; M-1 to G-197; M-1 to H-196; M-I to S-195; M-1 to G-
194; M-
1 to A-193; M-I to R-192; M-I to N-191; M-I to V-190; M-1 to D-189; M-1 to I-
188;
M-1 to R-187; M-1 to L-186; M-1 to V-185; M-1 to K-184; M-1 to G-183; M-1 to L-
182; M-1 to L-181; M-1 to S-180; M-1 to S-179; M-1 to K-178; M-1 to N-177; M-1
to
Q-176; M-1 to A-175; M-1 to N-174; M-1 to G-173; M-1 to F-172; M-I to L-171; M-
I
to G-170; M-1 to F-169; M-1 to P-168; M-1 to D-167; M-1 to G-166; M-1 to A-
165; M-
1 to Q-164; M-1 to G-163; M-I to G-162; M-I to D-161; M-1 to G-160; M-1 to T-
159;
M-1 to F-158; M-1 to I-157; M-1 to Y-156; M-1 to M-155; M-1 to Y-154; M-1 tv G-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
153; M-i to D-152; M-1 to L-151; M-1 to G-150; M-1 to F-149; M-1 to L-148; M-1
to
L-147; M-I to Q-146; M-1 to G-I45; M-1 to G-144; M-1 to N-143; M-1 to H-i42; M-
1
to N-141; M-1 to S-140; M-1 to A-139; M-1 to P-138; M-1 to E-137; M-1 to E-
136; M-1
to I-135; M-1 to E-I34; M-1 to L-133; M-I to I-132; M-1 to V-131; M-1 to R-
130; M-I
S to E-129; M-1 to S-128; M-1 to K-127; M-1 to L-126; M-1 to D-125; M-1 to A-
124; M-
I to K-123; M-1 to N-122; M-I to P-121; M-I to D-120; M-1 to A-119; M-1 to R-
118;
M-1 to S-117; M-1 to V-116; M-1 to K-I15; M-1 to M-114; M-I to E-113; M-1 to S-
112; M-I to I-I I I; M-1 to R-110; M-1 to I-109; M-1 to K-108; M-1 to E-107; M-
1 to V-
I06; M-I to K-105; M-1 to K-I04; M-I to K-I03; M-I to D-102; M-1 to L-101; M-1
to
10 C-I00; M-1 to S-99; M-1 to Y-98; M-1 to Y-97; M-1 to I-96; M-1 to Y-95; M-1
to F-94;
M-I to K-93; M-1 to R-92; M-1 to N-91; M-1 to H-90; M-I to R-89; M-I to F-88;
M-1
to K-87; M-1 to P-86; M-1 to H-85; M-1 to F-84; M-I to A-83; M-1 to L-82; M-1
to G-
81; M-1 to L-80; M-1 to F-79; M-I to G-78; M-1 to R-77; M-1 to E-76; M-I to D-
75; M-
1 to G-74; M-1 to I-73; M-1 to W-72; M- I to P-71; M-1 to T-70; M-1 to T-69; M-
I to L-
15 68; M-1 to V-67; M-1 to I-66; M-1 to N-65; M-1 to K-64; M-1 to L-63; M-1 to
D-62; M-
1 to L-61; M-1 to F-60; M-1 to P-59; M-1 to Q-58; M-1 to E-57; M-1 to L-_56; M-
1 to R-
55; M-1 to S-54; M-1 to G-53; M-I to D-52; M-1 to P-51; M-I to L-50; M-1 to Y-
49; M-
1 to V-48; M-1 to W-47; M-I to V-46; M-1 to V-45; M-1 to G-44; M-1 to V-43; M-
1 to
Q-42; M-1 to E-41; M-1 to A-40; M-1 to V-39; M-1 to F-38; M-1 to F-37; M-I to
R-36;
20 M-i to H-35; M-1 to T-34; M-1 to G-33; M-1 to D-32; M-1 to G-31; M-1 to A-
30; M-1
to H-29; M-1 to V-28; M-1 to M-27; M-1 to S-26; M-1 to V-25; M-1 to P-24; M-1
to N-
23; M-1 to R-22; M-I to L-21; M-1 to G-20; M-1 to N-19; M-1 to A-18; M-1 to V-
17;
M-1 to E-16; M-1 to S-15; M-1 to L-14; M-1 to C-13; M-1 to L-12; M-1 to Q-11;
M-1 to
L-10; M-1 to C-9; M-1 to G-8; M-1 to Q-7; of SEQ ID N0:29. Polypeptides
encoded by
2_5 these polynucleotides are also encompassed by the invention.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/Z5031
21
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, developmental disorders, and degenerative disorders;
osteoarthritis, and lung
cancer. Similarly, polypeptides and antibodies directed to these polypeptides
are useful in
providing immunological probes for differential identification of the
tissue{s) or cell
S type(s). For a number of disorders of the above tissues or cells,
particularly of developing
tissues, cartilage, and bone, expression of this gene at significantly higher
or lower levels
is routinely detected in certain tissues or cell types (e.g. bone, lung,
cancerous and
wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial
fluid and
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 29 as residues: Asp-52 to Glu-57, Arg-89 to Tyr-95, Asp-
102 to
Glu-107, Ser-117 to Ser-128, Glu-137 to Gly-145, Arg-192 to Arg-199, Val-231
to Gly-
243, Val-250 to Glu-256, Arg-312 to Asn-318, Glu-338 to Asp-349, Pro-405 to
Lys-417,
Thr-423 to Ile-428, Lys-442 to Ser-453, Glu-467 to Ala-475, Thr-478 to Arg-
494, Pro-
497 to Arg-526. Polynucleotides encoding said polypeptides are also provided.
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID NO:11 and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 2595 of SEQ ID NO:11, b is an integer
of 15 to
2609, where both a and b correspond to the positions of nucleotide residues
shown in
SEQ ID NO:11, and where b is greater than or equal to a + 14.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
22
FEATURES OF PROTEIN ENCODED BY GENE NO: 2
The translation product of this gene, sometimes referred to herein as TIDE
(for
S Ten Integrin Domains with EGF homology), shares sequence homology with
integrins,
which are a superfamily of dimeric ab cell-surface glycoproteins that mediate
the
adhesive functions of many cell types, enabling cells to interact with one
another and
with the extracellular mataix (See Genomics 56, 169-178 (1999); all
information and
references contained within this publication are hereby incorporated herein by
reference).
Eight human integrin b subunits have been described to date, and in
combination with the
12 known a subunits form a large family of heterodimeric cell surface
receptors that
mediate cell adhesion to counter-receptors on neighboring cells, and to ECM
proteins
(reviewed by Hynes, 1992). Integrin-ligand interactions are crucial for
fundamental
biological processes such as cell migration and motility, and lymphocyte
extravasation.
In another embodiment, polypeptides comprising the amino acid sequence of the
open reading frame upstream of the predicted signal peptide are contemplated
by the
present invention. Specifically, polypeptides of the invention comprise the
following
amino acid sequence:
TSTPPRAVPLPKSSQAAHQRNCNSGWSPGPASLGVRGSVCPAICWWHLS
LLPPPSVNPTLQKCSSPGAAQELSMRPPGFRNFLLLASSLLFAGLSAVPQSFSPSLR
SWPGAACRLSRAESERRCRAPGQPPGAALCHGRGRCDCGVCICHVTEPGMFFGP
LCECHEW VCETYDGSTCAGHGKCDCGKCKCDQGWYGDACQYPTNCDLTKKK
SNQMCKNSQDIICSNAGTCHCGRCKCDNSDGSGLVYGKFCECDDRECIDDETEEI
CGGHGKCYCGNCYCKAGWHGDKCEFQCDITPWESKRRCTSPDGKICSNRGTCV
CGECTCHDVDPTGDWGDIHGDTCECDERDCRAVYDRYSDDFCSGHGQCNCGR
CDCKAGWYGKKCEHPQSCTLSAEESIRKCQGSSDLPCSGRGKCECGKCTCYPPG
DRRVYGKTCECDDRRCEDLDGVVCGGHGTCSCGRCVCERGWFGKLCQHPRKC
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
23
NMTEEQSKNLCESADGILCSGKGSCHCGKCICSAEEWYISGEFCDCDDRDCDKH
DGLICTGNGICSCGNCECWDGWNGNACEI WLGSEYP (SEQ ID NO:SO).
Polynucleotides encoding these polypeptides are also provided.
Included in this invention as preferred domains are EGF-like domain signature
1
S and 2 domains, which were identified using the ProSite analysis tool (Swiss
Institute of
Bioinformatics). A sequence of about thirty to forty amino-acid residues long
found in
the sequence of epidermal growth factor (EGF) has been shown [ 1 to 6] to be
present, in
a more or less conserved form, in a large number of other, mostly animal
proteins. The
functional significance of EGF domains in what appear to be unrelated proteins
is not yet
clear. However, a common feature is that these repeats are found in the
extracellular
domain of membrane-bound proteins or in proteins known to be secreted
(exception:
prostaglandin G/H synthase). The EGF domain includes six cysteine residues
which have
been shown (in EGF) to be involved in disulfide bonds. The main structure is a
two-
stranded beta-sheet followed by a loop to a C-terminal short two-stranded
sheet.
1S Subdomains between the conserved cysteines strongly vary in length as shown
in the
following schematic representation of the EGF-like domain:
+___________________+ +_________________________+
I I I I
x(4)-C-x(0,48)-C-x(3,12)-C-x(1;70)-C-x(1,6)-C-x(2)-a-a-x(0,21)-Q-x(2)-C-x
+___________________+
************************************
'C': conserved cysteine involved in a disulfide bond. 'G': often conserved
glycine 'a':
2S often conserved aromatic amino acid '*': position of both patterns. 'x':
any residue The
region between the Sth and 6th cysteine contains two conserved glycines of
which at
least one is present in most EGF-like domains. The concensus pattern is as
follows: C-x-
C-x(S)-G-x(2)-C [The 3 C's are involved in disulfide bonds].
Preferred polypeptides of the invention comprise the following amino acid
sequence: GKCDCGKCKCDQGWYGDACQYPTNCDLTK (SEQ ID NO: S1),
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
24
GGHGKCYCGNCYCKAGWHGDKCEFQCDIT (SEQ ID N0:52),
HGQCNCGRCDCKAGWYGKKCEHPQSCTLS (SEQ :ID NO: 53),
HGTCSCGRCVCERGWFGKLCQHPRKCNMT (SEQ ID NO: 54),
GNGICSCGNCECWDGWNGNACEIWLGSEY (SEQ ID NO: 55), and
ICGGHGKCYCGNCYCKAGWHGDKCEFQCDITPWESK (SEQ ID NO: 73).
Polynucleotides encoding these polypeptides are also provided.
Further preferred are poiypeptides comprising the EGF-like domain signature 1
and 2 domains of the sequence referenced in Table I for this gene, and at
least 5, 10, 15,
20, 25, 30, _50, or 75 additional contiguous amino acid residues of this
referenced
sequence. The additional contiguous amino acid residues is N-terminal or C-
terminal to
the EGF-like domain signature I and 2 domains.
Alternatively, the additional contiguous amino acid residues is both N-
terminal
and C-terminal to the EGF-like domain signature 1 and 2 domains, wherein the
total N-
and C-terminal contiguous amino acid residues equal the specified number. The
above
preferred polypeptide domain is characteristic of a signature specific to EGF-
like domain
1 and 2 containing proteins. Based on the sequence similarity, the translation
product of
this gene is expected to share at least some biological activities with EGF-
like containing
proteins. Such activities are known in the art, some of which are described
elsewhere
herein.
Included in this invention as preferred domains are integrins beta chain
cysteine-
rich domains, which were identified using the ProSite analysis tool (Swiss
Institute of
Bioinformatics). Integrins [7,8] are a large family of cell surface receptors
that mediate
cell to cell as well as cell to matrix adhesion. Some integrins recognize the
R-G-D
sequence in their extracellular matrix protein ligand. Structurally, integrins
consist of a
dimer of an alpha and a beta chain. Each subunit has a large N-terminal
extracellular
domain followed by a transmembrane domain and a short C-terminal cytoplasmic
region.
Some receptors share a common beta chain while having different alpha chains.
All the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PGT/US99/25031
integrin beta chains contain four repeats of a forty amino acid region in the
C-terminal
extremity of their extracellular domain. Each of the repeats contains eight
cysteines. The
concensus pattern is as follows: C-x-[GNQ]-x(1,3)-G-x-C-x-C-x(2)-C-x-C [The
five C's
are probably involved in disulfide bonds].
5 Preferred polypeptides of the invention comprise the following amino acid
sequence: GQPPGAALCHGRGRCDCGVCICHVTEPGMFFGPLC (SEQ ID NO: 74),
ETYDGSTCAGHGKCDCGKCKCDQGWYGDACQYP (SEQ ID N0:58),
MCKNSQDIICSNAGTCHCGRCKCDNSDGSGLVYG (SEQ ID N0:59),
IDDETEEICGGHGKCYCGNCYCKAGWHGDKC (SEQ ID N0:60),
10 KRRCTSPDGKICSNRGTCVCGECTCHDVDPTGDW (SEQ ID N0:61),
DRYSDDFCSGHGQCNCGRCDCKAGWYGKKCEHPQ (SEQ ID N0:62),
CQGSSDLPCSGRGKCECGKCTCYPPGDRRVYGK (SEQ ID N0:63),
CEDLDGVVCGGHGTCSCGRCVCERGWFGKLC (SEQ ID N0:64),
SADGILCSGKGSCHCGKCICSAEEWYISGEFC (SEQ ID N0:65), and
15 CDKHDGLICTGNGICSCGNCECWDGWNGNACEI (SEQ ID NO: 66).
Polynucleotides encoding these polypeptides are also provided.
Further preferred are polypeptides comprising the integrins beta chain
cysteine-
rich domain of the sequence referenced in Table XIII for this gene, and at
least 5, 10, 15,
20, 25, 30, 50, or 75 additional contiguous amino acid residues of this
referenced
20 sequence. The additional contiguous amino acid residues is N-terminal or C-
terminal to
the integrins beta chain cysteine-rich domain.
Alternatively, the additional contiguous amino acid residues is both N-
terminal
and C-terminal to the integrins beta chain cysteine-rich domain, wherein the
total N- and
C-terminal contiguous amino acid residues equal the specified number. The
above
25 preferred polypeptide domain is characteristic of a signature specific to
integrin proteins.
Based on the sequence similarity, the translation product of this gene is
expected to share
at least some biological activities with integrin proteins, and specifically
those containing
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
26
an integrins beta chain cysteine-rich domain. Such activities are known in the
art, some
of which are described elsewhere herein. The following publications were
referenced
above and are hereby incorporated herein by reference: [ 1) Davis C.G., New
Biol.
2:410-419(1990); [ 2) Blomquist M.C., Hunt L.T., Barker W.C., Proc. Natl.
Acad. Sci.
U.S.A. 81:7363-7367(1984); [ 3] Barker W.C., Johnson G.C., Hunt L.T., George
D.G.,
Protein Nucl. Acid Enz. 29:54-68(1986); [ 4) Doolittle R.F., Feng D.F.,
Johnson M.S.,
Nature 307:558-_560( 1984); [ 5) Appella E., Weber 1.T., Blasi F., FEBS Lett.
231:1-
4(1988); [ 6) Campbell LD., Bork P., Cun-. Opin. Struct. Biol. 3:385-
392(1993); [ 7)
Hynes R.O., Cell 48:549-554(1987); and [ $] Albelda S.M., Buck C.A., FASEB J.
4:2868-2880( 1990).
The polypeptide of the present invention has been putatively identified as a
member of the integrin family and has been termed Ten Integrin Domains with
EGF
homology ("TIDE"). This identification has been made as a result of amino acid
sequence homology to the human integrin beta-8 subunit (See Genbank Accession
No.
gi ~ 184521 ).
Figures 4A-C shows the nucleotide (SEQ ID N0:.12) and deduced amino acid
sequence (SEQ ID N0:30) of TIDE. Predicted amino acids from about 1 to about
23
constitute the predicted signal peptide (amino acid residues from about 1 to
about 23 in
SEQ ID N0:30) and are represented by the underlined amino acid regions; amino
acids
from about 108 to about 136, from about 195 to about 223, from about 291 to
about 319,
from about 379 to about 407, and/or from about 465 to about 493 constitute the
predicted
EGF-like domain signature 1 and 2 domains (amino acids from about 108 to about
136,
from about 195 to about 223, from about 291 to about 319, from about 379 to
about 407,
and/or from about 465 to about 493 in SEQ ID N0:30) and are represented by the
double
underlined amino acids; and amino acids from about 55 to about 89, from about
97 to
about 129, from about 142 to about 175, from about 186 to about 216, from
about 228 to
about 261, from about 281 to about 314, from about 327 to about 359, from
about 368 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
27
about 398, from about 417 to about 448, and/or from about 455 to about 487
constitute
the predicted integrins beta chain cysteine-rich domains (amino acids from
about 55 to
about 89, from about 97 to about 129, from about 142 to about 175, from about
186 to
about 216, from about 228 to about 261, from about 281 to about 314, from
about 327 to
about 359, from about 368 to about 398, from about 417 to about 448, and/or
from about
455 to about 487 in SEQ ID N0:30) and are represented by the shaded amino
acids.
Figure 5 shows the regions of similarity between the amino acid sequences of
the
Ten Integrin Domains with EGF homology (TIDE) protein {SEQ ID N0:30) and the
human integrin beta-8 subunit {SEQ ID NO: 67).
Figure 6 shows an analysis of the Ten Integrin Domains with EGF homology
(TIDE) amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity
and
hydrophobicity; amphipathic regions; flexible regions; antigenic index and
surface
probability are shown.
A polynucleotide encoding a polypeptide of the present invention is obtained
from human osteoblasts, synovial hypoxia tissue, osteoblast and osteoclast,
bone marrow
stromal cells, umbilical vein, smooth muscle, placenta, and fetal lung. The
polynucleotide of this invention was discovered in a human osteoblast II cDNA
library.
Its translation product has homology to the characteristic integrins beta
chain cysteine-
rich domains of integrin family members. The polynucleotide contains an open
reading
frame encoding the TIDE polypeptide of 494 amino acids. TIDE exhibits a high
degree
of homology at the amino acid level to the human integrin beta-8 subunit (as
shown in
Figure 5).
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the TIDE polypeptide having the amino acid sequence
shown in
Figures 4A-C (SEQ ID N0:30). The nucleotide sequence shown in Figures 4A-C
(SEQ
ID N0:12) was obtained by sequencing a cloned cDNA (HOHCH55), which was
deposited on November 17 at the American Type Culture Collection, and given
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
28
Accession Number 203484. The present invention is further directed to
fragments of the
isolated nucleic acid molecules described herein. By a fragment of an isolated
DNA
molecule having the nucleotide sequence of the deposited eDNA or the
nucleotide
sequence shown in SEQ ID N0:12 is intended DNA fragments at least about l5nt,
and
more preferably at least about 20 nt, still more preferably at least about 30
nt, and even
more preferably, at least about 40 nt in length which are useful as diagnostic
probes and
primers as discussed herein. Of course, larger fragments 50-1500 nt in length
are also
useful according to the present invention, as are fragments corresponding to
most, if not
all, of the nucleotide sequence of the deposited cDNA or as shown in SEQ ID
N0:12. By
a fragment at least 20 nt in length, for example, is intended fragments which
include 20
or more contiguous bases from the nucleotide sequence of the deposited cDNA or
the
nucleotide sequence as shown in SEQ ID N0:12. In this context "about" includes
the
particularly recited size, larger or smaller by several (5, 4, 3, 2, or 1)
nucleotides, at
either terminus or at both termini. Representative examples of TIDE
polynucleotide
fragments of the invention include, for example, fragments that comprise, or
alternatively, consist of, a sequence from about nucleotide 1 to about 50,
from about 51
to about 100, from about 101 to about 150, from about 151 to about 200, from
about 201
to about 250, from about 251 to about 300, from about 301 to about 350, from
about 351
to about 400, from about 401 to about 450, from about 451 to about 500, from
about 501
to about 550, from about 551 to about 600, from about 601 to about 650, from
about 651
to about 700, from about 701 to about 750, from about 751 to about 800, from
about 801
to about 850, from about 851 to about 900, from about 901 to about 950, from
about 951
to about 1000, from about 1001 to about 1050, from about 1051 to about 1100,
from
about 1101 to about 1150, from about 1151 to about 1200, from about 1201 to
about
1250, from about 1251 to about 1300, from about 1301 to about 1350, from about
1351
to about 1400, from about 1401 to about 1450, from about 1451 to about 1500,
from
about 1501 to about 1550, from about 1551 to about 1600, from about 1601 to
about
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC'T/US99/25031
29
1650, from about 1651 to about 1700, from about 1701 to about 1750, from about
1751
to about 1800, from about 1801 to about 1850, from about 1851 to about 1900,
from
about 1901 to about 1950, from about 1951 to about 2000, from about 2001 to
about
2050, from about 2051 to about 2100, from about 2101 to about 2150, from about
2151
to about 2200, from about 2201 to about 22_50, from about 2251 to about 2300,
from
about 2301 to about 2350, from about 2351 to about 2400, from about 2401 to
about
2450, from about 2451 to about 2499, from about 289 to about 1705, and/or from
about
221 to about 1705 of SEQ ID N0:12, or the complementary strand thereto, or the
cDNA
contained in the deposited gene. In this context "about" includes the
particularly recited
ranges, larger or smaller by several (5, 4, 3, 2, or 1 ) nucleotides, at
either terminus or at
both termini.
Preferred nucleic acid fragments of the present invention include nucleic acid
molecules encoding a member selected from the group: a polypeptide comprising
or
alternatively, consisting of, the mature TIDE protein (amino acid residues
from about
221 to about 1705 in Figures 4A-C (amino acids from about 221 to about 1705 in
SEQ
ID N0:30). Since the location of these domains have been predicted by computer
analysis, one of ordinary skill would appreciate that the amino acid residues
constituting
these domains may vary slightly (e.g., by about 1 to 15 amino acid residues)
depending
on the criteria used to define each domain. In additional embodiments, the
polynucleotides of the invention encode functional attributes of TIDE.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha arnphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions of TIDE. The
data
representing the structural or functional attributes of TIDE set forth in
Figure 6 and/or
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99l25031
Table II, as described above, was generated using the various modules and
algorithms of
the DNA*STAR set on default parameters. In a preferred embodiment, the data
presented in columns VIII, IX, XIII, and XIV of Table II can be used to
determine
regions of TIDE which exhibit a high degree of potential for antigenicity.
Regions of
5 high antigenicity are determined from the data presented in columns VIII,
IX, XIII,
and/or XIV by choosing values which represent regions of the polypeptide which
are
likely to be exposed on the surface of the polypeptide in an environment in
which antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 6, but may,
as
10 shown in Table II, be represented or identified by using tabular
representations of the
data presented in Figure 6. The DNA*STAR computer algorithm used to generate
Figure
6 (set on the original default parameters) was used to present the data in
Figure 6 in a
tabular format (See Table II). The tabular format of the data in Figure 6 is
used to easily
determine specific boundaries of a preferred region. The above-mentioned
preferred
15 regions set out in Figure 6 and in Table II include, but are not limited
to, regions of the
aforementioned types identified by analysis of the amino acid sequence set out
in Figures
4A-C. As set out in Figure 6 and in Table II, such preferred regions include
Garnier-
Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-
Fasman alpha-
regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions
and I-~opp-
20 Woods hydrophobic regions, Eisenberg alpha- and beta-amphipathic regions,
Karplus-
Schulz flexible regions, Jameson-Wolf regions of high antigenic index and
Emini
surface-forming regions. Even if deletion of one or more amino acids from the
N-
terminus of a protein results in modification of loss of one or more
biological functions
of the protein, other functional activities (e.g., biological activities,
ability to
25 multimerize, etc.) may still be retained. For example, the ability of
shortened TIDE
muteins to induce and/or bind to antibodies which recognize the complete or
mature
forms of the polypeptides generally will be retained when less than the
majority of the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
31
residues of the complete or mature polypeptide are removed from the N-
terminus.
Whether a particular polypeptide lacking N-terminal residues of a complete
polypeptide
retains such immunologic activities can readily be determined by routine
methods
described herein and otherwise known in the art. It is not unlikely that an
TIDE mutein
with a large number of deleted N-terminal amino acid residues may retain some
biological or immunogenic activities. In fact, peptides composed of as few as
six TIDE
amino acid residues may often evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the TIDE amino acid sequence
shown
in Figures 4A-C, up to the leucine residue at position number 489 and
poiynucleotides
encoding such poiypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-494 of Figures 4A-C, where
nl is an
integer from 2 to 489 corresponding to the position of the amino acid residue
in Figures
4A-C (which is identical to the sequence shown as SEQ ID N0:30). In another
embodiment, N-terminal deletions of the TIDE polypeptide can be described by
the
general formula n2-494, where n2 is a number from 2 to 489, corresponding to
the
position of amino acid identified in Figures 4A-C. N-terminal deletions of the
TIDE
polypeptide of the invention shown as SEQ ID N0:30 include polypeptides
comprising
the amino acid sequence of residues: N-terminal deletions of the TIDE
polypeptide of the
invention shown as SEQ ID N0:30 include polypeptides comprising the amino acid
sequence of residues: R-2 to P-494; P-3 to P-494; P-4 to P-494; G-5 to P-494;
F-6 to P-
494; R-7 to P-494; N-8 to P-494; F-9 toP-494; L-10 to P-494; L-11 to P-494; L-
12 to P-
494; A-13 to P-494; S-14 to P-494; S-15 to P-494; L-16 to P-494; L-17 to P-
494;F-18 to
P-494; A-19 to P-494; G-20 to P-494; L-21 to P-494; S-22 to P-494; A-23 to P-
494; V-
24 to P-494; P-25 to P-494; Q-26to P-494; S-27 to P-4.94; F-28 to P-494; S-29
to P-494;
P-30 to P-494; S-31 to P-494; L-32 to P-494; R-33 to P-494; S-34 toP-494; W-35
to P-
494; P-36 to P-494; G-37 to P-494; A-38 to P-494; A-39 to P-494; C-40 to P-
494; R-41
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
32
to P-494; L-42 toP-494; S-43 to P-494; R-44 to P-494; A-45 to P-494; E-46 to P-
494; S-
47 to P-494; E-48 to P-494; R-49 to P-494; R-50 toP-494; C-51 to P-494; R-52
to P-494;
A-53 to P-494; P-54 to P-494; G-55 to P-494; Q-56 to P-494; P-57 to P-494; P-
58 toP-
494; G-59 to P-494; A-60 to P-494; A-61 to P-494; L-62 to P-494; C-63 to P-
494; H-64
to P-494; G-65 to P-494; R-66 toP-494; G-67 to P-494; R-68 to P-494; C-69 to P-
494; D-
70 to P-494; C-71 to P-494; C~-72 to P-494; V-73 to P-494; C-74 toP-494; I-75
to P-494;
C-76 to P-494; H-77 to P-494; V-78 to P-494; T-79 to P-494; E-80 to P-494; P-
81 to P-
494; G-82 to P-494;M-83 to P-494; F-84 to P-494; F-85 to P-494; G-86 to P-494;
P-87 to
P-494; L-88 to P-494; C-89 to P-494; E-90 to P-494; C-9lto P-494; H-92 to P-
494; E-93
to P-494: W-94 to P-494; V-95 to P-494; C-96 to P-494; E-97 to P-494; T-98 to
P-494;
Y-99 toP-494; D-100 to P-494; G-101 to P-494; S-102 to P-494; T-103 to P-494;
C-104
to P-494; A-105 to P-494; G-106 to P-494;H-107 to P-494; G-108 to P-494; K-109
to P-
494; C- I I 0 to P-494; D-111 to P-494; C-112 to P-494; G-113 to P-494; K- I
14 toP-494;
C-I 15 to P-494; K-116 to P-494; C-117 to P-494; D-118 to P-494; Q-119 to P-
494; G-
120 to P-494; W-121 to P-494;Y-122 to P-494; G-123 to P-494; D-124 to P-494; A-
125
to P-494; C-126 to P-494; Q-127 to P-494; Y-128 to P-494; P-129 toP-494; T-130
to P-
494; N-131 to P-494; C-132 to P-494; D-133 to P-494; L-134 to P-494; T-135 to
P-494;
K-136 to P-494;x-137 to P-494; K-138 to P-494; S-139 to P-494; N-140 to P-494;
Q-
141 to P-494; M-142 to P-494; C-143 to P-494; K-144 toP-494; N-145 to P-494; S-
146
to P-494; Q-147 to P-494; D-l48 to P-494; I-149 to P-494; I-150 to P-494; C-
151 to P-
494; S-152to P-494; N-153 to P-494; A-154 to P-494; G~-155 to P-494; T-156 to
P-494;
C-157 to P-494; H-158 to P-494; C-159 to P-494;6-160 to P-494; R-161 to P-494;
C-162
to P-494; K-163 to P-494; C-164 to P-494; D-165 to P-494; N-166 to P-494; S-
167 toP-
494; D-168 to P-494; G-169 to P-494; S-170 to P-494; G-171 to P-494; L-172 to
P-494;
V-173 to P-494; Y-174 to P-494;6-175 to P-494; K-I76 to P-494; F-177 to P-494;
C-178
to P-494; E-179 to P-494; C-180 to P-494; D-181 to P-494; D-182 toP-494; R-183
to P-
494; E-184 to P-494; C-185 to P-494; I-186 to P-494; D-187 to P-494; D-188 to
P-494;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
33
E-189 to P-494; T-190to P-494; E-191 to P-494; E-192 to P-494; I-193 to P-494;
C-194
to P-494; G-195 to P-494; G-196 to P-494; H-197 to P-494;6-198 to P-494; K-199
to P-
494; C-200 to P-494; Y-201 to P-494; C-202 to P-494; G-203 to P-494; N-204 to
P-494;
C-205 toP-494; Y-206 to P-494; C-207 to P-494; K-208 to P-494; A-209 to P-494;
G-
210 to P-494; W-211 to P-494; H-212 to P-494;6-213 to P-494; D-214 to P-494; K-
215
to P-494; C-216 to P-494; E-217 to P-494; F-218 to P-494; Q-219 to P-494; C-
220 toP-
494; D-221 to P-494; I-222 to P-494; T-223 to P-494; P-224 to P-494; W-225 to
P-494;
E-226 to P-494; S-227 to P-494;x-228 to P-494; R-229 to P-494; R-230 to P-494;
C-231
to P-494; T-232 to P-494; S-233 to P-494; P-234 to P-494; D-235 toP-494; G-236
to P-
494; K-237 to P-494; I-238 to P-494; C-239 to P-494; S-240 to P-494; N-241 to
P-494;
R-242 to P-494;G-243 to P-494; T-244 to P-494; C-245 to P-494; V-246 to P-494;
C-247
to P-494; G-248 to P-494; E-249 to P-494; C-2_50 toP-494; T-251 to P-494; C-
252 to P-
494; H-2.53 to P-494; D-254 to P-494; V-255 to P-494; D-256 to P-494; P-257 to
P-
494;T-258 to P-494; G-259 to P-494; D-260 to P-494; W-261 to P-494; G-262 to P-
494;
D-263 to P-494; I-264 to P-494; H-265 toP-494; G-266 to P-494; D-267 to P-494;
T-268
to P-494; C-269 to P-494; E-270 to P-494; C-271 to P-494; D-272 to P-494;E-273
to P-
494; R-274 to P-494; D-275 to P-494; C-276 to P-494; R-277 to P-494; A-278 to
P-494;
V-279 to P-494; Y-280 toP-494; D-281 to P-494; R-282 to P-494; Y-283 to P-494;
S-284
to P-494; D-285 to P-494; D-286 to P-494; F-287 to P-494;C-288 to P-494; S-289
to P-
494; G-290 to P-494; H-291 to P-494; G-292 to P-494; Q-293 to P-494; C-294 to
P-494;
N-295 toP-494; C-296 to P-494; G-297 to P-494; R-298 to P-494; C-299 to P-494;
D-
300 to P-494; C-301 to P-494; K-302 to P-494;A-303 to P-494; G-304 to P-494; W-
305
to P-494; Y-306 to P-494; G-307 to P-494; K-308 to P-494; K-309 to P-494; C-
310 toP-
494; E-311 to P-494; H-312 to P-494; P-313 to P-494; Q-314 to P-494; S-315 to
P-494;
C-316 to P-494; T-317 to P-494;L-318 to P-494; S-319 to P-494; A-320 to P-494;
E-321
to P-494; E-322 to P-494; S-323 to P-494; I-324 to P-494; R-325 toP-494; K-326
to P-
494; C-327 to P-494; Q-328 to P-494; G-329 to P-494; S-330 to P-494; S-331 to
P-494;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
34
D-332 to P-494;L-333 to P-494; P-334 to P-494; C-335 to P-494; S-336 to P-494;
G-337
to P-494; R-338 to P-494; G-339 to P-494; K-340 toP-494; C-341 to P-494; E-342
to P-
494; C-343 to P-494; G-344 to P-494; K-345 to P-494; C-346 to P-494; T-347 to
P-
494;C-348 to P-494; Y-349 to P-494; P-350 to P-494; P-351 to P-494; G-352 to P-
494;
D-353 to P-494; R-354 to P-494; R-355 toP-494; V-356 to P-494; Y-357 to P-494;
6-
358 to P-494; K-359 to P-494; T-360 to P-494; C-361 to P-494; E-362 to P-494;C-
363 to
P-494; D-364 to P-494; D-365 to P-494; R-366 to P-494; R-367 to P-494; C-368
to P-
494; E-369 to P-494; D-370 toP-494; L-371 to P-494; D-372 to P-494; G-373 to P-
494;
V-374 to P-494; V-375 to P-494; C-376 to P-494; G-377 to P-494;6-378 to P-494;
H-
379 to P-494; G-380 to P-494; T-381 to P-494; C-382 to P-494; S-383 to P-494;
C-384
to P-494; G-385 toP-494; R-386 to P-494; C-387 to P-494; V-388 to P-494; C-389
to P-
494; E-390 to P-494; R-391 to P-494; G-392 to P-494;W-393 to P-494; F-394 to P-
494;
G-395 to P-494; K-396 to P-494; L-397 to P-494; C-398 to P-494; Q-399 to P-
494; H-
400 toP-494; P-401 to P-494; R-402 to P-494; K-403 to P-494; C-404 to P-494; N-
405 to
P-494; M-406 to P-494; T-407 to P-494;E-408 to P-494; E-409 to P-494; Q-410 to
P-
494; S-411 to P-494; K-412 to P-494; N-4I3 to P-494; L-414 to P-494; C-415 toP-
494;
E-416 to P-494; S-417 to P-494; A-418 to P-494; D-419 to P-494; G-420 to P-
494; I-421
to P-494; L-422 to P-494; C-423to P-494; S-424 to P-494; G-425 to P-494; K-426
to P-
494; G-427 to P-494; S-428 to P-494; C-429 to P-494; H-430 to P-494;C-431 to P-
494;
G-432 to P-494; K-433 to P-494; C-434 to P-494; I-435 to P-494; C-436 to P-
494; S-437
to P-494; A-438 toP-494; E-439 to P-494; E-440 to P-494; W-441 to P-494; Y-442
to P-
494; I-443 to P-494; S-444 to P-494; G-445 to P-494;E-446 to P-494; F-447 to P-
494; C-
448 to P-494; D-449 to P-494; C-450 to P-494; D-451 to P-494; D-452 to P-494;
R-453
toP-494; D-454 to P-494; C-455 to P-494; D-456 to P-494; K-457 to P-494; H-458
to P-
494; D-459 to P-494; G-460 to P-494;L-461 to P-494; I-462 to P-494; C-463 to P-
494;
T-464 to P-494; G-465 to P-494; N-466 to P-494; G-467 to P-494; I-468 toP-494;
C-469
to P-494; S-470 to P-494; C-471 to P-494; G-472 to P-494; N-473 to P-494; C-
474 to P-
SUBSTITUTE SHEET (RULE 25)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
494; E-475 to P-494;C-476 to P-494; W-477 to P-494; D-478 to P-494; G-479 to P-
494;
W-480 to P-494; N-481 to P-494; G-482 to P-494; N-483 toP-494; A-484 to P-494;
C-
485 to P-494; E-486 to P-494; I-487 to P-494; W-488 to P-494; L-489 to P-494;
of SEQ
ID N0:30. Polypeptides encoded by these polynucleotides are also encompassed
by the
in vention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities may still be retained.
For example the
ability of the shortened TIDE mutein to induce and/or bind to antibodies which
recognize
10 the complete or mature forms of the polypeptide generally will be retained
when less
than the majority of the residues of the complete or mature polypeptide are
removed
from the C-terminus. Whether a particular polypeptide lacking C-terminal
residues of a
complete polypeptide retains such immunologic activities can readily be
determined by
routine methods described herein and otherwise known in the art. It is not
unlikely that
15 an TIDE mutein with a large number of deleted C-terminal amino acid
residues may
retain some biological or immunogenic activities. In fact, peptides composed
of as few as
six TIDE amino acid residues may often evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the TIDE
20 polypeptide shown in Figures 4A-C, up to the phenylalanine residue at
position number
6, and polynucleotides encoding such polypeptides. In particular, the present
invention
provides polypeptides comprising the amino acid sequence of residues 1-ml of
Figure 1,
where ml is an integer from 6 to 494 corresponding to the position of the
amino acid
residue in Figures 4A-C. Moreover, the invention provides polynucleotides
encoding
25 polypeptides comprising, or alternatively consisting of, the amino acid
sequence of C-
terminal deletions of the TIDE polypeptide of the invention shown as SEQ ID
N0:30
include polypeptides comprising the amino acid sequence of residues: M-1 to Y-
493; M-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
36
1 to E-492; M-1 to S-491; M-1 to G-490; M-1 to L-489; M-1 to W-488; M-1 toI-
487; M-
1 to E-486; M-1 to C-485; M-1 to A-484; M-1 to N-483; M-1 to G-482; M-1 to N-
481;
M-1 to W-480; M-1 to G-479;M-1 to D-478; M-1 to W-477; M-1 to C-476; M-1 to E-
475; M-1 to C-474; M-1 to N-473; M-1 to G-472; M-1 to C-471; M-1 toS-470; M-1
to
C-469; M-1 to I-468; M-1 to Ci-467; M-1 to N-466; M-1 to G-465; M-1 to T-464;
M-1 to
C-463; M-1 to I-462; M-1 to L-461; M-1 to G-460; M-1 to D-459; M-1 to H-458: M-
1 to
K-457; M-1 to D-456; M-1 to C-455; M-1 to D-454; M-1 to R-453;M-1 to D-452; M-
1
to D-451; M-1 to C-450; M-1 to D-449; M-1 to C-448; M-1 to F-447; M-1 to E-
446; M-
1 to G-445; M-1 toS-444; M-1 to I-443: M-1 to Y-442; M-1 to W-441; M-1 to E-
440; M-
1 to E-439; M-1 to A-438; M-1 to S-437; M-1 to C-436; M-Ito I-435; M-1 to C-
434; M-
1 to K-433; M-1 to G-432; M-1 to C-431; M-1 to H-430; M-1 to C-429; M-1 to S-
428;
M-1 to G-427;M-1 to K-426; M-1 to G-425; M-1 to S-424; M-1 to C-423; M-1 to L-
422;
M-I to I-421; M-1 to G-420; M-1 to D-419; M-1 toA-418; M-1 to S-417; M-1 to E-
416;
M-1 to C-415; M-1 to L-414; M-1 to N-413; M-1 to K-412; M-1 to S-411; M-1 to Q-
410;M-1 to E-409; M-1 to E-408; M-1 to T-407; M-1 to M-406; M-1 to N-405; M-1
to
C-404; M-1 to K-403; M-1 to R-402; M-1 toP-401; M-1 to H-400; M-1 to Q-399; M-
1 to
C-398; M-1 to L-397; M-1 to K-396; M-1 to G-395; M-1 to F-394; M-1 to W-393;M-
1
to G-392; M-1 to R-391; M-1 to E-390; M-1 to C-389; M-1 to V-388; M-1 to C-
387; M-
1 to R-386; M-1 to G-385; M-1 toC-384; M-1 to S-383; M-1 to C-382; M-1 to T-
381; M-
1 to G-380; M-1 to H-379; M-1 to G-378; M-1 to G-377; M-1 to C-376;M-1 to V-
375;
M-1 to V-374; M-1 to G-373; M-1 to D-372; M-1 to L-371; M-1 to D-370; M-1 to E-
369; M-I to C-368; M-1 toR-367; M-1 to R-366; M-1 to D-365; M-1 to D-364; M-1
to
C-363; M-1 to E-362; M-1 to C-361; M-1 to T-360; M-1 to K-359;M-1 to G-358; M-
1 to
Y-357; M-1 to V-356; M-1 to R-355; M-1 to R-354; M-1 to D-353; M-1 to G-352; M-
1
to P-351; M-1 toP-350; M-I to Y-349; M-1 to C-348; M-1 to T-347; M-1 to C-346;
M-1
to K-345; M-1 to G-344; M-1 to C-343; M-1 to E-342;M-1 to C-341; M-1 to K-340;
M-1
to G-339; M-1 to R-338; M-1 to G-337; M-1 to S-336; M-1 to C-335; M-1 to P-
334; M-1
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
37
toL-333; M-1 to D-332; M-1 to S-331; M-1 to S-330; M-1 to G-329; M-1 to Q-328;
M-1
to C-327; M-1 to K-326; M-1 to R-325;M-1 to I-324; M-1 to S-323; M-1 to E-322;
M-1
to E-321; M-I to A-320; M-1 to S-319; M-1 to L-318; M-1 to T-317; M-1 toC-316;
M-1
to S-315; M-1 to Q-314; M-1 to P-313; M-1 to H-312; M-1 to E-311; M-1 to C-
310; M-1
to K-309; M-1 to K-308;M-1 to G-307; M-1 to Y-306; M-1 to W-305; M-1 to G-304;
M-
1 to A-303; M-1 to K-302; M-1 to C-301; M-1 to D-300; M-1 toC-299; M-1 to R-
298;
M-1 to G-297; M-1 to C-296; M-1 to N-295; M-1 to C-294; M-1 to Q-293; M-1 to 6-
292; M-1 to H-291;M-1 to G-290; M-1 to S-289; M-1 to C-288; M-1 to F-287; M-1
to
D-286; M-1 to D-285; M-1 to S-284; M-1 to Y-283; M-1 toR-282; M-1 to D-281; M-
1 to
Y-280; M-1 to V-279; M-1 to A-278; M-1 to R-277; M-1 to C-276; M-1 to D-275; M-
I
to R-274;M-1 to E-273; M-1 to D-272; M-1 to C-271; M-1 to E-270; M-1 to C-269;
M-1
to T-268; M-1 to D-267; M-1 to G-266; M-l toH-265; M-1 to I-264; M-1 to D-263;
M-1
to G-262; M-1 to W-261; M-1 to D-260; M-1 to G-259; M-1 to T-258; M-1 to P-
257;M-
1 to D-256; M-1 to V-255; M-1 to D-254; M-1 to H-253; M-1 to C-252; M-1 to T-
251;
M-1 to C-250; M-1 to E-249; M-1 toG-248; M-1 to C-247; M-1 to V-246; M-1 to C-
245;
M-1 to T-244; M-1 to G-243; M-1 to R-242; M-1 to N-241; M-1 to S-240;M-1 to C-
239;
M-1 to I-238; M-1 to K-237; M-1 to G-236; M-1 to D-235; M-1 to P-234; M-1 to S-
233;
M-1 to T-232; M-1 toC-231; M-1 to R-230; M-1 to R-229; M-1 to K-228; M-1 to S-
227;
M-1 to E-226; M-1 to W-225; M-1 to P-224; M-1 to T-223;M-1 to I-222; M-1 to D-
221;
M-1 to C-220; M-1 to Q-219; M-1 to F-218; M-1 to E-217; M-1 to C-216; M-1 to K-
215; M-1 toD-214; M-1 to G-213; M-1 to H-212; M-1 to W-211; M-1 to G-210; M-1
to
A-209; M-I to K-208; M-1 to C-207; M-1 to Y-206;M-1 to C-205; M-1 to N-204; M-
1
to G-203; M-1 to C-202; M-1 to Y-201; M-1 to C-200; M-1 to K-199; M-1 to G-
198; M-
1 toH-197; M-1 to G-196; M-1 to G-195; M-1 to C-I94; M-1 to I-193; M-1 to E-
192; M-
1 to E-191; M-1 to T-190; M-1 to E-189; M-lto D-188; M-1 to D-187; M-1 to I-
186; M-
1 to C-185; M-1 to E-184; M-1 to R-183; M-1 to D-182; M-1 to D-I81; M-1 to C-
180;M-1 to E-179; M-1 to C-178; M-I to F-177; M-1 to K-176; M-1 to G-175; M-1
to
SUBSTITUTE SHEET (RULE 2~
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
38
Y-174; M-1 to V-173; M-1 to L-172; M-1 toG-171; M-1 to S-170; M-1 to G-169; M-
1 to
D-168; M-1 to S-167; M-1 to N-166; M-I to D-165; M-1 to C-164; M-1 to K-163;M-
1 to
C-162; M-I to R-161; M-1 to G-160; M-1 to C-159; M-1 to H-158; M-1 to C-157; M-
I
to T-156; M-1 to G-155; M-1 toA-154; M-1 to N-153; M-1 to S-152; M-1 to C-151;
M-1
to I-150; M-1 to I-149; M-1 to D-148; M-1 to Q-147; M-1 to S-146; M-lto N-145;
M-1
to K-144; M-1 to C-143; M-1 to M-142; M-1 to Q-141; M-1 to N-140; M-1 to S-
139; M-
1 to K-138; M-1 to K-137;M-1 to K-136; M-1 to T-135; M-1 to L-134; M-1 to D-
133;
M-I to C-132; M-1 to N-131; M-1 to T-130; M-1 to P-129; M-1 toY-128; M-1 to Q-
127;
M-1 to C-126; M-1 to A-125; M-1 to D-124; M-1 to G-123; M-1 to Y-122; M-1 to W-
121; M-1 to G-120;M-1 to Q-119; M-1 to D-118; M-I to C-117; M-1 to K-116; M-1
to
C-I 15; M-1 to K-114; M-1 to G-l I3; M-1 to C-112; M-1 toD-111; M-1 to C-110;
M-1 to
K-109; M-1 to G-108; M-1 to H-107; M-1 to G- I 06; M- I to A-105; M-1 to C-
104; M-1
to T-103;M-1 to S-102; M-1 to G-101; M-1 to D-100; M-1 to Y-99; M-1 to T-98; M-
1 to
E-97; M-1 to C-96; M-1 to V-95; M-1 to W-94;M-1 to E-93; M-1 to H-92; M-I to C-
91;
M-1 to E-90; M-1 to C-89; M-1 to L-88; M-1 to P-87; M-1 to G-86; M-1 to F-85;
M-1
toF-84; M-1 to M-83; M-1 to G-82; M-1 to P-81; M-1 to E-80; M-1 to T-79; M-I
to V-
78; M-1 to H-77; M-.1 to C-76; M-1 to I-75;M-1 to C-74; M-1 to V-73; M-1 to G-
72; M-
1 to C-71; M-I to D-70; M-1 to C-69; M-1 to R-68; M-1 to G-67; M-1 to R-66; M-
1
toG-65; M-1 to H-64; M-1 to C-63; M-1 to L-62; M-1 to A-61; M-1 to A-60; M-1
to G-
59; M-I to P-58; M-1 to P-57; M-1 to Q-56;M-1 to G-55; M-1 to P-54; M-1 to A-
53; M-
1 to R-52; M-1 to C-51; M-1 to R-50; M-1 to R-49; M-1 to E-48; M-1 to S-47; M-
1 toE-
46; M-1 to A-45; M-1 to R-44; M-1 to S-43; M-1 to L-42; M-1 to R-41; M-1 to C-
40; M-
1 to A-39; M-I to A-38; M-1 to G-37;M-1 to P-36; M-1 to W-35; M-1 to S-34; M-1
to
R-33; M-1 to L-32; M-1 to S-31; M-1 to P-30; M-1 to S-29; M-1 to F-28; M-1 toS-
27;
M-I to Q-26; M-1 to P-25; M-1 to V-24; M-1 to A-23; M-1 to S-22; M-I to L-21;
M-1 to
G-20; M-1 to A-19; M-1 to F-18;M-1 to L-17; M-1 to L-16; M-1 to S-15; M-1 to S-
14;
M-1 to A-13; M-1 to L-12; M-1 to L-11; M-1 to L-10; M-1 to F-9; M-1 toN-8; M-1
to R-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
39
7; M-1 to F-6; of SEQ ID N0:30. Polypeptides encoded by these polynucleotides
are
also encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:12 which have been
determined
from the following related cDNA genes: HLHFV34R (SEQ ID N0:68), HSRDA85R
(SEQ ID N0:69), HSRAZ62R (SEQ ID N0:70), HSRDA 17R (SEQ ID N0:71 ), and
HSLEC45R (SEQ ID N0:72).
Based on the sequence similarity to the human integrin beta-8 subunit,
translation
product of this gene is expected to share at least some biological activities
with integrin
proteins, and specifically the human inteQrin beta-8 subunit. Such activities
are known in
the art, some of which are described elsewhere herein.
Specifically, polynucleotides and polypeptides of the invention are also
useful for
modulating the differentiation of normal and malignant cells, modulating the
proliferation and/or differentiation of cancer and neoplastic cells, and
modulating the
immune response. Polynucleotides and polypeptides of the invention may
represent a
diagnostic marker for hematopoietic and immune diseases and/or disorders. The
full
length protein should be a secreted protein, based upon homology to the
integrin family.
Therefore, it is secreted into serum, urine, or feces and thus the levels is
assayable from
patient samples. Assuming specific expression levels are reflective of the
presence of
immune disorders, this protein would provide a convenient diagnostic for early
detection.
In addition, expression of this gene product may also be linked to the
progression of
immune diseases, and therefore may itself actually represent a therapeutic or
therapeutic
target for the treatment of cancer. Polynucleotides and polypeptides of the
invention may
play an important role in the pathogenesis of human cancers and cellular
transformation,
particularly those of the immune and hematopoietic systems. Polynucleotides
and
polypeptides of the invention may also be involved in the pathogenesis of
developmental
abnormalities based upon its potential effects on proliferation and
differentiation of cells
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/2503I
and tissue cell types. Due to the potential proliferating and differentiating
activity of said
polynucleotides and polypeptides, the invention is useful as a therapeutic
agent in
inducing tissue regeneration, for treating inflammatory conditions (e.g.,
inflammatory
bowel syndrome, diverticulitis, etc.). Moreover, the invention is useful in
modulating the
5 immune response to aberrant polypeptides, as may exist in rapidly
proliferating cells and
tissue cell types, particularly in adenocarcinoma cells, and other cancers.
Alternatively, the expression within cellular sources marked by proliferating
cells
indicates this protein may play a role in the regulation of cellular division,
and may show
utility in the diagnosis, treatment, and/or prevention of developmental
diseases and
10 disorders, including cancer, and other proliferative conditions.
Representative uses are
described in the "Hyperproliferative Disorders" and "Regeneration" sections
below and
elsewhere herein. Briefly, developmental tissues rely on decisions involving
cell
differentiation and/or apoptosis in pattern formation.
Dysregulation of apoptosis can result in inappropriate suppression of cell
death,
15 as occurs in the development of some cancers, or in failure to control the
extent of cell
death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA).
Alternatively, this gene product is involved in the pattern of cellular
proliferation
that accompanies early embryogenesis. Thus, aberrant expression of this gene
product in
20 tissues - particularly adult tissues - may correlate with patterns of
abnormal cellular
proliferation, such as found in various cancers. Because of potential roles in
proliferation
and differentiation, this gene product may have applications in the adult for
tissue
regeneration and the treatment of cancers. It may also act as a morphogen to
control cell
and tissue type specification. 'Cherefore, the polynucleotides and
polypeptides of the
25 present invention are useful in treating, detecting, and/or preventing said
disorders and
conditions, in addition to other types of degenerative conditions. Thus this
protein may
modulate apoptosis or tissue differentiation and is useful in the detection,
treatment,
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
41
and/or prevention of degenerative or proliferative conditions and diseases.
The protein is
useful in modulating the immune response tv aberrant polypeptides, as may
exist in
proliferating and cancerous cells and tissues. The protein can also be used to
gain new
insight into the regulation of cellular growth and proliferation. Furthermore,
the protein
may also be used to determine biological activity, to raise antibodies, as
tissue markers,
to isolate cognate ligands or receptors, to identify agents that modulate
their interactions,
in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy
targets for
the above listed tissues.
The translation product of this gene, sometimes referred to herein as TIDE
(for
Ten Integrin Domains with EGF homology), shares sequence homology with
integrins,
which are a superfamily of dirneric ab cell-surface glycoproteins that mediate
the
adhesive functions of many cell types, enabling cells to interact with one
another and
with the extracellular matrix (See Genomics 56, 169-178 ( 1999); all
information and
references contained within this publication are hereby incorporated herein by
reference).
The gene encoding the disclosed cDNA is believed to reside on chromosome 13,
at locus 13q33. Accordingly, polynucleotides related to this invention are
useful as a
marker in linkage analysis for chromosome 13, generally, and particularly at
locus
13q33.
This gene is expressed primarily in synovial hypoxia tissue, osteoblast and
osteoclast, bone marrow stromal cells, and to a lesser extent in umbilical
vein, smooth
muscle, placenta, and fetal lung cDNA libraries. Therefore, polynucleotides
and
polypeptides of the invention are useful as reagents for differential
identification of the
tissues) or cell types) present in a biological sample and for diagnosis of
diseases and
conditions which include, but are not limited to, disorders of bone and
connective tissues,
immune and hematopoietic diseases and/or disorders, vascular disorders, and
other
disorders involving aberrations in cell-surface interactions. Similarly,
polypeptides and
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
42
antibodies directed to these polypeptides are useful in providing
irnmunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders of
the above tissues or cells, particularly of the connective tissue and skeletal
system,
expression of this gene at significantly higher or lower levels is routinely
detected in
certain tissues or cell types (e.g. cartilage, bone, vascular, hypoxic tissue,
and cancerous
and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,
synovial fluid
and spinal fluid) or another tissue or cell sample taken from an individual
having such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 30 as residues: Met-1 to Phe-6, Arg 44 to Arg-52, His-64
to Cys-
69, Tyr-99 to Gln-147, His-158 to Gly-169, Phe-177 to Asp-182, Cys-194 to Cys-
202,
Gly-213 to Phe-218, Pro-224 to Gly-236, Asp-254 to Trp-261, Asp-263 to Ala-
303, Trp-
305 to Cys-316, Lys-326 to Asp-332, Pro-334 to Cys-343, Pro-350 to Asp-370,
Thr-407
to Asn-413, Gly-425 to Cys-431, Asp-449 to Asp-459, Gly-472 to Asn-483.
Polynucleotides encoding said polypeptides are also provided.
The tissue distribution and homology to the human integrin beta-8 subunit
indicates polynucleotides and polypeptides corresponding to this gene are
useful for the
diagnosis and treatment of a variety of immune system disorders.
Representative uses are
described in the "Immune Activity" and "infectious disease" sections below, in
Example
11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein.
Briefly, the expression indicates a role in regulating the proliferation;
survival;
differentiation; and/or activation of hematopoietic cell lineages, including
blood stem
cells. Involvement in the regulation of cytokine production, antigen
presentation, or other
processes indicates a usefulness for treatment of cancer (e.g. by boosting
immune
responses). Expression in cells of lymphoid origin, indicates the natural gene
product is
involved in immune functions. Therefore it would also be useful as an agent
for
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99I25031
43
immunological disorders including arthritis, asthma, immunodeficiency diseases
such as
AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel
disease, sepsis, acne, neutropenia, neutrophilia, psoriasis,
hypersensitivities, such as T-
cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as
_5 host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as
autoimmune infertility, Tense tissue injury, demyelination, systemic lupus
erythematosis,
drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and
scleroderma. Moreover, the protein may represent a secreted factor that
influences the
differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to
sites of injury. Thus, this gene product is thought to be useful in the
expansion of stem
cells and committed progenitors of various blood lineages, and in the
differentiation
and/or proliferation of various cell types. Based upon the tissue distribution
of this
protein, antagonists directed against this protein is useful in blocking the
activity of this
protein. Accordingly, preferred are antibodies which specifically bind a
portion of the
translation product of this gene.
Also provided is a kit for detecting tumors in which expression of this
protein
occurs. Such a kit comprises in one embodiment an antibody specific for the
translation
product of this gene bound to a solid support. Also provided is a method of
detecting
these tumors in an individual which comprises a step of contacting an antibody
specific
for the translation product of this gene to a bodily fluid from the
individual, preferably
serum, and ascertaining whether antibody binds to an antigen found in the
bodily fluid.
Preferably the antibody is bound to a solid support and the bodily fluid is
serum. The
above embodiments, as well as other treatments and diagnostic tests (kits and
methods),
are more particularly described elsewhere herein.
Furthermore, the protein may also be used to determine biological activity,
raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents
that modulate their interactions, in addition to its use as a nutritional
supplement. Protein,
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/U899/25031
44
as well as, antibodies directed against the protein may show utility as a
tumor marker
and/or irnmunotherapy targets for the above listed tissues.
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID N0:12 and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 2485 of SEQ ID N0:12, b is an integer
of 15 to
2499, where both a and b correspond to the positions of nucleotide residues
shown in
SEQ ID N0:12, and where b is greater than or equal to a + 14.
FEATURES OF PROTEIN ENCODED BY GENE NO: 3
The translation product of this gene shares sequence homology with RAMP3
(receptor-activity-modifying proteins), which another group has recently
published,
which is thought to be important in the transport of the calcitonin-receptor-
like receptor
(CRLR) to the plasma membrane. RAMPS regulate the transport and ligand
specificity of
the calcitonin-receptor-like-receptor. There are two other related receptor-
activity-
modifying proteins, known as RAMP1 and RAMP2 (Nature 1998 May
28;393(6683):333-9). RAMP1 is thought to present the receptor at the cell
surface as a
mature glycoprotein and a Calcitonin-gene-related peptide (CGRP) receptor.
Alternatively, RAMP2-transported receptors are core-glycosylated and are
adrenomedullin receptors. CGRP (a 37-amino-acid neuropeptide) and its
receptors are
widely distributed in the body, and it is the most potent endogenous
vasodilatory peptide
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
4S
discovered so far (Crit Rev Neurobiol 1997;11(2-3):167-239). Specific binding
sites for
adrenomedullin were present in every region of human brain (cerebral cortex,
cerebellum, thalamus, hypothalamus, pons and medulla oblongata), suggesting
that a
novel neurotransmitter/neuromodulator role may exist for adrenomedullin in
human
brain (Peptides 1997;18(8):1125-9).
Figures 7A-B show the nucleotide (SEQ ID N0:13) and deduced amino acid
sequence (SEQ ID N0:31 ) of the Intestine derived extraceilular protein.
Predicted amino
acids from about 1 to about 27 constitute the predicted signal peptide (amino
acid
residues from about 1 to about 27 in SEQ ID N0:31 ) and are represented by the
underlined amino acid regions; and amino acids from about 122 to about 138
constitute
the predicted transmembrane domain (amino acid residues from about 122 to
about 138
in SEQ ID N0:31) and are represented by the double-underlined amino acids.
Figure 8 shows the regions of similarity between the amino acid sequences of
the
Intestine derived extracellular protein SEQ ID N0:31, and the RAMP3 protein
(gi~4587099) (SEQ ID NO: 75).
Figure 9 shows an analysis of the amino acid sequence of SEQ ID NO: 31.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic regions; flexible regions; antigenic index and surface probability
are shown.
Northern analysis indicates that a l.4kb transcript of this gene is primarily
expressed in small intestine tissue, and to a lesser extent in colon and
prostate tissue.
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the polypeptide having the amino acid sequence shown
in
Figure 1 (SEQ ID N0:3I), which was determined by sequencing a cloned cDNA
(HTLEW81). The nucleotide sequence shown in Figures 7A-B (SEQ ID N0:13) was
2_5 obtained by sequencing a cloned cDNA (HTLEW81), which was deposited on
Nov. 17,
1998 at the American Type Culture Collection, and given Accession Number
203484.
The deposited gene is inserted in the pSport plasmid (Life Technologies,
Rockville, MD)
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99I25031
46
using the SaII/NotI restriction endonuclease cleavage sites. The present
invention is
further directed to fragments of the isolated nucleic acid molecules described
herein. By
a fragment of an isolated DNA molecule having the nucleotide sequence of the
deposited
cDNA or the nucleotide sequence shown in SEQ ID N0:13 is intended DNA
fragments
S at least about lSnt, and more preferably at least about 20 nt, still more
preferably at least
about 30 nt, and even more preferably, at least about 40 nt in length which
are useful as
diagnostic probes and primers as discussed herein. Of course, larger fragments
SO-1500
nt in length are also useful according to the present invention, as are
fragments
cowesponding to most, if not all. of the nucleotide sequence of the deposited
cDNA or as
shown in SEQ ID N0:13. By a fragment at least 20 nt in length, for example, is
intended
fragments which include 20 or more contiguous bases from the nucleotide
sequence of
the deposited cDNA or the nucleotide sequence as shown in SEQ ID N0:13. In
this
context "about" includes the particularly recited size, larger or smaller- by
several (S, 4, 3,
2, or 1) nucleotides, at either terminus or at both termini. Representative
examples of
1 S polynucleotide fragments of the invention include, for example, fragments
that comprise,
or alternatively, consist of, a sequence from about nucleotide 1 to about 50,
from about
S1 to about 100, from about 101 to about 150, from about 1S1 to about 200,
from about
201 to about 250, from about 251 to about 300, from about 301 to about 350,
from about
3S 1 to about 400, from about 401 to about 450, from about 451 to about 500,
and from
about SO 1 to about _550, and from about SS 1 to about 600, from about 601 to
about 650,
from about 651 to about 700, from about 701 to about 750, from about 7S 1 to
about 800,
from about 801 to about 850, from about 8S 1 to about 900, from about 901 to
about 950,
from about 951 to about i 000, from about 1001 to about 1050, from about l OS
1 to about
1100, from about 11 O 1 to about 11 S0, from about 11 S 1 to about 1200, from
about 1201
2S to about 1250, from about 12S 1 to about 1300, from about 1301 to about
1339 of SEQ
ID N0:13, or the complementary strand thereto, or the cDNA contained in the
deposited
gene. In this context "about" includes the particularly recited ranges, larger
or smaller by
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
47
several (5, 4, 3, 2, or 1 ) nucleotides, at either terminus or at both
termini. In additional
embodiments, the polynucleotides of the invention encode functional attributes
of the
corresponding protein.
Preferred embodiments of the invention in this regard include fragments that
_5 comprise alpha-helix and alpha-helix forming regions {"alpha-regions"),
beta-sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions. The data
representing
the structural or functional attributes of the protein set forth in Figure 9
and/or Table lIl,
as described above, was generated using the various modules and algorithms of
the
DNA''STAR set on default parameters. In a preferred embodiment, the data
presented in
columns VIII, IX, XIII, and XIV of Table IIII can be used to determine regions
of the
protein which exhibit a high degree of potential for antigenicity. Regions of
high
antigenicity are determined from the data presented in columns VIII, IX, XIII,
and/or
XIV by choosing values which represent regions of the polypeptide which are
likely to
be exposed on the surface of the polypeptide in an environment in which
antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 9, but may,
as
shown in Table III, be represented or identified by using tabular
representations of the
data presented in Figure 9. The DNA*STAR computer algorithm used to generate
Figure
9 (set on the original default parameters) was used to present the data in
Figure 9 in a
tabular format (See Table III). The tabular format of the data in Figure 9 is
used to easily
determine specific boundaries of a preferred region. The above-mentioned
preferred
2_5 regions set out in Figure 9 and in Table III include, but are not limited
to, regions of the
aforementioned types identified by analysis of the amino acid sequence set out
in Figures
7A-B. As set out in Figure 9 and in Table III, such preferred regions include
Garnier-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
48
Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-
Fasman alpha-
regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions
and Hopp-
Woods hydrophobic regions, Eisenberg alpha- and beta-amphipathic regions,
Karplus-
Schulz flexible regions, Jameson-Wolf regions of high antigenic index and
Emini
surface-forming regions. Even if deletion of one or more amino acids from the
N-
terminus of a protein results in modification of loss of one or more
biological functions
of the protein, other functional activities (e.g., biological activities,
ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened muteins to
induce and/or bind to antibodies which recognize the complete or mature forms
of the
polypeptides generally will be retained when less than the majority of the
residues of the
complete or mature polypeptide are removed from the N-terminus. Whether a
particular
polypeptide lacking N-terminal residues of a complete polypeptide retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the amino acid sequence shown
in
Figures 7A-B, up to the arginine residue at position number 143 and
polynucleotides
encoding such polypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-148 of Figures 7A-B, where
nl is an
integer from 2 to 143 corresponding to the position of the amino acid residue
in Figures
7A-B (which is identical to the sequence shown as SEQ ID N0:31). N-terminal
deletions
of the polypeptide of the invention shown as SEQ ID N0:31 include polypeptides
comprising the amino acid sequence of residues: E-2 to L-148; T-3 to L-148; G-
4 toL-
148; A-5 to L-148; L-6 to L-148; R-7 to L-148; R-8 to L-148;P-9 to L-148; Q-10
to L-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00129435 PCT/US99/25031
49
148; L-11 to L-148; L-12 to L-148; P-l3to L-I48; L-14 to L-148; L-1S to L-148;
L-16 to
L-148; L-17 toL-148; L-18 to L-148; C-19 to L-148; G-20 to L-148; G-21 toL-
148; C-22
to L-148; P-23 to L-148; R-24 to L-148; A-25 toL-I48; G-26 to L-148; G-27 to L-
148;
C-28 to L-148; N-29 toL-148; E-30 to L-148; T-31 to L-148; G-32 to L-148; M-33
toL-
148; L-34 to L-148; E-35 to L-148; R-36 to L-148; L-37 toL-148; P-38 to L-148;
L-39 to
L-148; C-40 to L-148; G-41 toL-148; K-42 to L-148; A-43 to L-148; F-44 to L-
148; A-
4_5 toL-148; D-46 to L-148; M-47 to L-148; M-48 to L-148; G-49 toL-148; K-50
to L-
148; V-51 to L-148; D-52 to l.-148; V-53 toL-148; W-54 to L-148; K-55 to L-
148; W-SG
to L-148; C-57 toL-148; N-58 to L-148; L-59 to L-I48; S-60 to L-I48; E-61 toL-
148; F-
62 to L-148; I-63 to L-148; V-64 to L-148; Y-65 toL-148; Y-66 to L-148; E-67
to L-148;
S-68 to L-148; F-69 toL-148; 'T-70 to L-148; N-71 to L-148; C-72 to L-148; T-
73 toL-
148; E-74 to L-148; M-75 to L-I48; E-76 to L-148; A-77 toL-148; N-78 to L-148;
V-79
to L-148; V-80 to L-148; G-81 toL-148; C-82 to L-148; Y-83 to L-148; W-84 to L-
148;
P-85 toL-148; N-86 to L-148; P-87 to L-148; L-88 to L-148; A-89 toL-148; Q-90
to L-
I48; G-91 to L-148; F-92 to L-148; I-93 toL-148; T-94 to L-148; G-95 to L-148;
I-96 to
L-148; H-97 toL-148; R-98 to L-148; Q-99 to L-148; F-100 to L-148; F-101 toL-
148; S-
102 to L-148; N-103 to L-148; C-104 to L-I48; T-10_5 toL-148; V-106 to L-148;
D-107
to L-148; R-108 to L-148; V-109 toL-148; H-110 to L-148; L-111 to L-148; E-112
to L-
148; D-1 I3 toL-148; P-114 to L-148; P-115 to L-148; D-I 16 to L-148; E-117
toL-148;
V-118 to L-148; L-119 to L-148; I-120 to L-148; P-121 toL-148; L-122 to L-148;
I-123
to L-148; V-124 to L-148; I-125 toL-148; P-126 to L-148; V-127 to L-148; V-128
to L-
148; L-129 toL-148; T-130 to L-148; V-131 to L-148; A-132 to L-148; M-133 toL-
148;
A-134 to L-148; G-135 to L-148; L-136 to L-148; V-137 toL-148; V-138 to L-148;
W-
139 to L-148; R-140 to L-148; S-141 toL-148; K-142 to L-148; R-143 to L-148;
of SEQ
ID N0:31. Polypeptides encoded by these polynucleotides are also encompassed
by the
invention.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities (e.g., ability
to illicit mitogenic activity, induce differentiation of normal or malignant
cells, bind to
5' EGF receptors, etc.)), may still be retained. For example the ability to
induce and/or bind
to antibodies which recognize the complete or mature. forms of the polypeptide
general ly
will be retained when less than the majority of the residues of the complete
or mature
polypeptide are removed from the C-terminus. Whether a particular polypeptide
lacking
C-terminal residues of a complete polypeptide retains such immunologic
activities can
10 readily be determined by routine methods described herein and otherwise
known in the
art. It is not unlikely that a mutein with a large number of deleted C-
terminal amino acid
residues may retain some biological or immunogenic activities. In fact,
peptides
composed of as few as six amino acid residues may often evoke an immune
response.
Accordingly, the present invention further provides poiypeptides having one or
15 more residues deleted from the carboxy terminus of the amino acid sequence
of the
polypeptide shown in Figures 7A-B, up to the arginine residue at position
number 7, and
polynucleotides encoding such polypeptides. In particular, the present
invention provides
polypeptides comprising the amino acid sequence of residues 1-ml of Figures 7A-
B,
where m1 is an integer from 7 to I47 corresponding to the position of the
amino acid
20 residue in Figures 7A-B. Moreover, the invention provides polynucleotides
encoding
polypeptides comprising, or alternatively consisting of, the amino acid
sequence of C-
terminal deletions of the polypeptide of the invention shown as SEQ ID N0:31
include
polypeptides comprising the amino acid sequence of residues: M-1 to L-147; M-1
to T-
146;M-I to D-145; M-1 to T-144; M-I to R-143; M-1 to K-142; M-1 toS-141; M-1
to R-
25 140; M-1 to W-139; M-1 to V-138; M-1 to V-137;M-1 to L-136; M-I to G-I35; M-
1 to
A-134; M-1 to M-133; M-1 toA-132; M-1 to V-131; M-1 to T-130; M-1 to L-129; M-
I
to V-128;M-1 to V-127; M-1 to P-126; M-1 to I-125; M-1 to V-124; M-1 toI-123;
M-1 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PGT/US99/x5031
51
L-122; M-1 to P-121; M-1 to I-120; M-1 to L-119;M-1 to V-118; M-1 to E-117; M-
1 to
D-116; M-1 to P-115; M-1 toP-114; M-1 to D-113; M-1 to E-112; M-1 to L-111; M-
1 to
H-110;M-1 to V-109; M-1 to R-108; M-1 to D-107; M-1 to V-106; M-1 toT-105; M-1
to
C-104; M-1 to N-103; M-1 to S-102; M-1 to F-lOI;M-1 to F-100; M-1 to Q-99; M-1
to
R-98; M-1 to H-97; M-1 toI-96; M-1 to G-95; M-1 to T-94; M-1 to I-93; M-1 to F-
92;
M-1 toG-91; M-1 to Q-90; M-1 to A-89; M-1 to L-88; M-1 to P-87; M-lto N-86; M-
1 to
P-8.5; M-1 to W-84; M-1 to Y-83; M-1 to C-82;M-1 to G-81; M-1 to V-80; M-1 to
V-79;
M-1 to N-78; M-1 toA-?7; M-1 to E-76; M-1 to M-75; M-1 to E-74; M-1 to T-73; M-
lto
C-72; M-1 to N-71; M-1 to T-70; M-1 to F-69; M-1 to S-68;M-1 to E-67; M-1 to Y-
66;
M-1 to Y-65; M-1 to V-64; M-1 to I-63;M-1 to F-62; M-1 to E-61; M-1 to S-60: M-
1 to
L-S9; M-1 to N-58; M-1 to C-S7; M-1 to W-56; M-1 to K-_55; M-1 to W-54; M-1
toV-
53; M-1 to D-52; M-1 to V-51; M-1 to K-50; M-1 to G-49; M-lto M-48; M-1 to M-
47:
M-I to D-46; M-1 to A-45; M-1 to F-44;M-1 to A-43; M-1 to K-42; M-1 to G-41; M-
l to
C-40; M-1 toL-39; M-1 to P-38; M-I to L-37; M-1 to R-36; M-1 to E-35; M-1 toL-
34;
M-1 to M-33; M-1 to G-32; M-1 to T-31; M-1 to E-30; M-lto N-29; M-1 to C-28; M-
1
to G-27; M-1 to G-26; M-1 to A-25;M-1 to R-24; M-1 to P-23; M-1 to C-22; M-1
to G-
21; M-1 toG-20; M-1 to C-19; M-1 to L-18; M-1 to L-17; M-1 to L-16; M-lto L-
15; M-1
to L-14; M-1 to P-13; M-1 to L-12; M-1 to L-11; M-lto Q-10; M-1 to P-9; M-1 to
R-8;
M-1 to R-7; of SEQ ID N0:31. Polypeptides encoded by these polynucleotides are
also
encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:31 which have been
determined
from the following related cDNA genes: HLHCH17RA (SEQ ID N0:76), HTOATS1R
(SEQ ID N0:77), and/or HBNB041R (SEQ ID N0:78).
The polypeptide of this gene has been determined to have a transmembrane
domain at about amino acid position 122 - 138 of the amino acid sequence
referenced in
Table XIII for this gene. Moreover, a cytoplasmic tail encompassing amino
acids 139 to
SUBSTTTUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
52
149 of this protein has also been determined. Based upon these
characteristics, it is
believed that the protein product of this gene shares structural features to
type Ia
membrane proteins.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, gastrointestinal and neurodeaenerative diseases and disorders.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the central
nervous and
gastrointestinal systems, expression of this gene at significantly higher or
lower levels is
routinely detected in certain tissues or cell types (e.g. brain, CNS,
gastrointestinal,
cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma,
urine,
synovial fluid and spinal fluid) or another tissue or cell sample taken from
an individual
IS having such a disorder, relative to the standard gene expression level,
i.e., the expression
level in healthy tissue or bodily fluid from an individual not having the
disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 31 as residues: Ala-5 to Gln-10, Pro-23 to Cys-28, Arg-140
to
Asp-145. Polynucleotides encoding said polypeptides are also provided.
The tissue distribution and homology to RAMP3 suggest that the translation
product of this gene is useful for the detection/treatment of
neurodegenerative disease
states and behavioural disorders such as Alzheimer's Disease, Parkinson's
Disease,
Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia,
paranoia,
obsessive compulsive disorder, panic disorder, learning disabilities, ALS,
psychoses,
autism, and altered behaviors, including disorders in feeding, sleep patterns,
balance, and
perception. In addition, the gene or gene product may also play a role in the
treatment
and/or detection of developmental disorders associated with the developing
embryo.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
53
Alternatively, the tissue distribution in small intestine and colon tissues
indicates
that polynucieotides and polypeptides corresponding to this gene are useful
for the
diagnosis and/or treatment of disorders involving the small intestine. This
may include
diseases associated with digestion and food absorption, as well as
hematopoietic
disorders involving the Peyer's patches of the small intestine, or other
hematopoietic cells
and tissues within the body. Similarly, expression of this gene product in
colon tissue
indicates again involvement in digestion, processing, and elimination of food,
as well as
a potential role for this gene as a diagnostic marker or causative agent in
the development
of colon cancer, and cancer in general. Protein, as well as, antibodies
directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for
the above
listed tissues.
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID N0:13 and may have been publicly available prior to conception of the
present
1S invention. Preferably, such related polynucleotides are specifically
excluded from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 1325 of SEQ ID NO:13> b is an integer
of IS to
1339, where both a and b correspond to the positions of nucleotide residues
shown in
SEQ ID N0:13, and where b is greater than or equal to a + 14.
FEATURES OF PROTEIN ENCODED BY GENE NO: 4
The translation product of this gene shares sequence homology with a
proteoglycan from Gallus gallus, and this proteoglycan is believed to
participate in the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
_54
osteogenic processes of cartilage ossification (See Genbank Accession No.
gi~222847).
Based on the sequence similarity. The translation product of this gene is
expected to
share biological activities with the Gallus gallus proteoglycan polypeptide.
Figures l0A-B shows the nucleotide (SEQ ID N0:14) and deduced amino acid
sequence (SEQ ID N0:32) of the retinal specific protein. Predicted amino acids
from
about I to about 21 constitute the predicted signal peptide (amino acid
residues from
about 1 to about 21 in SEQ ID N0:32) and are represented by the underlined
amino acid
regions.
Figure I 1 shows the regions of similarity between the amino acid sequences of
the retinal specific protein SEQ ID N0:32, and the Gallus gallus proteoglycan
(SEQ ID
N0:79).
Figure 12 shows an analysis of the amino acid sequence of SEQ ID NO: 32.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic regions; flexible regions; antigenic index and surface probability
are shown.
Northern analysis indicates that this gene is expressed in adrenal cortex and
adrenal medulla tissues. This gene is also expressed in retinal tissue.
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the polypeptide having the amino acid sequence shown
in
Figures l0A-B (SEQ ID N0:32), which was determined by sequencing a cloned cDNA
(HARA044). The nucleotide sequence shown in Figures IOA-B (SEQ ID N0:14) was
obtained by sequencing a cloned cDNA (HARA044), which was deposited on Nov.
17,
1998 at the American Type Culture Collection, and given Accession Number
203484.
The deposited gene is inserted in the pSport plasmid (Life Technologies,
Rockville, MD)
using the SaII/NotI restriction endonuclease cleavage sites.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited eDNA or the nucleotide sequence shown in
SEQ ID
SUBSTITUTE SHEET (RULE 2b)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
N0:14 is intended DNA fragments at least about l5nt, and more preferably at
least about
20 nt, still more preferably at least about 30 nt, and even more preferably,
at least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
course, larger fragments SO-1500 nt in length are also useful according to the
present
5 invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:14. By a fragment at least 20
nt in
length, for example, is intended fragments which include. 20 or more
contiguous bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
shown in SEQ ID N0;14. In this context "about" includes the particularly
recited size,
10 larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either
terminus or at both
termini.
Representative examples of polynucleotide fragments of the invention include,
for example, fragments that comprise, or alternatively, cansist of, a sequence
from about
nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about
150> from
1 _5 about 151 to about 200, from about 201 to about 250, from about 251 to
about 300, from
about 301 to about 350, from about 351 to about 400, from about 401 to about
450, from
about 451 to about 500, and from about 501 to about 550, and from about 551 to
about
600, from about 601 to about 650, from about 651 to about 700, from about 701
to about
750, from about 7S 1 to about 800, from about 801 to about 850, from about 851
to about
20 900, from about 901 to about 950, from about 9S 1 to about 1000, from about
1001 to
about 1050, from about 1051 to about 1100, from about .l 101 to about 1150,
from about
11 S 1 to about 1200, from about 1201 to about 1250, from about 1251 to about
1300,
from about 1301 to about 1350, from about 1351 to about 1389, and from about
187 to
about 1119 of SEQ ID N0:14, or the complementary strand thereto, or the cDNA
25 contained in the deposited gene. In this context "about" includes the
particularly recited
ranges, larger or smaller by several (5, 4, 3, 2, or 1 ) nucleotides, at
either terminus or at
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
SG
both termini. In additional embodiments, the polynucleotides of the invention
encode
functional attributes of the corresponding protein.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
_5 beta-sheet forming regions ("beta-regions"), turn and tum-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions. The data
representing
the structural or functional attributes of the protein set forth in Figure 12
and/or Table IV,
as described above, was generated using the various modules and algorithms of
the
DNA=~STAR set on default parameters. In a prefewed embodiment, the data
presented in
columns VIII, IX, XIII, and XIV of Table IV can be used to determine regions
of the
protein which exhibit a high degree of potential for antigenicity. Regions of
high
antigenicity are deternnined from the data presented in columns VIII, IX,
XIII, and/or
XIV by choosing values which represent regions of the polypeptide which are
likely to
be exposed on the surface of the polypeptide in an environment in which
antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 12, but may,
as
shown in Table IV, be represented or identified by using tabular
representations of the
data presented in Figure 12. The DNA*STAR computer algorithm used to generate
Figure 12 (set on the original default parameters) was used to present the
data in Figure
12 in a tabular format (See Table IV). The tabular format of the data in
Figure 12 is used
to easily determine specific boundaries of a preferred region. The above-
mentioned
preferred regions set out in Figure 12 and in Table IV include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figures l0A-B. As set out in Figure 12 and in Table IV, such preferred
regions
include Gamier-Robson alpha-regions, beta-regions, turn-regions, and coil-
regions,
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
S7
Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic
regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-
amphipathic
regions, Karplus-Schulz flexible regions, Jameson-Wolf regions of high
antigenic index
and Emini surface-forming regions. Even if deletion of one or more amino acids
from the
N-terminus of a protein results in modification of loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities, ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened muteins to
induce and/or bind to antibodies which recognize the complete or mature forms
of the
polypeptides generally will be retained when less than the majority of the
residues of the
complete or mature poiypeptide are removed from the N-terminus. Whether a
particular
polypeptide lacking N-terminal residues of a complete polypeptide retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the amino acid sequence shown
in
Figures l0A-B, up to the proline residue at position number 327 and
polynucleotides
encoding such polypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-332 of Figures l0A-B, where
nl is an
integer from 2 to 327 corresponding to the position of the amino acid residue
in Figures
l0A-B (which is identical to the sequence shown as SEQ ID N0:32). N-terminal
deletions of the polypeptide of the invention shown as SEQ ID N0:32 include
polypeptides comprising the amino acid sequence of residues: R-2 to T-332; L-3
to T-
332; L-4 to T-332; A-5 to T-332;F-6 to T-332; L-7 to T-332; S-8 to T-332; L-9
to T-332;
L-10 to T-332; A-11 to T-332; L-12 to T-332; V-13 to T-332;L-14 to T-332; Q-15
to T-
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
58
332; E-16 to T-332; T-17 to T-332; G-18 to T-332; T-19 to T-332; A-20 to T-
332; S-21
toT-332; L-22 to T-332; P-23 to T-332; R-24 to T-332; K-25 to T-332; E-26 to T-
332; R-
27 to T-332; K-28 to T-332;8-29 to T-332; R-30 to T-332; E-31 to T-332; E-32
to T-
332; Q-33 to T-332; M-34 to T-332; P-35 to T-332; R-36 toT-332; E-37 to T-332;
G-38
to T-332; D-39 to T-332; S-40 to T-332; F-41 to T-332; E-42 to T-332; V-43 to
T-332;L-
44 to T-332: P-45 to T-332; L-46 to T-332; R-47 to T-332; N-48 to T-332; D-49
to T-
332; V-50 to T-332; L-51 toT-332; N-52 to T-332; P-53 to T-332; D-54 to T-332;
N-55
to T-332; Y-56 to T-332; G-57 to T-332; E-58 to T-332;V-59 to T-332; I-60 to T-
332; D-
61 to T-332; L-62 to T-332; S-63 to T-332; N-64 to T-332; Y-65 to T-332; E-66
toT-
332; E-67 to T-332; L-68 to T-332; T-69 to T-332; D-70 to T-332; Y-71 to T-
332; G-72
to T-332; D-73 to T-332;Q-74 to T-332; L-75 to T-332; P-76 to T-332; E-77 to T-
332;
V-78 to T-332; K-79 to T-332; V-80 to T-332; T-81 toT-332: S-82 to T-332; L-83
to T-
332; A-84 to T-332; P-85 to T-332; A-86 to T-332; T-87 to T-332; S-88 to T-
332;I-89 to
T-332; S-90 to T-332; P-91 to T-332; A-92 to T-332; K-93 to T-332; S-94 to T-
332; T-
95 to T-332; T-96 toT-332; A-97 to T-332; P-98 to T-332; G-99 to T-332; T-100
to T-
332; P-101 to T-332; S-102 to T-332; S-103 toT-332; N-104 to T-332; P-105 to T-
332;
T-106 to T-332; M-107 to T-332; T-108 to T-332; R-109 to T-332; P-110 toT-332;
T-
111 to T-332; T-112 to T-332; A-113 to T-332; G-114 to T-332; L-115 to T-332;
L-I 16
to T-332; L-117 toT-332; S-118 to T-332; S-119 to T-332; Q-120 to T-332; P-121
to T-
332; N-122 to T-332; H-123 to T-332; G-124 toT-332; L-125 to T-332; P-126 to T-
332;
T-127 to T-332; C-128 to T-332; L-129 to T-332; V-130 to T-332; C-131 toT-332;
V-
132 to T-332; C-133 to T-332; L-134 to T-332; G-135 to T-332; S-136 to T-332;
S-137
to T-332; V-138 toT-332; Y-139 to T-332; C-140 to T-332; D-141 to T-332; D-I42
to T-
332; I-143 to T-332; D-144 to T-332; L-145 toT-332; E-146 to T-332; D-147 to T-
332;
I-148 to T-332; P-149 to T-332; P-150 to T-332; L-151 to'T-332; P-152 toT-332;
R-153
to T-332; R-154 to T-332; T-155 to T-332; A-156 to T-332; Y-157 to T-332; L-
158 to T-
332; Y-159 toT-332; A-160 to T-332; R-161 to T-332; F-162 to T-332; N-163 to T-
332;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
59
R-164 to T-332; I-165 to T-332; S-166 toT-332; R-167 to T-332; I-168 to T-332;
R-169
to T-332; A-170 to T-332; E-171 to T-332; D-172 to T-332; F-173 toT-332; K-174
to T-
332; G-175 to T-332; L-176 to T-332; T-177 to T-332; K-178 to T-332; L-179 to
T-332;
K-180 toT-332; R-181 to T-332; I-182 to T-332; D-183 to T-332; L-184 to T-332;
S-185
to T-332; N-186 to T-332; N-187 toT-332; L-188 to T-332; I-189 to T-332; S-190
to T-
332; S-191 to T-332; I-192 to T-332; D-193 to T-332; N-.194 toT-332; D-195 to
T-332;
A-196 to T-332; F-197 to T-332; R-198 to T-332; L-199 to T-332; L-200 to T-
332; H-
201 toT-332; A-202 to T-332; L-203 to T-332; Q-204 to T-332; D-205 to T-332; L-
206
to T-332; I-207 to T-332; L-208 toT-332; P-209 to T-332; E-210 to T-332; N-211
to T-
332; Q-2I2 to T-332;1_-213 to T-332; E-214 to T-332; A-215 toT-332; L-216 to T-
332;
P-217 to T-332; V-218 to T-332; L-219 to T-332; P-220 to T-332; S-221 to T-
332: G-
222 toT-332; I-223 to T-332; E-224 to T-332; F-225 to T-332; L-226 to T-332; D-
227 to
T-332; V-228 to T-332; R-229 toT-332; L-230 to T-332; N-231 to T-332; R-232 to
T-
332; L-233 to T-332; Q-234 to T-332; S-235 to T-332; S-236 toT-332; G-237 to T-
332;
1.5 I-238 to T-332; Q-239 to T-33'Z; P-240 to T-332; A-241 to T-332; A-242 to
T-332; F-
243 toT-332; R-244 to T-332; A-245 to T-332: M-246 to 'T-332; E-247 to T-332;
K-248
to T-332; L-249 to T-332; Q-250 toT-332; F-251 to T-332; L-252 to T-332; Y-253
to T-
332; L-254 to T-332; S-255 to T-332; D-256 to T-332; N-257 toT-332; L-258 to T-
332;
L-259 to T-332; D-260 to T-332; S-261 to T-332; I-262 to T-332; P-263 to T-
332; G-264
toT-332; P-265 to T-332; L-266 to T-332; P-267 to T-332; P-268 to T-332; S-269
to T-
332; L-270 to T-332; R-271 toT-332; S-272 to T-332; V-273 to T-332; H-274 to T-
332;
L-275 to T-332; Q-276 to T-332; N-277 to T-332; N-278 toT-332; L-279 to T-332;
I-280
to T-332; E-281 to T-332; T-282 to T-332; M-283 to T-332; Q-284 to T-332; R-
285 toT
332; D-286 to T-332; V-287 to T-332; F-288 to T-332; C-289 to T-332; D-290 to
T-332;
P-291 to T-332; E-292 toT-332; E-293 to T-332; H-294 to T-332; K-295 to T-332;
H
296 to T-332; T-297 to T-332; R-298 to T-332; R-299 toT-332; Q-300 to T-332; L-
301
to T-332; E-302 to T-332; D-303 to T-332; I-304 to T-332; R-305 to T-332; L-
306 toT-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
332; D-307 to T-332; G-308 to T-332; N-309 to T-332; P-310 to T-332; I-311 to
T-332;
N-3I2 to T-332; L-313 toT-332; S-314 to T-332; L-315 to T-332; F-316 to T-332;
P-317
to T-332; S-318 to T-332; A-319 to T-332; Y-320 toT-332; F-321 to T-332; C-322
to T-
332; L-323 to T-332; P-324 to T-332; R-325 to T-332; L-326 to T-332; P-327 toT-
332;
5 of SEQ ID N0:32. Polypeptides encoded by these polynucleotides are also
encompassed
by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities (e.g., ability
10 to illicit mitogenic activity, induce differentiation of normal or
malignant cells, bind to
EGF receptors, etc.)), may still be retained. For example the ability to
induce and/or bind
to antibodies which recognize the complete or mature forms of the polypeptide
generally
will be retained when less than the majority of the residues of the complete
or mature
polypeptide are removed from the C-terminus. Whether a particular polypeptide
lacking
15 C-terminal residues of a complete polypeptide retains such immunologic
activities can
readily be determined by routine methods described herein and otherwise known
in the
art. It is not unlikely that a mutein with a large number of deleted C-
terminal amino acid
residues may retain some biological or immunogenic activities. In fact,
peptides
composed of as few as six amino acid residues may often evoke an immune
response.
20 Accordingly, the present invention further provides polypeptides having one
or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
polypeptide shown in Figures l0A-B, up to the glutamine residue at position
number 7,
and polynucleotides encoding such polypeptides. In particular, the present
invention
provides polypeptides comprising the amino acid sequence of residues 1-ml of
Figures
25 l0A-B, where ml is an integer from 7 to 331 corresponding to the position
of the amino
acid residue in Figures l0A-B. Moreover, the invention provides
polynucleotides
encoding polypeptides comprising, or alternatively consisting of, the amino
acid
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
61
sequence of C-terminal deletions of the polypeptide of the invention shown as
SEQ ID
N0:32 include polypeptides comprising the amino acid sequence of residues: M-1
to F-
331; M-1 to R-330; M-1 to G-329; M-1 to I-328; M-1 to P-327; M-1 to L-326; M-1
to 8-
325; M-1 to P-324; M-1 to L-323; M-1 to C-322; M-1 to F-321; M-lto Y-320; M-1
to A-
319; M-I to S-318; M-1 to P-317; M-I to F-316; M-1 to L-315; M-1 to S-314; M-1
to L-
313; M-lto N-312; M-1 to I-31 l; M-1 to P-310; M-I to N-309; M-1 to G-308; M-1
to D-
307; M-1 to L-306; M-1 to R-305; M-lto I-304; M-1 to D-303; M-1 to E-302; M-1
to L-
301; M-1 to Q-300; M-1 to R-299; M-1 to R-298; M-1 to T-297; M-lto H-296; M-1
to
K-295; M-1 to H-294; M-1 to E-293; M-1 to E-292; M-1 to P-291; M-1 to D-290; M-
1
to C-289; M-lto F-288; M-1 to V-287; M-1 to D-286; M-1 to R-285; M-1 to Q-284;
M-1
to M-283; M-1 to T-282; M-1 to E-281; M-lto I-280; M-1 to L-279; M-1 to N-278;
M-1
to N-277; M-1 to Q-276; M-I to L-27.5; M-I to H-274; M-1 to V-273; M-lto S-
272; M-1
to R-271; M-1 to L-270; M-1 to S-269; M- I to P-268; M-1 to P-267; M-1 to L-
266; M-1
to P-265; M-1 to G-264; M- I to P-263; M-1 to I-262; M-1 to S-261; M-1 to D-
260; M-1
to L-259; M-1 to L-258; M-1 to N-257; M-lto D-256; M-1 to S-255; M-1 to L-254;
M-1
to Y-253; M-1 to L-252; M-1 to F-251; M-1 to Q-250; M-1 to L-249; M-lto K-248;
M-I
to E-247; M-1 to M-246; M-1 to A-245; M-1 to R-244; M-1 to F-243; M-1 to A-
242; M-
1 to A-241;M-I to P-240; M-1 to Q-239; M-1 to 1-238; M-I to G-237; M-1 to S-
236; M-
1 to S-235; M-1 to Q-234; M-1 to L-233;M-1 to R-232; M-1 to N-231; M-1 to L-
230; M-
1 to R-229; M-1 to V-228; M-1 to D-227; M-1 to L-226; M-1 to F-225;M-1 to E-
224; M-
1 to I-223; M-1 to G-222; M-1 to S-221; M-1 to P-220; M-1 to L-219; M-1 to V-
218; M-
1 to P-217;M-1 to L-216; M-1 to A-215; M-1 to E-214; M-1 to L-213; M-1 to Q-
212; M-
1 to N-211; M-1 to E-210; M-1 to P-209;M-1 to L-208; M-1 to I-207; M-1 to L-
206; M-
1 to D-205; M-I to Q-204; M-1 to L-203; M-1 to A-202; M-1 to H-201;M-1 to L-
200;
M-1 to L-199; M-1 to R-198; M-1 to F-197; M-1 to A-196; M-1 to D-195; M-1 to N-
194; M-1 to D-193;M-I to I-192; M-I to S-191; M-1 to S-190; M-1 to I-189; M-I
to L-
188; M-I to N-187; M-I to N-186; M-1 to S-185;M-1 to L-184; M-I to D-183; M-1
to I-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
62
182; M-1 to R-181; M-1 to K-180; M-1 to L-179; M-1 to K-178; M-1 to T-177;M-1
to
L-176; M-1 to G-175; M-1 to K-174; M-1 to F-173; M-.1 to D-I72; M-1 to E-171;
M-1
to A-170; M-1 to R-169;M-1 to I-168; M-1 to R-167; M-1 to S-166; M-1 to I-165;
M-1
to R-164; M-1 to N-163; M-1 to F-162; M-1 to R-161;M-1 to A-160; M-1 to Y-159;
M-1
to L-158; M-1 to Y-157; M-1 to A-156; M-1 to T-155; M-1 to R-154; M-1 to R-
153;M-1
to P-152; M-I to L-151; M-1 to P-150; M-1 to P-149; M-1 to I-148; M-1 to D-
147; M-1
to E-146; M-1 to L-145;M-1 to D-144; M-1 to I-143; M-1 to D-142; M-1 to D-141:
M-1
to C-I40; M-1 to Y-139; M-1 to V-138; M-I to S-I37;M-I to S-136; M-1 to G-135;
M-1
to L-134; M-1 to C-133; M-I to V-132; M-1 to C-131; M-1 to V-130; M-1 to L-
129;M-I
to C-128; M-I to T-127; M-1 to P-126; M-1 to L-12.5; M-I to G-124; M-1 to H-
123: M-1
to N-122; M-1 to P-12I;M-1 to Q-120; M-1 to S-119; M-1 to S-118; M-1 to L-117:
M-1
to L-116; M-I to L-115; M-1 to G-114; M-1 to A-1 I3;M-1 to T-112; M-1 to T-
111; M-1
to P-110; M-1 to R-109; M-1 to T-108; M-1 to M-107; M-1 to T-106; M-1 to P-
105;M-1
to N-104; M-1 to S-I03; M-1 to S-102; M-1 to P-101; M-1 to T-100; M-1 to G-99:
M-1
I5 to P-98; M-1 to A-97;M-1 to T-96; M-1 to T-95; M-1 to S-94; M-1 to K-93; M-
1 to A-
92; M-1 to P-91; M-1 to S-90; M-1 to I-89; M-1 toS-88; M-1 to T-87; M-I to A-
86; M-1
to P-85; M-1 to A-84; M-1 to L-83; M-1 to S-82; M-I to T-81; M-1 to V-80; M-
lto K
79; M-1 to V-78; M-1 to E-77; M-1 to P-76; M-1 to L-75; M-1 to Q-74; M-1 to D-
73;
M-1 to G-72; M-1 to Y-71;M-1 to D-70; M-1 to T-69; M-1 to L-68; M-1 to E-67; M-
1 to
E-66; M-1 to Y-65; M-1 to N-64; M-1 to S-63; M-1 toL-62; M-1 to D-61; M-1 to I-
60;
M-1 to V-59; M-1 to E-58; M-1 to G-57; M-1 to Y-56; M-1 to N-55; M-1 to D-54;M-
I
to P-53; M-1 to N-52; M-1 to L-51; M-1 to V-50; M-1 to D-49; M-1 to N-48; M-I
to R-
47; M-1 to L-46; M-1 toP-45; M-1 to L-44; M-1 to V-43; M-1 to E-42; M-1 to F-
41; M-1
to S-40; M-1 to D-39; M-1 to G-38; M-1 to E-37; M-lto R-36; M-1 to P-35; M-1
to M-
34; M-1 to Q-33; M-1 to E-32; M-1 to E-31; M-1 to R-30; M-I to R-29; M-1 to K-
28;M-
1 to R-27; M-1 to E-26; M-I to K-25; M-1 to R-24; M-1 to P-23; M-I to L-22; M-
1 to S-
21; M-1 to A-20; M-1 toT-19; M-1 to G-18; M-1 to T-17; M-1 to E-16; M-1 to Q-
15; M-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
63
1 to L-14; M-1 to V-13; M-1 to L-12; M-1 to A-11;M-1 to L-10; M-1 to L-9; M-1
to S-8;
M-1 to L-7; of SEQ ID N0:32. Polypeptides encoded by these polynucleotides are
also
encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
S sequences related to extensive portions of SEQ ID N0:14 which have been
determined
from the following related cDNA genes: HARAY79R (SEQ ID N0:80), HARA044R
(SEQ ID N0:81), HARAJ74R (SEQ ID N0:82), HARA066R (SEQ ID N0:83),
HARAN 19R (SEQ ID N0:84), and HARAT78R (SEQ ID N0:85).
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, retinal disorders. Similarly, polypeptides and antibodies directed
to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the retina, expression of this gene at significantly higher or
lower levels is
routinely detected in certain tissues or cell types (e.g. retinal, cancerous
and wounded
tissues) or bodily fluids {e.g., lymph, serum, plasma, urine, synovial fluid
and spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 32 as residues: Leu-22 to Asp-39, Asn-64 to Pro-76, Pro-98
to
Thr-111, Pro-291 to Glu-302. Polynucleotides encoding said poIypeptides are
also
provided.
The tissue distribution in retinal tissue, and the homology to a Gallus gallus
proteoglycan involved in the ossification process indicates that
polynucleotides and
polypeptides corresponding to this gene are useful for the treatment of
disorders of the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
64
retina which involve the adhesion of tissues, or the binding of certain
proteins to the cell
surface. The translation products of this gene are useful for the treatment of
retinal
disorders such as retinal detachment in individuals suffering from myopia, or
in the
treatment of macular degeneration. Furthermore, this gene may serve as a tumor
marker
for retinoblastomas, or related tumors. More generally, the tissue
distribution in retinal
tissue indicates that The translation product of this gene is useful for the
diagnosis,
detection and/or treatment of eye disorders including blindness, color
blindness, impaired
vision, short and long sightedness, retinitis pigmentosa, retinitis
proliferans, and
retinoblastoma, retinochoroiditis, retinopathy and retinoschisis. Based upon
the tissue
distribution of this protein. antagonists directed against this protein is
useful in blocking
the activity of this protein. Accordingly, prefen-ed are antibodies which
specifically bind
a portion of the translation product of this gene.
Also provided is a kit for detecting tumors in which expression of this
protein
occurs. Such a kit comprises in one embodiment an antibody specific for the
translation
product of this gene bound to a solid support. Also provided is a method of
detecting
these tumors in an individual which comprises a step of contacting an antibody
specific
for the translation product of this gene to a bodily fluid from the
individual, preferably
serum, and ascertaining whether antibody binds to an antigen found in the
bodily fluid.
Preferably the antibody is bound to a solid support and the bodily fluid is
serum. The
above embodiments, as well as other treatments and diagnostic tests (kits and
methods),
are more particularly described elsewhere herein. Furthermore, the protein may
also be
used to determine biological activity, to raise antibodies, as tissue markers,
to isolate
cognate ligands or receptors, to identify agents that modulate their
interactions, in
addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy
targets for
the above listed tissues.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PGT/US99/25031
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID N0:14 and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
5 scope of the present invention. To list every related sequence is
cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 1375 of SEQ ID N0:14, b is an integer
of 15 to
1389, where both a and b correspond to the positions of nucleotide residues
shown in
10 SEQ ID N0:14, and where b is greater than or equal to a + 14.
FEATURES OF PROTEIN ENCODED BY GENE NO: 5
15 The translation product of this gene shares sequence homology with the CD33
protein (See Genbank Accession No. gi~2913995). The expression pattern of CD33
within the hematopoietic system indicates a potential role in the regulation
of myeloid
cell differentiation. However, this expression is absent from hematopoietic
stem cells.
CD33 is expressed in clonogenic leukemia cells in about 90% of patients
suffering from
20 acute myeloid leukemia (AML). While about 60-70% of adults suffering from
AML
experience complete remission due to chemotherapy application, most of these
patients
will ultimately die of relapsed leukemia. It is believed that, like CD33, the
CD33-like
protein of the present invention is also expressed by clonogenic leukemia
cells from the
vast majority of patients with AML. Thus, there is a clear need to identify
and isolate
2S nucleic acid molecules encoding additional polypeptides having
CD33-like protein activity. It is believed that cancerous tissue contains
significantly
greater amounts of CD33-like protein gene copy number and expresses
significantly
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
66
enhanced levels of CD33-like protein and mRNA encoding the CD33-like protein
when
compared to a "standard" mammal, i.e.-a mammal of the same species not having
the
cancer or inflammatory disease. Thus, enhanced levels of the CD33-like protein
will be
detected in certain bodily fluids (e.g., serum, plasma, urine, synovial fluid
and spinal
.5 fluid) from mammals when compared to sera from mammals of the same species
not
having the cancer or inflammatory disease.
Two related cDNA genes, HDPIB36 and HEOMHIO, have been isolated. These
cDNA genes appear to encode splice variants of this gene. Preferred
polynucleotides
comprise the following sequences:
CGACCCACGCGTCCGCCGCCTTCGGCTTCCCCTTCTGCCAA
GAGCCCTGAGCCACTCACAGCACGACCAGAGA (SEQ ID NO: 86),
GTATGGAATGGGGTGGGAACCCCTGCCTCTCACACTGGGGAGGGACCCTGGG
GACAGCCTATGGGCTGAGCAGAGAGGGCTCTCAGGGACCCCTGCAGCACAA
GAATCTCCCACCACGGTCTCTGTCCCAGCCCTGACTCAGAAGCCTGATGTCTA
CATCCCCGAGACCCTGGAGCCCGGGCAGCCGGTGACGGTCATCTGTGTGTTT
AACTGGGCCTTTGAGGAATGTCCACCCCCTTCTTTCTCCTGGACGGGGGCTGC
CCTCTCCTCCCAAGGAACCAAACCAACGACCTCCCACTTCTCAG(SEQID NO:
87),
ATCCTCCAGAGAACCTGAGAGTGATGGTTTCCCAAGCAAACAGGACAGGTA
GGAAAGGGGACAGAGGAGCCAAGGCCTCTCAGTGCCGAATTGGGGGCCCAG
GAGTCTGGAGGGTCCCCACGCAGGAGGGTCCCTGAGCCCTGAGCTGCTCATC
GATTCTGCCTCTTCCTTCCCT (SEQ ID NO: 88),
GTGAGTGGGGGAAAGGGGACACCTGGGTCCCAGGAAGGGGACCCTGCTGAG
TCCTGTCCTCCCTCCCCTCAG (SEQ ID NO: 89),
CTGGCCCCCTGGCTCAGAAGCGGAATCAGAAAGCCACACCAAACAGTCCTCG
GACCCCTCTTCCACCAGGTGCTCCCTCCCCAGAATCAAAGAAGAACCAGAAA
AAGCAGTATCAGTTGCCCAGTTTCCCAGAACCCAAATCATCCACTCAAGCCC
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
67
CAGAATCCCAGGAGAGCCAAGAGGAGCTCCATTATGCCACGCTCAACTTCCC
AGGCGTCAGACCCAGGCCTGAGGCCCGGATGCCCAAGGGCACCCAGGCGGA
TTATGCAGAAGTCAAGTTCCAATGAGGGTCTCT'rAGGCTTTAGGACTGGGAC
TTCGGCTAGGGAGGAAGGTAGAGTAAGAGGTTC3AAGATAACAGAGTGCAAA
GTTTCCTTCTCTCCCTCTCTCTCTCTCTTTCTCTCTCTCTCTCTCTTTCTCTCTCT
TTT (SEQ ID NO: 90), and/or
AAAAAAACATCTGGCCAGGGCACAGTGGCTCACGCCTGTAATCCCAGCACTT
TGGGAGGTTGAGGTGGGCAGATCGCCTGAGGTCGGGAGTTCGAGACCAGCC
TGGCCAACTTGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCTGGG
CATGGTGGCAGGCGCCTGTAATCCTACTACTTGGGAAGCTGAGGCAGGAGAA
TCACTTGAACCTGGGAGACGGAGGTTGCAGTGAGCCAAGATCACACCATTGC
ACGCCAGCTTGGGCAACAAAGCGAGACTCCATC'TCAAAAAAAAAATCCTCC
AAATGGGTTGGGTGTCTGTAATCCCAGCACTTTGGGAGGCTAAGGTGGGTGG
ATTGCTTGAGCCCAGGAGTTCGAGACCAGCCTGGGCAACATGGTGAAACCCC
ATCTCTACAAAAAATACAAAACATAGCTGGGCTTGGTGGTGTGTGCCTGTAG
TCCCAGCTGTCAGACA'I'T"TAAACCAGAGCAACTCCCATCTGGAATGGGAGCT
GAATAAAATGAGGCTGAGACCTACTGGGCTGCCATTCTCAGACAGTGGAGGC
CATTCTAAGTCACAGGATGAGACAGGAGGTCCGTACAAGATACAGGTCATA
AAGACTTTGCTGATAAAACAGATTGCAGTAAAGAAGCCAACCAAATCCCACC
AAAACCAAGTTGGCCACGAGAGTGACCTCTGGTCGTCCTCACTGCTACACTC
CTGACAGCACCATGACAGTTTACAAATGCCATGGCAACATCAGGAAGTTACC
CGATATGTCCCAAAAGGGGGAGGAATGAATAATCCACCCCTTGTTTAGCAAA
TAAGCAAGAAATAACCATAAAAGTGGGCAACCAGCAGCTCTAGGCGCTGCT
CTTGTCTATGGAGTAGCCATTCTTTTGTTCCTTTACTTTCTTAATAAACTTGCT
TTCACCTTAAAAAAAAAAAAAAAAAAAAAA (SEQ ID N0:91 ). Also preferred
are the polypeptides encoded by these polynucleotides.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
68
Figures 13A-C shows the nucleotide (SEQ ID NO:15) and deduced amino acid
sequence (SEQ ID N0:33) of the CD33-like protein. Predicted amino acids from
about 1
to about 16 constitute the predicted signal peptide (amino acid residues from
about 1 to
about 16 in SEQ ID N0:33) and are represented by the underlined amino acid
regions;
and amino acids from about 496 to about 512 constitute the predicted
transmembrane
domain (amino acid residues from about 496 to about 512 in SEQ ID N0:33) and
are
represented by the double-underlined amino acid regions.
Figure 14 shows the regions of similarity between the amino acid sequences of
the CD33-like protein SEQ ID N0:33, and the CD33L1 protein (gi~88178) (SEQ ID
NO:
92).
Figure 15 shows an analysis of the amino acid sequence of SEQ ID N0:33.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic regions; flexible regions; antigenic index and surface probability
are shown.
Northern analysis indicates that this gene is expressed highest in spleen
tissue and
peripheral blood leukocytes, and to a lesser extent in ovary and lung tissue.
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the polypeptide having the amino acid sequence shown
in
Figures 13A-C (SEQ ID N0:33), which was determined by sequencing a cloned cDNA
(HDPCLOS). The nucleotide sequence shown in Figures 13A-C (SEQ ID NO:15) was
obtained by sequencing a cloned cDNA (HDPCLOS), which was deposited on Nov.
17,
1998 at the American Type Culture Collection, and given Accession Number
203484.
The deposited gene is inserted in the pSport plasmid (Life Technologies,
Rockville, MD)
using the SaII/NotI restriction endonuclease cleavage sites.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
NO;15 is intended DNA fragments at least about l5nt, and more preferably at
least about
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
69
20 nt, still more preferably at least about 30 nt, and even more preferably,
at least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
course, larger fragments 50-1500 nt in length are also useful according to the
present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:15. By a fragment at least 20
nt in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
shown in SEQ ID N0:15. In this context "about" includes the particularly
recited size,
larger or smaller by several (S, 4, 3, 2, or 1) nucleotides, at either
terminus or at both
termini. Representative examples of polynucleotide fragments of the invention
include.
for example, fragments that comprise, or alternatively, consist of, a sequence
from about
nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about
150. from
about 1 _51 to about 200, from about 201 to about 250, from about 251 to about
300, from
about 301 to about 350, from about 351 to about 400, from about 401 to about
450, from
1 S about 451 to about 500, from about 501 to about _550, from about 5_51 to
about 600, from
about 601 to about 650, from about 651 to about 700, from about 701 to about
750, from
about 751 to about 800, from about 801 to about 850, from about 851 to about
900, from
about 901 to about 950, from about 951 to about 1000, from about 1001 to about
1050,
from about 1051 to about 1100, from about 1101 to about 11 S0, from about 1151
to
about 1200, from about 1201 to about 1250, from about 1251 to about 1300, from
about
1301 to about 1350, from about 1351 to about 1400, from about 1401 to about
1450,
from about 1451 to about 1500, from about 1501 to about 1550, from about 1551
to
about 1600, from about 1601 to about 1650, from about 1651 to about 1700, from
about
1701 to about 1750, from about 1751 to about 1800, from about 1801 to about
1850,
from about 1851 to about 1900, from about 1901 to about 1950, from about 1951
to
about 2000, from about 2001 to about 2050, from about 2051 to about 2100, from
about
2101 to about 21 S0, from about 2151 to about 2200, from about 2201 to about
22_50,
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
from about 2251 to about 2295, from about 307 to about 1977, and from about
106 to
about 1977, of SEQ ID NO:15, or the complementary strand thereto, or the cDNA
contained in the deposited gene. In this context "about" includes the
particularly recited
ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either
terminus or at
5 both termini. In additional embodiments, the polynucleotides of the
invention encode
functional attributes of the corresponding protein.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
10 regions"), coil and coil-foaming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions. The data
representing
the structural or functional attributes of the protein set fouth in Figure 1_5
and/or Table V,
as described above, was generated using the various modules and algorithms of
the
15 DNA"'STAR set on default parameters. In a preferred embodiment, the data
presented in
columns VIII, IX, XIII, and XIV of Table V can be used to determine regions of
the
protein which exhibit a high degree of potential for antigenicity. Regions of
high
antigenicity are determined from the data presented in columns VIII, IX, XIII,
and/or
XIV by choosing values which represent regions of the polypeptide which are
likely to
20 be exposed on the surface of the polypeptide in an environment in which
antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 15, but may,
as
shown in Table V; be represented or identified by using tabular
representations of the
data presented in Figure 15. The DNA*STAR computer algorithm used to generate
2_5 Figure 15 (set on the original default parameters) was used to present the
data in Figure
15 in a tabular format (See Table V). The tabular format of the data in Figure
15 is used
to easily determine specific boundaries of a preferred region. The above-
mentioned
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
71
preferred regions set out in Figure 15 and in Table V include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figures 13A-C. As set out in Figure 15 and in Table V, such preferred
regions
include Gamier-Robson alpha-regions, beta-regions, turn-regions, and coil-
regions,
S Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic
regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-
amphipathic
regions, Karplus-Schulz flexible regions, Jameson-Wolf regions of high
antigenic index
and Emini surface-forming regions. Even if deletion of one or more amino acids
from the
N-terminus of a protein results in modification of loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities, ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened muteins to
induce andJor bind to antibodies which recognize the complete or mature forms
of the
polypeptides generally will be retained when less than the majority of the
residues of the
complete or mature polypeptide are removed from the N-terminus. Whether a
particular
polypeptide lacking N-terminal residues of a complete polypeptide retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the amino acid sequence shown
in
Figures 13A-C, up to the alanine residue at position number 634 and
polynucleotides
encoding such polypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-639 of Figures 13A-C, where
nl is an
integer from 2 to 634 corresponding to the position of the amino acid residue
in Figures
13A-C (which is identical to the sequence shown as SEQ ID N0:33). N-terminal
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
72
deletions of the polypeptide of the invention shown as SEQ ID N0:33 include
polypeptides comprising the amino acid sequence of residues: L-2 to Q-639; L-3
to Q-
639; P-4 to Q-639;L-5 to Q-639; L-6 to Q-639; L-7 to Q-639; S-8 to Q-639; S-9
toQ-
639; L-10 to Q-639; L-11 to Q-639; G-12 to Q-639; G-13 toQ-639; S-14 to Q-639;
Q-15
to Q-639; A-16 to Q-639; M-17 toQ-639; D-18 to Q-639; G-19 to Q-639; R-20 to Q-
639;
F-21 toQ-639; W-22 to Q-639; I-23 to Q-639; R-24 to Q-639; V-2_5 toQ-639; Q-26
to Q-
639; E-27 to Q-639; S-28 to Q-639; V-29 toQ-639; M-30 to Q-639; V-31 to Q-G39;
P-32
to Q-639; E-33 toQ-639; A-34 to Q-639; C-35 to Q-639; D-3G to Q-639; I-37 toQ-
639;
S-38 to Q-639; V-39 to Q-639; P-40 to Q-639; C-41 toQ-639; S-42 to Q-639; F-43
to Q-
639; S-44 to Q-G39; Y-45 toQ-G39; P-46 to Q-G39; R-47 to Q-639; Q-48 to Q-639;
D-49
toQ-639; W-50 to Q-639; T-51 to Q-639; G-52 to Q-G39; S-53 toQ-639; T-54 to Q-
639;
P-5_5 to Q-639; A-56 to Q-639; Y-57 toQ-639; G-58 to Q-639; Y-59 to Q-639; W-
60 to
Q-639; F-61 toQ-639; K-62 to Q-639; A-63 to Q-639; V-64 to Q-639; T-6_5 toQ-
639; E-
66 to Q-639; T-67 to Q-639; T-G8 to Q-639; K-69 toQ-639; G-70 to Q-639; A-71
to Q-
639; P-72 to Q-639; V-73 toQ-639; A-74 to Q-639; T-75 to Q-639; N-76 to Q-639;
H-77
toQ-639; Q-78 to Q-639; S-79 to Q-639; R-80 to Q-639; E-81 toQ-639; V-82 to Q-
639;
E-83 to Q-639; M-84 to Q-639; S-85 toQ-639; T-86 to Q-639; R-87 to Q-639; G-88
to
Q-639; R-89 toQ-639; F-90 to Q-639; Q-91 to Q-639; L-92 to Q-639; T-93 toQ-
639; G-
94 to Q-639; D-95 to Q-639; P-96 to Q-639; A-97 toQ-639; K-98 to Q-639; G-99
to Q-
639; N-100 to Q-639; C-101 toQ-639; S-102 to Q-639; L-103 to Q-639; V-104 to Q-
639;
I-105 toQ-639; R-106 to Q-639; D-107 to Q-639; A-108 to Q-639; Q-109to Q-639;
M-
110 to Q-639; Q-111 to Q-639; D-112 to Q-639;E-113 to Q-639; S-114 to Q-639; Q-
115
to Q-639; Y-116 to Q-639;F-117 to Q-639; F-118 to Q-639; R-119 to Q-639; V-120
to
Q-639;E-121 to Q-639; R-122 to Q-639; G-123 to Q-639; S-124 toQ-639; Y-125 to
Q-
639; V-126 to Q-639; R-127 to Q-639; Y-128to Q-639; N-129 to Q-639; F-130 to Q-
639; M-131 to Q-639;N-132 to Q-639; D-133 to Q-639; G-134 to Q-639; F-135 toQ-
639; F-136 to Q-639; L-137 to Q-639; K-138 to Q-639; V-139to Q-639; T-140 to Q-
639;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
73
V-141 to Q-639; L-142 to Q-639; S-143to Q-639; F-144 to Q-639; T-145 to Q-639;
P-
l46 to Q-639; R-147to Q-639; P-148 to Q-639; Q-149 to Q-639; D-150 to Q-639;H-
151
to Q-639; N-I52 to Q-639; T-153 to Q-639; D-154 toQ-639; L-155 to Q-639; T-156
to
Q-639; C-157 to Q-639; H-158to Q-639; V-159 to Q-639; D-160 to Q-639; F-161 to
Q-
639; S-162to Q-639; R-163 to Q-639; K-164 to Q-639; G-165 to Q-639;V-166 to Q-
639;
S-167 to Q-639; A-168 to Q-639; Q-169 toQ-639; R-170 to Q-639; T-171 to Q-639;
V-
172 to Q-639; R-173to Q-639: L-174 to Q-639; R-175 to Q-639; V-176 to Q-639;A-
177
to Q-639; Y-178 to Q-639; A-179 to Q-639; P-180 toQ-639; R-181 to Q-639; D-182
to
Q-639; L-183 to Q-639; V-184to Q-639; I-185 to Q-639; S-186 to Q-639; I-187 to
Q-
639; S-188to Q-639; R-189 to Q-639; D-190 to Q-639; N-191 to Q-639;T-192 to Q-
639;
P-193 to Q-639; A-194 to Q-639; L-195 to Q-639;E-196 to Q-639; P-197 to Q-639;
Q-
198 to Q-639; P-199 to Q-639;Q-200 to Q-639; G-201 to Q-639; N-202 to Q-639; V-
203
toQ-639; P-204 to Q-639; Y-205 to Q-639; L-206 to Q-639; E-207 toQ-639; A-208
to Q-
639; Q-209 to Q-639; K-210 to Q-639; G-211 to Q-639; Q-212 to Q-639; F-213 to
Q-
639; L-214 to Q-639; R-215to Q-639; L-216 to Q-639; L-217 to Q-639; C-218 to Q-
639;
A-219to Q-639; A-220 to Q-639; D-221 to Q-639; S-222 to Q-639;Q-223 to Q-639;
P-
224 to Q-639; P-225 to Q-639; A-226 to Q-639;T-227 to Q-639; L-228 to Q-639; S-
229
to Q-639; W-230 toQ-639; V-231 to Q-639; L-232 to Q-639; Q-233 to Q-639; N-
234to
Q-639; R-235 to Q-639; V-236 to Q-639; L-237 to Q-639; S-238to Q-639; S-239 to
Q-
639; S-240 to Q-639; H-241 to Q-639; P-242to Q-639; W-243 to Q-639; G-244 to Q-
639; P-245 to Q-639;8-246 to Q-639; P-247 to Q-639; L-248 to Q-639; G-249 toQ-
639;
L-250 to Q-639; E-251 to Q-639; L-252 to Q-639; P-253 toQ-639; G-254 to Q-639;
V-
255 to Q-639; K-256 to Q-639; A-257to Q-639; G-258 to Q-639; D-259 to Q-639; S-
260
to Q-639;6-261 to Q-639; R-262 to Q-639; Y-263 to Q-639; T-264 toQ-639; C-265
to
Q-639; R-266 to Q-639; A-267 to Q-639; E-268to Q-639; N-269 to Q-639; R-270 to
Q-
639; L-271 to Q-639;6-272 to Q-639; S-273 to Q-639; Q-274 to Q-639; Q-275 toQ-
639;
R-276 to Q-639; A-277 to Q-639; L-278 to Q-639; D-279to Q-639; L-280 to Q-639;
S-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
74
281 to Q-639; V-282 to Q-639; Q-283to Q-639; Y-284 to Q-639; P-285 to Q-639; P-
286
to Q-639; E-287to Q-639; N-288 to Q-639; L-289 to Q-639; R-290 to Q-639;V-291
to
Q-639; M-292 to Q-639; V-293 to Q-639; S-294 toQ-639; Q-295 to Q-639; A-296 to
Q-
639; N-297 to Q-639; R-298to Q-639; T-299 to Q-639; V-300 to Q-639; L-301 to Q-
639;
S E-302to Q-639; N-303 to Q-639; I~ 304 to Q-639; G-30S to Q-639;N-306 to Q-
639; G-
307 to Q-639; T-308 to Q-639; S-309 toQ-639; L-310 to Q-639; P-311 to Q-639; V-
312
to Q-639; L-313 toQ-639; E-314 to Q-639; G-315 to Q-639; Q-316 to Q-639; S-
317to Q-
639; L-318 to Q-639; C-319 to Q-639; L-320 to Q-639; V-32 I to Q-639; C-322 to
Q-639;
V-323 to Q-639; T-324 to Q-639;H-325 to Q-639; S-326 to Q-639; S-327 to Q-639;
P-
328 to Q-639;P-329 to Q-639; A-330 to Q-639; R-331 to Q-639; L-332 to Q-639;S-
333
to Q-639; W-334 to Q-639; T'-335 to Q-639; Q-336 toQ-639; R-337 to Q-639; G-
338 to
Q-639; Q-339 to Q-639; V-340to Q-639; L-341 to Q-639; S-342 to Q-639; P-343 to
Q-
639; S-344to Q-639; Q-345 to Q-639; P-346 to Q-639; S-347 to Q-639; D-348to Q-
639;
P-349 to Q-639; G-350 to Q-639; V-351 to Q-639;L-352 to Q-639; E-353 to Q-639;
L-
354 to Q-639; P-355 to Q-639;8-356 to Q-639; V-357 to Q-639; Q-358 to Q-639; V-
359
toQ-639; E-360 to Q-639; H-361 to Q-639; E-362 to Q-639; G-363to Q-639; E-364
to Q-
639; F-365 to Q-639; T-366 to Q-639; C-367to Q-639; H-368 to Q-639; A-369 to Q-
639;
R-370 to Q-639;H-371 to Q-639; P-372 to Q-639; L-373 to Q-639; G-374 toQ-639;
S-
375 to Q-639; Q-376 to Q-639; H-377 to Q-639; V-378to Q-639; S-379 to Q-639; L-
380
to Q-639; S-381 to Q-639; L-382to Q-639; S-383 to Q-639; V-384 to Q-639; H-385
to
Q-639;Y-386 to Q-639; S-387 to Q-639; P-388 to Q-639; K-389 toQ-639; L-390 to
Q-
639; L-391 to Q-639; G-392 to Q-639; P-393 toQ-639; S-394 to Q-639; C-395 to Q-
639;
S-396 to Q-639; W-397to Q-639; E-398 to Q-639; A-399 to Q-639; E-400 to Q-
639;G-
401 to Q-639; L-402 to Q-639; H-403 to Q-639; C-404 toQ-639; S-405 to Q-639; C-
406
to Q-639; S-407 to Q-639; S-408 toQ-639; Q-409 to Q-639; A-410 to Q-639; S-411
to
Q-639; P-412 toQ-639; A-413 to Q-639; P-414 to Q-639; S-415 to Q-639; L-416
toQ-
639; R-417 to Q-639; W-418 to Q-639; W-419 to Q-639; L-420to Q-639; G-421 to Q-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
639; E-422 to Q-639; E-423 to Q-639; L-424to Q-639; L-4.25 to Q-639; E-426 to
Q-639;
G-427 to Q-639;N-428 to Q-639; S-429 to Q-639; S-430 to Q-639; Q-431 toQ-639;
D-
432 to Q-639; S-433 to Q-639; F-434 to Q-639; E-435 toQ-639; V-436 to Q-639; T-
437
to Q-639; P-438 to Q-639; S-439 toQ-639; S-440 to Q-639; A-441 to Q-639; G-442
to
5 Q-639; P-443to Q-639; W-444 to Q-639; A-445 to Q-639; N-446 to Q-639;S-447
to Q-
639; S-448 to Q-639; L-449 to Q-639; S-450 to Q-639;L-451 to Q-639; H-452 to Q-
639;
G-453 to Q-639; G-454 toQ-639; L-45_5 to Q-639; S-456 to Q-639; S-4_57 to Q-
639; G-
458 toQ-639; L-459 to Q-639; R-460 to Q-639; L-461 to Q-639; R-462 toQ-639; C-
463
to Q-639; E-464 to Q-639; A-465 to Q-639; W-466to Q-639; N-467 to Q-639; V-468
to
10 Q-639; H-469 to Q-639;6-470 to Q-639; A-471 to Q-639; Q-472 to Q-639; S-473
toQ-
639; G-474 to Q-639; S-475 to Q-639; I-476 to Q-639; L-477 toQ-639; Q-478 to Q-
639;
L-479 to Q-639; P-480 to Q-639; D-481 toQ-639; K-482 to Q-639; K-483 to Q-639;
G-
484 to Q-639; L-485to Q-639; I-486 to Q-639; S-487 to Q-639; T-488 to Q-639; A-
489to
Q-639; F-490 to Q-639; S-491 to Q-639; N-492 to Q-639;6-493 to Q-639; A-494 to
Q-
15 639; F-495 to Q-639; L-496 toQ-639; G-497 to Q-639; I-498 to Q-639; G-499
to Q-639;
I-500 toQ-639; T-501 to Q-639; A-502 to Q-639; L-503 to Q-639; L-504 toQ-639;
F-505
to Q-639; L-506 to Q-639; C-507 to Q-639; L-508 toQ-639; A-509 to Q-639; L-510
to
Q-639; I-511 to Q-639; I-512 toQ-639; M-513 to Q-639; K-514 to Q-639; I-515 to
Q-
639; L-516 toQ-639; P-517 to Q-639; K-518 to Q-639; R-519 to Q-639; R-520to Q-
639;
20 T-521 to Q-639; Q-S22 to Q-639; T-523 to Q-639; E-524to Q-639; T-525 to Q-
639; P-
526 to Q-639; R-527 to Q-639; P-528to Q-639; R-529 to Q-639; F-530 to Q-639; S-
531
to Q-639; R-532to Q-639; H-533 to Q-639; S-534 to Q-639; T-S35 to Q-639; I-
536to Q-
639; L-537 to Q-639; D-538 to Q-639; Y-539 to Q-639; I-540to Q-639; N-541 to Q-
639;
V-542 to Q-639; V-543 to Q-639;P-544 to Q-639; T-545 to Q-639; A-546 to Q-639;
G-
2.5 547 toQ-639; P-_548 to Q-639; L-549 to Q-639; A-550 to Q-639; Q-551 toQ-
639; K-552
to Q-639; R-553 to Q-639; N-554 to Q-639; Q-555to Q-639; K-556 to Q-639; A-557
to
Q-639; T-558 to Q-639;P-559 to Q-639; N-560 to Q-639; S-561 to Q-639; P-562 to
Q-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
76
639;8-563 to Q-639; T-564 to Q-639; P-565 to Q-639; L-566 to Q-639;P-567 to Q-
639;
P-568 to Q-639; G-569 to Q-639; A-570 toQ-639; P-571 to Q-639; S-572 to Q-639;
P-
573 to Q-639; E-574 toQ-639; S-575 to Q-639; K-576 to Q-639; K-577 to Q-639; N-
578to Q-639; Q-579 to Q-639; K-580 to Q-639; K-581 to Q-639;Q-582 to Q-639; Y-
583
to Q-639; Q-584 to Q-639; L-585 toQ-639; P-586 to Q-639; S-587 to Q-639; F-588
to Q-
639; P-589 toQ-639; E-590 to Q-639; P-591 to Q-639; K-592 to Q-639; S-593 toQ-
639;
S-594 to Q-639; T-59S to Q-639; Q-596 to Q-639; A-597 toQ-639; P-598 to Q-639;
E-
599 to Q-639; S-600 to Q-G39; Q-601 toQ-639; E-602 to Q-639; S-603 to Q-639; Q-
604
to Q-639; E-605 toQ-639; E-606 to Q-639; L-607 to Q-639; H-608 to Q-639; Y-
609to Q-
639; A-610 to Q-639; T-611 to Q-639; L-612 to Q-639;N-613 to Q-639; F-614 to Q-
639;
P-61 S to Q-639; G-616 toQ-639; V-617 to Q-639; R-618 to Q-639; P-619 to Q-
639; R-
620to Q-639; P-621 to Q-639; E-622 to Q-639; A-623 to Q-639; R-624to Q-639; M-
625
to Q-639; P-626 to Q-639; K-627 to Q-639;6-628 to Q-639; T-629 to Q-639; Q-630
to
Q-639; A-631 toQ-639; D-632 to Q-639; Y-633 to Q-639; A-634 to Q-639; of SEQID
N0:33. Polypeptides encoded by these polynucleotides are also encompassed by
the
mvent~on.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities (e.g., ability
to illicit mitogenic activity, induce differentiation of normal or malignant
cells, bind to
EGF receptors, etc.)), may still be retained. For example the ability to
induce and/or bind
to antibodies which recognize the complete or mature forms of the polypeptide
generally
will be retained when less than the majority of the residues of the complete
or mature
polypeptide are removed from the C-terminus. Whether a particular polypeptide
lacking
C-terminal residues of a complete polypeptide retains such immunologic
activities can
readily be determined by routine methods described herein and otherwise known
in the
art. It is not unlikely that a mutein with a large number of deleted C-
terminal amino acid
SUBSTITUTE SHEET (RULE 2~
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
77
residues may retain some biological or immunogenic activities. In fact,
peptides
composed of as few as six amino acid residues may often evoke an immune
response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
polypeptide shown in Figures 13A-C, up to the leucine residue at position
number 7, and
polynucleotides encoding such polypeptides. In particular, the present
invention
provides polypeptides comprising the amino acid sequence of residues 1-ml of
Figures
13A-C, where ml is an integer from 7 to 638 corresponding to the position of
the amino
acid residue in Figures 13A-C. Moreover, the invention provides
polynucleotides
encoding polypeptides comprising, or alternatively consisting of, the amino
acid
sequence of C-terminal deletions of the polypeptide of the invention shown as
SEQ ID
N0:33 include polypeptides comprising the amino acid sequence of residues: M-I
to F-
638; M-1 to K-637;M-I to V-636; M-1 to E-63_5; M-1 to A-634; M-1 to Y-633; M-1
toD-632; M-1 to A-631; M-1 to Q-630; M-1 to T-629; M-I to G-628;M-1 to K-627;
M-1
to P-626; M-1 to M-625; M-1 to R-624; M-1 toA-623; M-1 to E-622; M-1 to P-621;
M-1
to R-620; M-1 to P-619;M-1 to R-618; M-1 to V-617; M-1 to G-616; M-1 to P-615;
M-1
toF-614; M-1 to N-613; M-1 to L-612; M-1 to T-61 l; M-1 to A-610;M-1 to Y-609;
M-1
to H-608; M-1 to L-607; M-1 to E-606; M-1 toE-605; M-1 to Q-604; M-1 to S-603;
M-1
to E-602; M-1 to Q-601;M-1 to S-600; M-1 to E-599; M-1 to P-598; M-1 to A-597;
M-1
toQ-596; M-1 to T-595; M-1 to S-594; M-1 to S-593; M-1 to K-592;M-1 to P-591;
M-1
to E-590; M-1 to P-589; M-1 to F-588; M-1 toS-587; M-1 to P-586; M-1 to L-585;
M-1
to Q-584; M-1 to Y-583;M-1 to Q-582; M-1 to K-581; M-1 to K-580; M-1 to Q-579;
M-
1 toN-578; M-1 to K-577; M-1 to K-576; M-1 to S-575; M-1 to E-574;M-1 to P-
573; M-
1 to S-572; M-1 to P-571; M-1 to A-570; M-1 toG-569; M-1 to P-568; M-1 to P-
567; M-
1 to L-566; M-1 to P-565;M-1 to T-564; M-1 to R-563; M-1 to P-562; M-1 to S-
561; M-
1 toN-560; M-1 to P-559; M-1 to T-SSB; M-1 to A-557; M-1 to K-556;M-1 to Q-
555; M-
1 to N-554; M-1 to R-553; M-1 to K-552; M-1 toQ-551; M-1 to A-550; M-1 to L-
549;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00!29435 PCT/US99/25031
78
M-1 to P-548; M-1 to G-547;M-1 to A-546; M-1 to T-545; M-I to P-544; M-1 to V-
543;
M-1 toV-542; M-1 to N-541; M-1 to I-540; M-1 to Y-539; M-1 to D-538;M-1 to L-
537;
M-1 to I-536; M-1 to T-535; M-1 to S-534; M-1 toH-533; M-1 to R-532; M-1 to S-
531;
M-1 to F-530; M-1 to R-529;M-1 to P-528; M-1 to R-527; M-1 to P-526; M-1 to T-
525;
M-1 toE-524; M-1 to T-523; M-1 to Q-522; M-1 to T-521; M-1 to R-520;M-1 to R-
519;
M-1 to K-518; M-I to P-.517; M-1 to L-516; M-1 toI-515; M-I to K-514; M-I to M-
513;
M-I to I-512; M-1 to I-SI1;M-1 to L-510; M-1 to A-509; M-1 to I_-508; M-1 to C-
507;
M-1 toL-506; M-1 to F-505; M-1 to L-504; M-1 to L-503; M-1 to A-502;M-1 to T-
501;
M-1 to I-500; M-1 to G-499; M-1 to I-498; M-1 toG-497; M-1 to L-496; M-1 to F-
495;
M-1 to A-494; M-I to G-493;M-1 to N-492; M-1 to S-491; M-1 to F-490; M-1 to A-
489;
M-I toT-488; M-1 to S-487; M-1 to I-486; M-1 to L-485; M-1 to G-484;M-1 to K-
483;
M-1 to K-482; M-1 to D-481; M-I to P-480; M-1 toL-479; M-1 to Q-478; M-1 to L-
477;
M-1 to I-476; M-1 to S-475;M-1 to G-474; M-1 to S-473; M-1 to Q-472; M-1 to A-
471;
M-I toG-470; M-1 to H-469; M-1 to V-468; M-1 to N-467; M-1 toW-466; M-1 to A-
465; M-I to E-464; M-I to C-463; M-1 to R-462;M-I to L-461; M-1 to R-460; M-1
to L-
459; M-1 to G-458; M-1 toS-457; M-1 to S-456; M-1 to L-455; M-1 to G-454; M-1
to G-
453;M-1 to H-452; M-1 to L-451; M-1 to S-450; M-1 to L-449; M-1 toS-448; M-I
to 5-
447; M-1 to N-446; M-1 to A-445; M-1 to W-444;M-1 to P-443; M-1 to G-442; M-1
to
A-441; M-1 to S-440; M-1 toS-439; M-1 to P-438; M-1 to T-437; M-1 to V-436; M-
1 to
E-435;M-1 to F-434; M-1 to S-433; M-I to D-432; M-1 to Q-431; M-1 toS-430; M-1
to
S-429; M-1 to N-428; M-1 to G-427; M-1 to E-426;M-1 to L-425; M-1 to L-424; M-
1 to
E-423; M-1 to E-422; M-1 toG-421; M-1 to L-420; M-1 to W-419; M-1 to W-418; M-
1
toR-417; M-1 to L-416; M-1 to S-415; M-1 to P-414; M-1 to A-413;M-1 to P-412;
M-1
to S-411; M-1 to A-410; M-1 to Q-409; M-1 toS-408; M-1 to S-407; M-1 to C-406;
M-1
to S-405; M-1 to C-404;M-1 to H-403; M-1 to L-402; M-1 to G-401; M-1 to E-400;
M-1
toA-399; M-1 to E-398; M-1 to W-397; M-1 to S-396; M-1 to C-395;M-1 to S-394;
M-1
to P-393; M-1 to G-392; M-1 to L-391; M-1 toL-390; M-1 to K-389; M-1 to P-388;
M-1
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
79
to S-387; M-1 to Y-386;M-1 to H-385; M-1 to V-384; M-1 to S-383; M-1 to L-382;
M-1
toS-381; M-1 to L-380; M-1 to S-379; M-1 to V-378; M-1 to H-377;M-1 to Q-376;
M-1
to S-375; M-1 to G-374; M-1 to L-373; M-1 toP-372; M-1 to H-371; M-1 to R-370;
M-1
to A-369; M-1 to H-368;M-1 to C-367; M-1 to T-366; M-1 to F-365; M-1 to E-364;
M-1
toG-363; M-1 to E-362; M-1 to H-361; M-1 to E-360; M-1 to V-359;M-1 to Q-358;
M-1
to V-357; M-1 to R-356; M-1 to P-355; M-1 toL-354; M-I to E-353; M-1 to L-352;
M-1
to V-351; M-1 to G-350;M-1 to P-349; M- I to D-348; M-1 to S-347; M-1 to P-
346; M-1
toQ-345; M-1 to S-344; M-1 to P-343; M-1 to S-342; M-1 to L-341;M-1 to V-340:
M-I
to Q-339; M-1 to G-338; M-1 to R-337; M-1 toQ-336; M-1 to T-335; M-1 to W-334;
M-
1 to S-333; M-1 to L-332;M-1 to R-331; M-1 to A-330; M-1 to P-329: M-1 to P-
328; M-
1 toS-327; M-I to S-326; M-1 to H-325; M-1 to T-324; M-1 to V-323;M-1 to C-
322; M-
I to V-321; M-1 to L-320; M-1 to C-319; M-1 toL-318; M-1 to S-317; M-1 to Q-
316; M-
1 to G-315; M-1 to E-314;M-1 to L-313; M-1 to V-312; M-1 to P-31 I; M-1 to L-
310; M-
1 toS-309; M-1 to T-308; M-1 to G-307; M-1 to N-306; M-1 to G-305;M-1 to L-
304; M-
1 to N-303; M-1 to E-302; M-1 to L-301; M-I toV-300; M-1 to T-299; M-1 to R-
298;
M-1 to N-297; M-1 to A-296;M-1 to Q-295; M-1 to S-294; M-1 to V-293; M-1 to M-
292; M-1 toV-291; M-1 to R-290; M-1 to L-289; M-1 to N-288; M-1 to E-287;M-1
to P-
286; M-1 to P-285; M-1 to Y-284; M-1 to Q-283; M-1 toV-282; M-1 to S-281; M-I
to L-
280; M-1 to D-279; M-1 to L-278;M-1 to A-277; M-1 to R-276; M-1 to Q-275; M-1
to
Q-274; M-1 toS-273; M-1 to G-272; M-1 to L-271; M-1 to R-270; M-1 to N-269;M-1
to
E-268; M-1 to A-267; M-1 to R-266; M-1 to C-265; M-1 toT-264; M-1 to Y-263; M-
1 to
R-262; M-1 to G-261; M-1 to S-260;M-1 to D-259; M-1 to G-258; M-1 to A-257; M-
1 to
K-256; M-1 toV-255; M-1 to G-254; M-1 to P-253; M-1 to L-252; M-1 to E-251;M-1
to
L-250; M-1 to G-249; M-1 to L-248; M-1 to P-247; M-1 toR-246; M-1 to P-245; M-
1 to
G-244; M-1 to W-243; M-1 to P-242;M-1 to H-241; M-1 to S-240; M-1 to S-239; M-
1 to
S-238; M-1 toL-237; M-1 to V-236; M-1 to R-235; M-1 to N-234; M-1 to Q-233;M-1
to
L-232; M-1 to V-231; M-1 to W-230; M-1 to S-229; M-1 toL-228; M-1 to T-227; M-
1 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT1US99/25031
A-226; M-1 to P-225 ; M-1 to P-224;M-1 to Q-223; M-1 to S-222; M-1 to D-221; M-
1 to
A-220; M-1 toA-219; M-1 to C-218; M-1 to L-217; M-1 to L-216; M-1 to R-215;M-1
to
L-214; M-1 to F-213; M-1 to Q-212; M-1 to G-211; M-1 toK-210; M-1 to Q-209; M-
1 to
A-208; M-1 to E-207; M-1 to L-206;M-1 to Y-205; M-1 to P-204; M-1 to V-203; M-
1 to
S N-202; M-1 toG-201; M-1 to Q-200; M-1 to P-199; M-1 to Q-198; M-1 to P-197;M-
1 to
E-196; M-1 to L-195; M-I to A-194; M-1 to P-193; M-1 toT-192; M-1 to N-191; M-
1 to
D-190; M-I to R-189; M-1 to S-188;M-1 to I-187; M-1 to S-186; M-I to I-185; M-
1 to
V-184; M-1 toL-183; M-1 to D-182; M-1 to R-18i; M-1 to P-180; M-1 to A-179:M-1
to
Y-178; M-I to A-177; M-1 to V-176; M-1 to R-175; M-.( toL-174; M-1 to R-173; M-
1 to
10 V-172; M-1 to T-171; M-1 to R-170;M-1 to Q-169; M-1 to A-168; M-1 to S-167;
M-I to
V-166; M-1 toG-165; M-1 to K-164; M-1 to R-163; M-I to S-162; M-1 to F-161;M-1
to
D-160; M-I to V-159; M-1 to H-158; M-1 to C-157; M-I toT-156; M-1 to L-155; M-
1 to
D-154; M-1 to T-153; M-1 to N-152;M-1 to H-151; M-1 to D-150; M-1 to Q-149; M-
1
to P-148; M-1 toR-147; M-1 to P-146; M-1 to T-145; M-1 to F-144; M-1 to S-
143;M-1
15 to L-142; M-1 to V-141; M-1 to T-140; M-1 to V-139; M-1 toK-138; M-1 to L-
137; M-1
to F-136; M-1 to F-135; M-1 to G-134;M-1 to D-133; M-1 to N-132; M-1 to M-131;
M-1
to F-130; M-1 toN-129; M-1 to Y-128; M-1 to R-127; M-1 to V-126; M-1 to Y-
125;M-1
to S-124; M-1 to G-123; M-1 to R-122; M-1 to E-121; M-1 toV-120; M-1 to R-119;
M-1
to F-118; M-1 to F-117; M-1 to Y-116;M-1 to Q-115; M-1 to S-114; M-1 to E-113;
M-1
20 to D-112; M-1 toQ-111; M-1 to M-I 10; M-1 to Q-109; M-1 to A-108; M-1 to D-
107;M-
1 to R-106; M-1 to I-105; M-1 to V-104; M-1 to L-103; M-1 toS-102; M-1 to C-
101; M-
1 to N-100; M-1 to G-99; M-1 to K-98;M-1 to A-97; M-1 to P-96; M-1 to D-95; M-
1 to
G-94; M-1 toT-93; M-1 to L-92; M-1 to Q-91; M-1 to F-90; M-1 to R-89; M-1 toG-
88;
M-1 to R-87; M-1 to T-86; M-1 to S-85; M-1 to M-84; M-lto E-83; M-1 to V-82; M-
1 to
25 E-81; M-1 to R-80; M-1 to S-79; M-lto Q-78; M-1 to H-77; M-1 to N-76; M-1
to T-75;
M-1 to A-74;M-1 to V-73; M-1 to P-72; M-1 to A-71; M-1 to G-70; M-1 toK-69; M-
1 to
T-68; M-1 to T-67; M-1 to E-66; M-1 to T-65; M-1 toV-64; M-1 to A-63; M-1 to K-
62;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
81
M-1 to F-61; M-1 to W-60; M-1 to Y-59; M-1 to G-58; M-1 to Y-57; M-1 to A-56;
M-1
to P-SS;M-1 to T-54; M-1 to S-53; M-1 to G-52; M-1 to T-51; M-1 toW-50; M-1 to
D-
49; M-1 to Q-48; M-1 to R-47; M-1 to P-46; M-lto Y-45; M-1 to S-44; M-1 to F-
43; M-
1 to S-42; M-1 to C-41; M-lto P-40; M-1 to V-39; M-1 to S-38; M-1 to I-37; M-1
to D-
S 36; M-Ito C-35; M-1 to A-34; M-1 to E-33; M-1 to P-32: M-1 to V-31;M-1 to M-
30; M-
1 to V-29; M-1 to S-28; M-1 to E-27; M-1 toQ-26; M-1 to V-25; M-1 to R-24: M-1
to I-
23; M-1 to W-22; M-1 to F-21; M-1 to R-20; M-1 to G-19; M-1 to D-18: M-1 to M-
17;M-1 to A-16; M-1 to Q-15; M-1 to S-14; M-1 to G-13; M-1 toG-12; M-1 to L-
11; M-
1 to L-i0: M-1 to S-9; M-1 to S-8; M-I toL-7; of SEQ ID N0:33. Polypeptides
encoded
l0 by these polynucleotides are also encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID NO:15 which have been
determined
from the following related cDNA genes: HTOFA26R (SEQ ID N0:93), HWAEM43R
(SEQ ID N0:94), HDPMQ69R (SEQ ID N0:95), HDPGA09RA (SEQ ID N0:96),
15 HEOMH10R (SEQ ID N0:97), and HFKCT73F (SEQ ID N0:98).
The polypeptide of this gene has been determined to have a transmembrane
domain at about amino acid position 496 - S 12 of the amino acid sequence
referenced in
Table XIII for this gene. Moreover, a cytoplasmic tail encompassing amino
acids 513 to
639 of this protein has also been determined. Based upon these
characteristics, it is
20 believed that the protein product of this gene shares structural features
to type Ia
membrane proteins.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of the following diseases and conditions
which
25 include, but are not limited to, disorders of the immune system, in
particular the
immunodiagnosis of acute leukemias. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful to provide immunological probes for differential
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
82
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the immune system, expression of this gene
at
significantly higher or lower levels is detected in certain tissues or cell
types (e.g.,
immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e., the
expression level in healthy tissue from an individual not having the disorder.
Prefewed epitopes include those comprising a sequence shown in SEQ ID NO: 33
as residues: Pro-46 to Gly-52, Asn-76 to Val-82, Ser-85 to Phe-90, Gly-94 to
Asn-100,
Gln-111 to Tyr-116, Pra-146 to Leu-155, Ser-188 to Asn-202, Ser-240 to Art-
X46, Gly-
258 to Tyr-263, Ala-267 to Arg-276, Ser-326 to Arg-331, Ser-333 to Gln-339,
Pro-343
to Asp-348, Glu-426 to Asp-432, Pro-S 17 to His-533, Ala-550 to Pro-565, Gly-
569 to
Gln-582, Pro-589 to Glu-606, Gly-616 to Ala-623, Met-62_5 to Ala-631.
CD33 monoclonal antibodies (MoAB) are important in the immunodiagnosis of
AML. CD33 MoABs have been used in preliminary therapeutic trials for purging
bone
marrow of AML patients, either before transplantation or for diseases
resistant to
chemotherapy. To prevent AML patients in remission from suffering relapse, or
due to
the lack of an appropriate allogenic bone marrow donor, a method is necessary
for
purging leukemia cells from the autografts of patients with advanced AML. By
the
invention, this method is provided by which bone marrow from an AML patient is
obtained by, for example, percutaneous aspirations from the posterior iliac
crest,
isolating bone marrow mononuclear by Ficoll-hypaque density gradient
centrifugation,
and incubating with an anti-CD33-like protein MoAB, for example, 3-5 times for
15-30
min. at 4-6 degrees C, followed by incubation with rabbit complement at about
37
degrees C for 30 minutes. The patient is then subject to myeloablative
chemotherapy,
followed by reinfusion of the treated autologous bone marrow according to
standard
techniques. By the invention, clonogenic tumor cells are depleted from the
bone marrow
SUBSTITUTE SHEET (RULE 2b)
CA 02348824 2001-04-27
WO 00!29435 PCT/US99/2503I
83
while sparing hematopoietic cells necessary for engraftment. In a further
embodiment,the invention provides an in vivo method for selectively killing or
inhibiting
growth of tumor cells expressing CD33-like protein antigen of the present
invention. The
method involves administering to the patient an effective amount of an
antagonist to
inhibit the CD33-like protein receptor signaling pathway. By the invention,
administering such antagonist of the CD33-like protein to a patient may also
be useful
for treating inflammatory diseases including arthritis and colitis.
Antagonists for use in
the present invention include polyclonal and monoclonal antibodies raised
aginst the
CD33-like protein or a fragment thereof, antisense molecules which control
gene
expression through antisensc DNA or RNA or through triple-helix formation,
proteins or
other compounds which bind the CD33-like protein domains, or soluble forms of
the
CD33-like protein, such as protein fragments including the extracellular
region from the
full length receptor, which antagonize CD33-like protein mediated signaling by
competing with the cell surface CD33-like protein for binding to CD33 receptor
ligands.
1S
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID NO:1S and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of
a-b, where a is any integer between 1 to 2281 of SEQ ID NO:1S, b is an integer
of 1S to
2295, where both a and b correspond to the positions of nucleotide residues
shown in
2S SEQ ID NO:1 S, and where b is greater than or equal to a + 14.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
84
FEATURES OF PROTEIN ENCODED BY GENE NO: 6
This invention relates to newly identified polynucleotides, polypeptides
encoded
S by such polynucleotides, the use of such polynucleotides and polypeptides,
as well as the
production of such polynucleotides and polypeptides. The polypeptide of the
present
invention has been putatively identified as a CD33 homolog derived from a
human
primary dendritic cells cDNA library. More particularly, the polypeptide of
the present
invention has been putatively identified as a human siglec homolog, sometimes
hereafter
referred to as "CD33-like 3" and/or "siglec 7". The invention also relates to
inhibiting
the action of such polypeptides.
The siglecs (sialic acid binding Ig-like lectins) are type 1 membrane proteins
that
constitute a distinct subset of the lg superfamily, characterised by their
sequence
similarities and abilities to bind sialic acids in glycoproteins and
glycolipid (Crocker,
P.R., et al., Glycobiology:8 (1998)). Members of the Ig Superfamily of
proteins are
defined as molecules that share domains of sequence similarity with the
variable or
constant domains of antibodies.
Many Ig superfamily proteins consist of multiple tandem Ig-like domains
connected to other domains, such as Fn-III repeat domains (Vaughn, D.E., and
P.J.
Bjorkman, Neuron, 16:261-73 (1996)). At the primary structural level,
traditional Ig-like
domains can be identified by the presence of two cysteine residues separated
by
approximately 55-75 amino acid residues, and an "invariant" tryptophan residue
located
10-15 residues C-terminal to the first of the two conserved cysteine residues.
The two
conserved cysteine residues are thought to be involved in disulfide bonding to
form the
folded Ig structures (Vaughn, D.E., (1996)).
Ig-like domains further share a common folding pattern, that of a sandwich or
fold structure of two b-sheets consisting of antiparallel b-strands containing
S-10 amino
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
SS
acids (Huang, Z., et al., Biopolymers, 43:367-82 (1997)). Ig-like domains are
divided,
based upon sequence and structural similarities, into four classifications
known as C1,
C2, I and V-like domains.
The functional determinants of the Ig-tike domains are presented on the faces
of
S b-sheets or the loop regions of the Ig-fold. Accordingly, protein-protein
interactions can
occur either between the faces of the b-sheets, or the loop regions of the lg-
fold (Huang,
Z., ( 1998)). These Ig-like domains are involved in mediating a diversity of
biological
functions such as intermolecular binding and protein-protein homophilic or
heterophilic
interactions.
Thus, Ig-like domains play an integral role in facilitating the activities of
proteins
of the Ig superfamily. In mammals, the group currently comprises
sialoadhesin/siglec-1,
CD22/siglec-2, CD33/siglec-3, myelin associated glycoprotein (MAG/siglec-4),
siglecs-
5, -6 and -7
(Crocker, P.R., et al., EMBO J., 13:4490-503 (1994); Sgroi, D., et al., J
Biol. Chem.,
268:7011-18 (1993); Freeman, D.S., et al., Blood, 85:2005-12 (1995); Kelm, S.,
et al.,
Curr Biol., 4:965-72 (1994); Cornish, A.L., et al., Blood, 92:2123-132 (1998);
Patel, N.,
et al., J Biol. Chem, 274:22729-738 (1999); Nicol, G., et al., J Biol. Chem.
In Press
(1999)). Siglec-7 has also recently been characterised independently as the NK
receptor
p75/AIRM1 (Falco, M., et al., J. Exp. Med., 190:793-802 (1999)). In addition,
the gene
encoding another siglec-like sequence, OBBP-like protein has been reported but
there is
no information on its binding activity (Yousef, G.M., et al., Biochem.
Biophys. Res.
Commun., In Press (1999)).
Each of these proteins has an extracellular region made up of a membrane
distal
V-set domain followed by varying numbers of C2 set domains which range from 16
in
sialoadhesin to 1 in CD33. In the cases of sialoadhesin, CD22, MAG and CD33,
the
sialic acid binding site has been mapped to the V-set domain and for
sialoadhesin it has
been further characterised at the molecular level by X-ray crystallography 11
(Nath, D.,
SUBSTITUTE SHEET (RULE Z6)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
86
et al., J Biol. Chem., 270:26184-91 (1995); van der Merwe, P.A., et al., J.
Biol. Chem.,
271:9273-80 (1996); Tang, S., et al., J. Cell Biol., 138:1355-66 (1997);
Taylor, V.C., et
al., J. Biol. Chem., 274:11505-12 (1999); May, A.P., et al., Molecular Cell,
1:719-28
( 1998)).
Apart from MAG and SMP that are found exclusively in the nervous system, all
siglecs characterised to date are expressed on discrete subsets of hemopoietic
cells and
can provide useful lineage-restricted markers. Thus, CD22 is present only on
mature B
cells, sialoadhesin is on macrophage subsets, CD33 is a marker of early
committed
myeloid progenitor cells, siglec-5 is expressed by monocytes and mature
neutrophils,
siglec-6 is on B cells and siglec-7 is expressed by NK cells and monocytes
(Dorken, B.,
et al., J. Immunology, 136:4470-79 (1986); Crocker, P.R., et al., J. Exp.
Med., 164:1862-
75 (1986); Peiper, S.C., et al., In Leukocyte Typing IV. Oxford University
Press, Oxford.
814-16 (1989); Cornish, A.L., et al., Blood, 92:2123-132 (1998); Patel, N., et
al., J Biol.
Chem, 274:22729-738 (1999); Nicol, G., et al., J Biol. Chem, In Press (1999)).
These
expression patterns indicate discrete functions amongst hemopoietic cell
subsets, but
apart from CD22, a well-characterised negative regulator of B cell activation
(reviewed
in Oyster, J.G. and C.C. Goodnow, Immunity, 6:509-17 ( 1997)), the biological
functions
of siglecs expressed in the hemopoietic system are unknown. Proposed functions
include
cell-cell interactions through recognition of sialylated glycoconjugates on
other cells.
However, a number of studies have also shown that cell-cell adhesion mediated
by
siglecs can be modulated by cis-interactions with sialic acids present in the
host plasma
membrane. This is particularly striking for CD22, CD33 and siglec-5, whose
binding
activities can be greatly increased if host cells are pretreated with
sialidase to remove the
cis-competing sialic acids (Freeman, D.S., et al., Blood, 8_5:2005-12 (1995);
Cornish,
A.L., et al., Blood, 92:2123-132 (1998); Sgroi, D., et al., P.N.A.S., 92:4026-
30 (1995)).
Besides potential roles in cellular interactions, there is growing evidence
that,
similar to CD22, the more recently characterised siglecs are involved in
signalling
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
87
functions. The cytoplasmic tails of CD33 and siglecs-5, -6 and -7 have two
well-
conserved tyrosine-based motifs that are similar to well-characterised
signaling motifs in
other leukocyte receptors (Gergely, J., et al., Immun. Lett., 68:3-15 (1999)).
Where
studied, both tyrosine residues can be phosphorylated by src-like kinase(s)
and, in the
case of the membrane proximal tyrosine, this leads to subsequent recruitment
of the
tyrosine phosphatases, SHP-1 and SHP-2 (Falco, M., et al., J. Exp. Med.,
190:793-802
(1999); Taylor, V.C., et al., J. Biol. Chem., 274:11.505-12 (1999)).
Thus there exists a clear need for identifying and exploiting novel members of
the siglec
family of immunoglobulin proteins. Although structurally related, such
proteins may
possess diverse and multifaceted functions in a variety of cell and tissue
types. The
inventive purified sigiec proteins are research tools useful for the
identification,
characterization and purification of cell signaling molecules. Furthermore,
the
identification of new siglecs permits the development of a range of
derivatives, agonists
and antagonists at the nucleic acid and protein levels which in turn have
applications in
1S the treatment and diagnosis of a range of conditions such as cancer,
inflammation,
neurological disorders and immunological disorders, amongst many other
conditions.
The polypeptide of the present invention has been putatively identified as a
member of
the siglec family and has been termed CD33-like 3. This identification has
been made as
a result of amino acid sequence homology to the human cd3311 (See Genbank
Accession
No. gi~2913995).
Figures 16A-B show the nucleotide (SEQ ID N0:16) and deduced amino acid
sequence (SEQ ID N0:34) of CD33-like 3. Predicted amino acids from about 1 to
about
18 constitute the predicted signal peptide (amino acid residues from about 1
to about 18
in SEQ ID N0:34) and are represented by the underlined amino acid regions; and
amino
acids from about 360 to about 376 constitute the predicted transmembrane
domain
(amino acids from about 360 to about 376 in SEQ ID N0:34) and are represented
by the
double underlined amino acids.
SUBSTITUTE SKEET (RULE Z6)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99IZ5031
8$
Figure 17 shows the regions of similarity between the amino acid sequences of
the CD33-like 3 protein (SEQ ID N0:34) and the human CD33L1 protein (SEQ ID
N0:99).
Figure 1$ shows an analysis of the CD33-like 3 amino acid sequence. Alpha,
beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic
regions;
flexible regions; antigenic index and surface probability are shown.
A polynucleotide encoding a polypeptide of the present invention is obtained
from human NK cells, T-cells, primary dendritic cells, placenta, spleen,
primary breast
cancer, gall bladder, apoptotic t-cells, macrophage, and chronic lymphocytic
leukemia
spleen. The polynucleotide of this invention was discovered in a human primary
dendritic cell cDNA library.
As shown in Figures 16A-B, CD33-like 3 has a transmembrane domain (the
transmembrane domains comprise amino acids from about 360 to about 376 of SEQ
ID
N0:34; which correspond to amino acids from about 360 to about 376 of Figures
16A-B
). The polynucleotide contains an open reading frame encoding the CD33-like 3
polypeptide of 467 amino acids. CD33-like 3 exhibits a high degree of homology
at the
amino acid level to the human CD33L1 (as shown in Figure 18).
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the CD33-like 3 polypeptide having the amino acid
sequence
shown in Figures 16A-B (SEQ ID N0:34). The nucleotide sequence shown in
Figures
16A-B (SEQ ID N0:16) was obtained by sequencing a cloned cDNA (HDPtJW68),
which was deposited on November 17 at the American Type Culture Collection,
and
given Accession Number 203484.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
N0:16 is intended DNA fragments at least about l5nt, and more preferably at
least about
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
89
20 nt, still more preferably at least about 30 nt, and even more preferably,
at least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
course, larger fragments 50-1500 nt in length are also useful according to the
present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:16. By a fragment at least 20
nt in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
shown in SEQ ID N0:16. In this context "about" includes the particularly
recited size,
larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either
terminus or at both
termini. Representative examples of CD33-like 3 polynucleotide fragments of
the
invention include, for example, fragments that comprise, or alternatively,
consist of, a
sequence from about nucleotide 1 to about 50, from about 51 to about 100, from
about
101 to about 150, from about 151 to about 200, from about 201 to about 2.50,
from about
251 to about 300, from about 301 to about 350, from about 351 to about 400,
from about
401 to about 450, from about 451 to about 500, from about 501 to about 550,
from about
551 to about 600, from about 601 to about 650, from about 651 to about 700,
from about
701 to about 750, from about 751 to about 800, from about 801 to about 850,
from about
851 to about 900, from about 901 to about 950, from about 951 to about 1000,
from
about 1001 to about 1050, from about 1051 to about 1100, from about 1101 to
about
1150, from about 1151 to about 1200, from about 1201 to about 1250, from about
1251
to about 1300, from about 1301 to about 1350, from about 1351 to about 1400,
from
about 1401 to about 1450, from about 1451 to about 1500, from about 1501 to
about
1550, from about 1551 to about 1600, from about 1601 to about 1650, from about
1651
to about 1700, from about 1701 to about 1748 of SEQ ID N0:16, or the
complementary
strand thereto, or the cDNA contained in the deposited gene. In this context
"about"
includes the particularly recited ranges, larger or smaller by several (5, 4,
3, 2, or 1)
nucleotides, at either terminus or at both termini.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/Z5031
Preferred nucleic acid fragments of the present invention include nucleic acid
molecules encoding a member selected from the group: a polypeptide comprising
or
alternatively, consisting of, the transmembrane domain (amino acid residues
from about
360 to about 376 in Figures 16A-B (amino acids from about 360 to about 376 in
SEQ ID
N0:34). Since the location of these domains have been predicted by computer
analysis,
one of ordinary skill would appreciate that the amino acid residues
constituting these
domains may vary slightly (e.g., by about l to 15 amino acid residues}
depending on the
crite~7a used to define each domain.
In additional embodiments, the polynucleotides of the invention encode
functional
10 attributes of CD33-like 3.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
15 hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions of CD33-like
3. The
data representing the structural or functional attributes of CD33-like 3 set
forth in Figure
18 and/or Table VI, as described above, was generated using the various
modules and
algorithms of the DNA~'STAR set on default parameters. In a preferred
embodiment, the
20 data presented in columns VIII, IX, XIII, and XIV of Table VI can be used
to determine
regions of CD33-like 3 which exhibit a high degree of potential for
antigenicity. Regions
of high antigenicity are determined from the data presented in columns VIII,
IX, XIII,
and/or XIV by choosing values which represent regions of the polypeptide which
are
likely to be exposed on the surface of the polypeptide in an environment in
which antigen
25 recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 18 , but may,
as
shown in Table VI, be represented or identified by using tabular
representations of the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
91
data presented in Figure 18 . The DNA*STAR computer algorithm used to generate
Figure 18 (set on the original default parameters) was used to present the
data in Figure
18 in a tabular format (See Table VI). The tabular format of the data in
Figure 18 is used
to easily determine specific boundaries of a preferred region. The above-
mentioned
preferred regions set out in Figure 18 and in Table VI include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figures 16A-B. As set out in Figure 18 and in Table VI, such preferred
regions
include Gamier-Robson alpha-regions, beta-regions, turn-regions, and coil-
regions,
Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-DooIittle
hydrophilic
regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-
amphipathic
regions, Karplus-Schulz flexible regions, Jameson-Wolf regions of high
antigenic index
and Emini surface-forming regions. Even if deletion of one or more amino acids
from the
N-terminus of a protein results in modification of loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities, ability to
multimerize, modulate cellular interaction, or signalling pathways, etc.) may
still be
retained. For example, the ability of shortened CD33-tike 3 muteins to induce
and/or
bind to antibodies which recognize the complete or mature forms of the
polypeptides
generally will be retained when less than the majority of the residues of the
complete or
mature polypeptide are removed from the N-terminus. Whether a particular
polypeptide
lacking N-terminal residues of a complete polypeptide retains such immunologic
activities can readily be determined by routine methods described herein and
otherwise
known in the art. It is not unlikely that an CD33-like 3 mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six CD33-like 3 amino acid
residues
may often evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the CD33-like 3 amino acid
sequence
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00129435
PCT/US99/25031
92
shown in Figures 16A-B , up to the glutamic acid residue at position number
462 and
poiynucleotides encoding such polypeptides. In particular, the present
invention
provides polypeptides comprising the amino acid sequence of residues nl-467 of
Figures
16A-B , where n 1 is an integer from 2 to 462 corresponding to the position of
the amino
acid residue in Figures 16A-B (which is identical to the sequence shown as SEQ
ID
N0:34). In another embodiment, N-terminal deletions c>f the CD33-like 3
poiypeptide
can be described by the general formula n2-467, where n2 is a number from 2 to
462.
cowesponding to the position of amino acid identified in Figures 16A-B . N-
terminal
deletions of the CD33-like 3 polypeptide of the invention shown as SEQ ID
N0:34
include polypeptides comprising the amino acid sequence of residues: N-
terminal
deletions of the CD33-like 3 polypeptide of the invention shown as SEQ ID
N0:34
include polypeptides comprising the amino acid sequence of residues: L-2 to K-
467; L-3
to K-467; L-4 to K-467; L-5 to K-467: L-6 to K-467; L-7 to K-467; P-8 to K-
467; L-9 to
K-467; L-10 toK-467; W-11 to K-467; G-12 to K-467; R-13 to K-467; E-14 to K-
467;
IS R-15 to K-467; V-16 to K-467; E-17 to K-467; G-18 to K-467;Q-19 to K-467; K-
20 to
K-467; S-21 to K-467; N-22 to K-467; R-23 to K-467; K-24 to K-467; D-25 to K-
467;
Y-26 to K-467; S-27 toK-467; L-28 to K-467; T-29 to K-467; M-30 to K-467; Q-31
to
K-467; S-32 to K-467; S-33 to K-467; V-34 to K-467; T-35 to K-467;V-36 to K-
467; Q-
37 to K-467; E-38 to K-467; G-39 to K-467; M-40 to K-467; C-41 to K-467; V-42
to K-
467; H-43 to K-467; V-44 toK-467; R-45 to K-467; C-46 to K-467; S-47 to K-467;
F-48
to K-467; S-49 to K-467; Y-SO to K-467; P-51 to K-467; V-52 to K-467;D-53 to K-
467;
S-54 to K-467; Q-55 to K-467; T-S6 to K-467; D-57 to K-467; S-58 to K-467; D-
59 to
K-467; P-60 to K-467; V-61 toK-467; H-62 to K-467; G-63 to K-467; Y-64 to K-
467;
W-65 to K-46?; F-66 to K-467; R-67 to K-467; A-68 to K-467; G-69 to K-467;N-70
to
K-467; D-71 to K-467; I-72 to K-467; S-73 to K-467; W-74 to K-467; K-75 to K-
467;
A-76 to K-467; P-77 to K-467; V-7$ toK-467; A-79 to K-467; T-80 to K-467; N-81
to
K-467; N-82 to K-467; P-$3 to K-467; A-84 to K-467; W-85 to K-467; A-86 to K-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
93
467;V-87 to K-467; Q-$8 to K-467; E-89 to K-467; E-90 to K-467; T-91 to K-467;
R-92
to K-467; D-93 to K-467; R-94 to K-467; F-95 toK-467; H-96 to K-467; L-97 to K-
467;
L-98 to K-467; G-99 to K-467; D-100 to K-467; P-101 to K-467; Q-102 to K-467;
T-103
toK-467; K-104 to K-467; N-105 to K-467; C-106 to K-467; T-107 to K-467; L-108
to
K-467; S-109 to K-467; I-110 to K-467; R-111 toK-467; D-112 to K-467; A-113 to
K-
467; R-114 to K-467; M-115 to K-467; S-116 to K-467; D-117 to K-467; A-118 to
K-
467; G-119 toK-467; R-120 to K-467; Y-121 to K-467; F-122 to K-467; F-123 to K-
467;
R-124 to K-467; M-125 to K-467; E-126 to K-467; K-127 toK-467; G-128 to K-467;
N-
129 to K-467; I-130 to K-467; K-131 to K-467; W-132 to K-467; N-133 to K-467;
Y-
134 to K-467; K-135to K-467; Y-136 to K-467; D-137 to K-467; Q-138 to K-467; L-
139
to K-467; S-140 to K-467; V-141 to K-467; N-142 to K-467; V-143to K-467; T-144
to
K-467; A-145 to K-467; L-146 to K-467; T-147 to K-467; H-148 to K-467; R-149
to K-
467; P-150 to K-467; N-151to K-467; 1-152 to K-467; I~ 153 to K-467; I-154 to
K-467;
P-155 to K-467; G-156 to K-467; T-157 to K-467; L-158 to K-467; E-159 toK-467:
S-
160 to K-467; G-161 to K-467; C-162 to K-467; F-163 to K-467; Q-164 to K-467;
N-
165 to K-467; L-166 to K-467; T-167 toK-467; C-168 to K-467; S-169 to K-467; V-
170
to K-467; P-171 to K-467; W-172 to K-467; A-173 to K-467; C-174 to K-467; E-
175
toK-467; Q-176 to K-467; G-177 to K-467; T-178 to K-467; P-179 to K-467; P-180
to
K-467; M-181 to K-467; I-182 to K-467; S-183 toK-467; W-184 to K-467; M-185 to
K-
467; G-186 to K-467; T-187 to K-467; S-188 to K-467; V-189 to K-467; S-190 to
K-
467; P-191 toK-467; L-192 to K-467; H-193 to K-467; P-194 to K-467; S-195 to K-
467;
T-196 to K-467; T-I97 to K-467; R-198 to K-467; S-199 toK-467; S-200 to K-467;
V-
201 to K-467; L-202 to K-467; T-203 to K-467; L-204 to K-467; I-205 to K-467;
P-206
to K-467; Q-207 toK-467; P-208 to K-467; Q-209 to K-467; H-210 to K-467; H-211
to
K-467; G-212 to K-467; T-213 to K-467; S-214 to K-467; L-215 toK-467; T-216 to
K-
467; C-217 to K-467; Q-218 to K-467; V-219 to K-467; T-220 to K-467; L-221 to
K-
467; P-222 to K-467; G-223 toK-467; A-224 to K-467; G-225 to K-467; V-226 to K-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435
PCT/US99/25031
94
467; T-227 to K-467; T-228 to K-467; N-229 to K-467; R-230 to K-467; T-231 toK-
467;
I-232 to K-467; Q-233 to K-467; L-234 to K-467; N-235 to K-467; V-236 to K-
467; 5-
237 to K-467; Y-238 to K-467; P-239 toK-467; P-240 to K-467; Q-241 to K-467; N-
242
to K-467; L-243 to K-467; T-244 to K-467; V-245 to K-467; T-246 to K-467; V-
247
toK-4G7; F-248 to K-467; Q-249 to K-4G7; G-250 to K-467; E-251 to K-467; G-
2_52 to
K-467; T-253 to K-4G7; A-254 to K-467; S-255 toK-467; T-256 to K-467; A-257 to
K-
467; L-258 to K-467; G-259 to K-467; N-260 to K-467; S-261 to K-467: S-2(2 to
K-
467; S-263 toK-467; L-264 to K-467; S-265 to K-467; V-266 to K-467; L-267 to K-
467;
E-268 to K-467; G-269 to K-467; Q-270 to K-467; S-271 toK-467; L-272 to K-467;
R-
273 to K-467; L-274 to K-467; V-275 to K-467; C-276 to K-467; A-277 to K-467;
V-
278 to K-4G7; D-279 toK-467; S-280 to K-467; N-281 to K-4G7; P-282 to K-467; P-
283
to K-467; A-284 to K-467; R-285 to K-467; L-286 to K-467; S-287 toK-467; W-288
to
K-467; T-289 to K-467; W-290 to K-467; R-291 to K-467; S-292 to K-467; L-293
to K-
467; T-294 to K-467; L-295 toK-467; Y-296 to K-467; P-297 to K-467; S-298 to K-
467;
Q-299 to K-467; P-300 to K-467; S-301 to K-467; N-302 to K-467; P-303 toK-467;
L-
304 to K-467; V-305 to K-467; L-306 to K-467; E-307 to K-467; L-308 to K-467;
Q-309
to K-467; V-310 to K-467; H-311 toK-467; L-312 to K-467; G-313 to K-467; D-314
to
K-467; E-315 to K-467; G-316 to K-467; E-317 to K-467; F-318 to K-467; T-319
toK-
467; C-320 to K-467; R-321 to K-467; A-322 to K-467; Q-323 to K-467; N-324 to
K-
467; S-325 to K-467; L-326 to K-467; G-327 toK-467; S-328 to K-467; Q-329 to K-
467;
H-330 to K-467; V-331 to K-467; S-332 to K-467; L-333 to K-467; N-334 to K-
467; L-
335 toK-467; S-336 to K-467; L-337 to K-467; Q-338 to K-467; Q-339 to K-467; E-
340
to K-467; Y-341 to K-467; T-342 to K-467; G-343 toK-467; K-344 to K-467; M-345
to
K-467; R-346 to K-467; P-347 to K-467; V-348 to K-467; S-349 to K-467; G-350
to K-
467; V-351 toK-467; L-352 to K-467; L-353 to K-467; Cr-354 to K-467; A-355 to
K-
467; V-356 to K-467; G-357 to K-467; G-358 to K-467; A-359 toK-467; G-360 to K-
467; A-361 to K-467; T-362 to K-467; A-363 to K-467; L-364 to K-467; V-365 to
K-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
9S
467; F-366 to K-467; L-367 toK-467; S-368 to K-467; F-369 to K-467; C-370 to K-
467;
V-371 to K-467; I-372 to K-467; F-373 to K-467; I-374 to K-467; V-37S toK-467;
V-
376 to K-467; R-377 to K-467; S-378 to K-467; C-379 to K-467; R-380 to K-467;
K-381
to K-467; K-382 to K-467; S-383 toK-467; A-384 to K-467; R-38S to K-4.67; P-
386 to
.5 K-467; A-387 to K-467: A-388 to K-467; D-389 to K-467; V-390 to K-467; G-
391 toK-
467; D-392 to K-467; 1-393 to K-467; G-394 to K-467; M-39S to K-467; K-396 to
K-
467; D-397 to K-467; A-398 to K-467; N-399 toK-467; T-400 to K-467; I-401 to K-
467;
R-402 to K-467; G-403 to K-467; S-404 to K-467; A-40S to K-467; S-406 to K-
467; Q-
407 toK-467; G-408 to K-467; N-409 to K-467; L-410 to K-467; T-411 to K-467; E-
412
to K-467; S-413 to K-467; W-414 to K-467; A-41 S toK-467; D-416 to K-467; D-
417 to
K-467; N-418 to K-467; P-419 to K-467; R-420 to K-467; H-42 i to K-467; H-422
to K-
467; G-423to K-467; L-424 to K-467; A-42S to K-467; A-426 to K-467; H-427 to K-
467; S-428 to K-467; S-429 to K-467; G-430 to K-467; E-431to K-467; E-432 to K-
467;
R-433 to K-467; E-434 to K-467; I-43S to K-467; Q-436 to K-467; Y-437 to K-
467; A-
1S 438 to K-467; P-439to K-467; L-440 to K-467; S-441 to K-467; F-442 to K-
467; H-443
to K-467; K-444 to K-467; G-44S to K-467; E-446 to K-467; P-447to K-467; Q-448
to
K-467; D-449 to K-467; L-4S0 to K-467; S-4S 1 to K-467; G-4S2 to K-467; Q-4S3
to K-
467; E-4S4 to K-467; A-4SSto K-467; T-4S6 to K-467; N-4S7 to K-467; N-458 to K-
467; E-4S9 to K-467; Y-460 to K-467; S-461 to K-467; E-462 to K-467; of SEQ ID
N0:34. Polypeptides encoded by these polynucleotides are also encompassed by
the
invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities may still be retained.
For example the
ZS ability of the shortened CD33-like 3 mutein to induce and/or bind to
antibodies which
recognize the complete or mature forms of the polypeptide generally will be
retained
when less than the majority of the residues of the complete or mature
polypeptide are
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
96
removed from the C-terminus. Whether a particular polypeptide lacking C-
terminal
residues of a complete polypeptide retains such immunologic activities can
readily be
determined by routine methods described herein and otherwise known in the art.
It is not
unlikely that a CD33-like 3 mutein with a large number of deleted C-terminal
amino acid
S residues may retain some biological or immunogenic activities. In fact,
peptides
composed of as few as six CD33-like 3 amino acid residues may often evoke an
immune
response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
CD33-like 3 polypeptide shown in Figures 16A-B , up to the leucine residue at
position
number 6, and polynucleotides encoding such polypeptides. In particular, the
present
invention provides polypeptides comprising the amino acid sequence of residues
1-ml of
Figure 1, where ml is an integer from 6 to 467 corresponding to the position
of the
amino acid residue in Figures 16A-B .
Moreover, the invention provides polynucleotides encoding polypeptides
comprising, or
alternatively consisting of, the amino acid sequence of C-terminal deletions
of the CD33-
like 3 polypeptide of the invention shown as SEQ ID N0:34 include polypeptides
comprising the amino acid sequence of residues: M-1 to P-466; M-1 to I-465; M-
1 to K-
464; M-1 to I-463; M-1 to E-462; M-1 to S-461; M-1 to Y-460; M-1 toE-459; M-1
to N-
458; M-1 to N-457; M-1 to T-456; M-1 to A-455; M-1 to E-454; M-1 to Q-453; M-1
to
G-452; M-1 to S-451; M-1 toL-450; M-1 to D-449; M-1 to Q-448; M-1 to P-447; M-
1 to
E-446; M-1 to G-445; M-1 to K-444; M-1 to H-443; M-1 to F-442; M-1 toS-441; M-
1 to
L-440; M-1 to P-439; M-1 to A-438; M-1 to Y-437; M-1 to Q-436; M-1 to I-435; M-
1 to
E-434; M-1 to R-433 ; M-1 toE-432; M-1 to E-431; M-1 to G-430; M-1 to S-429; M-
1 to
S-428; M-1 to H-427; M-1 to A-426; M-1 to A-425; M-1 to L-424; M-1 toG-423; M-
1 to
H-422; M-1 to H-421; M-1 to R-420; M-1 to P-419; M-1 to N-418; M-1 to D-417; M-
1
to D-416: M-1 to A-415; M-1 toW-414; M-1 to S-413; M-1 to E-412; M-1 to T-41
l; M-1
SUBSTITUTE S)EiEET (RULE Z6)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
97
to L-410; M-1 to N-409; M-1 to G-4.08; M-1 to Q-407; M-1 to S-406; M-1 toA-
405; M-1
to S-404; M-1 to G-403; M-1 to R-402; M-1 to I-401; M-1 to T-400; M-1 to N-
399; M-1
to A-398; M-1 to D-397; M-1 toK-396; M-1 to M-395; M-1 to G-394; M-1 to I-393;
M-1
to D-392; M-1 to G-391; M-1 to V-390; M-1 to D-389; M-1 to A-388; M-1 toA-387;
M-
1 to P-386; M-I to R-385; M-1 to A-384; M-1 to S-383; M-1 to K-382; M-1 to K-
381;
M-1 to R-380; M-I to C-379; M-1 toS-378; M-1 to R-377; M-1 to V-376; M-1 to V-
375;
M-1 to I-374; M-1 to F-373; M-l to I-372; M-I to V-371; M-1 to C-370; M-1 toF-
369;
M-1 to S-368; M-1 to L-367; M-1 to F-366; M-1 to V-365; M-I to L-364; M-I to A-
363;
M-1 to T-362; M-1 to A-361; M-I toG-360; M-1 to A-359; M-1 to G-358; M-1 to G-
357; M-1 to V-356; M-I to A-35_5; M-1 to G-354; M-i to L-353; M-1 to L-352; M-
1
toV-35 i; M-1 to G-350; M-i to S-349; M-1 to V-348; M-1 to P-347; M-1 to R-
346; M-1
to M-34_5; M-1 to K-344; M-1 to G-343; M-1 toT-342; M-1 to Y-341; M-1 to E-
340; M-
1 to Q-339; M-I to Q-338; M-1 to L-337; M-1 to S-336; M-1 to L-335; M-1 to N-
334;
M-1 toL-333; M-1 to S-332; M-1 to V-331; M-1 to H-330; M-1 to Q-329; M-1 to S-
328;
M-1 to G-327; M-1 to L-326; M-1 to S-325; M-I toN-324; M-1 to Q-323; M-1 to A-
322;
M-1 to R-321; M-1 to C-320; M-1 to T-319; M-1 to F-3 I 8; M-1 to E-317; M-1 to
G-316;
M-1 toE-315; M-1 to D-314; M-I to G-313; M-1 to L-312; M-1 to H-3i 1; M-1 to V-
310;
M-1 to Q-309; M-1 to L-308; M-1 to E-307; M-1 toL-306; M-1 to V-305; M-1 to L-
304;
M-1 to P-303; M-1 to N-302; M-1 to S-301; M-1 to P-300; M-1 to Q-299; M-1 to S-
298;
M-1 toP-297; M-1 to Y-296; M-1 to L-295; M-1 to T-294; M-1 to L-293; M-1 to S-
292;
M-1 to R-291; M-1 to W-290; M-1 to T-289; M-1 toW-288; M-1 to S-287; M-1 to L-
286; M-1 to R-285; M-1 to A-284; M-1 to P-283; M-1 to P-282; M-1 to N-281; M-1
to
S-280; M-1 toD-279; M-1 to V-278; M-1 to A-277; M-1 to C-276; M-1 to V-275; M-
1 to
L-274; M-1 to R-273; M-1 to L-272; M-1 to S-271; M-1 toQ-270; M-1 to G-269; M-
1 to
E-268; M-1 to L-267; M-1 to V-266; M-1 to S-265; M-1 to L-264; M-1 to S-263; M-
1 to
S-262; M-1 toS-261; M-1 to N-260; M-1 to G-259; M-1 to L-258; M-1 to A-257; M-
1 to
T-256; M-1 to S-255; M-i to A-254; M-1 to T-253; M-1 toG-252; M-1 to E-251; M-
1 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435
PCT/U899/25031
98
G-250; M-1 to Q-249; M-1 to F-248; M-1 to V-247; M-1 to T-246; M-1 to V-245; M-
1
to T-244; M-1 toL-243; M-1 to N-242; M-1 to Q-241; M-1 to P-240; M-1 to P-239;
M-1
to Y-238; M-1 to S-237; M-1 to V-236; M-1 to N-235; M-1 toL-234; M-1 to Q-233;
M-1
to I-232; M-1 to T-231; M-1 to R-230; M-1 to N-229; M-I to T-228; M-1 to T-
227; M-1
to V-226; M-I toG-225; M-1 to A-224; M-1 to G-223; M-1 to P-222; M-1 to L-22I;
M-1
to T-220; M-1 to V-219; M-1 to Q-218; M-J to C-217; M-I toT-216; M-1 to L-2i5;
M-1
to S-214; M-I to T-213; M-I to G-212; M-1 to H-211; M-1 to H-210; M-1 to Q-
209; M-
1 to P-208; M-1 toQ-207; M-1 to P-206; M-1 to I-205; M-1 to L-204; M-I to T-
203; M-1
to L-202; M-1 to V-201; M-1 to S-200; M-1 to S-199; M-1 toR-198; M-1 to T-197;
M-1
to T-I96; M-1 to S-195; M-I to P-194; M-1 to H-193; M-1 to L-192; M-I to P-
191: M-1
to S-190; M-I toV-189; M-1 to S-188; M-1 to T-187; M-1 to G-186; M-1 to M-
18_5; M-I
to W-184; M-1 to S-183; M-1 to I-182; M-1 to M-181; M-1 toP-180; M-1 to P-179;
M-1
to T-178; M-1 to G-177; M-1 to Q-176; M-1 to E-I75; M-I to C-174; M-1 to A-
173; M-
1 to W-172; M-I toP-171; M-1 to V-170; M-1 to S-169; M-1 to C-168; M-1 to T-
167;
M-1 to L-166; M-1 to N-165; M-I to Q-164; M-1 to F-163; M-1 toC-162; M-1 to G-
161;
M-I to S-160; M-1 to E-159; M-1 to L-158; M-1 to T-157; M-1 to G-156; M-1 to P-
155;
M-1 to I-154; M-1 toL-153; M-1 to I-152; M-I to N-151: M-1 to P-150; M-1 to R-
149;
M-1 to H-148; M-1 to T-147; M-1 to L-146; M-1 to A-145; M-1 toT-144; M-I to V-
143;
M-1 to N-142; M-1 to V-141; M-1 to S-140; M-1 to L-139; M-1 to Q-138; M-1 to D-
137; M-1 to Y-136; M-1 toK-135; M-1 to Y-134; M-1 to N-133; M-1 to W-132; M-1
to
K-131; M-1 to I-130; M-1 to N-129; M-1 to G-128; M-1 to K-127; M-1 toE-126; M-
1 to
M-125; M-1 to R-124; M-1 to F-123; M-1 to F-122; M-1 to Y-12I; M-1 to R-120; M-
1
to G-119; M-1 to A-I 18; M-I toD-117; M-1 to S-116; M-1 to M-115; M-1 to R-
114; M-
1 to A-113; M-1 to D-I12; M-1 to R-111; M-1 to I-110; M-1 to S-109; M-1 toL-
108; M-
1 to T-107; M-1 to C-106; M-1 to N-105; M-1 to K-104; M-1 to T-103; M-1 to Q-
102;
M-1 to P-1 O 1; M-1 to D-100; M-1 toG-99; M-1 to L-98; M-1 to L-97; M-1 to H-
96; M-1
to F-95; M-1 to R-94; M- I to D-93; M-1 to R-92; M-1 to T-91; M- I to E-90; M-
1 toE-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
99
89; M-1 to Q-88; M-1 to V-87; M-1 to A-86; M-1 to W-85; M-1 to A-84; M-1 to P-
83;
M-1 to N-82; M-1 to N-81; M-1 to T-80; M-1 toA-79; M-1 to V-78; M-1 to P-77; M-
1 to
A-76; M-1 to K-75; M-1 to W-74; M-1 to S-73; M-1 to I-72; M-1 to D-71; M-1 to
N-70;
M-1 toG-69; M-1 to A-68; M-1 to R-67; M-1 to F-66; M-1 to W-65; M-1 to Y-64; M-
1
to G-63; M-1 to H-62; M-1 to V-61; M-1 to P-60; M-1 toD-S9; M-1 to S-_58; M-1
to D-
57; M-1 to T-56; M-I to Q-55; M-1 to S-54; M-1 to D-53; M-1 to V-52; M-1 to P-
51; M-
1 to Y-50; M-1 toS-49; M-1 to F-48; M-1 to S-47; M-1 to C-46; M-1 to R-45; M-1
to V-
44; M-1 to H-43; M-1 to V-42; M-1 to C-41; M-1 to M-40; M-1 toG-39; M-1 to E-
38:
M-1 to Q-37; M-1 to V-36; M-1 to T-35; M-1 to V-34; M-1 to S-33; M-1 to S-32;
M-1 to
Q-31; M-1 to M-30; M-1 toT'-29; M-1 to L-28; M-1 to S-27; M-1 to Y-26; M-1 to
D-2_5;
M-1 to K-24; M-1 to R-23; M-1 to N-22; M-1 to S-21; M- l to K-20; M-1 toQ-19;
M-1 to
G-18; M-1 to E-17; M-1 to V-16: M-1 to R-15; M-1 to E-14; M-1 to R-13; M-1 to
G-12;
M-1 to W-11; M-1 to L-10: M-1 toL-9; M-1 to P-8; M-1 to L-7; M-1 to L-6; of
SEQ ID
N0:34. Polypeptides encoded by these polynucleotides are also encompassed by
the
invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:16 which have been
determined
from the following related cDNA genes: HGBAY02R (SEQ ID NO:100) and
HLYBY62R (SEQ ID N0:101).
Based on the sequence similarity to the human CD33L1, translation product of
this gene is expected to share at least some biological activities with CD33
proteins, and
specifically myeloid modulatory proteins and/or siglec proteins. Such
activities are
known in the art, some of which are described elsewhere herein.
Specifically, polynucleotides and polypeptides of the invention are also
useful for
modulating the differentiation of normal and malignant cells, modulating the
proliferation and/or differentiation of cancer and neoplastic cells, and
modulating the
immune response. Polynucleotides and polypeptides of the invention may
represent a
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
100
diagnostic marker for hematopoietic and immune diseases and/or disorders. The
full-
length protein should be a secreted protein, based upon homology to the CD33
family.
Therefore, it is secreted into serum, urine, ar feces and thus the levels is
assayable from
patient samples. Assuming specific expression levels are reflective of the
presence of
immune disorders, this protein would provide a convenient diagnostic for early
detection.
In addition, expression of this gene product may also be linked to the
progression of
immune diseases, and therefore may itself actually represent a therapeutic or
therapeutic
target for the treatment of cancer.
Polynucleotides and polypeptides of the invention may play an important role
in
the pathogenesis of human cancers and cellular transformation, particularly
those of the
immune and hematopoietic systems. Polynucleotides and polypeptides of the
invention
may also be involved in the pathogenesis of developmental abnormalities based
upon its
potential effects on proliferation and differentiation of cells and tissue
cell types. Due to
the potential proliferating and differentiating activity of said
polynucleotides and
polypeptides, the invention is useful as a therapeutic agent in inducing
tissue
regeneration, for treating inflammatory conditions (e.g., inflammatory bowel
syndrome,
diverticulitis, etc.). Moreover, the invention is useful in modulating the
immune
response to aberrant polypeptides, as may exist in rapidly proliferating cells
and tissue
cell types, particularly in adenocarcinoma cells, and other cancers.
This gene is expressed predominantly on NK cells, and to a lesser extent on T-
cells. Therefore, polynucleotides and polypeptides of the invention are useful
as reagents
for differential identification of the tissues) or cell types) present in a
biological sample
and for diagnosis of the following diseases and conditions which include, but
are not
limited to, immune disorders and cancer, as well as the immunodiagnosis of
acute
leukemias. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful to provide immunological probes for differential identification of the
tissues) or
cell type(s). For a number of disorders of the above tissues or cells,
particularly of the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC'C/US99/25031
101
immune system, and breast tissue, expression of this gene at significantly
higher or
lower levels is detected in certain tissues or cell types (e.g. immune,
cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
from an individual not having the disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 34 as residues: Gly-12 to Tyr-26, VaI-52 to Asp-59, Gln-88
to
Asp-93, Arg-124 to Asn-129, His-193 to Arg-198, Gln-207 to Thr-213, Gln-338 to
Arg-
346, Ser-378 to Ala-384, Ser-413 to Arg-420, Ser-428 to Glu-434, His-443 to
Ser-451,
Glu-454 to Ser-461. Polynucleotides encoding said polypeptides are also
provided.
The tissue distribution in NK cells, in combination with the homology to
siglec
family of proteins indicates the protein product of this gene is useful for
the diagnosis
and treatment of a variety of immune system disorders. NK cells are bone-
marrow
derived granular lymphocytes that play an important role in natural immunity
to
infectious diseases and have the capacity to kill certain virally-infected
cells and tumor
cells that have down-regulated MHC Class-I antigen expression. The killing and
proinflammatory activities of NK cells are regulated through a variety of cell
surface
receptors that can mediate either activity or inhibitory signals. The best
understood
receptors are those that recognize MHC Class I molecules at the cell surface
and deliver
a negative signal, thereby protecting normal host cells from cytotoxicity.
These
receptors can belong either to the C-type lectin superfamily or the Ig
superfamily,
although in humans the majority are members of the Ig superfamily known as
killer cell
Ig-like receptors (KIRs). Representative uses are described in the "Immune
Activity" and
"infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20,
and 27, and
elsewhere herein. Briefly, the expression indicates a role in regulating the
proliferation;
survival; differentiation; and/or activation of hematopoietic cell lineages,
including blood
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/Z5031
102
stem cells. Involvement in the regulation of cytokine production, antigen
presentation,
or other processes indicates a usefulness for treatment of cancer (e.g. by
boosting
immune responses). Expression in cells of lymphoid origin, indicates the
natural gene
product is involved in immune functions. Therefore it would also be useful as
an agent
for immunological disorders including arthritis, asthma, immunodeficiency
diseases
such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease,
inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis,
hypersensitivities, such
as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues,
such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such
as autoimmune infertility, Tense tissue injury, demyelination, systemic lupus
erythematosis> drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease,
and scleroderma. Moreover, the protein may represent a secreted factor that
influences
the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells
to sites of injury. Thus, this gene product is thought to be useful in the
expansion of
stem cells and committed progenitors of various blood lineages, and in the
differentiation
and/or proliferation of various cell types. Based upon the tissue distribution
of this
protein, antagonists directed against this protein is useful in blocking the
activity of this
protein. Accordingly, preferred are antibodies which specifically bind a
portion of the
translation product of this gene.
Also provided is a kit for detecting tumors in which expression of this
protein
occurs. Such a kit comprises in one embodiment an antibody specific for the
translation
product of this gene bound to a solid support. Also provided is a method of
detecting
these tumors in an individual which comprises a step of contacting an antibody
specific
for the translation product of this gene to a bodily fluid from the
individual, preferably
serum, and ascertaining whether antibody binds to an antigen found in the
bodily fluid.
Preferably the antibody is bound to a solid support and the bodily fluid is
serum. The
above embodiments, as well as other treatments and diagnostic tests (kits and
methods),
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
103
are more particularly described elsewhere herein. Furthermore, the protein may
also be
used to determine biological activity, raise antibodies, as tissue markers, to
isolate
cognate ligands or receptors, to identify agents that modulate their
interactions, in
addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy
targets for
the above listed tissues.
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID NO:1G and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 1734 of SEQ ID NO:1G, b is an integer
of 15 to
174$, where both a and b correspond to the positions of nucleotide residues
shown in
SEQ ID N0:16, and where b is greater than or equal to a + 14.
FEATURES OF PROTEIN ENCODED BY GENE NO: 7
This invention relates to newly identified polynucleotides, polypeptides
encoded
by such polynucleotides, the use of such polynucleotides and polypeptides, as
well as the
production of such polynucleotides and polypeptides. The polypeptide of the
present
invention has been putatively identified as a human integrin alpha 11 homolog
derived
from a human vsteoblast I1 cDNA library. More particularly, the polypeptide of
the
present invention has been putatively identified as a human integrin alpha 11-
subunit
homolog, sometimes hereafter referred to as "integrin alpha 11 ", "integrin
alpha 11-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
104
subunit", "al l", "Al l-subunit", and/or "Integrin al l-subunit". The
invention also relates
to inhibiting the action of such polypeptides.
The integrins are a large family of cell adhesion molecules consisting of
noncovalently
associated ab heterodimers.
We have cloned and sequenced a novel human integrin a -subunit cDNA,
designated al 1. The al l cDNA encodes a protein with a 22 amino acid signal
peptide, a
large 1120 residue extracellular domain that contains an I-domain of 207
residues and is
linked by a transmembrane domain to a short cytoplasmic domain of 24 amino
acids. The
deduced al l protein shows the typical structural features of integrin a-
subunits and is
similar to a distinct group of a-subunits from collagen-binding integrins.
However, it
differs from most integrin a-chains by an incompleteteiy preserved cytoplasmic
GFFKR
motif.
The human ITGA I 1 gene was located to bands q22.3-23 on chromosome 15, and
its transcripts were found predominantly in bone, cartilage as well as in
cardiac and
skeletal muscle. Expression of the 5.5 kilobase al l mRNA was also detectable
in ovary
and small intestine.
All vertebrate cells express members of the integrin family of cell adhesion
molecules,
which mediate cellular adhesion to other cells and extracellular subtratum,
cell migration
and participate in important physiologic processes from signal transduction to
cell
proliferation and differentiation {Hypes, 92; Springer, 92 }.
Integrins are structurally homologous heterodimeric type-I membrane
glycoproteins formed by the noncovalent association of one of eight b -
subunits with one
of the 17 different a-subunits described to date, resulting in at least 22
different ab
complexes. Their binding specificities for cellular and extracellular ligands
are
determined by both subunits and are dynamically regulated in a cell-type-
specific mode
by the cellular environment as well as by the developmental and activation
state of the
cell {Diamond and Springer, 94}. In integrin a -subunits, the aminoterminal
region of the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
105
large extracellular domain consists of a seven-fold repeated structure which
is predicted
to fold into a b -propeller domain {Corbi et al., 1987; Springer, 1997 }. The
three or four
C-terminal repeats contain putative divalent cation binding motifs that are
thought to be
important for ligand binding and subunit association {Diamond and Springer,
94}. The
al, a2, a 10, aD, aE, aL, aM and aX-subunits contain an approximately 200
amino acid I-
domain inserted between the second and third repeat that is not present in
other a-chains
{ Larson et al., 1989 }. Several isolated I-domains have been shown to
independently bind
the ligands of the parent integrin heterodimer {Kamata and Takada, 1994; Randi
and
Hogg, 1994}. The a3, a5-8, aIIb and aV-subunits are proteolytically processed
at a
conserved site into disulphide-linked heavy and light chains, while the a4-
subunit is
cleaved at a more aminoterminal site into two fragments that remain
noncovalently
associated {Hemler et al., 90}. Additional a-subunit variants are generated by
alternative
splicing of primary transcripts {Ziober et al., 93; Delwel et al., 95; Leung
et al., 98 }.
The extracellular domains of a-integrin subunits are connected by a single
spanning transmembrane domain to short, diverse cytoplasmic domains whose only
conserved feature is a membrane-proximal KXGFF(K/R)R motif { Sastry and
Horwitz,
1993 }. The cytoplasmic domains have been implicated in the cell-type-specific
modulation of integrin affinity states { Williams et al., 1994 }.
The polypeptide of the present invention has been putatively identified as a
member of the integrin family and has been termed integrin alpha 11 subunit
("al l").
This identification has been made as a result of amino acid sequence homology
to the
human integrin alpha 1 subunit (See Genbank Accession No. gi~346210).
Figures 19A-F show the nucleotide (SEQ ID N0:17) and deduced amino acid
sequence (SEQ ID N0:35) of al 1. Predicted amino acids from about 1 to about
22
constitute the predicted signal peptide (amino acid residues from about 1 to
about 22 in
SEQ ID N0:35) and are represented by the underlined amino acid regions; amino
acids
from about 666 to about 682, and/or amino acids from about 114_5 to about 1161
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
106
constitute the predicted transmembrane domains (amino acids from about 666 to
about
682, and/or amino acids from about I 145 to about 1161 in SEQ ID N0:35) and
are
represented by the double underlined amino acids; and amino acids from about
64 to
about 96 constitute the predicted immunoglobulin and major histocompatibility
complex
protein domain (amino acids from about 64 to about 96 in SEQ ID N0:35) and are
represented by the bold amino acids.
Figure 20 shows the regions of similarity between the amino acid
sequences of the integrin alpha 11 subunit (al l) protein (SEQ ID N0:35) and
the human
integrin alpha 1 subunit (SEQ ID NO: 103).
Figure 21 shows an analysis of the integrin alpha 11 subunit (al l) amino acid
sequence. Alpha, beta, turn and coil regions; hydrophilicity and
hydrophobicity;
amphipathic regions; flexible regions; antigenic index and surface probability
are shown.
A polynucleotide encoding a polypeptide of the present invention is obtained
from human ovary ,small intestine, fetal heart, fetal brain, large intestine,
osteoblasts,
human trabelcular bone cells, messangial cells, adipocytes, osteosarcoma,
chondrosarcoma, breast cancer cells, and bone marrow tissues and cells. The
polynucleotide of this invention was discovered in a human osteoblast II cDNA
library.
Its translation product has homology to the characteristic immunoglobulin and
major
histocompatibility complex protein domain of integrin family members. As shown
in
Figures 19A-F, al l has transmembrane domains (the transmembrane domains
comprise
amino acids 666 - 682 and/or 1145 - 1161 of SEQ ID N0:35; which correspond to
amino acids 666 - 682 and/or 1145 - 1161 of Figures 19A-F) with strong
conservation
between other members of the integrin family. The polynucleotide contains an
open
reading frame encoding the al 1 polypeptide of I 189 amino acids. The present
invention
exhibits a high degree of homology at the amino acid level to the human
integrin alpha 1
subunit (as shown in Figure 20).
Preferred polypeptides of the invention comprise the following amino acid
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00129435 PCT/US99/25031
107
sequence: TNGYQKTGDVYKCPVIHGNCTKLNLGRVTLSNV (SEQ ID NO:102).
Polynucleotides encoding these polypeptides are also provided.
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the al I polypeptide having the amino acid sequence
shown in
Figures 19A-F (SEQ ID N0:35). The nucleotide sequence shown in Figures 19A-F
(SEQ ID N0:35) was obtained by sequencing a cloned cDNA (HOHBY69), which was
deposited on November 17 at the American Type Culture Collection, and given
Accession Number- 2034$4.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. I3y a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
N0:17 is intended DNA fragments at least about l5nt, and more preferably at
least about
nt, still more preferably at least about 30 nt, and even more preferably, at
least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
15 course, larger fragments 50-1500 nt in length are also useful according to
the present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:17. By a fragment at least 20
nt in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
20 shown in SEQ ID N0:17. In this context "about" includes the particularly
recited size,
larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either
terminus or at both
termini. Representative examples of al l polynucleotide fragments of the
invention
include, for example, fragments that comprise, or alternatively, consist of, a
sequence
from about nucleotide 1 to about 50, from about 51 to about 100, from about
101 to
about 150, from about 151 to about 200, from about 201 to about 250, from
about 251 to
about 300, from about 301 to about 350, from about 351 to about 400, from
about 401 to
about 450, from about 451 to about 500, from about 501 to about 550, from
about 551 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
108
about 600, from about 601 to about 650, from about 651 to about 700, from
about 701 to
about 750, from about 751 to about 800, from about 801 to about 850, from
about 851 to
about 900, from about 901 to about 950, from about 951 to about 1000, from
about 1001
to about 1050, from about 1051 to about 1100, from about 1101 to about 1150,
from
about 1151 to about i 200, from about 1201 to about 1250, from about 1251 to
about
1300, from about 1301 to about 1350, from about 1351 to about 1400, from about
1401
to about 1450, from about 14_51 to about 1500, from about 1_501 to about 1550,
from
about 1551 to about 1600, from about 1601 to about 1650, from about 1651 to
about
1700, from about 1701 to about 1750, from about 1751 to about 1800, from about
1801
to about 1850, from about 1851 to about 1900, from about 1901 to about 1950,
from
about 1951 to about 2000, from about 2001 to about 2050, from about 2051 to
about
2100, from about 2101 to about 2150, from about 2151 to about 2200, from about
2201
to about 2250, from about 2251 to about 2300, from about 2301 to about 2350,
from
about 2351 to about 2400, from about 2401 to about 2450, from about 245 i to
about
2500, from about 2501 to about 2550, from about 2551 to about 2600, from about
2601
to about 2650, from about 2651 to about 2700, from about 2701 to about 2750,
from
about 2751 to about 2800, from about 2801 to about 2850, from about 2851 to
about
2900, from about 2901 to about 2950, from about 2951 to about 3000, from about
3001
to about 3050, from about 3051 to about 3100, from about 3101 to about 3150,
from
about 3151 to about 3200, from about 3201 to about 3250, from about 3251 to
about
3300, from about 3301 to about 3350, from about 3351 to about 3400, from about
3401
to about 3450, from about 3451 to about 3500, from about 3501 to about 3550,
from
about 3551 to about 3600, from about 3601 to about 3650, from about 3651 to
about
3700, from about 3701 to about 3750, from about 3751 to about 3800, from about
3801
to about 3850, from about 3851 to about 3900, from about 3901 to about 3950,
from
about 3951 to about 4000, from about 4001 to about 4050, from about 4051 to
about
4100, from about 4101 to about 4150, from about 4151 to about 4200, from about
4201
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
109
to about 4250, from about 42S 1 to about 4300, from about 4301 to about 4350,
from
about 4351 to about 4400, from about 4401 to about 4450, from about 4451 to
about
4500, from about 4501 to about 4550, from about 4SS 1 to about 4600, from
about 4601
to about 4650, from about 46S 1 to about 4700, from about 4701 to about 4750,
from
S about 47S 1 to about 4800, from about 4801 to about 4850, from about 48S 1
to about
4900, from about 4901 to about 4950, from about 49S 1 to about 4995, from
about, from
about 1 to about 236, from about 144 to about 188, from about 231 to about 276
of SEQ
ID N0:17, or the complementary strand thereto, or the cDNA contained in the
deposited
gene. In this context "about" includes the particularly recited ranges, larger
or smaller by
several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.
Prefen-ed nucleic acid fragments of the present invention include nucleic acid
molecules encoding a member selected from the group: a poiypeptide comprising
or
alternatively, consisting of, any one of the transmembrane domains (amino acid
residues
from about 666 to about 682 and/or 1145 to about 1161 in Figures 19A-F (amino
acids
1 S from about 666 to about 682 and/or 1145 to about 1161 in SEQ ID N0:3S), in
addition to
the immunoglobulin and major histocompatibility complex protein domain (amino
acid
residues from about 64 to about 96 in Figures 19A-F (amino acids from about 64
to
about 96 in SEQ ID N0:3S). Since the location of these domains have been
predicted by
computer analysis, one of ordinary skill would appreciate that the amino acid
residues
constituting these domains may vary slightly (e.g., by about 1 to 1S amino
acid residues)
depending on the criteria used to define each domain. In additional
embodiments, the
polynucleotides of the invention encode functional attributes of al 1.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
2S beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/IJS99/25031
110
regions, surface-forming regions and high antigenic index regions of the
present
invention.
The data representing the structural or functional attributes of al l set
forth in
Figure 21 and/or Table VII, as described above, was generated using the
various modules
and algorithms of the DNA*STAR set on default parameters. In a preferred
embodiment, the data presented in columns VIII, IX, XIII, and XIV of Table VII
can be
used to determine regions of al I which exhibit a high degree of potential for
antigenicity. Regions of high antigenicity are determined from the .data
presented in
columns VIII, IX, XIII, and/or XIV by choosing values which represent regions
of the
polypeptide which are likely to be exposed on the surface of the polypeptide
in an
environment in which antigen recognition may occur in the process of
initiation of an
immune response.
Certain preferred regions in these regards are set out in Figure 21, but may,
as
shown in Table VII, be represented or identified by using tabular
representations of the
IS data presented in Figure 21. The DNA*STAR computer algorithm used to
generate
Figure 21 (set on the original default parameters) was used to present the
data in Figure
21 in a tabular format (See Table VII). The tabular format of the data in
Figure 21 is
used to easily determine specific boundaries of a preferred region. The above-
mentioned
preferred regions set out in Figure 21 and in Table VII include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figures 19A-F. As set out in Figure 21 and in Table VII, such preferred
regions
include Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-
regions,
Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic
regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-
amphipathic
regions, Karplus-Schu(z flexible regions, Jameson-Wolf regions of high
antigenic index
and Emini surface-forming regions. Even if deletion of one or more amino acids
from the
N-terminus of a protein results in modification of loss of one or more
biological
SUBSTITUTE SHEET (RULE Z6)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
111
functions of the protein, other functional activities (e.g., biological
activities, ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened al l
muteins to induce and/or bind to antibodies which recognize the complete or
mature
forms of the polypeptides generally will be retained when less than the
majority of the
residues of the complete or mature polypeptide are removed from the N-
terminus.
Whether a particular polypeptide lacking N-terminal residues of a complete
polypeptide
retains such immunologic activities can readily be determined by routine
methods
described herein and otherwise known in the art. It is not unlikely that an al
l mutein
with a large number of deleted N-terminal amino acid residues may retain some
biological or immunogenic acaivities. In tact, peptides composed of as few as
six al I
amino acid residues may often evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted fram the amino terminus of the al 1 amino acid sequence
shown in
Figures 19A-F, up to the threonine residue at position number 1184 and
polynucleotides
encoding such polypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-1189 of Figures 19A-F, where
nl is
an integer from 2 to 1184 corresponding to the position of the amino acid
residue in
Figures 19A-F (which is identical to the sequence shown as SEQ ID N0:35). In
another
embodiment, N-terminal deletions of the al l polypeptide can be described by
the general
formula n2-1189, where n2 is a number from 2 to 1184, corresponding to the
position of
amino acid identified in Figure 19. N-terminal deletions of the al l
polypeptide of the
invention shown as SEQ ID N0:35 include polypeptides comprising the amino acid
sequence of residues: N-terminal deletions of the al l polypeptide of the
invention shown
as SEQ ID N0:35 include polypeptides comprising the amino acid sequence of
residues:
D-2 to E-1189; L-3 to E-1189; P-4 to E-1189; R-5 toE-1189; G-6 to E-1189; L-7
to E-
1189; V-8 to E-1189; V-9 to E-1189;A-10 to E-1189; W-11 to E-1189; A-12 to E-I
189;
L-13 to E-1189;S-14 to E-1189: L-15 to E-1189; W-16 to E-1189; P-17 to E-
1189;6-18
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
112
to E-1189; F-19 to E-i 189; T-20 to E-1189; D-21 to E-1189;T-22 to E-1189; F-
23 to E-
1189; N-24 to E-1189; M-25 to E-1189;D-26 to E-1189; T-27 to E-1189; R-28 to E-
1189; K-29 to E-1189;P-30 to E-1189; R-31 to E-1189; V-32 to E-1189; I-33 to E-
1189;P-34 to E-1189; G-35 to E-1189; S-36 to E-1189; R-37 to E-1189;T-38 to E-
1189;
A-39 to E-1189; F-40 to E-1189; F-41 to E-1189;6-42 to E-1189; Y-43 to E-1189;
T-44
to E-1189; V-45 to E-1189;Q-46 to E-1189; Q-47 to E-1189; H-48 to E-1189; D-49
to E-
1189;I-50 to E-1189; S-51 to E-1189; G-52 to E-1189; N-53 to E-1189;x-54 to E-
1189;
W-55 to E-1189; L-56 to E-1189; V-57 to E-1189;V-58 to E-1189; G-59 to E-1189;
A-
60 to E-1189; P-61 to E-1189;L-62 to E-1189; E-63 to E-1189; T-64 to E-1 I89;
N-65 to
E-1189:6-66 to E-1189; Y-67 to E-1189; Q-68 to E-1189; K-69 to E-1189;T-70 to
E-
1189; G-71 to E-1 189; D-72 to E-1189; V-73 to E-1189;Y-74 to E-1189; K-75 to
E-
1189; C-76 to E-1189; P-77 to E-1189;V-78 to E-1189; I-79 to E-1189; H-80 to E-
1189;
G-81 to E-1189;N-82 to E-1189; C-83 to E-1189; T-84 to E-1189; K-8S to E-
1189;L-86
to E-1189; N-87 to E-1189; L-88 to E-1189; G-89 to E-1189;8-90 to E-1189; V-91
to E-
1189; T-92 to E-1189; L-93 to E-1189;5-94 to E-1189; N-95 to E-1189; V-96 to E-
1189;
S-97 to E-1189;E-98 to E-1189; R-99 to E-1189; K-100 to E-1189; D-101 to E-
1189;N-
102 to E-1189; M-103 to E-I 189; R-104 to E-1189; L-105 toE-1189; G-106 to E-
1189;
L-107 to E-1189; S-108 to E-1189; L-109to E-1189; A-110 to E-1189; T-111 to E-
1189;
N-112 to E-1189;P-113 to E-1189; K-114 to E-1189; D-115 to E-1189; N-116 toE-
1189;
S-117 to E-1189; F-118 to E-1189; L-119 to E-1189; A-120to E-1189; C-121 to E-
1189;
S-122 to E-1189; P-123 to E-1189;L-124 to E-1189; W-125 to E-1189; S-126 to E-
1189;
H-127 toE-1189; E-128 to E-1189; C-129 to E-1189; G-130 to E-1189; S-131to E-
1189;
S-132 to E-1189; Y-133 to E-1189; Y-134 to E-1189;T-135 to E-1189; T-136 to E-
1189;
G-137 to E-1189; M-138 toE-1189; C-139 to E-1189; S-140 to E-1189; R-141 to E-
1189; V-142to E-1189; N-143 to E-1189; S-144 to E-1189; N-145 to E-1189;F-146
to E-
1189; R-147 to E-1189; F-148 to E-1189; S-149 toE-1189; K-150 to E-1189; T-151
to E-
1189; V-152 to E-1189; A-153to E-1189; P-154 to E-1189; A-155 to E-1189; L-156
to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
113
E-1189;Q-157 to E-1189; R-158 to E-1189; C-159 to E-1189; Q-160 toE-1189; T-
161 to
E-1189; Y-162 to E-1189; M-163 to E-1189; D-164to E-1189; I-165 to E-1189; V-
166 to
E-1189; I-167 to E-1189; V-168to E-1189; L-169 to E-I 189; D-170 to E-1189; G-
171 to
E-1189;S-172 to E-1189; N-173 to E-1189; S-174 to E-1189; I-175 toE-1189; Y-
176 to
E-1189; P-177 to E-1189; W-178 to E-1189; V-179to E-1189; E-180 to E-1189; V-
181
to E-1189; Q-182 to E-I 189;H-183 to E-1189; F-184 to E-1189; L-18_5 to E-
1189; I-186
toE-1189; N-187 to E-1189; I-188 to E-1189; L-189 to E-1189; K-190to E-1189; K-
191
to E-1189; F-192 to E-1189; Y-193 to E-1189;1-194 to E-1189; G-195 to E-1189;
P-196
to E-1189; G-197 toE-1189; Q-198 to E-1189; I-199 to E-1189; Q-200 to E-1189;
V-
201to E-i 189; G-202 to E-1189; V-203 to E-I 189; V-204 to E-1189;Q-205 to E-
1189;
Y-206 to E-1189; G-207 to E-1189; E-208 toE-1189; D-209 to E-1189; V-210 to E-
1189; V-21 I to E-I 189; H-212to E-1189; E-213 to E-1189; F-214 to E-1189; H-
215 to
E-1189;L-2i6 to E-1189; N-217 to E-1189; D-218 to E-1189; Y-219 toE-1189; R-
220 to
E-1189; S-221 to E-1189; V-222 to E-1189; K-223to E-.l 189; D-224 to E-1189; V-
22_5
to E-1189; V-226 to E-I 189;E-227 to E-1189; A-228 to E-1189; A-229 to E-1189;
S-230
toE-1189; H-231 to E-1189; I-232 to E-1189; E-233 to E-1189; Q-234to E-1189; R-
235
to E-1189; G-236 to E-1189; G-237 to E-1189;T-238 to E-1189; E-239 to E-1189;
T-240
to E-1189; R-241 toE-1189; T-242 to E-1189; A-243 to E-1189; F-244 to E-1189;
G-
245to E-1189; I-246 to E-1189; E-247 to E-1189; F-248 to E-1189;A-249 to E-
1189; R-
250 to E-1189; S-251 to E-1189; E-252 toE-1189; A-253 to E-1189; F-254 to E-
1189; Q
255 to E-1189; K-256to E-1189; G-257 to E-1189; G-258 to E-1189; R-259 to E
I 189;x-260 to E-1189; G-261 to E-1189; A-262 to E-1189; K-263 toE-1189; K-264
to
E-1189; V-265 to E-1189; M-266 to E-1189; I-267to E-1189; V-268 to E-1189; I-
269 to
E-1189; T-270 to E-1189;D-271 to E-1189; G-272 to E-1189; E-273 to E-1189; S-
274
toE-1189; H-275 to E-1189; D-276 to E-1189; S-277 to E-1189; P-278to E-1189; D-
279
to E-1189; L-280 to E-1189; E-281 to E-1189;x-282 to E-1189; V-283 to E-1189;
I-284
to E-1189; Q-285 toE-1189; Q-286 to E-1189; S-287 to E-1189; E-288 to E-1189;
R-
SUBSTITUTE SHEET {RULE 26)
CA 02348824 2001-04-27
W4 00/29435 PCT/US99/25031
114
289to E-1189; D-290 to E-1189; N-291 to E-1189; V-292 to E-1189;T-293 to E-
1189;
R-294 to E-I 189; Y-295 to E-1189; A-296 toE-1189; V-297 to E-1189; A-298 to E-
1189; V-299 to E-1189; L-300to E-1189; G-301 to E-1189; Y-302 to E-1189; Y-303
to
E-I 189;N-304 to E-1189; R-305 to E-1189; R-306 to E-1189; G-307 toE-1189; I-
308 to
E-1189; N-309 to E-1189; P-310 to E-1189; E-31 lto E-1189; T-312 to E-I 189; F-
313 to
E-1189; L-314 to E-1189;N-315 to E-1189; E-316 to E- I 189; I-317 to E- I 189;
K-318
toE-1189; Y-319 to E-1189; I-320 to E-1189; A-321 to E-1189; S-322to E-1189; D-
323
to E-1189; P-324 to E-1189; D-325 to E-1189;D-326 to E-1189; K-327 to E-1189;
H-
328 to E-1189; F-329 toE-1189; F-330 to E-1189: N-331 to E-1189; V-332 to E-
1189; T-
333to E-1189; D-334 to E-1189; E-335 to E-1189; A-3:36 to E-1189;A-337 to E-
1189; L-
338 to E-1189; K-339 to E-1189; D-340 toE-1189; I-341 to E-1189; V-342 to E-I
189;
D-343 to E-I 189; A-344to E-1189; L-345 to E-1189; G-346 to E-1189; D-347 to E-
1189;8-348 to E-1189; I-349 to E-1189; F-350 to E-1189; S-351 toE-1189; L-352
to E-
1189; E-353 to E-1189; G-354 to E-1189; T-355to E-1189; N-356 to E-1189; K-357
to
E-1189; N-358 to E-1189;E-359 to E-1189; T-360 to E-1189; S-361 to E-1189; F-
362
toE-1189; G-363 to E-1189; L-364 to E-1189; E-365 to E-1189; M-366to E-I 189;
S-367
to E-1189; Q-368 to E-1189; T-369 to E-1189;6-370 to E-1189; F-371 to E-1189;
S-372
to E-1189; S-373 toE-1189; H-374 to E-1189; V-375 to E-1189; V-376 to E-1189;
E-
377to E-1189; D-378 to E-1189; G-379 to E-1189; V-380 to E-1189;L-381 to E-
1189; L-
382 to E-1189; G-383 to E-1189; A-384 toE-1189; V-385 to E-1189; G-386 to E-
1189;
A-387 to E-1189; Y-388to E-1189; D-389 to E-1189; W-390 to E-1189; N-391 to E-
1189;6-392 to E-1189; A-393 to E-1189; V-394 to E-1189; L-395 toE-1189; K-396
to
E-1189; E-397 to E-1189; T-398 to E-1189; S-399to E-1189; A-400 to E-1189; G-
401 to
E-1189; K-402 to E-1189;V-403 to E-1189; I-404 to E-1189; P-405 to E-1189; L-
406
toE-1189; R-407 to E-1189; E-408 to E-1189; S-409 to E-1189; Y-410to E-1189; L-
411
to E-1189; K-412 to E-1189; E-413 to E-1189;F-414 to E-1189; P-415 to E-I 189;
E-416
to E-1189; E-417 toE-1189; L-418 to E-1189; K-419 to E-1189; N-420 to E-1189;
H-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
115
421to E-1189; G-422 to E-1189; A-423 to E-1189; Y-424 to E-1189;L-425 to E-
1189;
G-426 to E-1189; Y-427 to E-1189; T-428 toE-1189; V-429 to E-1189; T-430 to E-
1189;
S-431 to E-1189; V-432to E-1189; V-433 to E-1189; S-434 to E-1189; S-435 to E-
1189;8-436 to E-1189; Q-437 to E-1189; G-438 to E-I 189; R-439 toE-1189; V-440
to
E-1189; Y-441 to E-1189; V-442 to E-1189; A-443to E-1189; G-444 to E-1189; A-
445
to E-1189; P-446 to E-1189;8-447 to E-1189; F-448 to E-1189; N-449 to E-1189;
H-450
toE-1189; T-451 to E-1189; G-4_52 to E-1189; K-453 to E-1189; V-454to E-1189;
I-455
to E-1189; L-456 to E-1189; F-457 to E-1189; T-458to E-1189; M-459 to E-1189;
H-460
to E-1189; N-461 to E-1189;N-462 to E-1189; R-463 to E-1189; S-464 to E-1189;
L-465
toE-1189; T-466 to E-1189; I-467 to E-1189; H-468 to E-1189; Q-469to E-1189; A-
470
to E-1189; M-471 to E-1189; R-472 to E-1189;G-473 to E-1189; Q-474 to E-1189;
Q-
475 to E-1189; I-476 toE-1189; G-477 to E-1189; S-478 to E-1189; Y-479 to E-
1189; F-
480to E-1189; G-481 to E-1189; S-482 to E-1189; E-483 to E-1189;1-484 to E-
1189; T-
485 to E-1189; S-486 to E-1189; V-487 toE-1189; D-488 to E-1189; I-489 to E-
1189; D-
490 to E-1189; G-491to E-1189; D-492 to E-1189; G-493 to E-1189; V-494 to E-
I 189;T-495 to E-1189; D-496 to E-1189; V-497 to E-1189; L-498 toE-1189; L-499
to E-
1189; V-500 to E-1189; G-501 to E-1189; A-502to E-1189; P-503 to E-1189; M-504
to
E-1189; Y-505 to E-1189;F-506 to E-I 189; N-507 to E-.1189; E-508 to E-1189; G-
_509
toE-1189; R-510 to E-1189; E-511 to E-1189; R-512 to E-1189; G-513to E-1189; K-
514
to E-1189; V-515 to E-1189; Y-516 to E-1189;V-517 to E-1189; Y-518 to E-1189;
E-
519 to E-I 189; L-520 toE-1189; R-521 to E-1189; Q-522 to E-1189; N-523 to E-
1189;
R-524to E-1189; F-525 to E-1189; V-526 to E-1189; Y-527 to E-1189;N-528 to E-
1189;
G-529 to E-1189; T-530 to E-1189; L-531 toE-1189; K-532 to E-1189; D-533 to E-
1189;
S-534 to E-1189; H-535to E-1189; S-536 to E-1189; Y-537 to E-1189; Q-538 to E-
1189;N-539 to E-1189; A-540 to E-1189; R-541 to E-1189; F-542 toE-1189; G-543
to E-
1189; S-544 to E-1189; S-545 to E-1189; I-546to E-1189; A-547 to E-1189; S-548
to E-
1189; V-549 to E-1189;8-550 to E-1189; D-551 to E-1189; L-552 to E-1189; N-553
SUBSTITUTE SHEET (RULE 26}
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/Z5031
116
toE-1189; Q-554 to E-1189; D-555 to E-1189; S-556 to E-1189; Y-557to E-1189; N-
558
to E-1189; D-559 to E-1189; V-560 to E-1189;V-561 to E-1 I89; V-562 to E-I
189; G-
563 to E-1189; A-564 toE-1189; P-565 to E-1 I89; L-566 to E-1189; E-567 to E-
1189;
D-568to E-1189; N-569 to E-1189; H-570 to E-1189; A-571 to E-1 I89;G-572 to E-
1189;
A-573 to E-1189; I-574 to E-1189; Y-_57.5 toE-1189; I-576 to E-1189; F-577 to
E-1189;
H-578 to E-I 189; G-579to E-1189; F-580 to E-1189; R-581 to E-1189; G-582 to E
1189;5-583 to E-I 189; I-584 to E-1189; L-.585 to E-1189; K-586 toE-1189; T-
_587 to E-
1189; P-588 to E-1189: K-589 to E-1189; Q-590to E-1189; R-591 to E-1189; I-592
to E-
1189; T-593 to E-1189;A-594 to E-1189; S-595 to E-1189; E-596 to E-1189; L-597
toE-
1189; A-598 to E-1189; T-599 to E-1189; G-600 to E-1189; L-601to E-1189: Q-602
to
E-1189; Y-603 to E-i 189; F-604 to E-1189;6-605 to E-1189: C-606 to E-1189; S-
607 to
E-1189; I-608 toE-1189; H-609 to E-1189; G-6I0 to E-1189; Q-611 to E-1189; L-
612to
E-1189; D-613 to E-1189; L-614 to E-1189; N-615 to E-1189;E-616 to E-1189; D-
6I7 to
E-1189; G-618 to E-1189; L-619 toE-1189; I-620 to E-1189; D-621 to E-1189; L-
622 to
E-1189; A-623to E-1189; V-624 to E-1189; G-625 to E-1189; A-626 to E-1189;L-
627 to
E-1189; G-628 to E-1189; N-629 to E-1189; A-630 toE-1189; V-631 to E-1189; I-
632 to
E-1189; L-633 to E-I 189; W-634to E-1189; S-635 to E-1189; R-636 to E-1189; P-
637 to
E-1189;V-638 to E-1189; V-639 to E-1189; Q-640 to E-1189; I-641 toE-1189; N-
642 to
E-1189; A-643 to E-1 I89; S-644 to E-1189; L-645to E-1189; H-646 to E-1189; F-
647 to
E-1189; E-648 to E-1189;P-649 to E-1189; S-650 to E-1189; K-651 to E-1189; I-
652
toE-1189; N-653 to E-1189;1-654 to E-1189; F-655 to E-1189; H-656to E-1189; R-
657
to E-1189; D-658 to E-1189; C-659 to E-1189;x-660 to E-1189; R-661 to E-1189;
S-662
to E-1189; G-663 toE-1189; R-664 to E-1189; D-665 to E-1189; A-666 to E-1189;
T-
667to E-1189; C-668 to E-1189; L-669 to E-1189; A-670 to E-1189;A-671 to E-
1189; F-
672 to E-1189; L-673 to E-1189; C-674 toE-1189; F-675 to E-I 189; T-676 to E-
1189; P-
677 to E-1189; I-678 toE-1189; F-679 to E-1189; L-680 to E-1189; A-681 to E-
1189; P-
682to E-1189; H-683 to E-1189; F-684 to E-1189;~Q-685 to E-1189;T-686 to E-
1189; T-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
117
687 to E-1189; T-688 to E-1189; V-689 toE-1189; G-690 to E-1189; I-691 to E-
1189; 8-
692 to E-1189; Y-693to E-1189; N-694 to E-1189; A-695 to E-1189; T-696 to E-
1189;M-697 to E-1189; D-698 to E-1189; E-699 to E-1 i89; R-700 toE-1189; R-701
to
E-1189; Y-702 to E-1189; T-703 to E-1189; P-704to E-1189; R-705 to E-1189; A-
706 to
E-1189; H-707 to E-1189;L-708 to E-1189; D-709 to E-1189; E-710 to E-1189; G-
711
toE-1189; G-712 to E-1189; D-713 to E-1189; R-714 to E-1189; F-715to E-1189; T-
716
to E-1189; N-717 to E-1189; R-718 to E-1189;A-719 to E-1189; V-720 to E-1189;
L-
721 to E- I 189; L-722 toE- I 189; S-723 to E-1 I 89; S-724 to E-1 I 89; G-725
to E-1189; Q-
726to E-1189; E-727 to E-1189; L-728 to E-1189; C-729 to E-1189;E-730 to E-
1189; 8-
731 to E-1189; I-732 to E-i 189; N-733 toE-1189; F-734 to E-I 189; H-735 to E-
1189; V-
736 to E-1189; L-737to E-1189; D-738 to E-1189; T-739 to E-1189; A-740 to E-
1189:D-
741 to E-1189; Y-742 to E-1189; V-743 to E-1189; K-744 toE-1189; P-745 to E-
1189;
V-746 to E-1189; T-747 to E-1189; F-748to E-1189; S-749 to E-1189; V-750 to E-
1189;
E-751 to E-1189;Y-752 to E-1189; S-753 to E-I 189; L-7.54 to E-I 189; E-755
toE-1189;
D-756 to E-1 I89; P-757 to E-1189; D-758 to E-1189; H-759to E-1189; G-760 to E-
I 189; P-761 to E-1 I89; M-762 to E-1189;L-763 to E-1189; D-764 to E-1189; D-
765 to
E-1189; G-766 toE-1189; W-767 to E-1189; P-768 to E-1189; T-769 to E-1189; T-
770to
E-1189; L-771 to E-1189; R-772 to E-1189; V-773 to E-1189;5-774 to E-1189; V-
775 to
E-1189; P-776 to E-1189; F-777 toE-1189; W-778 to E-1189; N-779 to E-1189; G-
780
to E-1189; C-781to E-1189; N-782 to E-1189; E-783 to E-1189; D-784 to E-1
i89;E-785
to E-1189; H-786 to E-1189; C-787 to E-1189; V-788 toE-1189; P-789 to E-1189;
D-790
to E-1189; L-791 to E-1189; V-792to E-1189; L-793 to E-1189; D-794 to E-1189;
A-795
to E-1189;8-796 to E-I 189; S-797 to E-1189; D-798 to E-1189; L-799 toE-1189;
P-800
to E-1189; T-801 to E-1189; A-802 to E-1189; M-803to E-1189; E-804 to E-1189;
Y-
805 to E-1189; C-806 to E-1189;Q-807 to E-1189; R-808 to E-1189; V-809 to E-
1189;
L-810 toE-1189; R-811 to E-1189; K-812 to E-1189; P-813 to E-1189; A-814to E-
118.9;
Q-815 to E-1189; D-816 to E-1189; C-817 to E-1189;5-818 to E-1189; A-819 to E-
1189;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
II$
Y-820 to E-1189; T-821 toE-1189; L-822 to E-1189; S-823 to E-1189; F-824 to E-
1189;
D-825to E-1189; T-826 to E-1189; T-827 to E-11$9; V-828 to E-1189;F-829 to E-
1189;
I-830 to E-I 189; I-831 to E-1189; E-832 to E-1189;S-833 to E-1189; T-834 to E-
1189;
R-835 to E-I 189; Q-836 toE-1189; R-837 to E-1189; V-838 to E-1189; A-839 to E-
1189; V-840to E-1189; E-841 to E-1189; A-842 to E-I 189; T-843 to E-1189;L-844
to E-
1189; E-845 to E-1189; N-846 to E-1189; R-847 toE-I 189; G-848 to E-1189; E-
849 to
E-1189; N-850 to E-I 189; A-851to E-I I$9; Y-852 to E-1189; S-853 to E-I 189;
T-854 to
E-1189;V-855 to E-1189; L-856 to E-1189; N-$57 to E-1189; I-858 toE-I 189; S-
859 to
E-1189; Q-860 to E-1189; S-861 to E-I 189; A-862to E-I 189; N-863 to E-1189; L-
$64 to
E-1189; Q-865 to E-1189;F-866 to E-1189; A-867 to E-1189; S-868 to E-1189; L-
869
toE-1189; I-870 to E-1189; Q-871 to E-1189; K-872 to E-1189; E-873to E-1189; D-
874
to E-1189; S-87_5 to E-1189; D-876 to E-1189;6-877 to E-I 189; S-878 to E-
1189; I-879
to E-1189; E-880 toE-1189; C-881 to E-1189; V-882 to E-I 189; N-883 to E-1189;
E-
884to E-1189; E-885 to E-1189; R-886 to E-11$9: R-887 to E-1189;L-888 to E-
1189; Q-
889 to E-11$9; K-890 to E-1189; Q-$91 toE-1189; V-892 to E-1189; C-893 to E-
1189;
N-894 to E-1189; V-895to E-1189; S-$96 to E-1189; Y-897 to E-1189; P-898 to E-
1189;F-899 to E-1189; F-900 to E-1189; R-901 to E-1189; A-902 toE-1189; K-903
to E-
1189; A-904 to E-1189; K-905 to E-1189; V-906to E-I 189; A-907 to E-1189; F-
908 to
E-1189; R-909 to E-1189;L-910 to E-1189; D-911 to E-1189; F-912 to E-1189; E-
913
toE-1189; F-914 to E-1189; S-915 to E-1189; K-916 to E-I 189; S-917to E-1189;
I-91$
to E-1189; F-919 to E-1189; L-920 to E-1189;H-921 to E-1189; H-922 to E-I 189;
L-923
to E-1189; E-924 toE-1 I89; I-925 to E-1189; E-926 to E-1189; L-927 to E-1189;
A-
928to E-1189; A-929 to E-1189; G-930 to E-1189; S-931 to E-1189;D-932 to E-
1189; S-
933 to E-1189; N-934 to E-1189; E-935 toE-1189; R-936 to E-1189; D-937 to E-
1189;
S-938 to E-I I$9; T-939to E-1189; K-940 to E-1189; E-941 to E-1189; D-942 to E-
1189;N-943 to E-1189; V-944 to E-1189; A-945 to E-1189; P-946 toE-1189; L-947
to E-
1189; R-948 to E-1189; F-949 to E-1189; H-950to E-1189; L-951 to E-1189; K-952
to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
119
E-1189; Y-953 to E-1189;E-954 to E-1189; A-955 to E-1189; D-956 to E-1189; V-
957
toE-1189; L-958 to E-1189; F-959 to E-1189; T-960 to E-1189; R-961to E-1189; S-
962
to E-1189; S-963 to E-1189; S-964 to E-1189;L-965 to E-1189; S-966 to E-1189;
H-967
to E-1189; Y-968 toE-1189; E-969 to E-1189; V-970 to E-1189; K-971 to E-1189;
L-
972to E-1189; N-973 to E-1189; S-974 to E-1189; S-97.5 to E-1189;L-976 to E-
1189; E-
977 to E-1189; R-978 to E-1189; Y-979 toE-1189; D-980 to E-1189; G-981 to E-
1189; 1-
982 to E-1189; G-983to E-1189; P-984 to E-1189; P-985 to E-1189; F-986 to E-
1189;5-
987 to E-1189; C-988 to E-1189; I-989 to E-1189; F-990 toE-I 189; R-991 to E-
1189; I-
992 to E-1189; Q-993 to E-1189; N-994to E-1189; L-99_5 to E-1189; G-996 to E-
1189;
L-997 to E-1189;F-998 to E-1189; P-999 to E-1189; I-1000 to E-1189; H-1001 toE-
1189; G-1002 to E-1189; 1-1003 to E-1189; M-1004 to E-1189;M-1005 to E-1189; K-
1006 to E-1189; I-1007 to E-1189; T-1008 toE-1189; I-1009 to E-1189; P-1 O 10
to E-
1189; I-1011 to E-1189;A-1012 to E-1189; T-1013 to E-1189; R-1014 to E-1189; S-
1015
toE-1189; G-1016 to E-1189; N-1017 to E-1189; R-1018 to E-1189;L-1019 to E-
1189;
L-1020 to E-1189; K-1021 to E-1189; L-1022 toE-1189; R-1023 to E-1 i89; D-1024
to
E-1189; F-1025 to E-1189;L-1026 to E-1189; T-1027 to E-1189; D-1028 to E-1189;
E-
l029 toE-i 189; V-1030 to E-1189; A-1031 to E-1189; N-1032 to E-1189;T-1033 to
E-
1189; S-1034 to E-1189; C-1035 to E-1189; N-1036 toE-1189; I-1037 to E-1189; W
1038 to E-1189; G-1039 to E-1189;N-1040 to E-1189; S-1041 to E-1189; T-1042 to
E
1189; E-1043 toE-1189; Y-1044 to E-1189; R-1045 to E-1189; P-1046 to E-1189;T-
1047 to E-1189; P-1048 to E-1189; V-1049 to E-1189; E-1050 toE-1189; E-1051 to
E-
1189; D-1052 to E-1189; L-1053 to E-1189;8-1054 to E-1189; R-1055 to E-1189; A-
1056 to E-1189; P-1057 toE-1189; Q-1058 to E-1189; L-1059 to E-1189; N-1060 to
E-
1189;H-1061 to E-1189; S-1062 to E-1189; N-1063 to E-1189; S-1064 toE-1189; D-
1065 to E-1189; V-1066 to E-1189; V-1067 to E-1189;5-1068 to E-1189; I-1069 to
E-
i 189; N-1070 to E-1189; C-1071 toE-1189; N-1072 to E-1189; I-1073 to E-1189;
8-
1074 to E-1189;L-107_5 to E-1189; V-1076 to E-1189; P-1077 to E-1189; N-1078
toE-
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99IZ5031
120
1189; Q-1079 to E-1189; E-1080 to E-1189; I-1081 to E-I189;N-1082 to E-1189; F-
1083 to E-1189; H-1084 to E-1189; L-1085 toE-1 i89; L-1086 to E-1189; G-1087
to E-
1189; N-1088 to E-1189;L-1089 to E-1189; W-1090 to E-1189; L-1091 to E-1189; 8-
1092 toE-1189; S-1093 to E-1189; L-1094 to E-1189; K-1095 to E-1189;A-1096 to
E-
S 1189; L-1097 to E-1189; K-1098 to E-1189; Y-1099 toE-1189; K-l 100 to E-
1189; 5-
1101 to E-1189; M-1102 to E-1189;x-1103 to E-1189; I--1104 to E-1189; M-1 lOS
to E-
1189; V-1106 toE-1189; N-1107 to E-1189; A-1108 to E-1189; A-1109 to E-1189;L-
1110 to E-1 I 89; Q- I 1 I 1 to E-1189; R-1112 to E-1189; Q-11 I 3 toE-1189; F-
1114 to E-
1189; H-I I1S to E-1189; S-1116 to E-1189;P-1117 to E-1189; F-1118 to E-1189;
I-1119
to E-1189; F-1120 toE-1189; K-1121 to E-1189; E-1122 to E-1189; E-1123 to E-
1189;D-
1124 to E-1189; P-1125 to E-1189; S-1126 to E-1189; R-1127 toE-1189; Q-1128 to
E-
1189; I-1129 to E-1189; V-1130 to E-1189;F-1131 to E-1189; E-1132 to E-1189; I-
1133
to E-1189; S-1134 toE-1189; K-1135 to E-1189; Q-1136 to E-I 189; E-1137 to E-
1189;D-1138 to E-1189; W-1139 to E-1189; Q-1140 to E-1189; V-1141 toE-1189; P-
1142 to E-1189; I-1143 to E-1189; W-I 144 to E-1189;I-1145 to E-1189; I-1146
to E-
1189; V-1147 to E-1189; G-1148 toE-1189; S-1149 to E-1189; T-1150 to E-1189; L-
1151 to E-1189;6-1152 to E-1189; G-1153 to E-1189; L-I IS4 to E-1189; L-1155
toE-
1189; L-1156 to E-1189; L-1157 to E-1189; A-1158 to E-1189;L-1159 to E-1189; L-
1160 to E-1189; V-1161 to E-1189; L-1162 toE-1189; A-i 163 to E-1189; L-1164
to E-
1189; W-1165 to E-1189;x-1166 to E-1189; L-1167 to E-1189; G-1168 to E-1189; F-
1169 toE-1189; F-1170 to E-1189; R-1171 to E-1189; S-1172 to E-1189;A-1173 to
E-
1189; R-1174 to E-1189; R-1175 to E-1189; R-1176 toE-1189; R-1177 to E-I 189;
E-
1178 to E-1189; P-1179 to E-1189;6-1180 to E-1189; L-1181 to E-1189; D-1182 to
E-
1189; P-1183 toE-1189; T-1184 to E-1189; of SEQ ID N0:3S. Polypeptides encoded
by
2S these polynucleotides are also encompassed by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
SUBSTITUTE SHEET (RULE 26)\
CA 02348824 2001-04-27
WO 00/29435 PCT/US99J25031
121
functions of the protein, other functional activities (e.g., biological
activities (e.g., ability
to illicit mitogenic activity, induce differentiation of normal or malignant
cells, ability to
multimerize, etc.) may still be retained. For example the ability of the
shortened al l
mutein to induce and/or bind to antibodies which recognize the complete or
mature forms
of the polypeptide generally will be retained when less than the majority of
the residues
of the complete or mature polypeptide are removed from the C-terminus. Whether
a
particular polypeptide lacking C-terminal residues of a complete polypeptide
retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that an al l mutein with a
large number
of deleted C-terminal amino acid residues may retain some biological or
immunoaenic
activities. In fact, peptides composed of as few as six al 1 amino acid
residues may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the al 1
polypeptide shown in Figures 19A-F, up to the glycine residue at position
number 6, and
polynucleotides encoding such polypeptides. In particular, the present
invention
provides polypeptides comprising the amino acid sequence of residues 1-ml of
Figures
19A-F, where ml is an integer from 6 to 1189 corresponding to the position of
the amino
acid residue in Figures 19A-F. Moreover, the invention provides
polynucleotides
encoding polypeptides comprising, or alternatively consisting of, the amino
acid
sequence of C-terminal deletions of the al 1 polypeptide of the invention
shown as SEQ
ID N0:35 include polypeptides comprising the amino acid sequence of residues:
M-1 to
L-118$; M-1 to V-1187; M-1 to K-1186;M-1 to P-1185; M-1 to T-1184; M-1 to P-
1183;
M-1 to D-1182; M-1 to L-1181; M-1 to G-1 I80; M-1 toP-1179; M-1 to E-1178; M-1
to
R-1177; M-1 to R-1176; M-1 to R-1175; M-1 to R-1174; M-1 to A-1173; M-lto S-
1172;
M-1 to R-1171; M-1 to F-1170; M-1 to F-1169; M-1 to G-I 168; M-1 to L-1167; M-
1 to
K-i 166;M-1 to W-1165; M-1 to L-1164; M-1 to A-1163; M-1 to L-1162; M-1 to V-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
122
1161; M-1 to L-1160; M-1 toL-1159; M-1 to A-1158; M-1 to L-1157; M-1 to L-
1156;
M-1 to L-1155; M-1 to L-1154; M-1 to G-1153; M-lto G-1152; M-1 to L-1 i51; M-1
to
T-1150; M-1 to S-1149; M-1 to G-1148; M-1 to V-1147; M-1 to I-1146;M-1 to I-
1145;
M-1 to W-1144; M-1 to I-1143; M-1 to P-1142; M-1 to V-1141; M-1 to Q-1140; M-1
toW-1139; M-1 to D-1138; M-1 to E-1137; M-1 to Q-1136; M-1 to K-1135; M-1 to S-
1134; M-I to I-1133; M-lto E-1132; M-I to F-1131; M-1 to V-1130; M-1 to I-
1129; M-
1 to Q-1128; M-1 to R-1127; M-1 to S-1126;M-I to P-I 125; M-1 to D-1124; M-1
to E-
1123; M-1 to E-1122; M-1 to R-1121; M-1 to F-1120; M-1 toI-1119; M-1 to F-
1118; M-
1 to P-1117; M-1 to S-1116; M-I to H-1115; M-1 to F-1114; M-1 to Q-11 i3; M-
lto R-
1112; M-1 to Q-1111; M-1 to L-11 I0; M-1 to A-1109; M-I to A-1108; M-I to N-
1107;
M-1 to V-1106;M-1 to M-1105; M-1 to I-1104; M-1 to K-1103; M-1 to M-1102; M-1
to
S-1101; M-1 to K-1100; M-1 toY-1099; M-1 to K-1098; M-1 to L-1097; M-1 to A-
1096;
M-1 to K-1095; M-1 to L-1094; M-1 to S-1093; M-lto R-1092; M-1 to L-1091; M-1
to
W-1090; M-1 to L-1089; M-1 to N-1088; M-1 to G-1087; M-1 to L-1086;M-1 to L-
1085; M-1 to H-1084; M-1 to F-1083; M-1 to N-1082; M-1 to I-1081; M-1 to E-
1080;
M-1 toQ-1079; M-1 to N-1078; M-1 to P-1077; M-I to V-1076; M-1 to L-1075; M-1
to
R-1074; M-1 to I-1073; M-lto N-1072; M-1 to C-1071; M-1 to N-1070; M-1 to I-
1069;
M-1 to S-1068; M-I to V-1067; M-1 to V-1066;M-1 to D-1065; M-1 to S-1064; M-1
to
N-1063; M-1 to S-1062; M-I to H-1061; M-1 to N-1060; M-1 toL-1059; M-1 to Q-
1058;
M-1 to P-1057; M-1 to A-1056; M-1 to R-1055; M-1 to R-1054; M-1 to L-1053; M-
lto
D-1052; M-1 to E-1051; M-1 to E-1050; M-1 to V-1049; M-1 to P-1048; M-1 to T-
1047;
M-1 to P-1046;M-1 to R-1045; M-1 to Y-1044; M-1 to E-1043; M-1 to T-1042; M-1
to
S-1041; M-1 to N-1040; M-1 toG-1039; M-1 to W-1038; M-1 to I-1037; M-1 to N-
1036;
M-1 to C-1035; M-1 to S-1034; M-1 to T-1033; M-lto N-1032; M-1 to A-1031; M-1
to
V-1030; M-1 to E-1029; M-1 to D-1028; M-1 to T-1027; M-1 to L-1026;M-1 to F-
1025;
M-1 to D-1024; M-1 to R-1023; M-1 to L-1022; M-1 to K-1021; M-1 to L-1020; M-I
toL-1019; M-1 to R-1018; M-1 to N-1017; M-1 to G-1016; M-1 to S-1015; M-i to R-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
123
1014; M-1 to T-1013; M-Ito A-1012; M-1 to I-1011; M-1 to P-1010; M-1 to I-
1009; M-
1 to T-1008; M-1 to I-1007; M-I to K-1006; M-lto M-1005; M-1 to M-1004; M-1 to
I-
1003; M-1 to G-1002; M-1 to H-1001; M-1 to I-1000; M-1 to P-999;M-1 to F-998;
M-1
to L-997; M-1 to G-996; M-1 to L-995; M-1 to N-994; M-1 to Q-993; M-1 to I-
992; M-1
toR-991; M-1 to F-990; M-1 to I-989; M-1 to C-988; M-1 to S-987; M-1 to F-986;
M-1
to P-985; M-1 to P-984;M-1 to G-983; M-1 to I-982; M-1 to G-981; M-1 to D-980;
M-l
to Y-979; M-1 to R-978; M-1 to E-977; M-1 toL-976; M-I to S-975; M-1 to S-974;
M-1
to N-973; M-1 to L-972; M-1 to K-971; M-1 to V-970; M-1 toE-969; M-1 to Y-968;
M-1
to H-967; M-I to S-966; M-1 to L-965; M-1 to S-964; M-I to S-963; M-1 to S-
962;M-1
to R-961; M-1 to T-960; M-1 to F-959; M-I to L-958; M-1 to V-957; M-1 to D-
956; M-1
to A-955; M-I toE-954; M-1 to Y-953; M-1 to K-952; M-1 to L-951; M-1 to H-950;
M-1
to F-949; M-1 to R-948; M-1 toL-947; M-1 to P-946; M-1 to A-945; M-1 to V-944;
M-1
to N-943; M-1 to D-942; M-1 to E-941; M-1 toK-940; M-1 to T-939; M-1 to S-938;
M-1
to D-937; M-1 to R-936; M-1 to E-935; M-1 to N-934; M-1 toS-933; M-1 to D-932;
M-1
to S-931; M-1 to G-930; M-1 to A-929; M-1 to A-928; M-1 to L-927; M-1 toE-926;
M-1
to I-925; M-1 to E-924; M-1 to L-923; M-1 to H-922; M-1 to H-921; M-1 to L-
920; M-1
to F-919;M-1 to I-918; M-1 to S-917; M-1 to K-916; M-1 to S-915; M-1 to F-914;
M-1
to E-9I3; M-1 to F-912; M-1 toD-911; M-1 to L-910; M-1 to R-909; M-1 to F-908;
M-1
to A-907; M-1 to V-906; M-1 to K-905; M-1 toA-904; M-I to K-903; M-1 to A-902;
M-
1 to R-901; M-1 to F-900; M-1 to F-899; M-1 to P-898; M-1 toY-897; M-1 to S-
896; M-
1 to V-895; M-1 to N-894; M-1 to C-893; M-1 to V-892; M-1 to Q-891; M-1 toK-
890;
M-1 to Q-889; M-1 to L-888; M-1 to R-887; M-1 to R-886; M-1 to E-885; M-1 to E-
884;
M-1 toN-883; M-1 to V-882; M-1 to C-881; M-1 to E-880; M-1 to I-879; M-1 to S-
878;
M-1 to G-877; M-1 to D-876;M-1 to S-875; M-1 to D-874; M-1 to E-873; M-1 to K-
872;
M-1 to Q-871; M-1 to I-870; M-1 to L-869; M-1 toS-868; M-1 to A-867; M-1 to F-
866;
M-1 to Q-865; M-1 to L-864; M-1 to N-863; M-I to A-862; M-1 toS-861; M-1 to Q-
860;
M-1 to S-859; M-1 to I-858; M-1 to N-857; M-1 to L-856; M-1 to V-855; M-1 to T-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
124
854;M-1 to S-853; M-1 to Y-852; M-1 to A-851; M-1 to N-850; M-1 to E-849; M-1
to
G-848; M-1 to R-847; M-lto N-846; M-1 to E-845; M-I to L-844; M-1 to T-843; M-
1 to
A-842; M-1 to E-841; M-1 to V-840; M-1 toA-839; M-1 to V-838; M-1 to R-837; M-
1 to
Q-836; M-1 to R-835; M-1 to T-834; M-1 to S-833; M-1 toE-832; M-! to I-831; M-
1 to
I-830; M-1 to F-829; M-1 to V-828; M-1 to T-827; M-1 to T-826; M-1 to D-825;M-
1 to
F-824; M-1 to S-823; M-1 to L-822; M-1 to T-821; M-1 to Y-820; M-I to A-819; M-
1 to
S-818; 1VI-1 toC-817; M-l to D-816; M-1 to Q-815; M-1 to A-814; M-1 to P-813;
M-1 to
K-812; M-1 to R-811; M-i toL-810; M-1 to V-809; M-1 to R-808; M-I to Q-807; M-
I to
C-806; M-I to Y-805; M-1 to E-804; M-1 toM-803; M-1 to A-802; M-1 to T-801; M-
1
to P-800; M-1 to L-799; M-1 to D-798; M-1 to S-797; M-1 toR-796; M-1 to A-795;
M-1
to D-794; M-1 to L-793; M-1 to V-792; M-1 to L-791; M-1 to D-790; M-1 toP-789;
M-1
to V-788; M-1 to C-787; M-1 to H-786; M-i to E-785; M-1 to D-784; M-1 to E-
783; M-
1 toN-782; M-1 to C-781; M-I to G-780; M-1 to N-779; M-1 to W-778; M-1 to F-
777;
M-1 to P-776; M-1 toV-775; M-1 to S-774; M-1 to V-773; M-1 to R-772; M-1 to L-
771;
M-1 to T-770; M-1 to T-769; M-1 to P-768;M-1 to W-767; M-1 to G-766; M-1 to D-
765;
M-1 to D-764; M-1 to L-763; M-I to M-762; M-1 to P-761; M-Ito G-760; M-1 to H-
759; M-1 to D-758; M-1 to P-?57; M-1 to D-756; M-1 to E-755; M-1 to L-754; M-1
toS-
753; M-1 to Y-752; M-1 to E-751; M-1 to V-750; M-1 to S-749; M-1 to F-748; M-1
to
T-747; M-1 to V-746;M-1 to P-745; M-1 to K-744; M-1 to V-743; M-1 to Y-742; M-
1 to
D-741; M-1 to A-740; M-1 to T-739; M-lto D-738; M-1 to L-737; M-1 to V-736; M-
1 to
H-735; M-1 to F-734; M-1 to N-733; M-1 to I-732; M-1 toR-73I; M-1 to E-730; M-
1 to
C-729; M-1 to L-728; M-1 to E-727; M-1 to Q-726; M-1 to G-725; M-1 toS-724; M-
1 to
S-723; M-1 to L-722; M-1 to L-721; M-1 to V-720; M-1 to A-719; M-1 to R-718; M-
i
toN-717; M-1 to T-716; M- i to F-715; M-1 to R-714; M-1 to D-713 ; M-1 to G-
712; M-1
to G-711; M-1 toE-710; M-1 to D-709; M-1 to L-708; M-I to H-707; M-1 to A-706;
M-1
to R-705; M-1 to P-704; M-1 toT-703; M-1 to Y-702; M-1 to R-701; M-1 to R-700;
M-1
to E-699; M-1 to D-698; M-1 to M-697; M-1 toT-696; M-1 to A-695; M-1 to N-694;
M-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
125
1 to Y-693; M-1 to R-692; M-1 to I-691; M-1 to G-690; M-1 toV-689; M-1 to T-
688; M-
1 to T-687; M-1 to T-686; M-1 to Q-685; M-1 to F-684; M-1 to H-683; M-1 to P-
682;M-
1 to A-681; M-1 to L-680; M-1 to F-679; M-1 to I-678; M-1 to P-677; M-1 to T-
676; M-
1 to F-675; M-1 toC-674; M-1 to L-673; M-1 to F-672; M-1 to A-671; M-1 to A-
670; M-
1 to L-669; M-1 to C-668; M-1 to T-667;M-1 to A-666; M-1 to D-665; M-1 to R-
664;
M-1 to G-663; M-I to S-662; M-1 to R-661; M-1 to K-660; M-lto C-659; M-1 to D-
658;
M-1 to R-6_57; M-1 to H-656; M-1 to F-655; M-1 to I-654; M-1 to N-653; M-1 toI-
652;
M-1 to K-651; M-1 to S-650; M-1 to P-649; M-1 to E-648; M-1 to F-647; M-1 to H-
646;
M-1 to L-645;M-1 to S-644; M-1 to A-643; M-1 to N-642; M-1 to I-641; M-1 to Q-
640;
M-1 to V-639; M-1 to V-638; M-1 toP-637; M-1 to R-636; M-1 to S-635; M-1 to W-
634;
M-1 to L-633; M-1 to I-632; M-1 to V-631; M-1 to A-630;M-1 to N-629; M-1 to G-
628;
M-1 to L-627; M-1 to A-626; M-1 to G-625; M-1 to V-624; M-1 to A-623; M-lto L-
622;
M-1 to D-621; M-1 to I-620; M-1 to L-619; M-1 to G-618; M-1 to D-617; M-I to E-
616;
M-1 toN-615; M-1 to L-614; M-1 to D-613; M-1 to L-612; M-1 to Q-611; M-1 to G-
610;
M-1 to H-609; M-1 toI-608; M-1 to S-607; M-1 to C-606; M-1 to G-605; M-1 to F-
604;
M-1 to Y-603; M-1 to Q-602; M-1 to L-601;M-1 to G-600; M-1 to T-599; M-1 to A-
598;
M-1 to L-597; M-1 to E-596; M-1 to S-595; M-1 to A-594; M-1 toT-593; M-1 to I-
592;
M-1 to R-591; M-1 to Q-590; M-1 to K-589; M-1 to P-588; M-1 to T-587; M-1 to K-
586;M-1 to L-585; M-1 to I-584; M-1 to S-583; M-1 to G-582; M-1 to R-581; M-1
to F-
580; M-1 to G-579; M-I toH-578; M-1 to F-577; M-1 to I-576; M-1 to Y-575; M-1
to I-
574; M-1 to A-573; M-1 to G-572; M-1 to A-571;M-1 to H-570; M-1 to N-569; M-1
to
D-568; M-1 to E-567; M-1 to L-566; M-1 to P-565; M-1 to A-564; M-lto G-563; M-
1 to
V-562; M-1 to V-561; M-1 to V-560; M-I to D-559; M-1 to N-558; M-1 to Y-557; M-
1
toS-5_56; M-1 to D-555; M-1 to Q-554; M-1 to N-553; M-1 to L-552; M-1 to D-
551; M-1
to R-550; M-1 toV-_549; M-I to S-548; M-1 to A-547; M-1 to I-546; M-1 to S-
545; M-1
to S-544; M-1 to G-543; M-1 to F-542;M-1 to R-541; M-1 to A-540; M-1 to N-539;
M-1
to Q-538; M- 1 to Y-537; M-1 to S-536; M-1 to H-535; M-lto S-534; M-1 to D-533;
M-1
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
126
to K-532; M-1 to L-531; M-1 to T-530; M-1 to G-529; M-1 to N-528; M-1 toY-527;
M-1
to V-526; M-1 to F-525; M-1 to R-524; M-1 to N-523; M-1 to Q-522; M-1 to R-
521; M-
1 toL-520; M-1 to E-519; M-1 to Y-518; M-1 to V-517; M-1 to Y-516; M-1 to V-
515;
M-1 to K-514; M-1 toG-513; M-1 to R-512; M-1 to E-511; M-1 to R-510; M-1 to G-
509;
M-1 to E-508; M-1 to N-507; M-1 toF-506; M-1 to Y-505; M-1 to M-504; M-1 to P-
503;
M-1 to A-502; M-1 to G-_501; M-I to V-500; M-I toL-499; M-1 to L-498; M-1 to V-
497;
M-1 to D-496; M-1 to T-495; M-I to V-494; M-1 to G-493; M-1 toD-492; M-1 to 6-
491; M-1 to D-490; M-1 to I-489; M- I to D-488; M-1 to V-487; M-1 to S-486; M-
1 to T-
485;M-1 to I-484; M-1 to E-483; M-I to S-482; M-1 to G-481; M-1 to F-480; M-1
to Y-
lU 479; M-1 to S-478; M-1 toG-477; M-1 to I-476; M-1 to Q-475; M-I to Q-474; M-
I to 6-
473; M-1 to R-472; M-1 to M-471; M-1 toA-470; M- I to Q-469; M-1 to H-468; M-1
to
I-467; M-1 to T-466; M-1 to L-465; M-1 to S-464; M-I to R-463;M-1 to N-462; M-
1 to
N-461; M-1 to H-460; M-1 to M-4_59; M-1 to T-458; M-1 to F-4_57; M-1 to L-456;
M-lto
I-455; M-1 to V-454; M-1 to K-453; M-1 to G-452; M-1 to T-451; M-1 to H-450; M-
1 to
N-449; M-1 toF-448; M-1 to R-447; M-1 to P-446; M-1 to A-445; M-1 to G-444; M-
1 to
A-443; M-1 to V-442; M-1 toY-441; M-1 to V-440; M-1 to R-439; M-1 to G-438; M-
1
to Q-437; M-1 to R-436; M-1 to S-435; M-1 toS-434; M-I to V-433; M-1 to V-432;
M-1
to S-431; M-1 to T-430; M-1 to V-429; M-1 to T-428; M-1 to Y-427;M-1 to G-426;
M-1
to L-425; M-1 to Y-424; M-1 to A-423; M-I to G-422; M-1 to H-421; M-1 to N-
420; M-
lto K-419; M-1 to L-418; M-1 to E-417; M-1 to E-416; M-1 to P-415; M-1 to F-
414; M-
1 to E-413; M-1 toK-412; M-i to L-411; M-1 to Y-410; M-1 to S-409; M-1 to E-
408; M-
1 to R-407; M-1 to L-406; M-1 to P-405;M-1 to I-404; M-1 to V-403; M-1 to K-
402; M-
1 to G-401; M-1 to A-400; M-1 to S-399; M-1 to T-398; M-1 toE-397; M-1 to K-
396;
M-1 to L-395; M-1 to V-394; M-i to A-393; M-1 to G-392; M-1 to N-391; M-1 toW-
390; M-1 to D-389; M-1 to Y-388; M-1 to A-387; M-1 to G-386; M-1 to V-385; M-1
to
A-384; M-1 toG-383; M-1 to L-382; M-1 to L-381; M-1 to V-380; M-1 to G-379; M-
1 to
D-378; M-1 to E-377; M-1 toV-376; M-1 to V-375; M-1 to H-374; M-I to S-373; M-
1 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
127
S-372; M-1 to F-371; M-1 to G-370; M-1 toT-369; M-1 to Q-368; M-I to S-367; M-
1 to
M-366; M-1 to E-365; M-1 to L-364; M-1 to G-363; M-1 toF-362; M-1 to S-361; M-
1 to
T-360; M-1 to E-359; M-1 to N-358; M-1 to K-357; M-1 to N-356; M-1 toT-355; M-
1 to
G-354; M-1 to E-353; M-1 to L-352; M-1 to S-351; M-1 to F-350; M-1 to I-349; M-
1 to
R-348;M-I to D-347; M-1 to G-346; M-1 to L-345; M-1 to A-344; M-1 to D-343; M-
1 to
V-342; M-1 to I-341; M-1 toD-340; M-I to K-339; M-1 to L-338; M-1 to A-337; M-
1 to
A-336; M-1 to E-335; M-1 to D-334; M-1 toT-333; M-1 to V-332; M-1 to N-331; M-
1 to
F-330; M-1 to F-329: M-1 to H-328; M-1 to K-327; M-1 toD-326; M-1 to D-325; M-
1 to
P-324; M-1 to D-323; M-1 to S-322; M-1 to A-321; M-1 to I-320; M-1 to Y-319;M-
1 to
K-318; M-1 to I-317; M-1 to E-316; M-1 to N-31 _5 ; M-1 to L-314; M-1 to F-
313: M-1 to
T-312; M-1 toE-311; M-1 to P-310; M-1 to N-309; M-1 to I-308; M-1 to G-307; M-
1 to
R-306; M-1 to R-305; M-1 toN-304; M-1 to Y-303; M-1 to Y-302; M-1 to G-301; M-
I
to L-300; M-1 to V-299; M-1 to A-298; M-1 toV-297; M-1 to A-296; M-1 to Y-295;
M-
1 to R-294; M-1 to T-293; M-I to V-292; M-1 to N-291; M-1 toD-290; M-1 to R-
289;
I5 M-1 to E-288; M-1 to S-287; M-1 to Q-286; M-1 to Q-285; M-1 to I-284; M-1
to V-
283;M-1 to K-282; M-1 to E-281; M-1 to L-280; M-1 to D-279; M-I to P-278; M-1
to S-
277; M-1 to D-276; M-1 toH-275; M-1 to S-274; M-1 to E-273; M-1 to G-272; M-1
to
D-271; M-1 to T-270; M-1 to I-269; M-1 to V-268;M-1 to I-267; M-1 to M-266; M-
1 to
V-265; M-1 to K-264; M-1 to K-263; M-1 to A-262; M-1 to G-261; M-1 to K-260; M-
1
to R-259; M-1 to G-258; M-1 to G-257; M-I to K-256; M-1 to Q-255; M-1 to F-
254; M-
1 toA-253; M-1 to E-252; M-1 to S-251; M-1 to R-250; M-1 to A-249; M-1 to F-
248; M-
1 to E-247; M-1 to I-246;M-1 to G-245; M-1 to F-244; M-1 to A-243; M-1 to T-
242; M-
I to R-241; M-1 to T-240; M-1 to E-239; M-1 toT-238; M-1 to G-237; M-1 to G-
236;
M-1 to R-235; M-1 to Q-234; M-1 to E-233; M-1 to I-232; M-1 toH-231; M-1 to S-
230;
M-1 to A-229; M-1 to A-228; M-1 to E-227; M-1 to V-226; M-1 to V-225; M-1 toD-
224; M-1 to K-223; M-1 to V-222; M-1 to S-221; M-1 to R-220; M-1 to Y-219; M-1
to
D-218; M-1 toN-217; M-1 to L-2I6; M-1 to H-215; M-1 to F-214; M-1 to E-213; M-
1 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
128
H-212; M-1 to V-211; M-1 toV-210; M-1 to D-209; M-1 to E-208; M-1 to G-207; M-
1
to Y-206; M-1 to Q-205; M-1 to V-204; M-1 toV-203; M-1 to G-202; M-1 to V-201;
M-
1 to Q-200; M-1 to I-199; M-1 to Q-198; M-1 to G-197; M-1 toP-196; M-1 to G-
195; M-
1 to I-194; M-1 to Y-193; M-1 to F-192; M-1 to K-191; M-1 to K-190; M-1 to L-
189;M-
1 to I-188; M-1 to N-187; M-1 to I-186; M-1 to L-185; M-I to F-184; M-1 to H-
183; M-
I to Q-182; M-1 toV-181; M-1 to E-180; M-1 to V-179; M-1 to W-178; M-1 to P-
177;
M-1 to Y-176; M-1 to I-175; M-1 to S-174;M-1 to N-173; M-I to S-I72; M-1 to G-
171;
M-1 to D-170; M-1 to L-169; M-I to V-168; M-1 to I-167; M-1 toV-166; M-1 to I-
165;
M-1 to D-164; M-1 to M-163; M-1 to Y-162; M-1 to T-161; M-1 to Q-160; M-1 toC-
159; M-1 to R-158; M-I to Q--157; M-1 to L-156; M-1 to A-155; M-1 to P-154; M-
1 to
A-153; M-I toV-152; M-1 to T-151; M-1 to K-150; M-1 to S-149; M-1 to F-148; M-
1 to
R-147; M-1 to F-146; M-1 toN-145; M-1 to S-144; M-1 to N-143; M-1 to V-142; M-
I to
R-141; M-1 to S-140; M-1 to C-139; M-1 toM-138; M-1 to G-137; M-1 to T-136; M-
1 to
T-135; M-1 to Y-134; M-1 to Y-133; M-1 to S-132; M-1 toS-131; M-1 to G-130; M-
1 to
C-129; M-1 to E-128; M-1 to H-127; M-1 to S-126; M-1 to W-125; M-1 toL-124; M-
1 to
P-123; M-1 to S-122; M-1 to C-121; M-1 to A-120; M-1 to L-119; M-I to F-118; M-
1 to
S-117;M-I to N-116; M-1 to D-115; M-1 to K-114; M-1 to P-113; M-1 to N-112; M-
1 to
T-111; M-1 to A-110; M-lto L-109; M-1 to S-108; M-1 to L-107; M-1 to G-106; M-
1 to
L-I05; M-1 to R-104; M-1 to M-103; M-1 toN-102; M-1 to D-101; M-1 to K-100: M-
1
to R-99; M-1 to E-98; M-1 to S-97; M-1 to V-96; M-1 to N-95; M-lto S-94; M-1
to L-
93; M-I to T-92; M-1 to V-91; M-1 to R-90; M-1 to G-89; M-1 to L-88; M-1 to N-
87;
M-lto L-86; M-1 to K-85; M-1 to T-84; M-1 to C-83; M-1 to N-82; M-1 to G-81; M-
1 to
H-80; M-1 to I-79; M-lto V-78; M-1 to P-77; M-1 to C-76; M-1 to K-75; M-1 to Y-
74;
M-1 to V-73; M-1 to D-72; M-1 to G-71; M-lto T-70; M-1 to K-69; M-1 to Q-68; M-
1
to Y-67; M-1 to G-66; M-1 to N-65; M-1 to T-64; M-1 to E-63; M-lto L-62; M-1
to P-
61; M-1 to A-60; M-1 to G-59; M-1 to V-58; M-1 to V-57; M-1 to L-56; M-1 to W-
55;
M-lto K-54; M-1 to N-53; M-1 to G-52; M-1 to S-51; M-1 to I-50; M-1 to D-49; M-
1 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00129435 PCT/US99/25031
129
H-48; M-1 to Q-47; M-1 to Q-46; M-1 to V-45 ; M-1 to T-44; M-1 to Y-43; M-1 to
G-42;
M-1 to F-41; M-1 to F-40; M-I to A-39; M-lto T-38; M-1 to R-37; M-1 to S-36; M-
1 to
G-35; M-1 to P-34; M-1 to I-33; M-1 to V-32; M-1 to R-31; M-1 toP-30; M-1 to K-
29;
M-1 to R-28; M-1 to T-27; M-1 to D-26; M-1 to M-25; M-1 to N-24; M-1 to F-23;
M-1
toT-22; M-1 to D-21; M-1 to T-20; M-1 to F-19; M-1 to G-18; M-1 to P- I 7; M-1
to W-
16; M-1 to L-15; M-1 toS-14; M-1 to L-13; M-1 to A-12; M-1 to W-11; M-1 to A-
10; M-
1 to V-9; M-1 to V-8; M-1 to L-7; M-1 to G-6; of SEQ ID N0:35. Polypeptides
encoded
by these polynucleotides are also encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:17 which have been
determined
from the following related cDNA genes: HEEAB54R (SEQ ID N0:104), HRDAF83R
(SEQ ID NO:105), HOUBC62R (SEQ ID N0:106), HCDBI19R (SEQ ID N0:107),
HOHCU94R (SEQ ID N0:108), HOACC13R (SEQ ID N0:109), HCDAP21R (SEQ ID
NO:l 10), HNHHA34R (SEQ ID NO:111), HOHEA75R (SEQ ID N0:112) and
HNGEL59R (SEQ ID N0:113).
Based on the sequence similarity to the human integrin alpha 1 subunit,
translation product of this gene is expected to share at least some biological
activities
with integrin proteins, and specifically the integrin alpha 1 protein. Such
activities are
known in the art, some of which are described elsewhere herein.
Specifically, polynucleotides and polypeptides of the invention are also
useful for
modulating the differentiation of normal and malignant cells, modulating the
proliferation and/or differentiation of cancer and neoplastic cells, and
modulating the
immune response. Polynucleotides and polypeptides of the invention may
represent a
diagnostic marker for hematopoietic and immune diseases and/or disorders. The
full-
length protein should be a secreted protein, based upon homology to the
integrin family.
Therefore, it is secreted into serum, urine, or feces and thus the levels is
assayable from
patient samples. Assuming specific expression levels are reflective of the
presence of
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
130
immune disorders, this protein would provide a convenient diagnostic for early
detection.
In addition, expression of this gene product may also be linked to the
progression of
immune diseases, and therefore may itself actually represent a therapeutic or
therapeutic
target for the treatment of cancer.
Polynucleotides and polypeptides of the invention may play an important role
in
the pathogenesis of human cancers and cellular transformation, particularly
those of the
immune and hematopoietic systems. Polynucleotides and polypeptides of the
invention
may also be involved in the pathogenesis of developmental abnormalities based
upon its
potential effects on proliferation and differentiation of cells and tissue
cell types. Due to
the potential proliferating and differentiating activity of said
polynucleotides and
polypeptides, the invention is useful as a therapeutic agent in inducing
tissue
regeneration, for treating inflammatory conditions (e.g., inflammatory bowel
syndrome,
diverticulitis, etc.). Moreover, the invention is useful in modulating the
immune
response to aberrant polypeptides, as may exist in rapidly proliferating cells
and tissue
cell types, particularly in adenocarcinoma cells, and other cancers.
Alternatively, the expression within cellular sources marked by proliferating
cells
indicates this protein may play a role in the regulation of cellular division,
and may show
utility in the diagnosis, treatment, andlor prevention of developmental
diseases and
disorders, including cancer, and other proliferative conditions.
Representative uses are
described in the "Hyperproliferative Disorders" and "Regeneration" sections
below and
elsewhere herein. Briefly, developmental tissues rely on decisions involving
cell
differentiation and/or apoptosis in pattern formation.
Dysregulation of apoptosis can result in inappropriate suppression of cell
death,
as occurs in the development of some cancers, or in failure to control the
extent of cell
death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA).
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
131
Alternatively, this gene product is involved in the pattern of cellular
proliferation
that accompanies early embryogenesis. Thus, aberrant expression of this gene
product in
tissues - particularly adult tissues - may correlate with patterns of abnormal
cellular
proliferation, such as found in various cancers. Because of potential roles in
proliferation
and differentiation, this gene product may have applications in the adult for
tissue
regeneration and the treatment of cancers. It may also act as a morphogen to
control cell
and tissue type specification. Therefore, the polynucleotides and polypeptides
of the
present invention are useful in treating, detecting, and/or preventing said
disorders and
conditions, in addition to other types of degenerative conditions. Thus
this protein may modulate apoptosis or tissue differentiation and is useful in
the
detection, treatment, and/or prevention of degenerative or proliferative
conditions and
diseases. The protein is useful in modulating the immune response to aberrant
polypeptides, as may exist in proliferating and cancerous cells and tissues.
The protein
can also be used to gain new insight into the regulation of cellular growth
and
proliferation. Furthermore, the protein may also be used to determine
biological activity,
to raise antibodies, as tissue markers, to isolate cognate ligands or
receptors, to identify
agents that modulate their interactions, in addition to its use as a
nutritional supplement.
Protein, as well as, antibodies directed against the protein may show utility
as a tumor
marker and/or immunotherapy targets for the above listed tissues.
This gene is expressed almost exclusively in osteoblasts, human trabelcular
bone
cells, messangial cells, adipocytes, and to a lesser extent in osteosarcoma,
chondrosarcoma, breast cancer cells, and bone marrow.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of the following diseases and conditions
which
include, but are not limited to, disorders of the skeletal system, connective
tissues, and
immune and hematpoietic diseases and/or disorders. Similarly, polypeptides and
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
132
antibodies directed to these polypeptides are useful to provide immunological
probes for
differential identification of the tissues) or cell type(s). For a number of
disorders of the
above tissues or cells, particularly of the connective tissue and skeletal
system,
expression of this gene at significantly higher or lower levels is detected in
certain
S tissues or cell types (e.g. immune, hematopoietic, skeletal, bone,
cartilage,
deveIpomental, reproductive, secretory, and cancerous and wounded tissues) or
bodily
fluids or cell types (e.g., lymph, serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue from an
individual not having the disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 35 as residues: Phe-23 to Arg-31, Leu-62 to Asp-72, Val-96
to
Asp-101, Thr-111 to Asn-116, Glu-128 to Thr-135, Val-142 to Ser-149, Asn-217
to Val-
222, Glu-233 to Arg-241, Gly-272 to Leu-280, Gln-286 to Thr-293, Tyr-303 to
Ile-308,
Gly-354 to Thr-360, Gtu-408 to Lys-419, Glu-508 to Lys-514, Arg-521 to Val-
526, Gly-
529 to Phe-542, Asp-551 to Tyr-557, Thr-587 to Thr-593, His-656 to Asp-665,
Met-697
to Arg-705, Asp-709 to Thr-716, Glu-755 to Gly-760, Asn-779 to His-786, Leu-
810 to
Asp-816, Leu-844 to Ala-851, Gln-871 to Gly-877, Glu-884 to Gln-889, Ser-931
to Asn-
943, Ser-974 to Ile-982, Gly-1039 to Gln-1058, Arg-1121 to Arg-1127, Ser-1134
to Trp-
1139, Ser-1172 to Pro-1183. Polynucleotides encoding said polypeptides are
also
provided.
The tissue distribution in osteoblasts and homology to integrin alpha subunit
10
indicates that the protein products of this gene are useful for the treatment
of disorders
and conditions affecting the skeletal system, in particular osteoporosis as
well as
disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis,
chrondomalacia
and inflammation), such as in the diagnosis and treatment of various
autoimmune
disorders such as rheumatoid arthritis, lupus, scleroderma, and
dermatomyositis~as well
SUBSTITUTE SHEET (RULE 2~
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
133
as dwarfism, spinal deformation, and specific joint abnormalities as well as
chondrodysplasias (ie. spondyioepiphyseal dysplasia congenita, familial
osteoarthritis,
Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid).
polynucleotides
and polypeptides corresponding to this gene are useful for the treatment and
diagnosis of
_5 hematopoietic related disorders such as anemia, pancytopenia, leukopenia,
thrombocytopenia or leukemia since stromal cells are important in the
production of cells
of hematopoietic lineages. Such a use is consistent with the observed homology
to
integrin family members, in conjunction with The tissue distribution in bone
marrow cells. Integrins play pivotal roles in cell migration, inflammation,
proliferation,
and cellular infiltration. Thus, the present invention is expected to share at
least some of
these activities. Representative uses are described in the "Immune Activity"
and
"infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20,
and 27, and
elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture,
bone
marrow transplantation, bone marrow reconstitution, radiotherapy or
chemotherapy of
neoplasia. The gene product may also be involved in lymphopoiesis, therefore,
it can be
used in immune disorders such as infection, inflammation, allergy,
immunodeficiency
etc. In addition, this gene product may have commercial utility in the
expansion of stem
cells and committed progenitors of various blood lineages, and in the
differentiation
and/or proliferation of various cell types. Based upon the tissue distribution
of this
protein, antagonists directed against this protein is useful in blocking the
activity of this
protein. Accordingly, preferred are antibodies which specifically bind a
portion of the
translation product of this gene.
Also provided is a kit for detecting tumors in which expression of this
protein
occurs. Such a kit comprises in one embodiment an antibody specific for the
translation
product of this gene bound to a solid support. Also provided is a method of
detecting
these tumors in an individual which comprises a step of contacting an antibody
specific
for the translation product of this gene to a bodily fluid from the
individual, preferably
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
134
serum, and ascertaining whether antibody binds to an antigen found in the
bodily fluid.
Preferably the antibody is bound to a solid support and the bodily fluid is
serum. The
above embodiments, as well as other treatments and diagnostic tests (kits and
methods),
are more particularly described elsewhere herein. Furthermore, the protein may
also be
used to determine biological activity, to raise antibodies, as tissue markers,
to isolate
cognate ligands or receptors, to identify agents that modulate their
interactions, in
addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy
targets for
the above listed tissues. Many polynucleotide sequences, such as EST
sequences, are
publicly available and accessible through sequence databases. Some of these
sequences
are related to SEQ ID N0:17 and may have been publicly available prior to
conception
of the present invention. Preferably, such related polynucleotides are
specifically
excluded from the scope of the present invention. To list every related
sequence is
cumbersome. Accordingly, preferably excluded from the present invention are
one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 4981 of SEQ ID N0:17, b is
an
integer of 15 to 4995, where both a and b correspond to the positions of
nucleotide
residues shown in SEQ ID N0:17, and where b is greater than or equal to a +
14.
FEATURES OF PROTEIN ENCODED BY GENE NO: 8
The present invention relates to three novel peptidoglycan recognition binding
proteins expressed by keratinocytes, wound-healing tissues and chondrosarcoma
tissue.
More specifically, isolated nucleic acid molecules are provided encoding a
human
peptidoglycan recognition protein-related protein, sometimes referred to
herein as
"human tag7" or "tag7" or "htag7". Further provided are vectors, host cells
and
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
135
recombinant methods for producing the same. The invention also relates to both
the
inhibition and enhancement of activities of the tag? protein, polypeptides and
diagnostic
methods for detecting tag? gene expression.
Peptidoglycan, as well as Lipopolysaccharide (LPS), is a surface component of
many bacteria which illicit a wide range of physiological and immune responses
in
humans. Specifically, peptidoglycan has been shown to manifest itself
clinically by
reproducing most of the symptoms of bacterial infection, including fever,
acute-phase
response, inflammation, septic shock, leukocytosis, sleepiness, malaise,
abcess
formation, and arthritis (see Dziarski et al., JBC, 273 (15): 8680 (1998)).
Furthermore,
the type of peptidoglycan (i.e.- the specific stereoisomers or analogs of
muramyl
dipeptide, N-acetylglucosaminyl-beta(1-4)-N-acteylmuramyl tetrapeptides,
etc.), were
shown to elicit a broad range of activities, including exhibiting greater
pyrogenicity,
inducing acute joint inflammation, stimulating macrophages, and causing
hemorrhagic
necrosis at a primed site (See Kotani et al., Fed Proc, 45(11): 2534 (1986)).
It has been
demonstrated in humans that a lipopolysaccharide binding protein exists that
was
discovered as a trace plasma protein (See Schumann et al., Science,
249(4975):1429
(1990)). It is thought that one of the modes of action by which this
lipopolysaccharide
binding protein functions is by forming high-affinity complexes with
lipopolysaccharide,
that then bind to macrophages and monocytes, inducing the secretion of tumor
necrosis
factor. Dziarski and Gupta (See Dziarski et al., JBC, 269(3): 2100 (1994))
demonstrated
that a 70kDa receptor protein present on the surface of mouse lymphocytes
served to
bind heparin, heparinoids, bacterial lipoteichoic acids, peptidoglycan, and
lipopolysaccharides. Recently, Dziarski et al. demonstrated that the CD14, a
glycosylphosphatidylinositol-linked protein present on the surface of
macrophage and
polymorphonuclear leukocytes, bound peptidoglycan and lipopolysaccharide.
Furthermore, the binding affinity of CD14 for lipopolysaccharide was
significantly increased in the presence of a LPS-binding protein present in
plasma. It is
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
136
thought that the LPS-binding protein functions as a transfer molecule, whereby
it binds
LPS and presents it to the CD14 receptor (See Dziarski et al., JBC, 273(15):
8680
(1998)). Yoshida et al. isolated a peptidoglycan binding protein from the
hemolymph of
the Silkworm, Bombyx mori, using column chromatography. This protein was found
to
have a very specific affinity for peptidogiycan (See Yoshida et al., JBC,
271(23): 13854
(1996)).
Additionally, Kang et al. recently cloned a peptidoglycan binding protein from
the moth Trichoplusia ni. The peptidoglycan binding protein was shown to bind
strongly
to insoluble peptidogiycan (See Kang etal., PNAS, 95( 17 ): 10078 ( 1998)). In
this study
the peptidoglycan binding protein was upregulated by a bacterial infection in
T. ni. The
insect immune system is regarded as a model for innate immunity. Thus, Kang et
al were
able to gene both mouse and human homologs of the T. ni peptidoglycan binding
protein.
All of these peptidoglycan binding proteins shared regions of homology, as
well as four
conserved cysteine residues which may function in the tertiary structure of
the protein,
possibly in helping to form binding domains. Given that peptidoglycan is an
integral
component of bacterial cell walls, and that it induces many physiological
responses from
cytokine secretion to inflammation and macrophage activation, it appears as if
this family
of proteins is a ubiquitous group involved in the binding and recognition of
peptidoglycan, the presentation of antigens (e.g., cell wall components,
etc.), and the
activation of the immune system, such as the secretion of cytokines, such as
TNF. TNF is
noted for its pro-inflammatory actions which result in tissue injury, such as
induction of
procoagulant activity on vascular endothelial cells (Pober, J.S. et al., J.
Immunol.
136:1680 (1986)), increased adherence of neutrophils and lymphocytes (Pober,
J.S. et al.,
J. Immunol. 138:3319 (1987)), and stimulation of the release of platelet
activating factor
from macrophages, neutrophils and vascular endothelial cells (Camussi, G. et
al., J. Exp.
Med. 166:1390 (1987)).
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
137
Recent evidence implicates TNF in the pathogenesis of many infections (Cerami,
A. et al., Immunol. Today 9:28 (1988)), immune disorders, neoplastic
pathology, e.g., in
cachexia accompanying some malignancies (Oliff, A. et al., Cell 50:555
(1987)), and in
autoimmune pathologies and graft-versus host pathology (Piguet, P.-F. et al.,
J. Exp.
Med. 166:1280 ( 1987)). The association of TNF with cancer and infectious
pathologies
is often related to the host's catabolic state. A major problem in cancer
patients is weight
loss, usually associated with anorexia. The extensive wasting which results is
known as
"cachexia" (Kern, K. A. et al. J. Parent. Enter. Nutr. 12:286-298 (1988)).
Cachexia
includes progressive weight loss, anorexia, and persistent erosion of body
mass in
response to a malignant growth. The cachectic state is thus associated with
significant
morbidity and is responsible for the majority of cancer mortality.
A number of studies have suggested that TNF is an important mediator of the
cachexia in cancer, infectious pathology, and in other catabolic states. TNF
is thought to
play a central role in the pathophysiological consequences of Gram-negative
sepsis and
endotoxic shock (Michie, H.R. et al., Br. J. Surg. 76:670-671 (1989); Debets,
J. M. H. et
al., Second Vienna Shock Forum, p.463-466 (1989); Simpson, S. Q. et al., Crit.
Care
Clin. 5:27-47 (1989)), including fever, malaise, anorexia, and cachexia.
Endotoxin is a
potent monocyte/macrophage activator which stimulates production and secretion
of
TNF (Kombluth, S.K. et al., J. Immunol. 137:2585-2591 ( 1986)) and other
cytokines.
Because TNF could mimic many biological effects of endotoxin, it was concluded
to be a
central mediator responsible for the clinical manifestations of endotoxin-
related illness.
TNF and other monocyte-derived cytokines mediate the metabolic and
neurohormonal
responses to endotoxin (Michie, H.R. et al., N. Eng. J. Med. 318:1481-1486
(1988)).
Endotoxin administration to human volunteers produces acute illness with flu-
like
symptoms including fever, tachycardia, increased metabolic rate and stress
hormone
release (Revhaug, A. et al., Arch. Surg. 123:162-170 (1988)). Elevated levels
of
circulating TNF have also been found in patients suffering from Gram-negative
sepsis
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
138
(Waage, A. et al., Lancet 1:355-357 (1987); Hammerle, A.F. et al., Second
Vienna Shock
Forum p. 715-718 ( 1989); Debets, J. M. H. et al., Crit. Care Med. 17:489-497
( 1989);
Calandra, T. et al., J. Infec. Dis. 161:982-987 (1990)). Passive immunotherapy
directed
at neutralizing TNF may have a beneficial effect in Gram-negative sepsis and
endotoxemia, based on the increased TNF production and elevated TNF levels in
these
pathology states, as discussed above.
Antibodies to a "modulator" material which was characterized as cachectin
(later
found to be identical to TNF) were disclosed by Cerami et al. (EPO Patent
Publication
0,212,489, March 4, 1987). Such antibodies were said to be useful in
diagnostic
immunoassays and in therapy of shock in bacterial infections. Rubin et al.
(EPO Patent
Publication 0,218,868, April 22, 1987) disclosed monoclonal antibodies to
human TNF,
the hybridomas secreting such antibodies, methods of producing such
antibodies, and the
use of such antibodies in immunoassay of TNF. Yone et al. (EPO Patent
Publication
0,288,088, October 26, 1988) disclosed anti-TNF antibodies, including mAbs,
and their
utility in immunoassay diagnosis of pathologies, in particular Kawasaki's
pathology and
bacterial infection. The body fluids of patients with Kawasaki's pathology
(infantile acute
febrile mucocutaneous lymph node syndrome; Kawasaki, T., Allergy 16:178
(1967);
Kawasaki, T., Shonica (Pediatrics) 26:935 (1985)) were said to contain
elevated TNF
levels which were related to progress of the pathology (Yone et al., supra).
Accordingly, there is a need to provide molecules that are involved in
pathological conditions. Such novel proteins could be useful in augmenting the
immune
system in such areas as immune recognition, antigen presentation, and immune
system
activation. Antibodies or antagonists directed against these proteins is
useful in reducing
or eliminating disorders associated with TNF and TNF-like cytokines, such as
endotoxic
shock and auto-immune disorders, for example.
The polypeptide of the present invention has been putatively identified as a
member of the novel peptidoglycan recognition binding protein family and has
been
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
139
termed human tag7. This identification has been made as a result of amino acid
sequence
homology to the mouse tag? (See Genbank Accession No. emb~CAA60133).
Figure 34 shows the nucleotide (SEQ ID N0:18) and deduced amino acid
sequence (SEQ ID N0:36) of htag7. Predicted amino acids from about 1 to about
21
constitute the predicted signal peptide (amino acid residues from about 1 to
about 21 in
SEQ ID N0:36) and are represented by the underlined amino acid regions; and
amino
acids from about 34 to about 117 constitute the predicted PGRP-like domain
(amino
acids from about 34 to about 117 in SEQ ID N0:36) and are represented by the
double
underlined amino acids.
Figure 35 shows the regions of similarity between the amino acid sequences of
the htag7 protein (SEQ ID N0:36) and the mouse taa7 protein (SEQ ID N0:114).
Figure 36 shows an analysis of the htag7 amino acid sequence. Alpha, beta,
turn
and coil regions; hydrophilicity and hydrophobicity; amphipathic regions;
flexible
regions; antigenic index and surface probability are shown.
A polynucleotide encoding a polypeptide of the present invention is obtained
from human chondrosarcoma cells, bone marrow, and neutrophils. The
polynucleotide of
this invention was discovered in a human chondrosarcoma cDNA library.
As shown in Figure 34, htag7 has a PGRP domain (the PGRP domain comprise
amino acids from about 34 to about 117 of SEQ ID N0:36; which correspond to
amino
acids from about 34 to about 117 of Figure 34). The polynucleotide contains an
open
reading frame encoding the htag7 polypeptide of 198 amino acids. htag7
exhibits a high
degree of homology at the amino acid level to the mouse tag? (as shown in
Figure 35).
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the htag7 polypeptide having the amino acid sequence
shown in
Figure 34 (SEQ ID N0:36). The nucleotide sequence shown in Figure 34 (SEQ ID
N0:18) was obtained by sequencing a cloned cDNA (HCDDP40), which was deposited
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
140
on November 17 at the American Type Culture Collection, and given Accession
Number
203484.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
N0:18 is intended DNA fragments at least about l5nt, and more preferably at
least about
20 nt, still more preferably at least about 30 nt, and even more preferably,
at least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
course, larger fragments 50-1500 nt in length are also useful according to the
present
invention. as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:18. By a fragment at least 20
nt in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
shown in SEQ ID N0:18. In this context "about" includes the particularly
recited size,
larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either
terminus or at both
termini. Representative examples of htag7 polynucleotide fragments of the
invention
include, for example, fragments that comprise, or alternatively, consist of, a
sequence
from about nucleotide 1 to about 50, from about 51 to about 100, from about
101 to
about 1.50, from about 151 to about 200, from about 201 to about 250, from
about 251 to
about 300, from about 301 to about 350, from about 3.51 to about 400, from
about 401 to
about 450, from about 451 to about 500, from about 501 to about 550, from
about 551 to
about 600, from about 601 to about 650, from about 651 to about 700, from
about 701 to
about 726, and from about 130 to about 379 of SEQ ID N0:18, or the
complementary
strand thereto, or the cDNA contained in the deposited gene. In this context
"about"
includes the particularly recited ranges, larger or smaller by several (5, 4,
3, 2, or 1 )
nucleotides, at either terminus or at both termini.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
141
Preferred nucleic acid fragments of the present invention include nucleic acid
molecules encoding a member selected from the group: a polypeptide comprising
or
alternatively, consisting of, the PGRP-like domain (amino acid residues from
about 34 to
about 117 in Figure 34 (amino acids from about 34 to about 117 in SEQ ID
N0:36).
_5 Since the location of these domains have been predicted by computer
analysis, one of
ordinary skill would appreciate that the amino acid residues constituting
these domains
may vary slightly (e.g., by about 1 to 15 amino acid residues) depending on
the criteria
used to define each domain. As indicated, nucleic acid molecules of the
present invention
which encode a htag7 polypeptide may include, but are not limited to those
encoding the
amino acid sequence of the PGRP-like domain of the polypeptide, by itself; and
the
coding sequence for the PGRP-like domain of the polypeptide and additional
sequences,
such as a pre-, or pro or prepro- protein sequence. In additional embodiments,
the
poiynucleotides of the invention encode functional attributes of htag7.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions of htag7.
The data
representing the structural or functional attributes of htag7 set forth in
Figure 36 and/or
Table XIl, as described above, was generated using the various modules and
algorithms
of the DNA*STAR set on default parameters. In a preferred embodiment, the data
presented in columns VIII, IX, XIII, and XIV of Table XII can be used to
determine
regions of htag7 which exhibit a high degree of potential for antigenicity.
Regions of
high antigenicity are determined from the data presented in columns VIII, IX,
XIII,
and/or XIV by choosing values which represent regions of the polypeptide which
are
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC'T/US99/25031
142
likely to be exposed on the surface of the polypeptide in an environment in
which antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 36, but may,
as
shown in Table XII, be represented or identified by using tabular
representations of the
data presented in Figure 36. The DNA*STAR computer algorithm used to generate
Figure 36 (set on the original default parameters) was used to present the
data in Figure
36 in a tabular format (See Table XII). The tabular format of the data in
Figure 36 is used
to easily determine specific boundaries of a prefewed region. The above-
mentioned
preferred regions set out in Figure 36 and in Table XII include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figure 34. As set out in Figure 36 and in Table XIL, such preferred
regions include
Gamier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions,
Chou-
Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic regions
and I-Iopp-Woods hydrophobic regions, Eisenberg alpha- and beta-amphipathic
regions,
Karplus-Schulz flexible regions, Jameson-Wolf regions of high antigenic index
and
Emini surface-forming regions. Even if deletion of one or more amino acids
from the N-
terminus of a protein results in modification of loss of one or more
biological functions
of the protein, other functional activities (e.g., biological activities,
ability to
multimerize; modulate cellular interaction, or signalling pathways, etc.) may
still be
retained. For example, the ability of shortened htag7 muteins to induce and/or
bind to
antibodies which recognize the complete or mature forms of the polypeptides
generally
will be retained when less than the majority of the residues of the complete
or mature
polypeptide are removed from the N-terminus. Whether a particular polypeptide
lacking
N-terminal residues of a complete polypeptide retains such immunologic
activities can
readily be determined by routine methods described herein and otherwise known
in the
art. It is not unlikely that an htag7 mutein with a large number of deleted N-
terminal
amino acid residues may retain some biological or immunogenic activities. In
fact,
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
143
peptides composed of as few as six htag7 amino acid residues may often evoke
an
immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the htag7 amino acid sequence
shown
in Figure 34, up to the proline residue at position number 191 and
polynucleotides
encoding such polypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-196 of Figure 34 , where nl
is an
integer from 2 to 191 con-esponding to the position of the amino acid residue
in Figure
34 (which is identical to the sequence shown as SEQ ID N0:36). In another
embodiment,
N-terminal deletions of the htag7 polypeptide can be described by the general
formula
n2-I96, where n2 is a number from 2 to 191, corresponding to the position of
amino acid
identified in Figure 34. N-terminal deletions of the htag7 polypeptide of the
invention
shown as SEQ ID N0:36 include polypeptides comprising the amino acid sequence
of
residues: N-terminal deletions of the htag7 polypeptide of the invention shown
as SEQ
ID N0:36 include polypeptides comprising the amino acid sequence of residues:
S-2 to
P-196; R-3 to P-196; R-4 to P-196; S-5 to P-196; M-6 to P-196; L-7 to P-196; L-
8 to P-
196; A-9 to P-I96; W-10 to P-196; A-11 to P-196; L-12 to P-196; P-13 to P-196;
S-14 to
P-196; L-15 to P-196; L-16 to P-196; R-17 to P-196; L-18 to P-196; G-19 to P-
196; A-20
to P-196; A-21 to P-196; Q-22 to P-196; E-23 to P-196; T-24 to P-196; E-25 to
P-196;
D-26 to P-196; P-27 to P-196; A-28 to P-196; C-29 to P-196; C-30 to P-196; S-
31 to P-
196; P-32 to P-196; I-33 to P-196; V-34 to P-196; P-3S to P-196; R-36 to P-
196; N-37 to
P-196; E-38 to P-I96; W-39 to P-196; K-40 to P-196; A-41 to P-196; L-42 to P-
I96; A-
43 to P-196; S-44 to P-196; E-45 to P-196; C-46 to P-196; A-47 to P-196; Q-48
to P-
I9b; H-49 to P-196; L-50 to P-I96; S-51 to P-I96; L-52 to P-196; P-53 to P-
196; L-54 to
P-196; R-55 to P-196; Y-56 to P-196; V-57 to P-196; V-58 to P-196; V-59 to P-
196; S-
60 to P-I96; H-61 to P-196; T-62 to P-196; A-63 to P-196; G-64 to P-196; S-65
to P-
I96; S-66 to P-196; C-67 to P-196; N-68 to P-196; T-69 to P-196; P-70 to P-
196; A-71
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
144
to P-196; S-72 to P-196; C-73 to P-196; Q-74 to P-196; Q-75 to P-196; Q-76 to
P-196;
A-77 to P-196; R-78 to P-196; N-79 to P-196; V-80 to P-196; Q-81 to P-196; H-
82 to P-
196; Y-83 to P-196; H-84 to P-196; M-85 to P-196; K-86 to P-196; T-87 to P-
196; L-88
to P-196; G-89 to P-196; W-90 to P-196; C-91 to P-196; D-92 to P-196; V-93 to
P-196;
G-94 to P-196; Y-95 to P-196; N-96 to P-196; F-97 to P-196; L-98 to P-196; I-
99 to P-
196; G-100 to P-196; E-101 to P-196; D-102 to P-196; G- I 03 to P-196; L-104
to P- I 96;
V-105 to P-196; Y-106 to P-196; E-107 to P-196; G-108 to P-196; R-109 to P-
196; 6-
110 to P-196; W-111 to P-196; N-112 to P-196; F-113 to P-196; T-I 14 to P-196;
G-115
to P-196; A-116 to P-196; H-117 to P- I 96; S- I L 8 to P-196 ; G-119 to P- I
96; H-120 to P-
196; L-121 to P-196; W-122 to P-196; N-123 to P-196; P-124 to P-196; M-125 to
P-196;
S-126 to P-196; I-127 to P-196; G-128 to P-196; I-129 to P-196: S-130 to P-
196; F-131
to P-196; M-132 to P-196; G-133 to P-196; N-134 to P-196; Y-135 to P-196; M-
136 to
P-196; D-137 to P-196; R-138 to P-196; V-139 to P-196; P-140 to P-196; T-141
to P-
196; P-142 to P-196; Q-143 to P-196; A-144 to P-196; I-145 to P-196; R-146 to
P-196;
A-147 to P-196; A-148 to P-196; Q-149 to P-196; G-150 to P-196; L-151 to P-
196; L-
152 to P-196; A-153 to P-196: C-154 to P-196; G-155 to P-196; V-156 to P-196;
A-157
to P-196; Q-158 to P-196; G-159 to P-196; A-160 to P-196; L-161 to P-196; R-
162 to P-
196; S-163 to P-196; N-164 to P-196; Y-165 to P-196; V-166 to P-196; I~ 167 to
P-196;
K-I68 to P-196; G-169 to P-196; H-170 to P-196; R-171 to P-196; D-172 to P-
196; V-
173 to P-196; Q-174 to P-196; R-175 to P-196; T-176 to P-196; L-177 to P-196;
S-178 to
P-196; P-179 to P-196; G-180 to P-196; N-181 to P-196; Q-182 to P-196; L-183
to P-
196; Y-184 to P-196; H-185 to P-196; L-186 to P-196; I-187 to P-196; Q-188 to
P-196;
N-189 to P-196; W-190 to P-196; P-191 to P-196; of SEQ ID N0:36. Polypeptides
encoded by these polynucleotides are also encompassed by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities ) may still
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
145
be retained. For example the ability of the shortened htag7 mutein to induce
and/or bind
to antibodies which recognize the complete or mature forms of the polypeptide
generally
will be retained when less than the majority of the residues of the complete
or mature
polypeptide are removed from the C-terminus. Whether a particular polypeptide
lacking
C-terminal residues of a complete polypeptide retains such immunologic
activities can
readily be determined by routine methods described herein and otherwise known
in the
art. It is not unlikely that a htag? mutein with a large number of deleted C-
terminal
amino acid residues may retain some biological or immunogenic activities. In
fact,
peptides composed of as few as six htag7 amino acid residues may often evoke
an
immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the htag7
polypeptide shown in Figure 34 , up to the methionine residue at position
number 6, and
polynucleotides encoding such polypeptides. In particular, the present
invention provides
polypeptides comprising the amino acid sequence of residues 1-ml of Figure 1,
where
ml is an integer from 6 to 196 corresponding to the position of the amino acid
residue in
Figure 34 . Moreover, the invention provides polynucleotides encoding
polypeptides
comprising, or alternatively consisting of, the amino acid sequence of C-
terminal
deletions of the htag7 polypeptide of the invention shown as SEQ ID N0:36
include
polypeptides comprising the amino acid sequence of residues: M-1 to S-195; M-1
to R-
194; M-1 to Y-193; M-1 to H-192; M-I to P-191; M-1 to W-190; M-1 to N-189; M-1
to
Q-188; M-I to I-187; M-1 to L-186; M-1 to H-185; M-I to Y-184; M-1 to L-183; M-
1 to
Q-182; M-1 to N-181; M-1 to G-180; M-1 to P-179; M-1 to S-178; M-I to L-177; M-
1 to
T-176; M-1 to R-175; M-1 to Q-174; M-1 to V-173; M-1 to D-172; M-1 to R-171; M-
1
to H-170; M-1 to G-169; M-I to K-168; M-1 to L-167; M-I to V-166; M-1 to Y-
165; M-
1 to N-164; M-1 to S-163; M-1 to R-162; M-1 to L-161; M-1 to A-160; M-1 to G-
1_59;
M-I to Q-158; M-1 to A-157; M-1 to V-156; M-I to G-155; M-1 to C-154; M-1 to A-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
146
153; M-1 to L-152; M-1 to L-151; M-1 to G-150; M-1 to Q-149; M-1 to A-148; M-1
to
A-147; M-1 to R-146; M-1 to I-145; M-1 to A-144; M-1 to Q-143; M-1 to P-142; M-
1 to
T-141; M-1 to P-140; M-1 to V-139; M-1 to R-138; M-1 to D-137; M-1 to M-136; M-
1
to Y-135; M-1 to N-134; M-1 to G-133; M-1 to M-132; M-1 to F-131; M-1 to S-
130; M-
.5 1 to I-129; M-1 to G-128; M-1 to I-127; M-1 to S-126; M-1 to M-125; M-1 to
P-124; M-
1 to N-123; M-1 to W-122; M-1 to L-121; M-1 to H-120; M-1 to G-119; M-1 to S-
118;
M-1 to H-117; M-1 to A-116; M-1 to G-1 I5; M-1 to T-114; M-1 to F-113; M-1 to
N-
112; M-1 to W-111; M-1 to G-110; M-1 to R-109; M-I to G-108; M-1 to E-107; M-1
to
Y-106; M-1 to V-i05; M-1 to L-104; M-1 to G-103; M-1 to D-102; M-1 to E-101; M-
I
to G-100; M-1 to I-99; M-1 to L-98; M-I to F-97; M-1 to N-96; M-I to Y-95; M-1
to G-
94; M-1 to V-93; M-1 to D-92; M-1 to C-91; M-1 to W-90; M-1 to G-89; M-1 to L-
88;
M-1 to T-87; M-1 to K-86; M-1 to M-8S; M-1 to H-84; M-1 to Y-83; M-1 to H-82;
M-l
to Q-81; M-1 to V-80; M-1 to N-79; M-1 to R-78; M- I to A-77; M-1 to Q-76; M-1
to Q-
75; M-1 to Q-74; M-1 to C-73; M-1 to S-72; M-1 to A-71; M-1 to P-70; M-I to T-
69; M-
1 to N-68; M-1 to C-67; M-1 to S-66; M-1 to S-65; M-1 to G-64; M-1 to A-63; M-
1 to T-
62; M-1 to H-61; M-1 to S-60; M-1 to V-59; M-1 to V-58; M-1 to V-57; M-1 to Y-
56;
M-1 to R-55; M-1 to L-54; M-1 to P-53; M-1 to L-52; M-1 to S-51; M-1 to L-50;
M-1 to
H-49; M-1 to Q-48; M-1 to A-47; M-1 to C-46; M-1 to E-45; M-1 to S-44; M-1 to
A-43;
M-1 to L-42; M-1 to A-41; M-1 to K-40; M-1 to W-39; M-1 to E-38; M-1 to N-37;
M-1
to R-36; M-1 to P-35; M-1 to V-34; M-1 to I-33; M-1 to P-32; M-1 to S-31; M-1
to C-
30; M-1 to C-29; M-1 to A-28; M-1 to P-27; M-1 to D-26; M-1 to E-25; M-1 to T-
24; M-
1 to E-23; M-1 to Q-22; M-1 to A-21; M-1 to A-20; M-1 to G-19; M-1 to L-18; M-
1 to
R-17; M-1 to L-16; M-1 to L-15; M-1 to S-14; M-1 to P-13; M-1 to L-12; M-1 to
A-11;
M-1 to W-10; M-1 to A-9; M-1 to L-8; M-1 to L-7; M-1 to M-6; of SEQ ID N0:36.
Polypeptides encoded by these polynucleotides are also encompassed by the
invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:36 which have been
determined
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
1 X17
from the following related cDNA genes: HBMTB79R (SEQ ID NO:115) and
HCDDP40R (SEQ ID N0:116).
Based on the sequence similarity to the mouse tag? and the PGRP-like domain,
translation product of this gene is expected to share at least some biological
activities
S with tag? proteins, and specifically cytokine modulatory proteins. Such
activities are
known in the art, some of which are described elsewhere herein. Specifically,
polynucleotides and polypeptides of the invention are also useful for
modulating the
differentiation of normal and malignant cells, modulating the proliferation
and/or
differentiation of cancer and neoplastic cells, and modulating the immune
response.
Polynucleotides and polypeptides of the invention may represent a diagnostic
marker for
hematopoietic and immune diseases and/or disorders. The full-length protein
should be a
secreted protein, based upon homology to the tag? protein. Therefore, it is
secreted into
serum, urine, or feces and thus the levels is assayable from patient samples.
Assuming
specific expression levels are reflective of the presence of immune disorders,
this protein
would provide a convenient diagnostic for early detection. In addition,
expression of this
gene product may also be linked to the progression of immune diseases, and
therefore
may itself actually represent a therapeutic or therapeutic target for the
treatment of
cancer.
Polynucleotides and polypeptides of the invention may play an important role
in
the pathogenesis of human cancers and cellular transformation, particularly
those of the
immune and hematopoietic systems. Polynucleotides and polypeptides of the
invention
may also be involved in the pathogenesis of developmental abnormalities based
upon its
potential effects on proliferation and differentiation of cells and tissue
cell types. Due to
the potential proliferating and differentiating activity of said
polynucleotides and
polypeptides, the invention is useful as a therapeutic agent in inducing
tissue
regeneration, for treating inflammatory conditions (e.g., inflammatory bowel
syndrome,
diverticulitis, etc.).
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
148
Moreover, the invention is useful in modulating the immune response to
aberrant
polypeptides, as may exist in rapidly proliferating cells and tissue cell
types, particularly
in adenocarcinoma cells, and other cancers. The translation product of this
gene shares
sequence homology with Tag7, which is a mouse cytokine that, in soluble form,
triggers
apoptosis in mouse L929 cells in vitro.
The translation product of this gene also shares sequence homology with
anti microbial BGP-A, a bovine antimicrobial peptide from bovine neutrophils.
Preferred
polypeptides of this invention comprise residues 184 to 196 shown in SEQ ID
NO: 36.
This polypeptide is believed to be the active mature form of the translation
product of
this gene.
This gene is expressed primarily in bone marrow and to a lesser extent in
human
chondrosarcoma and neutrophils.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, infections, cancer, and disorders of the immune system. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of infected
tissues and the
immune system, expression of this gene at significantly higher or lower levels
is
routinely detected in certain tissues or cell types (e.g. immune,
hematopoietic, and
cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma,
urine,
synovial fluid and spinal fluid) or another tissue or cell sample taken from
an individual
having such a disorder, relative to the standard gene expression level, i.e.,
the expression
level in healthy tissue or bodily fluid from an individual not having the
disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 36 as residues: Ala-63 to Asn-68, Ala-71 to Gln-81, Tyr-
135 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
149
Thr-141, Leu-167 to Gln-174, Pro-191 to Pro-196. Polynucleotides encoding said
polypeptides are also provided.
FEATURES OF PROTEIN ENCODED BY GENE NO: 9
This invention relates to newly identified polynucleotides, polypeptides
encoded
by such polynucleotides, the use of such polynucleotides and poiypeptides, as
well as the
production of such polynucleotides and polypeptides. The polypeptide of the
present
invention has been putatively identified as a human butyrophilin homolog
derived from a
human testes tumor cDNA library. The polypeptide of the present invention is
sometimes
hereafter referred to as "Butyrophlin and B7-like 1gG superfamily receptor ",
and/or
"BBIR II". The invention also relates to inhibiting the action of such
polypeptides.
Butyrophilin is a glycoprotein of the immunoglobulin superfamily that is
secreted
in association with the milk-fat-globule membrane from mammary epithelial
cells. The
butyrophilin gene appears to have evolved from a subset of genes in the
immunoglobulin
superfamily and genes encoding the B30.2 domain, which is conserved in a
family of
zinc-finger proteins. Furthermore, expression analysis of butyrophilin genes
has shown
that butyrophilin expression increases during lactation in conjunction with an
increase in
milk fat content. These results suggest that the stage-specific expression of
milk fat
globule membrane glycoproteins in mammary epithelial cells is regulated in a
similar but
not necessarily identical mechanism to that of a major milk protein, beta-
casein.
The polypeptide of the present invention has been putatively identified as a
member of the milk fat globule membrane glycoprotein family, and more
particularly the
butyrophilin family, and has been termed Butyrophlin and B7-like IgG
superfamily
receptor ("BBIR II"). This identification has been made as a result of amino
acid
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
150
sequence homology to the bovine butyrophilin precursor (See Genbank Accession
No.
gi ~ 162773 ).
Preferred polypeptides of the invention comprise the following nucleic acid
sequence:
ACATCCATGGCTCTAATGCTCAGTTTGGTTCTGAGTCTCCTCAAGCTGGGATC
AGGGCAGTGGCAGGTGTTTGGGCCAGACAAGCCTGTCCAGGCCTTGGTGGGG
GAGGACGCAGCATTCTCCTGTTTCCTGTCTCCTAAGACCAATGCAGAGGCCA
TGGAAGTGCGGTTCTTCAGGGGCCAGTTCTCTAGCGTGGTCCACCTCTACAG
GGACGGGAAGGACCAGCCATTTATGCAGATGCCACAGTATCAAGGCAGGAC
AAAACTGGTGAAGGATTC.'TATTGCGGAGGGGCGCATCTCTCTGAGGCTGGAA
AACATTACTGTGTTGGATGCTGGCCTCTATGGGTGCAGGATTAGTTCCCAGTC
TTACTACCAGAAGGCCATCTGGGAGCTACAGGTGTCAGCACTGGGCTCAGTT
CCTCTCATTTCCATCACGGGATATGTTGATAGAGACATCCAGCTACTCTGTCA
GTCCTCGGGCTGGTTCCCCCGGCCCACAGCGAAGTGGAAAGGTCCACAAGGA
I5 CAGGATTTGTCCACAGACTCCAGGACAAACAGAGACATGCATGGCCTGTTTG
ATGTGGAGATCTCTCTGACCGTCCAAGAGAACGCCGGGAGCATATCCTGTTC
CATGCGGCATGCTCATCTGAGCCGAGAGGTGGAATCCAGGGTACAGATAGG
AGATACCTTTTTCGAGCCTATATCGTGGCACCTGGCTACCAAAGTACTGGGA
ATACTCTGCTGTGGCCTA'I'T'TT'TTGGCATTGTTGG.ACTGAAGATTTTCTTCTCC
AAATTCCAGTGGAAAATCCAGGCGGAACTGGACTGGAGAAGAAAGCACGGA
CAGGCAGAATTGAGAGACGCCCGGAAACACGCAGTGGAGGTGACTCTGGAT
CCAGAGACGGCTCACCCGAAGCTCTGCGTTTCTGATCTGAAAACTGTAACCC
ATAGAAAAGCTCCCCAGGAGGTGCCTCACTCTGAGAAGAGATTTACAAGGA
AGAGTGTGGTGGCTTCTCAGAGTTTCCAAGCAGGGAAACATTACTGGGAGGT
GGACGGAGGACACAATAAAAGGTGGCGCGTGGGAGTGTGCCGGGATGATGT
GGACAGGAGGAAGGAGTACGTGACTTTGTCTCCCGATCATGGGTACTGGGTC
CTCAGACTGAATGGAGAACATTTGTATTTCACATTAAATCCCCGTTTTATCAG
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
151
CGTCTTCCCCAGGACCCCACCTACAAAAATAGGGGTCTTCCTGGACTATGAG
TGTGGGACCATCTCCTTCTTCAACATAAATGACCAGTCCCTTATTTATACCCT
GACATGTCGGTTTGAAGGCTTATTGAGGCCCTACATTGAGTATCCGTCCTATA
ATGAGCAAAATGGAACTCCCAGAGACAAGCAACAGTGAGTCCTCCTCACAG
S GCAACCACGCCCTTCCTCCCCAGGGGTGAAATGTAGGATGAATCACATCCCA
CATTCTTCTTTAGGGATATTAAGGTCTCTCTCCCAGATCCAAAGTCCCGCAGC
AGCCGGCCAAGGTGGCTTCCAGATGAAGGGGGACTGGCCTGTCCACATGGG
AGTCAGGTGTCATGGCTGCCCTGAGCTGGGAGGC~AAGAAGGCTGACATTAC
ATTTAGTTTGCTCTCACTCCATCTGGCTAAGTGATCTTGAAATACCACCTCTC
AGGTGAAGAACCGTCAGGAATTCCCATCTCACAGGCTGTGGTGTAGATTAAG
TAGACAAGGAATGTGAATAATGC'TTAGATCTTATTGATGACAGAGTGTATCC
TAATGGTTTGTTCATTATATTACACTTTCAGTAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAA (SEQ ID N0:117), and/or
ATGGCTCTAATGCTCAGTTTGGTTCTGAGTCTCCTCAAGCTGGGATCAGGGCA
GTGGCAGGTGTTTGGGCCAGACAAGCCTGTCCAGGCCTTGGTGGGGGAGGAC
GCAGCATTCTCCTGTTTCCTGTCTCCTAAGACCAATGCAGAGGCCATGGAAG
TGCGGTTCTTCAGGGGCCAGTTCTCTAGCGTGGTCCACCTCTACAGGGACGG
GAAGGACCAGCCATTTATGCAGATGCCACAGTATCAAGGCAGGACAAAACT
GGTGAAGGATTCTATTGCCiGAGGGGCGCATCTCTCTGAGGCTGGAAAACATT
ACTGTGTTGGATGCTGGCCTCTATGGGTGCAGGATTAGTTCCCAGTCTTACTA
CCAGAAGGCCATCTGGGAGCTACAGGTGTCAGCACTGGGCTCAGTTCCTCTC
ATTTCCATCACGGGATATGTTGATAGAGACATCCAGCTACTCTGTCAGTCCTC
GGGCTGGTTCCCCCGGCCCACAGCGAAGTGGAAAGGTCCACAAGGACAGGA
T"I'TGTCCACAGACTCCAGGACAAACAGAGACATGCATGGCCTGT'ITGATGTG
GAGATCTCTCTGACCGTCCAAGAGAACGCCGGGAGCATATCCTGTTCCATGC
GGCATGCTCATCTGAGCCGAGAGGTGGAATCCAGGGTACAGATAGGAGATA
CCTTTIfCGAGCCTATATCGTGGCACCTGGCTACCAAAGTACTGGGAATACTC
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29x35 PCT/US99/25031
152
TGCTGTGGCCTATTTTTTGGCATTGTTGGACTGAAGATTTTCTTCTCCAAATTC
CAGTGGAAAATCCAGGCGGAACTGGACTGGAGAAGAAAGCACGGACAGGCA
GAATTGAGAGACGCCCGGAAACACGCAGTGGAGGTGACTCTGGATCCAGAG
ACGGCTCACCCGAAGCTCTGCGTTTCTGATCTGAAAACTGTAACCCATAGAA
AAGCTCCCCAGGAGGTGCCTCACTCTGAGAAGAGATTTACAAGGAAGAGTGT
GGTGGCTTCTCAGAGTTTCCAAGCAGGGAAACATTACTGGGAGGTGGACGGA
GGACACAATAAAAGGTGGCGCGTGGGAGTGTGCCGGGATGATGTGGACAGG
AGGAAGGAGTACGTGACTTTGTCTCCCGATCATGGGTACTGGGTCCTCAGAC
TGAATGGAGAACATTTGTATTTCACATTAAATCCCCGTTTTATCAGCGTCTTC
CCCAGGACCCCACCTACAAAAATAGGGGTCTTCCTGGACTATGAGTGTGGGA
CCATCTCCTTCTTCAACATAAATGACCAGTCCCT'TATTTATACCCTGACATGT
CGGTTTGAAGGCTTATTGAGGCCCTACATTGAGTATCCGTCCTATAATGAGC
AAAATGGAACTCCCAGAGACAAGCAACAGTGA (SEQ ID NO:118). Polypeptide
encoded by these polynucleotides are a3so provided.
Preferred polypeptides of the invention comprise the following amino acid
sequence:
MALMLSLVLSLLKLGSGQWQVFGPDKPVQALVGEDAAFSCFLSPKTNAEAMEV
RFFRGQFSS V VHLYRDGKDQPFMQMPQYQGRTKLV KDSIAEGRISLRLENITVL
DAGLYGCRISSQSYYQKAI WELQVSALGS VPLISITCiY VDRDIQLLCQSSGWFPRP
TAKWKGPQGQDLSTDSRTNRDMHGLFDVEISLTVQENAGSISCSMRHAHLSREV
ESR VQIGDTFFEPIS WHLATK VLGILCCGLFFGI V GLKIFFSKFQWKIQAELDWRR
KHGQAELRDARKHAVEVTLDPETAHPKLCVSDLKTVTHRKAPQEVPHSEKRFT
RKSVVASQSFQAGKHYWEVDGGHNKRWRVGVCRDDVDRRKEYVTLSPDHGY
W VLRLNGEHLYFTLNPRFIS VFPRTPPTKIG VFLDYECGTISFFNINDQSLI YTLTC
RFEGLLRPYIEYPSYNEQNGTPRDKQQ (SEQ ID NO::I 19). Polynucleotides encoding
these polypeptides are also provided.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00!29435 PCT/US99/25031
153
A preferred polynucleotide splice variant of the invention comprises the
following nucleic acid sequence:
ACCTTTTTCGAGCCTATATCGTGGCACCTGGCTACCAAAGTACTGGGAATACT
CTGCTGTGGCCTATTTTTTGGCATTGTTGGACTGAAGATTTTCTTCTCCAAATT
CCAGTGGAAAATCCAGGCGGAACTGGACTGGAGAAGAAAGCACGGACAGGC
AGAATTGAGAGACGCCCGGAAACACGCAGTGGAGGTGACTCTGGATCCAGA
GACGGCTCACCCGAAGCTCTGCGTTTCTGATCTGAAAACTGTAACCCATAGA
AAAGCTCCCCAGGAGGTGCCTCACTCTGAGAAGAGATTTACAAGGAAGAGT
GTGGTGGCTTCTCAGAGTTTCCAAGCAGGGAAAC'.ATTACTGGGAGGTGGACG
GAGGACACAATAAAAGGTGGCGCGTGGGAGTGTGCCGGGATGATGTGGACA
GGAGGAAGGAGTACGTGACTTTGTCTCCCGATCATGGGTACTGGGTCCTCAG
ACTGAATGGAGAACATTTGTATTTCACATTAAATCCCCGTTTTATCAGCGTCT
TCCCCAGGACCCCACCTACAAAAATAGGGGTCTTCCTGGACTATGAGTGTGG
GACCATCTCCTTCTTCAAC'.ATAAA'I'GACCAGTCCCTTATTTATACCCTGACAT
GTCGGTTTGAAGGCTTATTGAGGCCCTACATTGAGTATCCGTCCTATAATGAG
CAAAATGGAACTCCCAGAGACAAGCAACAGTGAGTCCTCCTCACAGGCAAC
CACGCCCTTCCTCCCCAGGGGTGAAATGTAGGATGAATCACATCCCACATTC
TTCTTTAGGGATATTAAGGTCTCTCTCCCAGATCCAAAGTCCCGCAGCAGCCG
GCCAAGGTGGCTTCCAGATGAAGGGGGACTGGCCTGTCCACATGGGAGTCA
GGTGTCATGGCTGCCCTGAGCTGGGAGGGAAGAAGGCTGACATTACATTTAG
TTTGCTCTCACTCCATCTGGCTAAGTGATCTTGAAATACCACCTCTCAGGTGA
AGAACCGTCAGGAATTCCCATCTCACAGGCTGTGGTGTAGATTAAGTAGACA
AGGAATGTGAATAATGCTTAGATCTTATTGATGACAGAGTGTATCCTAATGG
TTTGTTCATTATATTACACTTTCAGTAAAAAAAAAAAAAAAAAAAAAAAAAA
2.5 AAAAAA (SEQ ID N0:120). Polypeptides encoded by these polynucleotides are
also
provided.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
154
Figures 22A-D show the nucleotide (SEQ ID N0:19) and deduced amino acid
sequence (SEQ ID N0:37) of BBIR II. Predicted amino acids from about 1 to
about 17
constitute the predicted signal peptide (amino acid residues from about 1 to
about 17 in
SEQ ID N0:37) and are represented by the underlined amino acid regions.
Figure 23 shows the regions of similarity between the amino acid sequences of
the Butyrophlin and B7-like IgG superfamily receptor (BBIR II) protein (SEQ ID
N0:37) and the bovine butyrophilin precursor (SEQ 1D N0:121 )
Figure 24 shows an analysis of the integrin alpha l 1 subunit (BBIR II) amino
acid sequence.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic regions; flexible regions; antigenic index and surface probability
are shown.
A polynucleotide encoding a polypeptide of the present invention is obtained
from human small intestine, colon tumor, and human testes tumor cells and
tissues. The
polynucleotide of this invention was discovered in a human testes tumor cDNA
library.
Its translation product has homology to the B30.2-like domain which is
characteristic of proteins containing zinc-binding B-box motifs, and
particularly for
butyrophilin family members. The polynucleotide contains an open reading frame
encoding the BBIR II polypeptide of 318 amino acids. BBIR II exhibits a high
degree of
homology at the amino acid level to the bovine butyrophilin precursor (as
shown in
Figure 23). The present invention provides isolated nucleic acid molecules
comprising a
polynucleotide encoding the BBIR II polypeptide having the amino acid sequence
shown
in Figures 22A-D (SEQ ID N0:37). The nucleotide sequence shown in Figures 22A-
D
(SEQ ID N0:19) was obtained by sequencing a cloned cDNA (HTTDB46), which was
deposited on November 17 at the American Type Culture Collection, and given
Accession Number 203484.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
155
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
N0:19 is intended DNA fragments at least about l5nt, and more preferably at
least about
20 nt, still more preferably at least about 30 nt, and even more preferably,
at least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
course, larger fragments 50-1500 nt in length are also useful according to the
present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:19. By a fragment at least 20
nt in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
shown in SEQ ID N0:19. In this context "about" includes the particularly
recited size,
larger or smaller by several (5, 4, 3, 2, or 1 ) nucleotides, at either
terminus or at both
termini. Representative examples of BBIR II polynucleotide fragments of the
invention
include, for example, fragments that comprise, or alternatively, consist of, a
sequence
from about nucleotide 1 to about 50, from about 51 to about 100, from about
101 to
about 150, from about 151 to about 200, from about 201 t.o about 250, from
about 251 to
about 300, from about 301 to about 350, from about 351 to about 400, from
about 401 to
about 450, from about 451 to about 500, from about 501 to about 550, from
about 551 to
about 600, from about 601 to about 650, from about 651 to about 700, from
about 701 to
about 750, from about 751 to about 800, from about 801 to about 850, from
about 851 to
about 900, from about 901 to about 950, from about 951 to about 1000, from
about 1001
to about 1050, from about 1051 to about 1100, from about 1101 to about 1150,
from
about 1151 to about 1200, from about 1201 to about 1250, from about 1251 to
about
1300, from about 1301 to about 1350, from about 1351 to about 1400, from about
1401
to about 1450, from about 1451 to about 1500, from about 1501 to about 1550,
From
about 1551 to about 1600, from about 1601 to about 1650, from about 1651 to
about
1700, from about 1701 to about 1750, from about 1751 to about 1800, from about
1801
to about 18_50, from about 1851 to about 1900, from about 1901 to about 1950,
from
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
156
about 1951 to about 2000, from about 2001 to about 2050, from about 2051 to
about
2100, from about 2101 to about 2150, from about 2151 to about 2200, from about
2201
to about 2250, from about 2251 to about 2300, from about 2301 to about 2350,
from
about 2351 to about 2400, from about 2401 to about 2450, from about 2451 to
about
2500, from about 2501 to about 2550, from about 2551 to about 2600, from about
2601
to about 2650, from about 2651 to about 2700, from about 2701 to about 2750,
from
about 27S 1 to about 2800, from about 2801 to about 2850, from about 2851 to
about
2900, from about 2901 to about 2950, from about 2951 to about 3000, from about
3001
to about 3050, from about 3051 to about 3059 of SEQ ID N0:19, or the
complementary
strand thereto, or the cDNA contained in the deposited gene. In this context
"about"
includes the particularly recited ranges, larger or smaller by several (5, 4,
3, 2, or 1 )
nucleotides, at either terminus or at both termini.
Preferred nucleic acid fragments of the present invention include nucleic acid
molecules encoding a member selected from the group: a polypeptide comprising
or
alternatively, consisting of, the mature BBIR II protein (amino acid residues
from about
I8 to about 318 in Figures 22A-D (amino acids from about 18 to about 318 in
SEQ ID
N0:37). Since the location of this form of the protein has been predicted by
computer
analysis, one of ordinary skill would appreciate that the amino acid residues
constituting
these domains may vary slightly (e.g., by about 1 to 15 amino acid residues)
depending
on the criteria used to define this location. In additional embodiments, the
polynucleotides of the invention encode functional attributes of BBIR II.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions of BBIR II.
The data
SUBSTITUTE SKEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
157
representing the structural or functional attributes of BBIR II set forth in
Figure 24
and/or Table VIII, as described above, was generated using the various modules
and
algorithms of the DNA*STAR set on default parameters. In a preferred
embodiment, the
data presented in columns VIII, IX, XIII, and XIV of Table VIII can be used to
determine regions of BBIR II which exhibit a high degree of potential for
antigenicity.
Regions of high antigenicity are determined from the data presented in columns
VIII, IX,
XIII, and/or XIV by choosing values which represent regions of the polypeptide
which
are likely to be exposed on the surface of the polypeptide in an environment
in which
antigen recognition may occur in the process of initiation of an immune
response.
Certain preferred regions in these regards are set out in Figure 24, but may,
as
shown in Table VIII, be represented or identified by using tabular
representations of the
data presented in Figure 24. The DNA*STAR computer algorithm used to generate
Figure 24 (set on the original default parameters) was used to present the
data in Figure
24 in a tabular format (See Table VIII). The tabular format of the data in
Figure 24 is
used to easily determine specific boundaries of a preferred region. The above-
mentioned
preferred regions set out in Figure 24 and in Table VIII include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figures 22A-D. As set out in Figure 24 and in Table VIII, such
preferred regions
include Gamier-Robson alpha-regions, beta-regions, turn-regions, and coil-
regions,
Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic
regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-
amphipathic
regions, Karplus-Schulz flexible regions, Jameson-Wolf regions of high
antigenic index
and Emini surface-forming regions. Even if deletion of one or more amino acids
from the
N-terminus of a protein results in modification of loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities, ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened BBIR II
muteins to induce and/or bind to.antibodies which recognize the complete or
mature
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
158
forms of the polypeptides generally will be retained when less than the
majority of the
residues of the complete or mature polypeptide are removed from the N-
terminus.
Whether a particular polypeptide lacking N-terminal residues of a complete
polypeptide
retains such immunologic activities can readily be determined by routine
methods
described herein and otherwise known in the art. It is not unlikely that an
BBIR II mutein
with a large number of deleted N-terminal amino acid residues may retain some
biological or immunogenic activities. In fact, peptides composed of as few as
six BBIR II
amino acid residues may often evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the BBIR II amino acid
sequence
shown in Figures 22A-D, up to the cystein residue at position number 313 and
polynucieotides encoding such polypeptides. In particular, the present
invention provides
polypeptides comprising the amino acid sequence of residues n 1-318 of Figures
22A-D,
where n 1 is an integer from 2 to 313 corresponding to the position of the
amino acid
residue in Figures 22A-D (which is identical to the sequence shown as SEQ ID
N0:37).
In another embodiment, N-terminal deletions of the BBIR II polypeptide can be
described by the general formula n2-318, where n2 is a number from 2 to 313,
corresponding to the position of amino acid identified in Figures 22A-D. N-
terminal
deletions of the BBIR II polypeptide of the invention shown as SEQ ID N0:37
include
polypeptides comprising the amino acid sequence of residues: N-terminal
deletions of the
BBIR II polypeptide of the invention shown as SEQ ID N0:37 include
polypeptides
comprising the amino acid sequence of residues: A-2 to T-318; L-3 to T-318; M-
4 to T-
318; L-5 to T-318; S-6to T-318; L-7 to T-318; V-8 to T-318; L-9 to T-318; S-10
to T-
318; L-11 to T-318; L-12 to T-318; K-13 toT-318; L-14 to T-318; G-15 to T-318;
S-16
to T-318; G-17 to T-318; Q-18 to T-318; W-19 to T-318; Q-20 toT-318; V-21 to T-
318;
F-22 to T-318; G-23 to T-318; P-24 to T-318; D-25 to T-318; K-26 to T-3I8; P-
27 toT-
318; V-28 to T-318; Q-29 to T-318; A-30 to T-318; L-31 to T-318; V-32 to T-
318; G-33
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
159
to T-318; E-34 toT-318; D-35 to T-318; A-36 to T-318; A-37 to T-318; F-38 to T-
318;
S-39 to T-318; C-40 to T-318; F-41 toT-318; L-42 to T-318; S-43 to T-318; P-44
to T-
318; K-45 to T-318; T-46 to T-318; N-47 to T-318; A-48 toT-318; E-49 to T-318;
A-50
to T-318; M-51 to T-318; E-52 to T-318; V-53 to T-318; R-54 to T-318; F-55 toT-
318;
F-56 to T-318; R-57 to T-318; G-58 to T-318; Q-59 to T-318; F-60 to T-318; S-
61 to T-
318; S-62 toT-318; V-63 to T-318; V-64 to T-318; H-65 to T-318; L-66 to T-318;
Y-67
to T-318; R-68 to T-318; D-69 toT-318; G-70 to T-318; K-71 to T-318; D-72 to T-
318;
Q-73 to T-318; P-74 to T-318; F-75 to T-318; M-76 toT-318; Q-77 to T-318; M-78
to T-
318; P-79 to T-318; Q-80 to T-318; Y-81 to T-318; Q-82 to T-318; G-83 toT-318;
R-84
to T-318; T-85 to T-318; K-86 to T-318; L-87 to T-318; V-88 to T-318; K-89 to
T-318;
D-90 toT-318; S-91 to T-318; I-92 to T-318; A-93 to T-318; E-94 to T-318: G-95
to T-
318; R-96 to T-318; I-97 toT-318; S-98 to T-318; L-99 to T-318; R-100 to T-
318; L-101
to T-318; E-102 to T-318; N-103 to T-318;I-104 to T-318; T-10_5 to T-318; V-
106 to T-
318; L-107 to T-318; D-108 to T-318; A-109 to T-318; G-110 toT-318; L-111 to T-
318;
Y-112 to T-318; G-113 to T-318; C-114 to T-318; R-115 to T-318; I-116 to T-
318;S-117
to T-318; S-118 to T-318; Q-119 to T-318; S-120 to T-318; Y-121 to T-318; Y-
122 to T-
318; Q-123 toT-318; K-124 to T-318; A-125 to T-318; I-126 to T-318; W-127 to T-
318;
E-128 to T-318; L-129 to T-318;Q-130 to T-318; V-131 to T-318; S-132 to T-318;
A-
133 to T-318; L-134 to T-318; G-135 to T-318; S-136 toT-318; V-137 to T-318; P-
138
to T-318; L-139 to T-318; I-140 to T-318; S-141 to T-318; I-142 to T-318;A-143
to T-
318; G-144 to T-318; Y-145 to T-318; V-146 to T-318; D-147 to T-318; R-148 to
T-318;
D-149to T-318; I-150 to T-318; Q-151 to T-318; L-152 to T-318; L-153 to T-318;
C-154
to T-318; Q-155 to T-318;5-156 to T-318; S-157 to T-318; G-158 to T-318; W-159
to T-
318; F-160 to T-318; P-161 to T-318; R-162to T-318; P-163 to T-318; T-164 to T-
318;
A-165 to T-318; K-166 to T-318; W-167 to T-318; K-168 toT-318; G-169 to T-318;
P-
170 to T-318; Q-171 to T-318; G-172 to T-318; Q-173 to T-318; D-174 to T-318;L-
175
to T-318; S-176 to T-318; T-177 to T-318; D-178 to T-318; S-179 to T-318; R-
180 to T-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00129435 PCT/US99/25031
160
318; T-181 toT-318; N-182 to T-318; R-183 to T-318; D-184 to T-3I8; M-185 to T-
318;
H-186 to T-318; G-187 to T-318;L-188 to T-318; F-189 to T-318; D-190 to T-318;
V-
191 to T-318; E-192 to T-318; I-193 to T-318; S-194 toT-318; L-195 to T-318; T-
196 to
T-318; V-197 to T-318; Q-198 to T-318; E-199 to T-318; N-200 to T-318;A-20l to
T-
318; G-202 to T-318; S-203 to T-318; I-204 to T-318; S-205 to T-318; C-206 to
T-318;
S-207 toT-318; M-208 to T-318; R-209 to T-318; H-210 to T-318; A-211 to T-318;
H-
212 to T-318; L-213 to T-318;5-214 to T-3 I 8; R-215 to 'r-318; E-216 to T-
318: V-217
to T-318; E-218 to T-318; S-219 to T-318; R-220 toT-318; V-221 to T-318; Q-222
to T-
318; I-223 to T-318; G-224 to T-318; D-225 to T-318; W-226 to T-318;8-227 to T-
318;
R-228 to T-318; K-229 to T-318; H-230 to T-318; G-231 to T-318; Q-232 to T-
318; A-
233to T-318; G-234 to T-318; K-235 to T-318; R-236 to T-318; K-237 to T-318; Y-
238
to T-318; S-239 toT-318; S-240 to T-318; S-241 to T-318; H-242 to T-318; I-243
to T-
318; Y-244 to T-318; D-245 to T-318;S-24G to T-318; F-247 to T-318; P-248 to T-
318;
S-249 to T-318; L-250 to T-318; S-251 to T-318; F-252 toT-318; M-253 to T-318;
D-
254 to T-318; F-255 to T-318; Y-256 to T-318; I-257 to T-318; L-258 to T-318;R-
259 to
T-318; P-260 to T-318; V-261 to T-318; G-262 to T-318; P-263 to T-318; C-264
to T-
318; R-265to T-318; A-266 to T-318; K-267 to T-318; L-268 to T-318; V-269 to T-
318;
M-270 to T-318; G-271 toT-318; T-272 to T-318; L-273 to T-318; K-274 to T-318;
L-
275 to T-318; Q-276 to T-318; I-277 to T-318;L-278 to T-318; G-279 to T-318; E-
280 to
T-318; V-281 to T-318; H-282 to T-318; F-283 to T-318; V-284to T-318; E-285 to
T-
318; K-286 to T-318; P-287 to T-318; H-288 to T-318; S-289 to T-318; L-290 toT-
318;
L-291 to T-318; Q-292 to T-318; I-293 to T-318; S-294 to T-318; G-295 to T-
318: 6-
296 to T-318;S-297 to T-318; T-298 to T-318; T-299 to T-318; L-300 to T-318; K-
301 to
T-318; K-302 to T-318; G-303to T-318; P-304 to T-318; N-305 to T-318; P-306 to
T-
318; W-307 to T-318; S-308 to T-318; F-309 toT-318; P-310 to T-318; S-311 to T-
318;
P-312 to T-318; C-313 to T-318; of SEQ ID N0:37. Polypeptides encoded by these
polynucleotides are also encompassed by the invention.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
161
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities (e.g., ability
to illicit mitogenic activity, induce differentiation of normal or malignant
cells, ability to
multimerize, etc.) may still be retained. For example the ability of the
shortened BBIR II
mutein to induce and/or bind to antibodies which recognize the complete or
mature forms
of the polypeptide generally will be retained when less than the majority of
the residues
of the complete or mature polypeptide are removed from the C-terminus. Whether
a
particular polypeptide lacking C-terminal residues of a complete polypeptide
retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that an BBIR II mutein with
a large
number of deleted C-terminal amino acid residues may retain some biological or
immunogenic activities. In fact, peptides composed of as few as six BBIR II
amino acid
residues may often evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
BBIR II polypeptide shown in Figures 22A-D, up to the serine residue at
position
number 6, and polynucleotides encoding such polypeptides. In particular, the
present
invention provides polypeptides comprising the amino acid sequence of residues
1-ml of
Figure 1, where ml is an integer from 6 to 318 corresponding to the position
of the
amino acid residue in Figures 22A-D. Moreover, the invention provides
polynucleotides
encoding polypeptides comprising, or alternatively consisting of, the amino
acid
sequence of C-terminal deletions of the BBIR II polypeptide of the invention
shown as
SEQ ID N0:37 include polypeptides comprising the amino acid sequence of
residues M-
1 to P-317; M-1 to F-316; M-1 to L-315;M-1 to A-314; M-1 to C-313; M-1 to P-
312; M-
1 to S-311; M-1 to P-310; M-1 to F-309; M-1 to S-308; M-lto W-307; M-1 to P-
306; M-
1 to N-305; M-I to P-304; M-1 to G-303; M-1 to K-302; M-1 to K-301; M-1 toL-
300;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
162
M-1 to T-299; M-1 to T-298; M-1 to S-297; M-1 to G-296; M-1 to G-295; M-1 to S-
294;
M-1 toI-293; M-1 to Q-292; M-1 to L-291; M-1 to L-290; M-1 to S-289; M-1 to H-
288;
M-1 to P-287; M-1 toK-286; M-1 to E-285; M-1 to V-284; M-1 to F-283; M-1 to H-
282;
M-1 to V-281; M-1 to E-280; M-1 toG-279; M-1 to L-27$; M-1 to I-277; M-1 to Q-
276;
M-1 to L-275; M-1 to K-274; M-1 to L-273; M-1 toT-272; M-1 to G-271; M-1 to M-
270;
M-1 to V-269; M-1 to L-268; M-1 to K-267; M-1 to A-266; M-1 toR-265; M-1 to C-
264;
M-1 to P-263; M-1 to G-262; M-1 to V-261; M-1 to P-260; M-1 to R-259; M-1 toL-
258;
M-1 to I-257; M-1 to Y-256; M-1 to F-255; M-1 to D-254; M-i to M-253; M-1 to F-
252;
M-1 toS-251; M-1 to L-250; M-1 to S-249; M-1 to P-248; M-1 to F-247; M-1 to S-
246;
M-1 to D-24_5; M-1 toY-244; M-1 to I-243; M-1 to H-242; M-1 to S-241; M-1 to S-
240;
M-1 to S-239; M-1 to Y-238; M-1 toK-237; M-1 to R-236; M-1 to K-235; M-1 to G-
234;
M-1 to A-233; M-i to Q-232; M-1 to G-231; M-1 toH-230; M-1 to K-229; M-1 to R-
228; M-1 to R-227; M-1 to W-226; M-1 to D-225; M-1 to G-224; M-1 toI-223; M-1
to
Q-222; M-1 to V-221; M-1 to R-220; M-1 to S-219; M-1 to E-218; M-1 to V-217; M-
1
toE-216; M-1 to R-215; M-i to S-214; M-1 to L-213; M-1 to H-212; M-1 to A-211;
M-1
to H-210; M-1 toR-209; M-1 to M-208; M-1 to S-207; M-1 to C-206; M-1 to S-205;
M-1
to I-204; M-1 to S-203 ; M-1 toG-202; M-1 to A-201; M-1 to N-200; M-1 to E-
199; M-1
to Q-198; M-1 to V-197; M-1 to T-196; M-1 toL-19_5; M-1 to S-194; M-1 to I-
193; M-1
to E-192; M-1 to V-191; M-1 to D-190; M-1 to F-189; M-1 toL-188; M-1 to G-187;
M-1
to H-186; M-1 to M-185; M-1 to D-184; M-1 to R-183; M-1 to N-182; M-1 toT-181;
M-
1 to R-180; M-1 to S-179; M-1 to D-178; M-1 to T-177; M-1 to S-176; M-1 to L-
175;
M-1 toD-174; M-1 to Q-173; M-1 to G-172; M-1 to Q-171; M-1 to P-170; M-1 to G-
169;
M-1 to K-168; M-1 toW-167; M-1 to K-166; M-1 to A-165; M-1 to T-164; M-1 to P-
163; M-1 to R-162; M-1 to P-161; M-1 toF-160; M-1 to W-159; M-1 to G-158; M-1
to
S-157; M-1 to S-156; M-1 to Q-155; M-1 to C-154; M-1 toL-153; M-1 to L-152; M-
1 to
Q-151; M-1 to I-150; M-1 to D-149; M-1 to R-148; M-1 to D-147; M-1 toV-146; M-
1 to
Y-145; M-1 to G-i44; M-1 to A-143; M-1 to I-142; M-1 to S-141; M-I to I-140; M-
1
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/1JS99/25031
163
toL-139; M-1 to P-138; M-I to V-137; M-1 to S-136; M-1 to G-135; M-1 to L-134;
M-1
to A-133; M-1 toS-132; M-1 to V-13I; M-1 to Q-130; M-1 to L-129; M-1 to E-128;
M-1
to W-127; M-1 to I-126; M-1 toA-125; M-1 to K-124; M-1 to Q-123; M-1 to Y-122;
M-1
to Y-121; M-1 to S-120; M-1 to Q-119; M-1 toS-118; M-1 to S-117; M-1 to I-116;
M-1
to R-115; M-1 to C-114; M-1 to G-113; M-1 to Y-112; M-1 toL-I 11; M-1 to G-
110; M-1
to A-109; M-1 to D-108; M-1 to L-107; M-1 to V-106; M-1 to T-105; M-1 toI-104:
M-1
to N-103: M-I to E-102; M-1 to L-101; M-1 to R-100; M-1 to L-99; M-1 to S-98;
M-I to
I-97;M-1 to R-96; M-l to G-95; M-1 to E-94; M-1 to A-93; M-I to I-92; M-1 to S-
91;
M-1 to D-90; M-1 to K-89;M-I to V-88; M-1 to L-87; M-1 to K-86; M-1 to T-85; M-
1 to
R-84; M-1 to G-83; M-1 to Q--82; M-1 to Y-81;M-1 to Q-80; M-1 to P-79; M-1 to
M-78;
M-1 to Q-77; M-I to M-76; M-1 to F-75; M-I to P-74; M-1 to Q-73;M-1 to D-72; M-
1 to
K-71; M-1 to G-70; M-1 to D-69; M-1 to R-68; M-1 to Y-67; M- I to L-66; M-1 to
H-
65;M-1 to V-64; M-1 to V-63; M-1 to S-62; M-1 to S-61; M-I to F-60; M-I to Q-
59; M-
1 to G-58; M-I to R-57;M-1 to F-56; M-I to F-55; M-1 to R-54; M-1 to V-53; M-1
to E-
52; M-I to M-51; M-1 to A-50; M-1 to E-49;M-1 to A-48; M-1 to N-47; M-1 to T-
46;
M-1 to K-45; M-1 to P-44; M-1 to S-43; M-1 to L-42; M-1 to F-41;M-1 to C-40; M-
1 to
S-39; M-1 to F-38; M-1 to A-37; M-1 to A-36; M-1 to D-35; M-1 to E-34; M-1 to
G-
33;M-I to V-32; M-1 to L-31; M-1 to A-30; M-1 to Q-29; M-1 to V-28; M-1 to P-
27; M-
1 to K-26; M-1 to D-25;M-1 to P-24; M-1 to G-23; M-1 to F-22; M-1 to V-21; M-1
to Q-
20; M-1 to W-19; M-1 to Q-18; M-1 to G-17;M-1 to S-I6; M-1 to G-15; M-1 to L-
14;
M-I to K-13; M-1 to L-12; M-1 to L-11; M-1 to S-10; M-1 to L-9;M-1 to V-8; M-1
to L-
7; M-I to S-6; of SEQ ID N0:37. Polypeptides encoded by these polynucleotides
are
also encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:19 which have been
determined
from the following related cDNA genes: HTTDB46R (SEQ ID N0:122), and HSIEA44R.
(SEQ ID N0:123).
SUBSTITUTE SHEET (RULE 26}
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
164
Based on the sequence similarity to the bovin butyrophilin precursor,
translation
product of this gene is expected to share at least some biological activities
with B30.2-
like domain containing proteins, and specifically butyrophilin proteins. Such
activities
are known in the art, some of which are described elsewhere herein.
Specifically,
polynucleotides and polypeptides of the invention are also useful for
modulating the
differentiation of normal and malignant cells, modulating the proliferation
and/or
differentiation of cancer and neoplastic cells, and regulation of cell growth
and
differentiation. Polynucleotides and polypeptides of the invention may
represent a
diagnostic marker for breast diseases and/or disorders, in addition to
disorders of
secretory organs and tissues (which include, testicular and gastrointestinal
disorders,
particularly those cells which serve secretory functions for seminal fluid or
gastrointestinal hormones, and disorders of the mucosal membranes of such
cells and
tissues, etc.).
The full-length protein should be a secreted protein, based upon homology to
the
butyrophilin family of proteins. Therefore, it is secreted into milk, serum,
urine, seminal
fluid, or feces and thus the levels is assayable from patient samples.
Assuming specific
expression levels are reflective of the presence of breast disorders (i.e.,
breast cancer,
breast dysfunction, etc.) this protein would provide a convenient diagnostic
for early
detection of such disorders
In addition, expression of this gene product may also be linked to the
progression
of breast diseases, and therefore may itself actually represent a therapeutic
or therapeutic
target for the treatment of breast cancer. Polynucleotides and polypeptides of
the
invention may play an important role in the pathogenesis of human cancers and
cellular
transformation, particularly those of secretory cells and tissues.
Polynucleotides and
polypeptides of the invention may also be involved in the pathogenesis of
developmental
abnormalities based upon its potential effects on proliferation and
differentiation of cells
and tissue cell types.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
165
Due to the potential proliferating and differentiating activity of said
polynucleotides and polypeptides, the invention is useful as a therapeutic
agent in
inducing tissue regeneration, for treating inflammatory conditions. Moreover,
the
invention is useful in modulating the immune response to aberrant
polypeptides, as may
exist in rapidly proliferating cells and tissue cell types, particularly in
cancers. The
invention, including agonists and/or antagonists thereof, is useful in
modulating the
nutritional value of milk, its caloric content, its fat content, and may
conceivably be
useful in mediating the adaption of breast secretory function as a delivery
vehicle for
therapeutics (i.e., transgenic breast secretory tissue for transferring
therapeutically active
proteins to infants).
Alternatively, the expression within cellular sources marked by proliferating
cells
indicates this protein may play a role in the regulation of cellular division,
and may show
utility in the diagnosis, treatment, and/or prevention of developmental
diseases and
disorders, including cancer, and other proliferative conditions.
Representative uses are
described in the "Hyperproliferative Disorders" and "Regeneration" sections
below and
elsewhere herein. Briefly, developmental tissues rely on decisions involving
cell
differentiation and/or apoptosis in pattern formation.
Dysregulation of apoptosis can result in inappropriate suppression of cell
death,
as occurs in the development of some cancers, or in failure to control the
extent of cell
death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA).
Alternatively, this gene product is involved in the pattern of cellular
proliferation
that accompanies early embryogenesis. Thus, aberrant expression of this gene
product in
tissues - particularly adult tissues - may correlate with patterns of abnormal
cellular
proliferation, such as found in various cancers. Because of potential roles in
proliferation
and differentiation, this gene product may have applications in the adult for
tissue
regeneration and the treatment of cancers. It may also act as a morphogen to
control cell
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC'T/US99/25031
166
and tissue type specification. Therefore, the polynucleotides and polypeptides
of the
present invention are useful in treating, detecting, andlor preventing said
disorders and
conditions, in addition to other types of degenerative conditions. Thus this
protein may
modulate apoptosis or tissue differentiation and is useful in the detection,
treatment,
and/or prevention of degenerative or proliferative conditions and diseases.
The protein is
useful in modulating the immune response to aberrant polypeptides, as may
exist in
proliferating and cancerous cells and tissues. The protein can also be used to
gain new
insight into the regulation of cellular growth and proliferation. Furthermore,
the protein
may also be used to determine biological activity, to raise antibodies, as
tissue markers,
to isolate cognate ligands or receptors, to identify agents that modulate
their interactions,
in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy
targets for
the above listed tissues.
This gene is expressed primarily in small intestine, colon tumor, and to a
lesser
extent in human testes tumor cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, gastrointestinal diseases and/or disorders, in addition to
lactation disorders,
and tumors of the testes. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune and reproductive systems, expression of this gene
at
significantly higher or lower levels is routinely detected in certain tissues
or cell types
(e.g. immune, testicular, gastrointestinal, and cancerous and wounded tissues)
or bodily
fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or
another tissue
or cell sample taken from an individual having such a disorder, relative to
the standard
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
167
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 37 as residues: Tyr-67 to Pro-74, Ser-117 to Gln-123, Pro-
161 to
Met-185, Gly-224 to His-242, Thr-299 to Trp-307. Polynucleotides encoding said
polypeptides are also provided.
FEATURES OF PROTEIN ENCODED BY GENE NO: 10
The translation product of this gene contains a serine protease motif and
accordingly is believed to possess serine protease activity. Assays for
determining such
activity are well known in the art. Preferred polypeptides of this invention
possess such
activity.
Included in this invention as preferred domains are serine protease histidine
active site domains, which were identified using the ProSite analysis tool
(Swiss Institute
of Bioinformatics). The catalytic activity of the serine proteases from the
trypsin family
is provided by a charge relay system involving an aspartic acid residue
hydrogen- bonded
to a histidine, which itself is hydrogen-bonded to a serine. The sequences in
the vicinity
of the active site serine and histidine residues are welt conserved in this
family of
proteases [1]. Consensus pattern: [LIVM)-[ST)-A-[STAG)-H-C , H is the active
site
residue.
Preferred polypeptides of the invention comprise the following amino acid
sequence: GTLVAEKHVLTAAHCIHDGKTYVKGTQ (SEQ ID NO: 124).
Polynucleotides encoding these polypeptides are also provided.
Further preferred are polypeptides comprising the serine protease histidine
active
site domain of the sequence referenced in Table XIII for this gene, and at
least 5, 10, 1S,
SUBSTITUTE SHEET (RULE Z6)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
168
20, 25, 30, 50, or 75 additional contiguous amino acid residues of this
referenced
sequence. The additional contiguous amino acid residues is N-terminal or C-
terminal to
the serine protease histidine active site domain.
Alternatively, the additional contiguous amino acid residues is both N-
terminal
and C-terminal to the serine protease histidine active site domain, wherein
the total N-
and C-terminal contiguous amino acid residues equal the specified number. The
above
preferred polypeptide domain is characteristic of a signature specific to
serine protease
proteins. Based on the sequence similarity, the translation product of this
gene is
expected to share at least some biological activities with serine proteases.
Such activities
are known in the art, some of which are described elsewhere herein.
In another embodiment, polypeptides comprising the amino acid sequence of the
open reading frame upstream of the predicted signal peptide are contemplated
by the
present invention. Specifically, polypeptides of the invention comprise the
following
amino acid sequence:
GTRGQAWEPRALSRRPHLSERRSEPRPGRAARRGT'VLGMAGIPGLLFLLFF
LLCAVGQVSPYSAPWKPTWPAYRLPV VLPQSTLNLAKPDFGAEAKLEVSSSCGP
QCHKGTPLPTYEEAKQYLS YETLYANGSRTETQ VGIYILSSSGDGAQHRDSGSSG
KSRRKRQIYGYDSRFSIFGKDFLLNYPFSTS VKLSTGCTGTLVAEKHVLTAAHCI
HDGKTYVKGTQKLRVGFLKPKFKDGGRGANDSTSAMPEQMKFQWIRVKRTHV
PKGWIKGNANDIGMDYDYALLELKKPHKRKFMKIGVSPPAKQLPGGRIHFSGYD
NDRPGNLVYRFCDVKDETYDLLYQQCDSQPGASGSGVYVRMWKRQHQKWER
KIIGMISGHQWVDMDGSPQEFTRGCSEITPLQYIPDISIGV (SEQ ID NO: 125).
Polynucleotides encoding these polypeptides are also provided.
A preferred polypeptide variant of the invention comprises the following amino
acid sequence:
MAGIPGLLFLLFFLLCAVGQVSPYSAPWKPTWPAYRLPV VLPQSTLNLAKPD
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99IZ5031
169
FGAEAKLEVSSSCGPQCHKGTPLPTYEEAKQYLSYETLYANGSRTETQVGIYILS
SSGDGAQHRDSGSSGKSRRKRQIYGYDSRFSIFGKDFLLNYPFSTS VKLSTGCTG
TLVAEKHVLT
AAHCIHDGKTYVKGTQKLRVGFLKPKFKDGGRGANDSTSAMPEQMKFQWIRV
KRTHVPKGWIKGNANDIGMDYDYALLELKKPHKRKFMKIGVSPPAKQLPGGRI
HFSGYDNDRPGNLVYRFCDVKDETYDLLYQQCDAQPGASGSGVYVRMWKRQ
QQKWERKIIGIFSGHQW VDMNGSPQDFNVAVRITPLKYAQICYWIKGNYLDCRE
G (SEQ ID NO: 126). Polynucleotides encoding these polypeptides are also
provided.
Figures 25 A-B show the nucleotide (SEQ ID N0:20) and deduced amino acid
sequence (SEQ ID N0:38) of the present invention. Predicted amino acids from
about 1
to about 19 constitute the predicted signal peptide (amino acid residues from
about 1 to
about 19 in SEQ ID N0:38) and are represented by the underiined amino acid
regions;
amino acids from about 162 to about 188 constitutes the predicted serine
protease
histidine active site domain (amino acids residues from about 162 to about 188
in SEQ
ID N0:38) and are represented by the double underlined amino acid regions; and
amino
acid residue 175 (amino acid residue 175 in SEQ ID N0:38) constitutes the
predicted
histidine active site residue and is represented by the bold amino acid.
Figure 26 shows the regions of similarity between the amino acid sequences of
the present invention SEQ ID N0:38, and the Human Pancreatic Elastase 2
protein
(gi~219620)(SEQ ID NO: 127).
Figure 27 shows an analysis of the amino acid sequence of SEQ ID N0:38.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic
regions; flexible regions; antigenic index and surface probability are shown.
Northern analysis indicates that this gene is expressed highest in HUVEC,
HUVEC +LPS, smooth muscle, fibroblasts, present in heart, brain, placenta,
lung, liver,
muscle, kidney, pancreas, spleen, thymus, prostate, testes, ovary, small
intestine, colon
and weakly in PBLs.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
I70
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the polypeptide having the amino acid sequence shown
in
Figures 25 A-B (SEQ ID N0:38), which was determined by sequencing a cloned
cDNA.
The nucleotide sequence shown in Figures 25 A-B (SEQ ID N0:20) was obtained by
sequencing a cloned cDNA (HUSAQOS), which was deposited on Nov. 17, 1998 at
the
American Type Culture Collection, and given Accession Number 203484. The
deposited
gene is inserted in the pSport plasmid (Life Technologies, Rockville, MD)
using the
SaII/NotI restriction endonuclease cleavage sites.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
N0:20 is intended DNA fragments at least about ISnt, and more preferably at
least about
nt, still more preferably at least about 30 nt, and even more preferably, at
least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
15 course, larger fragments 50-1500 nt in length are also useful according to
the present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:20. By a fragment at least 20
nt in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
20 shown in SEQ ID N0:20. In this context "about" includes the particularly
recited size,
larger or smaller by several (5, 4, 3, 2, or 1 ) nucleotides, at either
terminus or at both
termini. Representative examples of polynucleotide fragments of the invention
include,
for example, fragments that comprise, or alternatively, consist of, a sequence
from about
nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about
150, from
about 151 to about 200, from about 201 to about 250, from about 251 to about
300, from
about 301 to about 350, from about 351 to about 400, from about 401 to about
450, from
about 451 to about 500, and from about 501 to about 550, and from about 551 to
about
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTIUS99/25031
I71
600, from about 601 to about 650, from about 651 to about 700, from about ?O1
to about
750, from about 751 to about 800, from about 801 to about 850, from about 851
to about
900, from about 901 to about 950, from about 951 to about 1000, from about
1001 to
about 1050, from about 1051 to about 1100, from about 1101 to about 1150, from
about
11 _51 to about 1200, from about 1201 to about 1250, from about 1251 to about
1300,
from about 1301 to about 1350, from about 13S 1 to about 1400, from about 1401
to
about 1450, from about 1451 to about 1500, from about 1501 to about 1550, from
about
I S_51 to about 1600, from about 1601 to abaut 1650, from about 1651 to about
1699 of
SEQ ID N0:20, or the complementary strand thereto, or the cDNA contained in
the
deposited gene. In this context "about" includes the particularly recited
ranges, larger or
smaller by several (5, 4, 3, 2, or 1 ) nucleotides, at either terminus or at
both termini. In
additional embodiments, the polynucleotides of the invention encode functional
attributes of the corresponding protein.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions. The data
representing
the structural or functional attributes of the protein set forth in Figure 27
and/or Table IX,
as described above, was generated using the various modules and algorithms of
the
DNA*STAR set on default parameters. In a preferred embodiment, the data
presented in
columns VIII, IX, XIII, and XIV of Table IX can be used to determine regions
of the
protein which exhibit a high degree of potential for antigenicity. Regions of
high
antigenicity are determined from the data presented in columns VIII, IX, XIII,
and/or
XIV by choosing values which represent regions of the polypeptide which are
likely to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
172
be exposed on the surface of the polypeptide in an environment in which
antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 27, but may,
as
shown in Table IX, be represented or identified by using tabular
representations of the
data presented in Figure 27. The DNA*STAR computer algorithm used to generate
Figure 27 (set on the original default parameters) was used to present the
data in Figure
27 in a tabular format (See Table IX). The tabular format of the data in
Figure 27 is used
to easily determine specific boundaries of a preferred region. The above-
mentioned
preferred regions set out in Figure 27 and in Table IX include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figure 1. As set out in Figure 27 and in Table IX, such preferred
regions include
Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions,
Chou-
Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic regions
and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-amphipathic
regions,
Karplus-Schulz flexible regions, Jameson-Wolf regions of high antigenic index
and
Emini surface-forming regions. Even if deletion of one or more amino acids
from the N-
terminus of a protein results in modification of loss of one or more
biological functions
of the protein, other functional activities (e.g., biological activities,
ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened muteins to
induce and/or bind to antibodies which recognize the complete or mature forms
of the
polypeptides generally will be retained when less than the majority of the
residues of the
complete or mature polypeptide are removed from the N-terminus. Whether a
particular
polypeptide lacking N-terminal residues of a complete polypeptide retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
173
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the amino acid sequence shown
in
Figures 25A-B, up to the aspartic acid residue at position number 370 and
polynucleotides encoding such polypeptides. In particular, the present
invention provides
polypeptides comprising the amino acid sequence of residues n I-375 of Figures
25A-B,
where n 1 is an integer from 2 to 370 corresponding to the position of the
amino acid
residue in Figures 25A-B (which is identical to the sequence shown as SEQ ID
N0:38).
N-terminal deletions of the polypeptide of the invention shown as SEQ ID N0:38
include polypeptides comprising the amino acid sequence of residues: A-2 to V-
375; G-3
to V-375; I-4 to V-375; P-5 to V-375; G-6 to V-375; L-7 to V-375; L-8 to V-
375; F-9 to
V-375; L-10 to V-375; L-11 to V-375; F-12 to V-375; F-13 to V-375; L-14 to V-
375; L-
to V-375; C-16 to V-375; A-17 to V-375; V-18 to V-375; G-19 to V-375; Q-20 to
V-
15 375; V-21 to V-375; S-22 to V-375; P-23 to V-375; Y-24 to V-375; S-25 to V-
375; A-26
to V-375; P-27 to V-375; W-28 to V-375; K-29 to V-375; P-30 to V-375; T-31 to
V-375;
W-32 to V-375; P-33 to V-375; A-34 to V-375; Y-35 to V-375; R-36 to V-375; L-
37 to
V-375; P-38 to V-375; V-39 to V-375; V-40 to V-375; L-41 to V-375; P-42 to V-
375; Q-
43 to V-375; S-44 to V-375; T-45 to V-375; L-46 to V-3?5; N-47 to V-375; L-48
to V-
375; A-49 to V-375; K-50 to V-375; P-51 to V-375; D-52 to V-375; F-53 to V-
375; G-54
to V-375; A-55 to V-375; E-56 to V-375; A-57 to V-375; K-58 to V-375; L-59 to
V-375;
E-60 to V-375; V-61 to V-375; S-62 to V-375; S-63 to V-375; S-64 to V-375; C-
65 to V-
375; G-66 to V-375; P-67 to V-375; Q-68 to V-375; C-69 to V-375; H-70 to V-
375; K-
71 to V-375; G-72 to V-375; T-73 to V-375; P-74 to V-375; L-75 to V-375; P-76
to V-
375; T-77 to V-375; Y-78 to V-375; E-79 to V-375; E-80 to V-375; A-81 to V-
375; K-82
to V-375; Q-83 to V-375; Y-84 to V-375; L-85 to V-37.5; S-86 to V-375; Y-87 to
V-375;
E-88 to V-375; T-89 to V-375; L-90 to V-375; Y-91 to V-375; A-92 to V-375; N-
93 to
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99I25031
174
V-375; G-94 to V-375; S-95 to V-375; R-96 to V-375; 'C-97 to V-375; E-98 to V-
375; T-
99 to V-375; Q-100 to V-375; V-101 to V-375; G-102 to V-375; I-103 to V-375; Y-
104
to V-375; I-105 to V-375; L-106 to V-375; S-107 to V-375; S-108 to V-375; S-
109 to V-
375; G-110 to V-375; D-111 to V-375; G-112 to V-375; A-113 to V-375; Q-114 to
V-
375; H-115 to V-375; R-I 16 to V-375; D-117 to V-375; S-118 to V-375; G-119 to
V-
375; S-120 to V-375; S-121 to V-375; G-122 to V-375; K-123 to V-375; S-124 to
V-
375; R-125 to V-375; R-126 to V-375; K-127 to V-375; R-128 to V-375; Q-129 to
V-
375; I-130 to V-375; Y-131 to V-375; G-132 to V-375; Y-133 to V-375; D-134 to
V-
375; S-135 to V-375; R-136 to V-375; F-137 to V-375; S-138 to V-375; I-139 to
V-375;
F-140 to V-375; G-141 to V-37_5; K-142 to V-375; D-143 to V-37_5; F-144 to V-
375; L-
145 to V-375; L-146 to V-375; N-147 to V-375; Y-148 to V-375; P-149 to V-375;
F-150
to V-375; S-151 to V-37_5; T-152 to V-375; S-153 to V-375; V-154 to V-375; K-
15_5 to
V-375; L-156 to V-375; S-157 to V-375; T-158 to V-37.5; G-1S9 to V-375; C-160
to V-
375; T-161 to V-375; G-162 to V-375; T-163 to V-375; L-164 to V-375; V-165 to
V-
375; A-166 to V-375; E-167 to V-375; K-168 to V-375; H-169 to V-375; V-170 to
V-
375; L-171 to V-375; T-172 to V-375; A-173 to V-375; A-174 to V-375; H-175 to
V-
375; C-176 to V-375; I-177 to V-375; H-178 to V-375; D-179 to V-375; G-180 to
V-
375; K-181 to V-375; T-182 to V-375; Y-183 to V-375; V-184 to V-375; K-185 to
V-
375; G-186 to V-375; T-187 to V-375; Q-188 to V-375; K-189 to V-375; L-190 to
V-
375; R-191 to V-375; V-192 to V-375; G-193 to V-375; F-194 to V-375; L-19S to
V-
375; K-196 to V-375; P-197 to V-375; K-198 to V-375; F-199 to V-375; K-200 to
V-
375; D-201 to V-375; G-202 to V-375; G-203 to V-375; R-204 to V-375; G-205 to
V-
375; A-206 to V-375; N-207 to V-375; D-208 to V-375; S-209 to V-375; T-210 to
V-
375; S-211 to V-375; A-212 to V-375; M-213 to V-375; P-214 to V-375; E-215 to
V-
375; Q-216 to V-375; M-217 to V-375; K-218 to V-375; F-219 to V-375; Q-220 to
V-
375; W-221 to V-375; I-222 to V-375; R-223 to V-375; V-224 to V-375; K-225 to
V-
375; R-226 to V-375; T-227 to V-375; H-228 to V-375; V-229 to V-375; P-230 to
V-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
175
375; K-231 to V-375; G-232 to V-375; W-233 to V-375; I-234 to V-375; K-235 to
V-
375; G-236 to V-375; N-237 to V-375; A-238 to V-375; N-239 to V-375; D-240 to
V-
375; I-241 to V-375; G-242 to V-375; M-243 to V-375; D-244 to V-375; Y-245 to
V-
375; D-246 to V-375; Y-247 to V-375; A-248 to V-375; L-249 to V-375; L-250 to
V-
375; E-251 to V-375; L-252 to V-375; K-253 to V-375; K-254 to V-37_5; P-255 to
V-
375; H-2S6 to V-375; K-257 to V-375; R-258 to V-375; K-259 to V-375; F-260 to
V-
375; M-261 to V-375; K-262 to V-375; I-263 to V-375; G-264 to V-375; V-265 to
V-
375; S-266 to V-375; P-267 to V-375; P-268 to V-375: A-269 to V-375; K-270 to
V-
375; Q-271 to V-375; L-272 to V-375; P-273 to V-375; G-274 to V-3?5; G-275 to
V-
375; R-276 to V-375; I-277 to V-375; H-278 to V-375; F-279 to V-375; S-280 to
V-375;
G-281 to V-375; Y-282 to V-375; D-283 to V-375; N-284 to V-375; D-285 to V-
375; 8-
286 to V-375; P-287 to V-37_5; G-288 to V-375; N-289 to V-375; L-290 to V-
37_5; V-291
to V-375; Y-292 to V-375; R-293 to V-375; F-294 to V-37.5; C-295 to V-375; D-
296 to
V-375; V-297 to V-37_5; K-298 to V-375; D-299 to V-375; E-300 to V-375; T-301
to V-
375; Y-302 to V-375; D-303 to V-375; L-304 to V-375; I; 305 to V-375; Y-306 to
V-
375; Q-307 to V-375; Q-308 to V-375; C-309 to V-375; D-310 to V-375; S-311 to
V-
375; Q-312 to V-375; P-313 to V-3?5; G-314 to V-375; A-315 to V-375; S-316 to
V-
375; G-317 to V-375; S-318 to V-375; G-319 to V-375; V-320 to V-375; Y-321 to
V-
375; V-322 to V-375; R-323 to V-375; M-324 to V-375; W-325 to V-375; K-326 to
V-
375; R-327 to V-375; Q-328 to V-375; H-329 to V-375; Q-330 to V-375; K-331 to
V-
375; W-332 to V-375; E-333 to V-375; R-334 to V-375; K-335 to V-375; I-336 to
V-
375; I-337 to V-375; G-338 to V-375; M-339 to V-375; I-340 to V-375; S-341 to
V-375;
G-342 to V-375; H-343 to V-375; Q-344 to V-375; W-345 to V-375; V-346 to V-
375;
D-347 to V-375; M-348 to V-375; D-349 to V-375; G-350 to V-375; S-351 to V-
375; P-
352 to V-375; Q-353 to V-375; E-354 to V-375; F-355 to V-375; T-356 to V-375;
R-357
to V-375; G-358 to V-375; C-359 to V-375; S-360 to V-375; E-361 to V-375; I-
362 to
V-375; T-363 to V-375; P-364 to V-375; L-365 to V-375; Q-366 to V-375; Y-367
to V-
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTlUS99/25031
176
375; I-368 to V-375; P-369 to V-375; D-370 to V-375; of SEQ ID N0:38.
Polypeptides
encoded by these polynucleotides are also encompassed by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities such as
ability to modulate the extracellular matrix, etc.) may still be retained. For
example the
ability to induce and/or bind to antibodies which recognize the complete or
mature forms
of the polypeptide generally will be retained when less than the majority of
the residues
of the complete or mature polypeptide are removed from the C-terminus. Whether
a
particular polypeptide lacking C-terminal residues of a complete polypeptide
retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted C-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
polypeptide shown in Figures 25A-B, up to the glycine residue at position
number 6, and
polynucleotides encoding such polypeptides. In particular, the present
invention provides
polypeptides comprising the amino acid sequence of residues 1-ml of Figures
25A-B,
where ml is an integer from 6 to 375 corresponding to the position of the
amino acid
residue in Figures 25A-B. Moreover, the invention provides polynucleotides
encoding
polypeptides comprising, or alternatively consisting of, the amino acid
sequence of C-
terminal deletions of the polypeptide of the invention shown as SEQ ID N0:38
include
polypeptides comprising the amino acid sequence of residues: M-1 to G-374; M-1
to I-
373; M-1 to S-372; M-1 to I-371; M-1 to D-370; M-1 to P-369; M-1 to I-368; M-1
to Y-
367; M-1 to Q-366; M-1 to L-365; M-1 to P-364; M-1 to T-363; M-1 to I-362; M-1
to E-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
177
361; M-1 to S-360; M-1 to C-359; M-1 to G-358; M-1 to R-357; M-1 to T-356; M-I
to
F-355; M-1 to E-354; M-1 to Q-353; M-1 to P-352; M-1 to S-351; M-1 to G-350; M-
1 to
D-349; M-1 to M-348; M-1 to D-347; M-1 to V-346; M-1 to W-345; M-I to Q-344; M-
1
to H-343; M-1 to G-342; M-1 to S-341; M-1 to I-340; M-1 to M-339; M-I to G-
338; M-
1 to I-337; M-1 to I-336; M-I to K-335; M-1 to R-334; M-1 to E-333; M-1 to W-
332; M-
1 to K-331; M-I to Q-330; M-1 to H-329; M-1 to Q-328; M-1 to R-327; M-I to K-
326;
M-1 to W-325; M-1 to M-324; M-1 to R-323; M-1 to V-322; M-1 to Y-321; M-1 to V-
320; M-1 to G-319; M-1 to S-318; M-1 to G-317; M-1 to S-316; M-1 to A-315; M-1
to
G-314; M-1 to P-313; M-1 to Q-312; M-1 to S-311; M-1 to D-310; M-1 to C-309; M-
1
to Q-308; M-1 to Q-307; M-1 to Y-306; M-1 to L-305; M-1 to L-304; M-1 to D-
303; M-
1 to Y-302; M-1 to T-301; M-1 to E-300; M-1 to D-299; M-1 to K-298; M-1 to V-
297;
M-1 to D-296; M-1 to C-295; M-1 to F-294; M-1 to R-293; M-1 to Y-292; M-1 to V-
291; M-1 to L-290; M-1 to N-289; M-1 to G-288; M-1 to P-287; M-I to R-286: M-I
to
D-285; M-1 to N-284; M-1 to D-283; M-1 to Y-282; M-1 to G-281; M-1 to S-280; M-
1
to F-279; M-1 to H-278; M-1 to I-277; M-1 to R-276; M-1 to G-275; M-1 to G-
274; M-1
to P-273; M-1 to L-272; M-1 to Q-271; M-1 to K-270; M-1 to A-269; M-I to P-
268; M-1
to P-267; M-1 to S-266; M-1 to V-265; M-1 to G-264; M-1 to I-263; M-1 to K-
262; M-1
to M-261; M-1 to F-260; M- I to K-259; M- I to R-258; M-1 to K-257; M- I to H-
256; M-
1 to P-255; M-1 to K-254; M-1 to K-253; M-1 to L-252; M-1 to E-251; M-I to L-
250;
M-1 to L-249; M-1 to A-248; M-1 to Y-247; M-1 to D-246; M-1 to Y-245; M-1 to D-
244; M-1 to M-243; M-1 to G-242; M-1 to I-241; M-1 to D-240; M-1 to N-239; M-1
to
A-238; M-1 to N-237; M-1 to G-236; M-1 to K-235; M-1 to I-234; M-1 to W-233; M-
1
to G-232; M-1 to K-231; M-1 to P-230; M-1 to V-229; M-1 to H-228; M-1 to T-
227; M-
1 to R-226; M-1 to K-225; M-1 to V-224; M-I to R-223; M-1 to I-222; M-1 to W-
221;
M-1 to Q-220; M-1 to F-219; M-1 to K-218; M-1 to M-217; M-1 to Q-216; M-1 to E-
215; M-1 to P-214; M-I to M-213; M-1 to A-212; M-1 to S-211; M-I to T-210; M-1
to
S-209; M-1 to D-208; M-I to N-207; M-1 to A-206; M-1 to G-205; M-1 to R-204; M-
1
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
178
to G-203; M-1 to G-202; M-1 to D-201; M-1 to K-200; M-1 to F-199; M-1 to K-
198; M-
1 to P-197; M-1 to K-196; M-1 to L-195; M-1 to F-194; M-1 to G-193; M-1 to V-
192;
M-1 to R-191; M-1 to L-190; M-1 to K-189; M-1 to Q-188; M-1 to T-187; M-1 to 6-
186; M-1 to K-185; M-1 to V-184; M-1 to Y-183; M-1 to T-182; M-1 to K-181; M-1
to
G-180; M-1 to D-179; M-1 to H-178; M-1 to I-177; M-1 to C-176; M-1 to H-175; M-
1 to
A-174; M-1 to A-173; M-1 to T-172; M-1 to L-171; M-1 to V-170; M-1 to H-169; M-
1
to K-168; M-1 to E-167; M-I to A-166; M-1 to V-165; M-1 to L-164; M-1 to T-
163; M-
I to G-162; M-1 to T-161; M-I to C-160; M-1 to G-159; M-1 to T-158; M-1 to S-
157;
M-I to L-156; M-1 to K-155; M-1 to V-154; M-1 to S-153; M-1 to T-152; M-1 to S-
151;
M-1 to F-150; M-I to P-149; M-1 to Y-148; M-1 to N-147; M-1 to L-146; M-1 to L-
145;
M-I to F-144; M-1 to D-143; M-1 to K-142; M-1 to G-141; M-1 to F-140; M-1 to I-
139;
M-1 to S-138; M-1 to F-137; M-1 to R-136; M-1 to S-135; M-1 to D-134; M-1 to Y-
133;
M-1 to G-132; M-1 to Y-131; M-1 to I-130; M-1 to Q-129; M-1 to R-128; M-I to K-
127;
M-1 to R-126; M-I to R-125; M-1 to S-124; M-1 to K-123; M-1 to G-122; M-1 to S-
121;
M-1 to S-120; M-1 to G-119; M-1 to S-118; M-1 to D-117; M-1 to R-116; M-1 to H-
115; M-1 to Q-114; M-1 to A-113; M-I to G-112; M-1 to D-11 l; M-1 to G-110; M-
1 to
S-109; M-1 to S-108; M-1 to S-107; M-1 to L-106; M-1 to I-105; M-1 to Y-104; M-
1 to
I-103; M-1 to G-102; M-1 to V-101; M-1 to Q-100; M-1 to T-99; M-1 to E-98; M-1
to T-
97; M-I to R-96; M-1 to S-95; M-1 to G-94; M-1 to N-93; M-1 to A-92; M-1 to Y-
91;
M-1 to L-90; M-1 to T-89; M-1 to E-88; M-1 to Y-87; M-1 to S-86; M-1 to L-85;
M-1 to
Y-84; M-1 to Q-83; M-1 to K-$2; M-1 to A-81; M-1 to E-80; M-1 to E-79; M-1 to
Y-78;
M-1 to T-77; M-1 to P-76; M-1 to L-75; M-1 to P-74; M-1 to T-73; M-1 to G-72;
M-1 to
K-71; M-1 to H-70; M-1 to C-69; M-1 to Q-68; M-1 to P-67; M-1 to G-66; M-1 to
C-65;
M-1 to S-64; M-1 to S-63; M-1 to S-62; M-1 to V-61; M-1 to E-60; M-1 to L-59;
M-1 to
K-58; M-1 to A-57; M-1 to E-56; M-1 to A-55; M-1 to G-54; M-1 to F-53; M-1 to
D-52;
M-1 to P-51; M-1 to K-50; M-1 to A-49; M-1 to L-48; M-1 to N-47; M-1 to L-46;
M-1
to T-45; M-I to S-44; M-1 to Q-43; M-1 to P-42; M-1 to L-41; M-1 to V-40; M-1
to V-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
179
39; M-1 to P-38; M-1 to L-37; M-1 to R-36; M-1 to Y-35; M-1 to A-34; M-1 to P-
33; M-
1 to W-32; M-1 to T-31; M-1 to P-30; M-1 to K-29; M-1 to W-28; M-1 to P-27; M-
1 to
A-26; M-1 to S-25; M-1 to Y-24; M-1 to P-23; M-1 to S-22; M-1 to V-21; M-1 to
Q-20;
M-1 to G-19; M-1 to V-18; M-1 to A-17; M-1 to C-16; M-1 to L-15; M-1 to L-14;
M-1
to F-13; M-1 to F-12; M-1 to L-11; M-1 to L-10; M-1 to F-9; M-1 to L-8; M-1 to
L-7;
M-1 to G-6; of SEQ ID N0:38. Polypeptides encoded by these polynucleotides are
also
encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:20 which have been
determined
from the following related cDNA genes: HFKCF40F (SEQ ID N0:128), HSRDF26R
(SEQ ID N0:129), HTEBE07R (SEQ ID N0:130)> HFTBP82R (SEQ ID N0:131),
HAQBJ 11 R (SEQ ID N0:132), HAFBB 1 I R (SEQ ID N0:133), HOEF08.SR (SEQ ID
N0:134), and HUVGY95R (SEQ ID N0:135).
The gene encoding the disclosed cDNA is believed to reside on chromosome 12.
Accordingly, polynucleotides related to this invention are useful as a marker
in linkage
analysis for chromosome 12.
This gene is expressed primarily in endothelial cells, fibroblasts, smooth
muscle,
and osteoblasts, and to a lesser extent in brain, heart, placental tissues,
lung, and many
other tissues. Moreover, the transcript is present in HUVEC, HUVEC +LPS,
smooth
muscle, fibroblasts; present in heart, brain, placenta, lung, liver, muscle,
kidney,
pancreas, spleen, thymus, prostate, testes, ovary, small intestine, colon and
weakly in
PBLs.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, disorders of vascularized tissues. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99l25031
180
differential identification of the tissues) or cell type(s). For a number of
disorders of the
above tissues or cells, particularly of the vascular tissues, expression of
this gene at
significantly higher or lower levels is routinely detected in certain tissues
or cell types
{e.g. vascular, skeletal, developmental, neural, cardiovascular, pulmonary,
renal,
immune, hematopoietic, reproductive, gastrointestinal, and cancerous and
wounded
tissues) or bodily fluids (e.g., lymph, seminal, fluid, amniotic fluid, serum,
plasma, urine,
synovial fluid and spinal fluid) or another tissue or cell sample taken from
an individual
having such a disorder, relative to the standard gene expression level, i.e.,
the expression
level in healthy tissue or bodily fluid from an individual not having the
disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 38 as residues: Pro-67 to Thr-73, Pro-76 to Gln-83, Asn-93
to
Thr-99, His-115 to Arg-128, His-178 to Lys-189, Pro-197 to Ala-212, Val-224 to
Trp-
233, Lys-253 to Lys-259, Ser-280 to Asn-289, Asp-296 to Tyr-302, Gln-308 to
Ala-315,
Arg-327 to Lys-335, Asp-349 to Gly-358. Polynucleotides encoding said
polypeptides
are also provided.
The tissue distribution in the vascularized endothelial cells indicates that
polynucleotides and polypeptides corresponding to this gene are useful for the
diagnosis
and treatment of diseases of vascularized tissues, such as atherosclerosis,
ataxia
malabsortion, and hyperlipidemia. These and other factors often result in
other
cardiovascular disease. Furthermore, translation product of this gene is
useful for the
treatment of wounds, and may facilitate the wound healing process. Moreover,
the
protein is useful in the detection, treatment, and/or prevention of a variety
of vascular
disorders and conditions, which include, but are not limited to miscrovascular
disease,
vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary
artery
disease, arteriosclerosis, and/or atherosclerosis. Based upon the tissue
distribution of this
protein, antagonists directed against this protein is useful in blocking the
activity of this
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
181
protein. Accordingly, preferred are antibodies which specifically bind a
portion of the
translation product of this gene.
Also provided is a kit for detecting tumors in which expression of this
protein
occurs. Such a kit comprises in one embodiment an antibody specific for the
translation
product of this gene bound to a solid support. Also provided is a method of
detecting
these tumors in an individual which comprises a step of contacting an antibody
specific
for the translation product of this gene to a bodily fluid from the
individual, preferably
serum, and ascertaining whether antibody binds to an antigen found in the
bodily fluid.
Preferably the antibody is bound to a solid support and the bodily fluid is
serum. The
above embodiments, as well as other treatments and diagnostic tests (kits and
methods),
are more particularly described elsewhere herein. Furthermore, the protein may
also be
used to determine biological activity, to raise antibodies, as tissue markers,
to isolate
cognate ligands or receptors, to identify agents that modulate their
interactions, in
addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy
targets for
the above listed tissues.
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID N0:20 and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 1685 of SEQ ID N0:20, b is an integer
of 15 to
1699, where both a and b correspond to the positions of nucleotide residues
shown in
SEQ ID N0:20, and where b is greater than or equal to a + 14.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
182
FEATURES OF PROTEIN ENCODED BY GENE NO: 11
The translation product of this gene shares sequence homology with Cytotoxic-
Regulatory T-Cell Associated Molecule (CRTAM) protein, which is thought to be
important in the regulation of celluar physiology, development,
differentiation or
function of various cell types, including haematopoietic cells and various T-
cell
progenitors. See for example, PCT publication WO 96/34102 incorporated herein
by
reference in its entirety. Moreover, the protein product of this gene also
shares homology
with the thymocyte activation and developmental protein and the class-I MHC-
restricted
T cell associated molecule (See Genbank Accession Nos. gi~2665790,
gb~AAB88491.1,
gb~AAC80267.1, and gi~3930163; all information and references contained within
these
accessions are hereby incorporated herein by reference). Based on the sequence
similarity, the translation product of this gene is expected to share at least
some
biological activities with T-cell modulatory proteins. Such activities are
known in the an,
some of which are described elsewhere herein.
Preferred polypeptides of the invention comprise the following amino acid
sequence:
MASV VLPSGSQCAAAAAAAAPPGLRLRLLLLLFSAAALIPTGDGQNLFTKDVTVI
EGEVATISCQVNKSDDSVIQLLNPNRQTIYFRDFRPLKDSRFQLLNFSSSELKVSL
TNVSISDEGRYFCQLYTDPPQESYTTITVLVPPRNLMIDIQKDTAVEGEEIEVNCT
AMASKPATTIRWFKGNTELKGKSEVEEWSDMYTVTSQLMLKVHKEDDGVPVIC
QVEHPAVTGNLQTQRYLEVQYKPQVHIQMTYPLQGLTREGDALELTCEAIGKPQ
PVM VTW VR VDDEMPQHA VLSGPNLFINNLNKTDNGTYRCEASNIVGKAHSDY
MLYVYDPPTTIPPPTT'I"I"TT'TTTTTT'I'ILTIITDSRAGEEGSIRAVDHAVIGGVVAV
V VFAMLCLLIILGRYFARHKGTYFTHEAKGADDAADADTAIINAEGGQNNSEEK
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
183
KEYFI (SEQ ID NO: 136). Polynucleotides encoding these polypeptides are also
provided.
The polypeptide of this latter embodiment has been determined to have a
transmembrane domain at about amino acid position 379 - 395 of the amino acid
_5 sequence referenced in Table XIII for this gene. Moreover, a cytoplasmic
tail
encompassing amino acids 396 to 442 of this protein has also been determined.
Based
upon these characteristics, it is believed that the protein product of this
gene shares
structural features to type Ia membrane proteins.
Preferred polynucleotides comprise the following sequence:
ATGGCGAGTGTAGTGC
TGCCGAGCGGATCCCAGTGTGCGGCGGCAGCGGCGGCGGCGGCGCCTCCCG
GGCTCCGGCTCCGGCTTCTGCTGTTGCTCTTCTCCGCCGCGGCACTGATCCCC
ACAGGTGATGGGCAGAATCTGTTTACGAAAGACGTGACAGTGATCGAGGGA
GAGGTTGCGACCATCAGTTGCCAAGTCAATAAGAGTGACGACTCTGTGATTC
AGCTACTGAATCCCAACAGGCAGACCATTTATT'rCAGGGACTTCAGGCCTTT
GAAGGACAGCAGGTTTCAGTTGCTGAATTTTTCTAGCAGTGAACTCAAAGTA
TCATTGACAAACGTCTCAATTTCTGATGAAGGAAGATACTTTTGCCAGCTCTA
TACCGATCCCCCACAGGAAAGTTACACCACCATCACAGTCCTGGTCCCACCA
CGTAATCTGATGATCGATATCCAGAAAGACACTGCGGTGGAAGGTGAGGAG
ATTGAAGTCAACTGCACTGCTATGGCCAGCAAGCCAGCCACGACTATCAGGT
GGTTCAAAGGGAACACAGAGCTAAAAGGCAAATCGGAGGTGGAAGAGTGGT
CAGACATGTACACTGTGACCAGTCAGCTGATGCTGAAGGTGCACAAGGAGG
ACGATGGGGTCCCAGTGATCTGCCAGGTGGAGCACCCTGCGGTCACTGGAAA
CCTGCAGACCCAGCGGTATCTAGAAGTACAGTATAAGCCTCAAGTGCACATT
CAGATGACTTATCCTCTACAAGGCTTAACCCGGGAAGGGGACGCGCTTGAGT
TAACATGTGAAGCCATCGGGAAGCCCCAGCCTGTGATGGTAACTTGGGTGAG
AGTCGATGATGAAATGCCTCAACACGCCGTACTGTCTGGGCCCAACCTGTTC
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC'T/US99/25031
184
ATCAATAACCTAAACAAAACAGATAATGGTACATACCGCTGTGAAGCTTCAA
ACATAGTGGGGAAAGCTCACTCGGATTATATGCTGTATGTATACGATCCCCC
CACAACTATCCCTCCTCCCACAACAACCACCACCACCACCACCACCACCACC
ACCACCATCCTTACCATCATCACAGATTCCCGAGCAGGTGAAGAAGGCTCGA
TCAGGGCAGTGGATCATGCCGTGATCGGTGGCGTCGTGGCGGTGGTGGTGTT
CGCCATGCTGTGCTTGCTCATCATTCTGGGGCG('TATTTTGCCAGACATAAAG
GTACATACTTCACTCATGAAGCCAAAGGAGCCGATGACGCAGCAGACGCAG
ACACAGCTATAATCAATGCAGAAGGAGGACAGAACAACTCCGAAGAAAAGA
AAGAGTACTTCA7'CTAG (SEQ ID N0:137). Also preferred are the polypeptides
encoded by these polynucleotides.
Figures 28A-B shows the nucleotide (SEQ ID N0:21) and deduced amino acid
sequence (SEQ ID N0:39) of the present invention. Predicted amino acids from
about l
to about 44 constitute the predicted signal peptide (amino acid residues from
about 1 to
about 44 in SEQ ID N0:39) and are represented by the underlined amino acid
regions.
Figure 29 shows the regions of similarity between the amino acid sequences of
the present invention SEQ ID N0:39, the human poliovirus receptor protein (gig
1524088)
(SEQ ID NO: 138), the human class-I MI-iC-restricted T cell associated
molecule
(W09634102) (SEQ ID N0:144), and the Gallus gallus thymocyte activation and
developmental protein (gb~AAB88491.1) (SEQ ID N0:145).
Figure 30 shows an analysis of the amino acid sequence of SEQ ID N0:39.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic
regions; flexible regions; antigenic index and surface probability are shown.
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the polypeptide having the amino acid sequence shown
in
Figures 28A-B (SEQ ID N0:39), which was determined by sequencing a cloned
cDNA.
The nucleotide sequence shown in Figures 28A-B (SEQ ID N0:21) was obtained by
sequencing a cloned cDNA (HOUDJ81 ), which was deposited on Nov. 17, 1998 at
the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99I25031
185
American Type Culiurc ColIcction, and given Accession Number 203484. The
deposited
gene is inserted in the pSport plasrztid (Life Technologies, lZockville, IV~D)
using the
SaII/Notz restriction endonuclease cleavage sites.
The pzescnt invention is fu~tlter dizeeted to fragments of the isolated
nucleic acid
molecules described herein. gy a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
N0:2I is intended DNA, fragments at Ieast about l5nt, and more preferably at
least about
20 nt, still mom preferably at least about 30 nt, and even more preferably, at
least about
40 nt in length which arc useful as diagnostic probes and primters as
discussed herein. Of
course, larger fragments 50-1500 nt in length are also useful according to the
present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA oz' as shown in SEQ iD N0:21. By a fragrxaent at least
20 nt in
length, for example, is intended fragnents which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
1S shown in SEQ ID Np.2X_ In this context "about" includes the particulat'ly
reciicd size,
larger or smaller by several ($, 4, 3, 2, or 1) nucleotides, at either
ternc~inus or at both
termini. Representative examples of polynucleotide fragmerzis of the invention
include,
for example, fragments that coztzprise, or alternatively, consist of, a
sequence from about
nucleotide 1 to about 50, front about 51 to about 100, from about 101 to about
150, from
about 151 to about 200, from about 201 to about 250, from about 251 to about
300, from
about 301 to about 350, from about 351 to about 400, firom about 401 to about
450, frozrt
about 451 to about 500, and from about 50I to about SSO, and ;from about 551
to about
600, from about 601 to about 650, from; about 651 to about 700, from about 701
to about
750, from about 7S 1 to about 800, from about 801 to about 850, from about 851
to about
900, from about 901 to about 950, from about 95i to about x000, from about
1001 to
about 1050, from about lOSI to about I 100, fmm about II01 to about 1150, from
about
1 I51 to about 1200, from about 1201 to about 1250, from about 1251 to about
1300,
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
186
from about 1301 to about 1350, from about 1351 to about 1400, from about 1401
to
about 1450, from about 14S 1 to about 1500, from about 1 SO 1 to about 1 S20
of SEQ ID
N0:21, or the complementary strand thereto, or the cDNA contained in the
deposited
gene. In this context "about" includes the particularly recited ranges, larger
or smaller by
S several {S, 4, 3, 2, or I) nucleotides, at either terminus or at both
termini. In additional
embodiments, the polynucleotides of the invention encode functional attributes
of the
corresponding protein.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet forming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions. The data
representing
the structural or functional attributes of the protein set forth in Figure 30
and/or Table X,
1S as described above, was generated using the various modules and algorithms
of the
DNA*STAR set on default parameters. In a preferred embodiment, the data
presented in
columns VIII, IX, XIII, and XIV of Table X can be used to determine regions of
the
protein which exhibit a high degree of potential for antigenicity. Regions of
high
antigenicity are determined from the data presented in columns VIII, IX, XIII,
and/or
XIV by choosing values which represent regions of the polypeptide which are
likely to
be exposed on the surface of the polypeptide in an environment in which
antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 30, but may,
as
shown in Table X, be represented or identified by using tabular
representations of the
2S data presented in Figure 30. The DNA*STAR computer algorithm used to
generate
Figure 30 (set on the original default parameters) was used to present the
data in Figure
in a tabular format {See Table X). The tabular format of the data in Figure 30
is used
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC'f/US99/25031
187
to easily determine specific boundaries of a preferred region. The above-
mentioned
preferred regions set out in Figure 30 and in Table X include, but are not
limited to,
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figures 28A-B. As set out in Figure 30 and in Table X, such preferred
regions
include Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-
regions,
Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle
hydrophilic
regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-
amphipathic
regions, Karplus-Schulz flexible regions, Jarneson-Wolf regions of high
antigenic index
and Emini surface-forming regions. Even if deletion of one or more amino acids
from the
N-terminus of a protein results in modification of loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities, ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened muteins to
induce and/or bind to antibodies which recognize the complete or mature forms
of the
polypeptides generally will be retained when less than the majority of the
residues of the
complete or mature polypeptide are removed from the N-terminus. Whether a
particular
polypeptide lacking N-terminal residues of a complete polypeptide retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the amino acid sequence shown
in
Figures 28A-B, up to the threonine residue at position number 359 and
polynucleotides
encoding such polypeptides. In particular, the present invention provides
polypeptides
comprising the amino acid sequence of residues nl-364 of Figures 28A-B, where
nl is an
integer from 2 to 359 corresponding to the position of the amino acid residue
in Figures
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
188
28A-B (which is identical to the sequence shown as SEQ ID N0:39). N-terminal
deletions of the polypeptide of the invention shown as SEQ ID N0:39 include
polypeptides comprising the amino acid sequence of residues: A-2 to R-364; S-3
to 8-
364; V-4 to R-364; V-5 to R-364; L-6 to R-364; P-7 to R-364; S-8 to R-364; G-9
to R-
364; S-10 to R-364; Q-11 to R-364; C-12 to R-364; A-13 to R-364; A-14 to R-
364; A-15
to R-364; A-16 to R-364; A-17 to R-364; A-18 to R-364; A-19 to R-364; A-20 to
R-364;
P-2l to R-364; P-22 to R-364; G-23 to R-364; L-24 to R-364; R-25 to R-364; L-
26 to 8-
364; R-27 to R-364; L-28 to R-364; L-29 to R-364; L-30 to R-364; L-31 to R-
364; L-32
to R-364; F-33 to R-364; S-34 to R-364; A-3_5 to R-364; A-36 to R-364; A-37 to
R-364;
l0 L-38 to R-364; I-39 to R-364; P-40 to R-364; T-41 to R-364; G-42 to R-364;
D-43 to R-
364; G-44 to R-364; Q-45 to R-364; N-46 to R-364; L-47 to R-364; F-48 to R-
364; T-49
to R-364; K-.50 to R-364; D-51 to R-364; V-52 to R-364; T-53 to R-364; V-54 to
R-364;
I-55 to R-364; E-56 to R-364; G-_57 to R-364; E-58 to R-364; V-59 to R-364; A-
60 to 8-
364; T-61 to R-364; I-62 to R-364; S-63 to R-364; C-64 to R-364; Q-65 to R-
364; V-66
to R-364; N-67 to R-364; K-68 to R-364; S-69 to R-364; D-70 to R-364; D-71 to
R-364;
S-72 to R-364; V-73 to R-364; I-74 to R-364; Q-75 to R-364; L-76 to R-364; L-
77 to 8-
364; N-78 to R-364; P-79 to R-364; N-80 to R-364; R-81 to R-364; Q-82 to R-
364; T-83
to R-364; I-84 to R-364; Y-85 to R-364; F-86 to R-364; R-87 to R-364; D-88 to
R-364;
F-89 to R-364; R-90 to R-364; P-91 to R-364; L-92 to R-364; K-93 to R-364; D-
94 to R-
364; S-95 to R-364; R-96 to R-364; F-97 to R-364; Q-98 to R-364; L-99 to R-
364; L-100
to R-364; N-101 to R-364; F-102 to R-364; S-103 to R-364; S-104 to R-364; S-
105 to 8-
364; E-106 to R-364; L-107 to R-364; K-108 to R-364; V-109 to R-364; S-110 to
R-364;
L-111 to R-364; T-112 to R-364; N-113 to R-364; V-114 to R-364; S-115 to R-
364; I-
116 to R-364; S-117 to R-364; D-118 to R-364; E-119 to R-364; G-120 to R-364;
R-121
to R-364; Y-122 to R-364; F-123 to R-364; C-124 to R-364; Q-125 to R-364; L-
126 to
R-364; Y-127 to R-364; T-128 to R-364; D-129 to R-364; P-130 to R-364; P-131
to 8-
364; Q-132 to R-364; E-133 to R-364; S-134 to R-364; Y-135 to R-364; T-136 to
R-364;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
189
T-137 to R-364; I-138 to R-364; T-139 to R-364; V-140 to R-364; L-141 to R-
364; V-
142 to R-364; P-143 to R-364; P-144 to R-364; R-145 to R-364; N-146 to R-364;
L-147
to R-364; M-148 to R-364; I-149 to R-364; D-150 to R-364; I-151 to R-364; Q-
152 to 8-
364; K-153 to R-364; D-154 to R-364; T-155 to R-364; A-156 to R-364; V-157 to
R-
364; E-158 to R-364; G-159 to R-364; E-160 to R-364; E-161 to R-364; I-162 to
R-364;
E-163 to R-364; V-164 to R-364; N-16S to R-364; C-166 to R-364; T-167 to R-
364; A-
168 to R-364; M-169 to R-364; A-170 to R-364; S-171 to R-364; K-172 to R-364;
P-173
to R-364; A-174 to R-364; T-175 to R-364; T-176 to R-364; I-177 to R-364; R-
178 to 8-
364; W-179 to R-364; F-180 to R-364; K-181 to R-364; G-182 to R-364; N-183 to
R-
364; T-184 to R-364; E-185 to R-364; L-186 to R-364; K-187 to R-364; G-188 to
R-364;
K-189 to R-364; S-190 to R-364; E-191 to R-364; V-192 to R-364; E-193 to R-
364; E-
194 to R-364; W-19S to R-364; S-196 to R-364; D-197 to R-364; M-198 to R-364;
Y-
199 to R-364; T-200 to R-364; V-201 to R-364; T-202 to R-364; S-203 to R-364;
Q-204
to R-364; L-205 to R-364; M-206 to R-364; L-207 to R-364; K-208 to R-364; V-
209 to
1 _5 R-364; H-210 to R-364; K-211 to R-364; E-212 to R-364; D-213 to R-364; D-
214 to R-
364; G-215 to R-364; V-216 to R-364; P-217 to R-364; V-218 to R-364; I-219 to
R-364;
C-220 to R-364; Q-221 to R-364; V-222 to R-364; E-223 to R-364; H-224 to R-
364; P-
225 to R-364; A-226 to R-364; V-227 to R-364; T-228 to R-364; G-229 to R-364;
N-230
to R-364; L-231 to R-364; Q-232 to R-364; T-233 to R-364; Q-234 to R-364; R-
235 to
R-364; Y-236 to R-364; L-237 to R-364; E-238 to R-364; V-239 to R-364; Q-240
to R-
364; Y-241 to R-364; K-242 to R-364; P-243 to R-364; Q-244 to R-364; V-245 to
8-
364; H-246 to R-364; I-247 to R-364; Q-248 to R-364; M-249 to R-364; T-250 to
R-364;
Y-251 to R-364; P-252 to R-364; L-253 to R-364; Q-254 to R-364; G-255 to R-
364; L-
256 to R-364; T-257 to R-364; R-258 to R-364; E-259 to R-364; G-260 to R-364;
D-261
2_5 to R-364; A-262 to R-364; L-263 to R-364; E-264 to R-364; L-265 to R-364;
T-266 to
R-364; C-267 to R-364; E-268 to R-364; A-269 to R-364; I-270 to R-364; G-271
to 8-
364; K-272 to R-364; P-273 to R-364; Q-274 to R-364; P-275 to R-364; V-276 to
R-364;
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
190
M-277 to R-364; V-278 to R-364; T-279 to R-364; W-280 to R-364; V-281 to R-
364; 8-
282 to R-364; V-283 to R-364; D-284 to R-364; D-285 to R-364; E-286 to R-364;
M-
287 to R-364; P-288 to R-364; Q-289 to R-364; H-290 to R-364; A-291 to R-364;
V-292
to R-364; L-293 to R-364; S-294 to R-364; G-295 to R-364; P-296 to R-364; N-
297 to
R-364; L-298 to R-364; F-299 to R-364; I-300 to R-364; N-301 to R-364; N-302
to R-
364; L-303 to R-364; N-304 to R-364; K-305 to R-364; T-306 to R-364; D-307 to
8-
364; N-308 to R-364; G-309 to R-364; T-310 to R-364; Y-311 to R-364; R-312 to
8-
364; C-313 to R-364; E-314 to R-364; A-315 to R-364; S-316 to R-364; N-317 to
R-364;
I-318 to R-364; V-319 to R-364; G-320 to R-364; K-321 to R-364; A-322 to R-
364; H-
323 to R-364; S-324 to R-364; D-325 to R-364; Y-326 to R-364; M-327 to R-364;
L-328
to R-364; Y-329 to R-364; V-330 to R-364; Y-331 to R-364; D-332 to R-364; P-
333 to
R-364; P-334 to R-364; T-33_5 to R-364; T-336 to R-364; I-337 to R-364; P-338
to 8-
364; P-339 to R-364; P-340 to R-364; T-341 to R-364; T-342 to R-364; T-343 to
R-364;
T-344 to R-364; T-345 to R-364; T-346 to R-364; T-347 to R-364; T-348 to R-
364; T-
349 to R-364; T-350 to R-364; T-351 to R-364; T-352 to R-364; T-353 to R-364;
I-354
to R-364; L-355 to R-364; T-356 to R-364; I-357 to R-364; I-358 to R-364; T-
359 to 8-
364; of SEQ ID N0:39. Polypeptides encoded by these polynucleotides are also
encompassed by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities such as
ability to modulate the extracellular matrix, etc.) may still be retained. For
example the
ability to induce and/or bind to antibodies which recognize the complete or
mature forms
of the polypeptide generally will be retained when less than the majority of
the residues
of the complete or mature polypeptide are removed from the C-terminus. Whether
a
particular polypeptide lacking C-terminal residues of a complete polypeptide
retains such
immunologic activities can readily be determined by routine methods described
herein
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT1US99/25031
191
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted C-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
polypeptide shown in Figures 28A-B, up to the leucine residue at position
number 6, and
polynucleotides encoding such polypeptides. In particular, the present
invention provides
polypeptides comprising the amino acid sequence of residues 1-ml of Figures
28A-B,
where ml is an integer from 6 to 364 cowesponding to the position of the amino
acid
residue in Figures 28A-B. Moreover, the invention provides polynucleotides
encoding
polypeptides comprising, or alternatively consisting of, the amino acid
sequence of C-
terminal deletions of the polypeptide of the invention shown as SEQ ID N0:39
include
polypeptides comprising the amino acid sequence of residues: M-1 to A-363; M-1
to R-
362; M-1 to S-361; M-1 to D-360; M-1 to T-359; M-1 to I-358; M-1 to I-357; M-1
to T-
356; M-1 to L-355; M-1 to I-354; M-1 to T-353; M-1 to T-352; M-1 to T-351; M-1
to T-
350; M-1 to T-349; M-1 to T-348; M-1 to T-347; M-1 to T-346; M-1 to T-345; M-1
to T-
344; M-1 to T-343; M-1 to T-342; M-1 to T-341; M-1 to P-340; M-1 to P-339; M-1
to P-
338; M-1 to I-337; M-1 to T-336; M-1 to T-335; M-1 to P-334; M-1 to P-333; M-1
to D-
332; M-1 to Y-331; M-1 to V-330; M-1 to Y-329; M-1 to L-328; M-1 to M-327; M-1
to
Y-326; M-1 to D-325; M-1 to S-324; M-1 to H-323; M-1 to A-322; M-1 to K-321; M-
1
to G-320; M-1 to V-319; M-1 to I-318; M-1 to N-317; M.-1 to S-316; M-1 to A-
315; M-1
to E-314; M-1 to C-313; M-1 to R-312; M-1 to Y-311; M-1 to T-310; M-1 to G-
309; M-
1 to N-308; M-1 to D-307; M-1 to T-306; M-1 to K-305; M-1 to N-304; M-1 to L-
303;
M-1 to N-302; M-1 to N-301; M-1 to I-300; M-1 to F-299; M-1 to L-298; M-1 to N-
297;
M-1 to P-296; M-1 to G-295; M-1 to S-294; M-1 to L-293; M-1 to V-292; M-1 to A-
291;
M-1 to H-290; M-1 to Q-289; M-1 to P-288; M-1 to M-287; M-1 to E-286; M-1 to D-
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
192
285; M-I to D-284; M-1 to V-283; M-1 to R-282; M-1 to V-281; M-I to W-280; M-1
to
T-279; M-1 to V-278; M-1 to M-277; M-1 to V-276; M-1 to P-275; M-I to Q-274; M-
1
to P-273; M-1 to K-272; M-1 to G-271; M-1 to I-270; M-1 to A-269; M-1 to E-
268; M-1
to C-267; M-1 to T-266; M-1 to L-265; M-1 to E-264; M-1 to L-263; M-1 to A-
262; M-1
to D-261; M-1 to G-260; M-1 to E-259; M-I to R-258; M-1 to T-257; M-1 to L-
256; M-
1 to G-255; M-I to Q-254; M-1 to L-253; M-1 to P-252; M-1 to Y-251; M-I to T-
250;
M-1 to M-249; M-1 to Q-248; M-1 to I-247; M-1 to H-246; M-I to V-245; M-1 to Q-
244: M-1 to P-243; M-1 to K-242; M-1 to Y-241; M-1 to Q-240; M-1 to V-239; M-1
to
E-238; M-1 to L-237; M-1 to Y-236; M-I to R-235; M-1 to Q-234; M-1 to T-233; M-
1
to Q-232; M-1 to L-231: M-I to N-230; M-1 to G-229; M-1 to T-228; M-1 to V-
227; M-
1 to A-226; M-1 to P-225; M-1 to H-224; M-1 to E-223; M-I to V-222; M-1 to Q-
221;
M-1 to C-220; M-1 to I-219; M-1 to V-218; M-I to P-217; M-1 to V-216; M-1 to G-
215;
M-1 to D-214; M-1 to D-213 ; M-1 to E-212 ; M-1 to K-211; M-1 to H-210; M-1 to
V-
209; M-1 to K-208; M-1 to L-207; M-1 to M-206; M-1 to L-205; M-1 to Q-204; M-I
to
S-203; M-1 to T-202; M-1 to V-201; M-1 to T-200; M-1 to Y-199; M-1 to M-198; M-
1
to D-197; M-1 to S-196; M-1 to W-195; M-1 to E-194; M-1 to E-193; M-1 to V-
192; M-
1 to E-191; M-1 to S-190; M-1 to K-189; M-1 to G-188; M-1 to K-187; M-1 to L-
186;
M-1 to E-185; M-1 to T-184; M-1 to N-183; M-1 to G-182; M-1 to K-181; M-1 to F-
180; M-1 to W-179; M-1 to R-178; M-1 to I-177; M-1 to T-176; M-1 to T-175; M-1
to
A-174; M-1 to P-173; M-1 to K-172; M-1 to S-171; M-1 to A-170; M-1 to M-169; M-
1
to A-168; M-1 to T-167; M-1 to C-166; M-1 to N-165; M-1 to V-164; M-1 to E-
163; M-
1 to I-162; M-1 to E-161; M-1 to E-160; M-1 to G-159; M-1 to E-158; M-1 to V-
157; M-
1 to A-156; M-1 to T-I55; M-1 to D-154; M-1 to K-153; M-I to Q-152; M-1 to I-
151;
M-1 to D-150; M-1 to I-149; M-1 to M-148; M-1 to L-147; M-1 to N-146; M-1 to R-
145; M-1 to P-144; M-1 to P-143; M-1 to V-142; M-1 to L-141; M-1 to V-140; M-1
to
T-139; M-I to I-138; M-1 to T-137; M-1 to T-136; M-1 to Y-135; M-1 to S-134; M-
I to
E-133; M-1 to Q-132; M-1 to P-131; M-1 to P-130; M-1 to D-129; M-1 to T-128; M-
I to
SUBSTITUTE SHEET (RULE 16)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
193
Y-127; M-1 to L-126; M-1 to Q-125; M-1 to C-124; M-1 to F-123; M-1 to Y-122; M-
1
to R-121; M-1 to G-120; M-1 to E-119; M-1 to D-118; M-1 to S-117; M-1 to I-
116; M-1
to S-115; M-1 to V-114; M-1 to N-113; M-1 to T-112; M-1 to L-111; M-1 to S-
110; M-1
to V-109; M-1 to K-108; M-1 to L-107; M-1 to E-106; M-1 to S-105; M-1 to S-
104; M-1
to S-103; M-1 to F-102; M-1 to N-101; M-1 to L-100; M-1 to L-99; M-1 to Q-98;
M-1 to
F-97; M-1 to R-96; M-1 to S-95; M-1 to D-94; M-1 to K-93; M-1 to L-92; M-1 to
P-91;
M-1 to R-90; M-1 to F-89; M-1 to D-88; M-1 to R-87; M-1 to F-86; M-1 to Y-85;
M-1 to
I-84; M-1 to T-83; M-I to Q-82; M-1 to R-81; M-1 to N-80; M-1 to P-79; M-1 to
N-78;
M-1 to L-77; M-1 to L-76; M-1 to Q-75; M-1 to I-74; M-1 to V-73; M-1 to S-72;
M-1 to
D-71; M-1 to D-70; M-1 to S-69; M-1 to K-68; M-1 to N-67; M-1 to V-66; M-1 to
Q-65;
M-1 to C-64; M-1 to S-63; M-1 to I-62; M-1 to T-61; M-1 to A-60; M-1 to V-59;
M-1 to
E-58; M-1 to G-57; M-1 to E-_56; M-1 to I-55; M-1 to V-54; M-1 to T-53; M-1 to
V-52;
M-1 to D-51; M-1 to K-50; M-1 to T-49; M-1 to F-48; M-1 to L-47; M-1 to N-46;
M-1
to Q-45; M-1 to G-44; M-1 to D-43; M-1 to G-42; M-1 to T-41; M-1 to P-40; M-1
to I-
39; M-1 to L-38; M-1 to A-37; M-1 to A-36; M-1 to A-:35; M-I to S-34; M-1 to F-
33; M-
1 to L-32; M-1 to L-31; M-1 to L-30; M-1 to L-29; M-1 to L-28; M-1 to R-27; M-
1 to L-
26; M-1 to R-25; M-1 to L-24; M- I to G-23; M-1 to P-22 ; M-1 to P-21; M-1 to
A-20; M-
1 to A-19; M-1 to A-18; M-1 to A-17; M-1 to A-16; M-1 to A-15; M-1 to A-14; M-
1 to
A-13; M-1 to C-12; M-1 to Q-11; M-1 to S-10; M-1 to G-9; M-1 to S-8; M-1 to P-
7; M-I
to L-6; of SEQ ID N0:39. Polypeptides encoded by these polynucleotides are
also
encompassed by the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:21 which have been
determined
from the following related cDNA genes: HSQFJ92R (SEQ ID N0:139), HFLAB 18F
(SEQ ID N0:140), HAQBH82R (SEQ ID N0:141 ), HLHTM lOR (SEQ ID N0:142),
and HLHAL65R (SEQ ID N0:143).
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
194
This gene is expressed primarily in immune system related tissues such as
ulcerative colitis, rejected kidney tissues, and to a lesser extent in thymus
and bone
marrow. Therefore, polynucleotides and polypeptides of the invention are
useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, immune and hematopoietic diseases and/or disorders, particularly
ulcerative
colitis and rejected organs. Similarly, polypeptides and antibodies directed
to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissue{s) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels is routinely detected in certain tissues or cell types (e.g.
transplanted kidney,
immune, hematopoeitic, renal, and cancerous and wounded tissues) or bodily
fluids (e.g.,
lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another
tissue or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
Preferred polypeptides of the present invention comprise immunogenic epitopes
shown in SEQ ID NO: 39 as residues: Gly-42 to Phe-48, Val-66 to Asp-71, Asn-78
to
Thr-83, Asp-88 to Arg-96, Tyr-127 to Tyr-135, Lys-181 to Trp-195, His-210 to
Gly-215,
Leu-303 to Thr-310, Thr-341 to Thr-350. Polynucleotides encoding said
polypeptides are
also provided.
The tissue distribution primarily in immune cells and tissues, combined with
the
homology to the CRTAM, thymocyte activation and developmental protein, the
class-I
MHC-restricted T cell associated molecule protein, and the polivirus receptor,
indicates
that the protein products of this gene are useful for the regulation of
celluar physiology,
development, differentiation or function of various cell types, including
haematopoietic
cells and particularly T-cell progenitors. Representative uses are described
in the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
195
"Immune Activity" and "infectious disease" sections below, in Example 11, 13,
14, 16,
18, 19, 20, and 27, and elsewhere herein. The proteins can be used to develop
products
for the diagnosis and treatment of conditions associated with abnormal
physiology or
development, including abnormal proliferation, e.g. cancers, or degenerative
conditions.
S The physiology or development of a cell can be modulated by contacting the
cell with an
agonist or antagonist (i.e. an anti- CRTAM-like peptide antibody). Further the
CRTAM-
like polypeptides of the present invention include treatment of ulcerative
colitis, organ
rejection and other immune system related disorders. Agonists or antagonists
may treat
or prevent such disorders as ulcerative colitis and rejected organs, such as
kidney. Based
upon the tissue distribution of this protein, antagonists directed against
this protein is
useful in blocking the activity of this protein. Accordingly, preferred are
antibodies
which specifically bind a portion of the translation product of this gene.
Also provided is a kit for detecting tumors in which expression of this
protein
occurs. Such a kit comprises in one embodiment an antibody specific for the
translation
product of this gene bound to a solid support. Also provided is a method of
detecting
these tumors in an individual which comprises a step of contacting an antibody
specific
for the translation product of this gene to a bodily fluid from the
individual, preferably
serum, and ascertaining whether antibody binds to an antigen found in the
bodily fluid.
Preferably the antibody is bound to a solid support and the bodily fluid is
serum. The
above embodiments, as well as other treatments and diagnostic tests (kits and
methods),
are more particularly described elsewhere herein. Furthermore, the protein may
also be
used to determine biological activity, to raise antibodies, as tissue markers,
to isolate
cognate ligands or receptors, to identify agents that modulate their
interactions, in
addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy
targets for
the above listed tissues.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
196
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
ID N0:21 and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 1506 of SEQ ID N0:21, b is an integer
of 15 to
1520, where both a and b correspond to the positions of nucleotide residues
shown in
SEQ ID N0:21, and where b is greater than or equal to a + 14.
FEATURES OF PROTE1N ENCODED BY GENE NO: 12
Figure 31 shows the nucleotide (SEQ ID N0:22) and deduced amino acid
sequence (SEQ ID N0:40) of the present invention. Predicted amino acids from
about 1
to about 23 constitute the predicted signal peptide (amino acid residues from
about 1 to
about 23 in SEQ ID N0:40) and are represented by the underlined amino acid
regions.
Figure 32 shows the regions of similarity between the amino acid sequences of
the present invention SEQ ID N0:40 and the human FAP protein (gi~1890647) (SEQ
ID
N0:146).
Figure 33 shows an analysis of the amino acid sequence of SEQ ID N0:40.
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity;
amphipathic regions; flexible regions; antigenic index and surface probability
are shown.
The present invention provides isolated nucleic acid molecules comprising a
polynucleotide encoding the polypeptide having the amino acid sequence shown
in
Figure 31 (SEQ ID N0:40), which was determined by sequencing a cloned cDNA.
The
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
197
nucleotide sequence shown in Figure 31 (SEQ ID N0:22) was obtained by
sequencing a
cloned cDNA (HPWCM76), which was deposited on Nov. 17, 1998 at the American
Type Culture Collection, and given Accession Number 203484. The deposited gene
is
inserted in the pSport plasmid (Life Technologies, Rockville, MD) using the
SaII/NotI
restriction endonuclease cleavage sites.
The present invention is further directed to fragments of the isolated nucleic
acid
molecules described herein. By a fragment of an isolated DNA molecule having
the
nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in
SEQ ID
N0:22 is intended DNA fragments at least about ISnt, and more preferably at
least about
20 nt, still more preferably at least about 30 nt, and even more preferably,
at least about
40 nt in length which are useful as diagnostic probes and primers as discussed
herein. Of
course, larger fragments 50-1500 nt in length are also useful according to the
present
invention, as are fragments corresponding to most, if not all, of the
nucleotide sequence
of the deposited cDNA or as shown in SEQ ID N0:22. By a fragment at least 20
ni in
length, for example, is intended fragments which include 20 or more contiguous
bases
from the nucleotide sequence of the deposited cDNA or the nucleotide sequence
as
shown in SEQ ID N0:22. In this context "about" includes the particularly
recited size,
larger or smaller by several (5, 4, 3, 2, or 1 ) nucleotides, at either
terminus or at both
termini. Representative examples of polynucleotide fragments of the invention
include,
for example, fragments that comprise, or alternatively, consist of, a sequence
from about
nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about
1 S0, from
about 1 S 1 to about 200, from about 201 to about 250, from about 251 to about
300, from
about 301 to about 350, from about 351 to about 400, from about 401 to about
450, from
about 451 to about 500, and from about 501 to about 550, and from about 551 to
about
600, from about 601 to about 650, from about 651 to about 700, from about 701
to about
750, from about 751 to about 800, from about 801 to about 807 of SEQ ID N0:22,
or the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99I25031
19$
complementary strand thereto, or the cDNA contained in the deposited gene. In
this
context "about" includes the particularly recited ranges, larger or smaller
by several (5, 4, 3, 2, or 1 ) nucleotides, at either terminus or at both
termini. In
additional embodiments, the polynucleotides of the invention encode functional
attributes of the corresponding protein.
Preferred embodiments of the invention in this regard include fragments that
comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-
sheet and
beta-sheet foaming regions ("beta-regions"), turn and turn-forming regions
("turn-
regions"), coil and coil-forming regions ("coil-regions"), hydrophilic
regions,
hydrophobic regions, alpha amphipathic regions, beta amphipathic regions,
flexible
regions, surface-forming regions and high antigenic index regions. The data
representing
the structural or functional attributes of the protein set forth in Figure 33
and/or Table XI,
as described above, was generated using the various modules and algorithms of
the
DNA'~STAR set on default parameters. In a preferred embodiment, the data
presented in
columns VIII, IX, XIII, and XIV of Table XI can be used to determine regions
of the
protein which exhibit a high degree of potential for antigenicity. Regions of
high
antigenicity are determined from the data presented in columns VIII, IX, XIII,
and/or
XIV by choosing values which represent regions of the polypeptide which are
likely to
be exposed on the surface of the polypeptide in an environment in which
antigen
recognition may occur in the process of initiation of an immune response.
Certain preferred regions in these regards are set out in Figure 33, but may,
as
shown in Table XI, be represented or identified by using tabular
representations of the
data presented in Figure 33. The DNA*STAR computer algorithm used to generate
Figure 33 (set on the original default parameters) was used to present the
data in Figure
33 in a tabular format (See Table XI). The tabular format of the data in
Figure 33 is used
to easily determine specific boundaries of a preferred region. The above-
mentioned
preferred regions set out in Figure 33 and in Table XI include, but are not
limited to,
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
199
regions of the aforementioned types identified by analysis of the amino acid
sequence set
out in Figure 31. As set out in Figure 33 and in Table XI, such preferred
regions include
Gamier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions,
Chou-
Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittie
hydrophilic regions
S and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-amphipathic
regions,
Karplus-Schulz flexible regions, Jameson-Wolf regions of high antigenic index
and
Emini surface-forming regions. Even if deletion of one or more amino acids
from the N-
terminus of a protein results in modification of loss of one or more
biological functions
of the protein, other functional activities (e.g., biological activities,
ability to
multimerize, etc.) may still be retained. For example, the ability of
shortened muteins to
induce and/or bind to antibodies which recognize the complete or mature forms
of the
polypeptides generally will be retained when less than the majority of the
residues of the
complete or mature polypeptide are removed from the N-terminus. Whether a
particular
polypeptide lacking N-terminal residues of a complete polypeptide retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted N-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the amino terminus of the amino acid sequence shown
in
Figure 31, up to the arginine residue at position number 61 and
polynucieotides encoding
such polypeptides. In particular, the present invention provides polypeptides
comprising
the amino acid sequence of residues nl-66 of Figure 31, where nl is an integer
from 2 to
61 corresponding to the position of the amino acid residue in Figure 31 (which
is
identical to the sequence shown as SEQ ID N0:40). N-terminal deletions of the
polypeptide of the invention shown as SEQ ID N0:40 include polypeptides
comprising
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
200
the amino acid sequence of residues: S-2 to N-66; S-3 to N-66; S-4 to N-66; S-
5 to N-66;
L-6 to N-66; K-7 to N-66; H-8 to N-66; L-9 to N-66; L-10 to N-66; C-11 to N-
66; M-12
to N-66; A-13 to N-66; L-14 to N-66; S-15 to N-66; W-16 to N-66; F-17 to N-66;
S-18
to N-66; S-19 to N-66; F-20 to N-66; I-21 to N-66; S-22 to N-66; G-23 to N-66;
E-24 to
N-66; T-25 to N-66; S-26 to N-66; F-27 to N-66; S-28 to N-66; L-29 to N-66; L-
30 to N-
66; N-31 to N-66; S-32 to N-66; F-33 to N-66; F-34 to N-66; L-35 to N-66; P-36
to N-
66; Y-37 to N-66; P-38 to N-66; S-39 to N-66; S-40 to N-66; R-41 to N-66; C-42
to N-
66; C-43 to N-66; C-44 to N-66; F-45 to N-66; S-46 to N-66; V-47 to N-66; Q-48
to N-
66; C-49 to N-66; S-50 to N-66; I-51 to N-66; L-S2 to N-66; D-53 to N-66; P-
.54 to N-
66; F-SS to N-66; S-56 to N-66; C-57 to N-66; N-58 to N-66; S-59 to N-66; M-60
to N-
66; R-61 to N-66; of SEQ ID N0:40. Poiypeptides encoded by these
polynucleotides are
also encompassed by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the
C-terminus of a protein results in modification or loss of one or more
biological
functions of the protein, other functional activities (e.g., biological
activities such as
ability to modulate the extracellular matrix, etc.) may still be retained. For
example the
ability to induce and/or bind to antibodies which recognize the complete or
mature forms
of the polypeptide generally will be retained when less than the majority of
the residues
of the complete or mature polypeptide are removed from the C-terminus. Whether
a
particular polypeptide lacking C-terminal residues of a complete polypeptide
retains such
immunologic activities can readily be determined by routine methods described
herein
and otherwise known in the art. It is not unlikely that a mutein with a large
number of
deleted C-terminal amino acid residues may retain some biological or
immunogenic
activities. In fact, peptides composed of as few as six amino acid residues
may often
evoke an immune response.
Accordingly, the present invention further provides polypeptides having one or
more residues deleted from the carboxy terminus of the amino acid sequence of
the
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
201
polypeptide shown in Figure 31, up to the leucine residue at position number
6, and
polynucleotides encoding such polypeptides. In particular, the present
invention provides
polypeptides comprising the amino acid sequence of residues 1-ml of Figure 31,
where
ml is an integer from 6 to 66 corresponding to the position of the amino acid
residue in
Figure 31. Moreover, the invention provides polynucleotides encoding
polypeptides
comprising, or alternatively consisting of, the amino acid sequence of C-
terminal
deletions of the polypeptide of the invention shown as SEQ ID N0:40 include
polypeptides comprising the amino acid sequence of residues: M-1 to E-65; M-1
to W-
64; M-1 to P-63; M-1 to F-62; M-1 to R-61; M-1 to M-60; M-1 to S-59; M-1 to N-
58;
M-1 to C-57; M-1 to S-56; M-1 to F-55; M-1 to P-54; M-1 to D-53; M-1 to L-52;
M-1 to
I-51; M-1 to S-50; M-1 to C-49; M-1 to Q-48; M-1 to V-47; M-1 to S-46; M-1 to
F-45;
M-1 to C-44; M-1 to C-43; M-1 to C-42; M-1 to R-41; M-1 to S-40; M-1 to S-39;
M-1 to
P-38; M-1 to Y-37; M-1 to P-36; M-1 to L-35; M-1 to F-34; M-1 to F-33; M-1 to
S-32;
M-1 to N-31; M-1 to L-30; M-1 to L-29; M-1 to S-28; M-1 to F-27; M-1 to S-26;
M-1 to
T-25; M-1 to E-24; M-1 to G-23; M-1 to S-22; M-1 to I-21; M-1 to F-20; M-1 to
S-19;
M-1 to S-18; M-1 to F-17; M-1 to W-16; M-I to S-15; M-1 to L-14; M-1 to A-13;
M-1
to M-12; M-1 to C-11; M-1 to L-10; M-1 to L-9; M-1 to H-8; M-1 to K-7; M-1 to
L-6; of
SEQ ID N0:40. Polypeptides encoded by these polynucleotides are also
encompassed by
the invention.
In addition, the invention provides nucleic acid molecules having nucleotide
sequences related to extensive portions of SEQ ID N0:22 which have been
determined
from the following related cDNA genes: HPWCM76R (SEQ ID N0:147).
This gene is expressed primarily in prostate BPH (benign prostatic
hyperplasia)
tissue. Therefore, polynucleotides and polypeptides of the invention are
useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are not
limited to, inflammation of the prostate, or related tissues. Similarly,
polypeptides and
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
202
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders of
the above tissues or cells, particularly of the prostate, expression of this
gene at
significantly higher or lower levels is routinely detected in certain tissues
or cell types
(e.g. prostate, cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid and spinal fluid) or another tissue or- cell sample
taken from an
individual having such a disorder, relative to the standard gene expression
level, i.e., the
expression level in healthy tissue or bodily fluid ti~om an individual not
having the
disorder.
The tissue distribution in prostate BPH tissue indicates that polynucleotides
and
polypeptides corresponding to this gene are useful for the treatment of
inflammatory
conditions which result in an enlargement of the prostate, or related tissues.
Polynucleotides and polypeptides corresponding to this gene are useful for the
treatment
and diagnosis of conditions concerning proper testicular function (e.g.
endocrine
function, sperm maturation), as well as cancer. Therefore, this gene product
is useful in
the treatment of male infertility and/or impotence. This gene product is also
useful in
assays designed to identify binding agents, as such agents (antagonists) are
useful as
male contraceptive agents. Similarly, the protein is believed to be useful in
the treatment
and/or diagnosis of testicular cancer. The testes are also a site of active
gene expression
of transcripts that is expressed, particularly at low levels, in other tissues
of the body.
Therefore, this gene product is expressed in other specific tissues or organs
where it may
play related functional roles in other processes, such as hematopoiesis,
inflammation,
bone formation, and kidney function, to name a few possible target
indications. Based
upon the tissue distribution of this protein, antagonists directed against
this protein is
useful in blocking the activity of this protein. Accordingly, preferred are
antibodies
which specifically bind a portion of the translation product of this gene.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
203
Also provided is a kit for detecting tumors in which expression of this
protein
occurs. Such a kit comprises in one embodiment an antibody specific for the
translation
product of this gene bound to a solid support. Also provided is a method of
detecting
these tumors in an individual which comprises a step of contacting an antibody
specific
for the translation product of this gene to a bodily fluid from the
individual, preferably
serum, and ascertaining whether antibody binds to an antigen found in the
bodily fluid.
Preferably the antibody is bound to a solid support and the bodily fluid is
serum. The
above embodiments, as well as other treatments and diagnostic tests (kits and
methods),
are more particularly described elsewhere herein. The homology to the FAP
protein
indicates that the protein product of this gene is useful in treating,
detecting, and/or
preventing iron metabolism disorders, particularly those resulting in high
oxidative
states, tissue damage, athersclerosis, free radical damage, vascular
disorders, iron binding
protein dysfunction, nitric oxide synthase dysfunction or aberration,
vasodilation
disorders, and tissue edema. Based on the sequence similarity, the translation
product of
this gene is expected to share at least some biological activities with iron
metabolism
modulatory proteins. Such activities are known in the art, some of which are
described
elsewhere herein. Furthermore, the protein may also be used to determine
biological
activity, to raise antibodies, as tissue markers, to isolate cognate ligands
or receptors, to
identify agents that modulate their interactions, in addition to its use as a
nutritional
supplement. Protein, as well as, antibodies directed against the protein may
show utility
as a tumor marker and/or immunotherapy targets for the above listed tissues.
Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related
to SEQ
TD N0:22 and may have been publicly available prior to conception of the
present
invention. Preferably, such related polynucleotides are specifically excluded
from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
204
polynucleotides comprising a nucleotide sequence described by the general
formula of a-
b, where a is any integer between 1 to 793 of SEQ ID N0:22, b is an integer of
15 to
807, where both a and b correspond to the positions of nucleotide residues
shown in SEQ
ID N0:22, and where b is greater than or equal to a + 14.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
205
Table I
Res I II III IV V VI VIIVIIIIX X XIXII XIII XIV
Position
Met 1 . . B . . . . -0.100.44 . . . -0.40 0.48
Val 2 . . B . . . . 0.080.01 . . . 0.15 0.63
Ala 3 . . $ . . . . 0.470.01 . . . 0.40 0.76
.
Gln 4 . . B . . . . 0.51-0.01. . . 1.401.33
Asp 5 . . . . . T C 0.23-0.20. . F 2.201.77
Pro 6 . . : . T T . 0.02-0.27* * F 2.50 0.94
Gln 7 . . . . T T . 0.88-0.09* * F 2.25 0.45
1~ Gly 8 . . . . T T . 0.66-0.09. * F 2.00 0.4?
Cys 9 . A B . . . . -0.010.60 . * . -0.10 0.25
Leu 10 . A B . . . . -0.820.74 . * . -0.35 0.08
Gln 11 . A B . . . . -0.911.03 . * . -0.60 0.06
Leu 12 . A B . . . . -0.910.99 . * . -0.60 0.16
15 Cys 13 . A B . . . . -1.420.41 . * . -0.60 0.34
Leu 14 . A B . . . . -1.340.37 * . . -0.30 0.14
Ser 15 . . A B . . . . -0.530.47 * * . -0.60 0.18
Glu 16 . A B . . . . -0.880.19 * . . -0.30 0.53
Val 17 . . B . . T . -0.880.04 * * . 0.10 0.63
Ala 18 A . . . . T . -0.100.04 * . . 0.10 0:39
Asn 19 . . . . T T . 0.71-0.34* . . 1.310.44
Gly 20 . . . . T T . 0.800.06 * * F 1.07 0.96
Leu 21 . . . . . . C -0.06-0.16* * F 1.631.47
Arg 22 . . . . . . C 0.50-0.01* * F 1.69 0.68
25 Asn 23 . . . . . T C 0.49-0.03* . F 2.10 0.92
Pro 24 . . 8 . . T . -0.370.16 * . F 1.241.10
Val 25 . . B . . T . -0.060.11.* * . 0.73 0.42
Ser 2b . . B . . T . 0.170.61 * * . 0.22 0.35
'
Met 27 . . B B . . . -0.290.71 * . . -0.39 0.23
V 28 . . B B . . . -0.290.71 . . . -0.60 0.31
al
His 29 . . B B . . . -0.420.07 . . . 0.00 0.38
Ala 30 A . B . . . . 0.120.11 . . . 0.50 0.38
,
Gly 31 . . . . T T . 0.39-0.01* . F 2.15 0.74
Asp 32 . . . . T T . 1.10-0.16* * F 2.45 0.74
35 .Gly 33 . . . . . T C 1.26-0.66 * F 3.001.44
Thr 34 . . . . . T C 0.59-0.37* * F 2.401.26
His 35 . . B B . . . 0.32-0.01* * . I ~0 0.65
Arg 36 . . B B . . . 0.080.63 . * . 0.00 0.49
Phe 37 . . B B . . . 0.080.70 . * . -0.30 0.34
Phe 38 . . B B . . . 0.420.21 . * . -0.30 0.:14
SUBSTITUTE SSEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
206
Val 39 A . . B . . . -0.12 0.11. * . -0.30
0.39
Ala 40 A . . B . . . -0.43 0.76
-0.60
0.33
Glu 41 A . . B . . . -1.40 0.40. * . -0.60
0.38
Gln 42 A . . B . . . -1.56 0.26. . . -0.30
0.38
$ Val 43 A . . B . . . -1.14 0.26. . . -0.30
0.28
Gly 44 . . B B . . . -1.14 0.67. . . -0.60
0.17
Vai 45 . . B B . . . -0.80 1.31. . . -0.60
0.07
Val 46 . . B B . . . -1.61 1.67. . . -0.60
0.15
Trp 47 . . B B . . . -1,82 1.71. . . -0.60
0.13
1~ Val 48 . . B B . . . -0.97 1.71. . . -0.60
0.27
Tyr 49 . . B . . . . -0.97 1.07. . . -0.16
0.60
Leu 50 . . B . . T . -0.41 0.86* . . 0.28
0.56
Pro 51 . . . . T T . 0.56 0.33* * F 1.521.01
Asp 52 . . . . T T . 0.03 -0.31. * F 2.361.27
1$ Gly 53 . . . . . T C 0.89 -0.39* * F 2.40
1.27
Ser 54 . A . . . . C 1.13 -1.0'7* . F 2.061.42
Arg 55 . A B . . . . 1.73 -1.10* * F 1.621.47
Leu 56 . A B . . . . 1.24 -0.67* . F 1.38
2.30
Glu 57 . A B . . . . 0.43 -0.31* . F 0.841.49
Gln 58 . A B . . . . 0.78 -0.01* * F 0.45
0.63
Pro 59 A A . . . . . 0.27 -0.Oi* * F 0.60
1 ?7
Phe 60 A A . . . . . 0.20 -0.O1* * . 0.30
O.bO
Leu 61 A A . . . . . I .Ol -0.01* . . 0.30
0.70
Asp 62 A A . . . . . 0.12 -0.01* . . 0.30
0.73
2$ Leu 63 A . . B . . . -0.73 0.24* . . -0.30
0.59
Lys 64 A . . B . . . -1.33 0.10. . . -0.30
0.53
Asn 65 . . B B . . . -0.94 0.10. . . -0.30
0.26
Ile 66 . . B B . . . -0.44 0.59. * . -0.60
0.4b
Val 67 . . B B . . . -0.66 0.39. . . -0.30
_ 0.33
30 Leu 68 . . B B . . . -0.13 0.81* . . -0.60
0.32
Thr 69 . . B B . . . -1.07 1.33. . F -0.45
0.48
Thr 70 . . B B . . . -1.41 1.33. . F -0.45
0.45
Pro 71 . . B B . . . -0.52 1.11. . F -0.45
0.54
Trp 72 . . . B T . . 0.33 0.43. . . -0.20
. 0.62
3$ Ile 73 . . B B . . . 1.26 -0.06. * . 0.610.75
Gly 74 . . B B . . . 1.22 -0.54. . F 1.37
0.95
Asp 75 . . . . . T C 0.83 -0.54. . F 2.28
0.89
Glu 76 . . B . . T . 0.23 -0.67. . F 2.541.10
Arg 77 . . . . T T . 0.18 -0.67. * F 3.10
0.92
Gly 78 . . . . T T . 0.26 -0.67. . F 2.79
0.54
Phe 79 A . . . . . . 0.01 0.01. * . 0.83
0.36
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
207
Leu 80 A . . . . . . -0.690.51. * . 0.22
0.13
Gly 81 A . . . . . . -0.721.30. * . -0.09
. 0.12
Leu 82 A . . . . . -1.041.37* * . -0.40
0.18
Ala 83 A . . . . . . -0.661.01. * . -0.40
0.34
Phe 84 A . . . . . . -0.660.33. * . -0.10
0.70
His 85 A . . . . T . 0.27 0.69* * . -0.20
0.73
Pro 86 A . . . . T . 0.58 0.00. * . 0.251.42
Lys 87 A . . . . T . 1.39 0.00. * . 0.56
2.23
Phe 88 A . . . T . 2.09 -039* * . 1.47
2.63
1~ Arg 89 A . . . . . 2.83 -0.89* * . 1.88
3.33
His 90 A . . . T T . 2.17 -1.31* * . 2.79
3.33
Asn 91 . . . , T T . 2.13 -0.53. * . 3.10
3.33
Arg 92 . . . . T T . 1.20 -0.56. * . 2.79
2:67
Lys 93 . . . . T T . 1.66 0.13* * . 1.581.37
IS Phe 94 . . . B T . . 1..300.39* * . 0.871.34
_
Tyr 95 . . B B . . . 1.03 0.74. . . -0.14
1.07
Ile .96 . . B B . . . 0.37 1.13* . . -0.60
0.72
Tyr 97 . . $ . . T . -0.561.70* . . -0.20
0.44
Tyr 98 . . B . . T . -0.601.60. * . -0.20
0.23
Ser 99 . . B . . T . 0.14 0.84. . . -0.20
0.56
Cys 100 A . . . . T . 0.43 0.16. . . 0.10
0.71
Leu 101 A A . . . . . 1.37 -0.60. . . 0.60
0.9I
Asp 102 A A . . . . . 0.76 -1.36. . F 0.901.35
Lys 103 A A . . . . . 1.00 -1.10. . F 0.901.87
ZS Lys 104 A A . . . . . 1.34 -1.67. . F 0.90
3.94
Lys 105 A A . . . . . 1.12 -2.36* * F 0.90
4.71
Val 106 A A . . . . . 2.04 -1.67. * F 0.901.65
Glu 107 A A . . . . . 1.16 -1.67. * F 0.901.62
Lys 108 A A . . . . . 0.81 -0.99. * F 0.75
. 0.57
Ile 109 A A . . . . . 0.77 -0.60. * F 0.901.02
Arg 110 A A . . . . . O.12 -1.24. . . 0.751.02
Ile 1 A A . . . . . 1.02 -0.63. * . 0.60
I 0.51
1 .
Ser 112 A A . . . . . 0. -0.63. * F 0.90
x 7 1.45
Glu t A A . . . . . -0.18-0.67 * F 0.75
13 0.55
35 Met 114 A A . . . . . 0.82 -0.29* * F 0.601.05
Lys 115 A A . . . . . 0.12 -0.97* . F 0.901.53
V I . A B . . . . 1.01 -0.86. . F 0.75
al 16 0.89
Ser l17 A A . . . . . 1.10 -0.86. * F 0.901.51
Arg Il8 A A . . . . . 1.10 -1.04. . F 0.901.17
40 Ala 119 A A . . . . 1.?4 -0.64* . F 0.90
. 2.52
Asp !?0 A . . . . T 1.1 -1.29* . F 1.30
. I 3.77
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
208
Pro 121 A . . . . T . 1.97 -1.17* . F 1.301.94
Asn 122 A . . . . T . x.46 -1.17. * F 1.30
~ 3.21
Lys 123 A . . . . T . 1.39 -0.99. * F 1.30
1.59
Ala 124 A A . . . . . 1.68 -0.99. * F 0.90
2.05
Asp 125 A A . . . . . 1.68 -1.03* . F 0.901.71
Leu 126 A A . . . . . 2.00 -1.43* * F 0.901.48
Lys 127 A A . . . . . 1.14 -1.43* * F 0.90
2.87
Ser 128 A A . . . . . 0.21 -1.29* * F 0.901.28
Glu 129 A A . . . . . -0.01 -0.60* * F 0.901.08
1~ Arg 130 A A . . . . . -0.01 -0.60* * F 0.75
0.45
Val 131 A A . . . . . -0.09 -0.60* * . 0.60
0.58
Ile 132 A A . . . . . -0.13 -0.30* * . 0.30
0.23
Leu 133 A A . . . . . 0.17 -0.30* * . 0.30
0.21
Glu 134 A A . . . . . -0.04 -0.30* * . 0.30
0.48
15 Ile 135 A A . . . . . -0.74 -0.51* * . 0.751.06
Glu 136 A A . . . . . -0.19 -0.70* * F 0.901.30
Glu 137 A A . . . . . 0.70 -1.00* . F 0.901.01
Pro 138 A . . . . T . 1.48 -0.60. * F 1.30
2.31
Ala 139 A . . . . T . 1.48 -0.79. . F 1.581.82
Ser 140 A . . . . T . 2.02 -0.39. . F 1.561.69
Asn 141 . . . . . T C 1.68 0.04. . F 1.441.08
His 142 . . , . . T C 1.68 0.04. . F 1.721.06
Asn 143 . . . . T T . 1.08 -0.06. . F 2.801.37
Gly 144 . . . . T T . 0.86 0.24. . F 1.77
0.?0
2$ Gly 145 . . . . T T . 0.46 0.53. . F 1.19
0.43
Gln 146 . A B B . . . 0.11 0.81. . F 0.110.23
Leu 147 . A B B . . . -0.67 0.84. * . -0.32
0.23
Leu 148 . A B B . . . -0.67 1.10. * . -0.60
0.19
Phe 149 . A B B . . . -0.67 0.67. * . -0.60
, 0.18
3~ Gly 150 . . B B . . . -0.57 0.70. * . -0.60
0.22
Leu 151 . . B . . T . -1.1? 0.77. * . -0.20
0.42
Asp 152 . . . . T T . -0.60 0.70. * . 0.20
. 0.48
Gly 153 . . . . T T . -0.68 0.67. . . 0.20
0.76
Tyr 154 . . B . . T . -0.68 0.93. * . -0.20
0.65
35 Met 155 . . B B . . . -0.64 1.03. . . -0.60
0.33
Tyr 156 . . B B . . . -0.18 1.51. * . -0.60
0.49
Ile 157 . . B B . . . -0.18 1.51. . . -0.60
0.31
Phe 158 . . B B . . . -0.18 0.76. . . -0.60
0.52
Thr 159 . . B B . . . -0.28 0.57. . F -0.45
0.33
Gly 160 . . . . T T . 0.32 0.24. . F 0.88
0.46
Asp 161 . . . . T T . -0.02 -0.04. . F 1.710.93
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
209
GIy 162 . . . . . T C 0.52-0.33. . F 1.74
0.65
Gly I63 . . . . . T C 1.22-0.39. . F 1.97
. 0.65
Gin 164 . . . . . . C 1.32-0.81* . F 2.30
0.65
Ala 165 . . . . . . C 0.97-0.39* . F 1.921.01
$ Gly 166 . . B . . . . 0.62-0.03. . F 1.34
0.89
Asp 167 . . B . . T . 0.16-0.03. . F 1.310.51
Pro 168 . . B . . T . -0.200.26 . . F 0.48
0.41
Phe 169 . . B . . T . -0.540.54 * . . -0.20
0.3b
Gly 170 . . B . . T . 0.040.54 * . . -0.20
0.21
1 Leu 171 . . B . . . . -0.200.94 . . . -0.40
~ 0.22
Phe 172 . . B . . . . -0.20LOl . . . -0.40
0.26
Gly 173 . . B . . . . 0.010.63 . * . -0.10
0.46
Asn 174 . . . . . . C 0.760.60 . * F 0.55
0.89
Ala 175 . . . . . . C 0.80-0.09. . F 1.90
2.05
15 Gln 176 . . . . . . C 1.31-0.49. * F 2.20
2.78
Asn 177 . . . . . T C 1.20-0.53. . F 3.00
2.32
Lys 178 . . . . T T . 0.73-0.24. * F 2.601.89
Ser 179 . . B . . T . 0.39-0.06. * F 1.75
0.90
Ser 180 . . B . . T . 1.02-0.03* * F 1.45
0.55
Zfl Leu 181 . . B . . . . 0.17-0.43* * F 0.95
0.55
Leu 182 . . B B . . . -0.640.21 * . F -0.15
0.31
Gly 183 . . B B . . , -0.580.51 * * F -0.45
0.19
Lys 184 . . B B , . . -1.170.13 * * . -0.30
0.45
Val 185 . . B B . . . -0.870.13 * * . -0.30
0.38
25 Leu 186 . . B B . . . -0.91-0.56* * . 0.60
0.64
Arg I 87 . B B . . . -0.10-0.34* * . 0.30
. 0.24
Ile 188 . . B B . . . 0.360.06 * . . -0.30
. 0.52
Asp 189 . . B . . T . -0.28-0.59* * . 1.151.23
Val 190 . . B . . T . 0.23-0.77* * . 1.00
~ 0.63
Asn 191 . . B . . T . 0.74-0.34* * F 0.85
0.89
Arg 192 . . B , . T . 0.60-0.64. * F 1.49
0.72
Ala 193 . . . . T . . 1.14-0.14* * F 1.881.32
Gly 194 . . . . T T . 1. -0.36* . F 2.27
l9 _ 0.81
Ser 195 . . . . . T C 2.16-0.76* . F 2.710.83
3$ His 196 . . . . T T . 1.91-0.76* * F 3.401.60
Gly 197 . . . . T T . 1.91-0.50* * F 3.06
2.54
Lys 198 . . B . . . . 1,64-0.93. * F 2.12
3.71
Arg 199 . . B B . . . 1,78-0.67. * F 1.58
2.02
Tyr 200 . . B B . . . 1,78-0.74. * . 1.433.16
40 Arg 201 . . 8 B . . . 1.81-0.79. * . 1.43
2.12
Val ?02 . . B B . . . 2.16-0.79. * F 1.931.81
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
210
Pro 203 . . B . . T . 1.90 -0.39. * F 2.361.85
Ser 204 . . . . T T . 1.09 -0.71. * F 3.401.46
Asp 205 . . . . . T C 0.48 0.07. * F 1.961.71
Asn 206 . . . . . T C 0.07 0.07. * F 1.47
0.82
$ Pro 207 . . . . . . C 0.92 0.03. . F 0.93
0.82
Phe 208 . . B . . . . 0.92 -0.36. . F 0.99
0.85
Val 209 . . B . . . . 0.88 0.07. . F 0.33
0.82
Ser 210 . . B . . . . 0.29 0.10. . F 0.610.52
Glu 2l 1 . . B . . T . 0.26 0.17. . F 1.09
' 0.61
1 Pro 212 . . . . T T . 0.26 -0.11. . F 2.52
~ 1.12
Gly 213 . . . . T T . 0.37 -0.33. . F 2.801.29
Ala 214 . . . . . T C 0.33 -0.21. . . 2.02
0.75
His 215 . . . . . . C 0.39 0.47. . . 0.64
0.34
Pro 216 . . B B . . . -0.200.80. . . -0.04
0.54
1$ Ala 2i7 . . B B . . . -0.230.87. . . -0.32
0.54
Ile 218 . . B B . . . -0.231.13. . . -0.60
0.62
Tyr 219 . . B . . T . -0.531.06. * . -0.20
0.40
A!a 220 . . B . . T . -0.391.31. . . -0.20
0.28
Tyr 221 . . B . . T . -0.180.81* . . -0.20
0.77
G1y 222 . . B . . T . -0.190.53* . . -0.20
0.79
Ile 223 . . B B . . . 0.41 0.39* * . -0.30
0.78
Arg 224 . . B B . . . 0.77 0.80* * . -0.60
0.52
Asn 225 . . . B T . . 0.69 0.04* * . 0.251.03
Met 226 . . . B T . . 0.34 0.19* * . 0.10
0.79
2$ Trp 227 . . B B . . . -0.170.00* * . 0.30
0.41
Arg 228 . . B . . . . 0.72 0.64* * . -0.40
0.19
Cys 229 . . B . . . . 0.72 0.24* * . 0.24
0.32
Ala 230 . . B . . . . 038 -0.37* . . 1.18
0.59
Val 231 . . B . . . . 0.98 -0.86* . . 1.82
. 0.30
Asp 232 . . . . T T . 1.06 -0.86* . F 2.910.93
Arg 233 . . . . T T . 0.06 -1.00* . F 3.401.42
Gly 234 . , . . T T . 0.41 -0.81* * F 3.061.34
Asp 235 . . . . . T C 1.11 -0.97* . F 2.521.16
Pro 236 . . B . . . . 1.97 -0.97* . F .1.781.16
3$ Ile 237 . . B . . . . 1.62 -0.57* * F 1.78
2.03
Thr 238 . . B . . . . 1.62 -0.57* * F 1.781.20
Arg 239 . . B . . . . 1.62 -0.57* * F 2.121.52
Gln 240 . . B . . . . 1.73 -0.57* * F 2.46
2.15
Gly 241 . . . . T T . 1.06 -1.26. * F 3.40
2.92
Arg 242 . . , . T T . i:L4 -1.06. * F 3.061.05
Gly 243 . . . . T T . 0.89 -0.27. * F 3:17
0.52
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
211
Arg 244 . . B . . T . 0.43-0.10. * F 1.53
0.28
Ile 245 . . B . . . . 0.43-0.10 *
. . . 0.84
0.14
Phe 246 . . B . . . . -0.08-0.10. * . 0.50
0.24
Cys 247 . . B . . T . -0.530.11 . * . 0.40
0.09
$ Gly 248 . . B . . T . -0.190.54 . . . 0.40
0.13
Asp 249 . . . . T T . -0.300.26 . . F 1.55
0.26
Val 250 . . . . . T C 0.70-0.13. . F 2.25
0.77
Gly 251 . . . . . T C 0.70-0.70. * F 3.001.53
Gin 252 . . . . . T C 1.37-0.34* . F 2.25
0.80
1~ Asn 253 . . . . . T C 1.71-0.34* . F 2.101.86
Arg 254 . . B . . T . 0.86-0.99* . F 1.90
3.25
Phe 255 A A . . . . . 1.71-0.77. . F 1.201.39
Glu 256 A A . . . . . 1.24-1.17. * F 0.901.45
Glu 257 A A . . . . . 0.36-0.89. * . 0.60
0.61
1$ Val 258 A A . B . . . -0.46-0.20* * . 0.300.49
Asp 259 A A . B . . . -0.52-0.30. * . 0.30
0.23
Leu 260 A A . B . . . -0.17-0.30* * . 0.30
0.27
Ile 261 A A . B . . . -0.510.13 * * . -0.30
0.36
Leu 262 A . . . . T . -0.51-0.09* * . 0.70
0.21
Lys 263 . . . . T T . 0.100.31 * * F 0.65
. 0.42
Gly 264 . . . . T T . -0.240.39 * . F 0.65
0.93
Gly 265 . . . . T T . 0.280.13 * * F 0.801.12
Asn 266 . . . . . T C 1.280.36 * ' F 0.45
0.59
Tyr 267 . . . . . T C 1.500.36 * * . 0.451.17
2$ Gly 268 . . . . . T C i.500.43 * * . 0.151.19
Trp 269 . . B . . T . 1.840.00 * * . 0.851.48
Arg 270 . A B . . . . 1.84-0.40* * . 0.451.63
Ala 271 . A B . . . . 1.14-0.73* * F 0.901.63
Lys 272 A A . . . . . . 0.80-0.37* * F 0.601.35
Glu 273 A A . . . . . 0.48-0.79* * F 0.75
0.69
Gly 274 A A . . . . . 0.52-0.21. * F 0.45
0.3?
Phe 275 A A . . . . . 0.410.04 * * . -0.30
0.29
Ala 276 A A . . . . . 1.040.04 * . . -0.30
0.28
Cys 277 A ' . . . T . 1.040.04 * . . 0.10
. 0.56
3$ Tyr 278 A . . . . T . 0.23-0.39* . . 0.851.30
Asp 279 A . . . . T . -0.09-0.49* . F 1.001.06
Lys 280 A . . . . T . 0.58-0.41* . F 1.001.06
Lys 281 A A . . . . . 1.17-0.49. . F 0.45
0.92
Leu 282 A A . . . . . i:24-0.84. . . 0.60
0.89
4flCys 283 A A . . . . . 1.19-0.34. * . 0.30
0.45
His 284 . A B . . . . 0.380.04 . * . -0.30
0.30
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435
ziz
PCT/US99/25031
Asn 285 . . . . T . 0.33 0.73 . . -0.20
B * 0,30
Ala 286 A . . . . T . 0.29 0.04 . . 0.10
. * 0.94
Ser 287 A . . . . T . 0.24 -O.S3. . 1.151.15
.
Leu 288 A . . . . T . 0.10 -0.39. F 0.85
. 0.53
Asp 289 . . B B . . . -0.08-0.10. F 0.45
. 0.43
Asp 290 . . B B . . . -0.97-0.17. F 0.45
* 0.50
Val 291 . . B B . . . -0.62O.I3 . . -0.30
. 0.42
Leu 292 . . B B . . . -0.910.20 . . -0.30
. 0.40
Pro 293 . . B B . . . -0.340.70 * . -0.60
. 0.24
1~ 11e 294 . . B , . . . -0.691.46 . . -0.60
B ~ . 0.51
Tyr 295 . . B . . T . -0.721.24 . . 0.20
. 0.61
Ala 296 . . B . . T . -0.461.06 . . -0.20
. 0.54
Tyr 29? . . B . . T . -0.501.13 . . -0.20
* 0.77
Gly 298 . . B . . T . -0.631.09 * . -0.20
. 0.37
15 His 299 . . B B . . . 0.30 0.76 * . -0.60
. 0.36
Ala 300 . . B B . . . 0.24 0.26 * . -0.30
. 0.46
Val 301 . . B B . . . -0.02-0.11* . 0.30
. O.b2
Gly 302 . . B . . T . -0.090.10 * F 0.25
. 0.34
Lys 303 . . B . . T . -0.090.09 * F 0.25
. 0.48
Scr 304 . . B . . T . -0.400.01 * F 0.25
. 0.64
Val 305 . . B . . T . -0.06-0.20. F 0.85
. 0.64
Thr 306 . . B . . T . -0.060.13 . F 0.25
. 0.50
Gly 307 . . B . . T . 0.04 0.77 . F -0.05
. 0.28
Gly 308 . . B . . T . 0.11 1.14 . F -0.05
. 0.59
25 Tyr 309 . . B . . T . 0.07 0.50 . . -0.20
. 0.80
Val 310 . . B . . . . 0.26 0.44 * . -0.40
. 0.80
Tyr 31l . . B . . T . 0.57 0.59 * . -0.20
. 0.43
Arg 312 . . B . . T . 0.61 0.16 * . 0.10
. 0.48
Gly 313 . . B . . T . 0.74 -0.21* F 1.13
. . 0.87
Cys 314 . . B . . T . 0.99 -0.43* F 1.410.85
*
Glu 315 . . B ~ . . . 1.03 -0.79* F 1.79
. * 0.70
Ser 316 . . . . . T C 1.28 -0.(0. F 2.170.58
*
Pro 317 . . . . T T . 0.82 -0.13. F 2.801.75
*
Asn 318 . . . . T T . 0.36 -0.27. F 2.521.00
.
35 Leu 319 . . . . T T . 0.78 0.41 . F 1.19
. 0.62
Asn 320 . . . B T . . -0.110.79 . . 0.36
. 0.63
Gly 321 . . B B . . . -0.511.04 . . -0.32
. 0.27
Leu 322 . . B B
-0.64 1.43 . . -0.60
. 0.29
Tyr 323 . . B B . . . -0.641.17 . . -0.60
* 0.18
4~ Ile 3?4 . . B B . . . -0.530.77 * . -0.60
. 0.30
Phe 3?S . . B B . . . -L 1.13 * . -0.60
l3 . 0.31
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
213
Gly 326 . . B B . . . -1.09. * . -0.60
1.06 . 0:?0
Asp 327 . . B . . . . -0.620.69 . . -0.40
- * 0.38
Phe 328 . ~ B
- . . . -0.270.43 . . -0.40
* 0.43
Met 329 A . . . . T . -0.19-0.36. . 0.70
* 0.85
Ser 330 . . . . . T C -0.09-0.10. F 1.05
* 0.42
Gly 331 A . . . . T . -0.330.51 . F -0.05
. 0.48
Arg 332 A . . . . T . -1.140.23 . . 0.10
. 0.49
Leu 333 A A . . . . . -0.440.30 . . -0.30
. 0.30
Met 334 A A ~. . . . . 0.16 0.31 . . -0.30
* 0.53
Ala 335 A A . . . . . 0.46 -0.11. . 0.30
* 0.47
Leu 336 A A . . . . . 0.91 -0.1 . . 0.30
I * 0.95
Gln 337 A A . . . . . 0.84 -0.80. . 0.751.87
.
Glu 338 A A . . . . . 1.66 -1.41. F 0.90
. 3.71
Asp 339 A A . . . . . 2.30 -1.51* F 0.90
. 7.23
1$ Arg 340 A A . . . . . 2.93 -2.20~ F 0.90
* 8.35
.
Lys 341 A A . . . . . 3.46 -2.60. F 0.90
* 9.64
Asn 342 A . . . . T . 3.50 -1.69* F 1.30
. 6.07
Lys 343 A . . . . T . 3.54 -1.69* F 1.30
. 6.20
Lys 344 A . . . . T . 3.54 -1.69* F 1.30
. 6.20
Trp 345 A . . . . T . 3.43 -1.29* F 1.30
. 6.68
Lys 346 A A . . . . . 2.58 -1.69. F 0.90
' 5.58
.
Lys 347 A A . . . . . 1.91 -1.00. F 0.90
. 2.30
Gln 348 . A B . . . . 1.06 -0.43* F 0.601.17
.
Asp 349 . A B . . . . 0.67 -0.66. F 0.75
. 0.48
z$ Leu 350 . A B . . . . 0.66 -0.23. F 0.45
. 0.24
Cys 351 . A B . . . . 0.30 0.16 . F -0.15
. 0.19
Leu 352 . A 8 . . . . -0.060.24 . F -0.15
. 0.16
Gly 353 . A . . T . . -0.360.73 . F -0.05
. 0?8
Ser 354 . . . . T T . -1.020.43 . F 0.35
. . 0.70
Thr 355 . . . . T T . -0.800.43 . F 0.35
. 0.45
Thr 356 . . B . . T . -0.830.24 . F 0.25
. 0.46
Ser 357 . . B . . T . -0.230.60 . F -0.05
. 0.30
Cys 358 . . B . . , . -0.230.64 . . -0.40
. 0.32
Ala 359 . . B . . . . -0.740.59 . . -0.40
. 0.22
Phe 360 ~. . B . . T . -1.320.79 . . -0.20
. O.t4
Pro 361 . . B . . T . -1.31t.09 . . -0.20
. 0.18
Gly 362 . . . . T T . -132 0.90 . . 0.20
. 0.24
Leu 363 . . B . . T . -0.690.89 . . -0.20
. 0.39
Ile 364 . . B . . . . -0.400.60 * . -0.40
. 0.35
4~ Ser 365 A . . . . T . 0.34 0.56 * . -0.20
* 0.47
Thr 366 A . . . . T . -0.140.13 * F 0.401.13
.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
214
His 36? A . . . . T . -0.690.23 * * F 0.401.40
Ser 368 . . B . . T . -0.770.23 * * F 0.25
. 0.73
Lys 369 . . B B . . . -0.180.53 * * . -0.60
0.36
Phe 370 . . B B . . . -0.580.43 * * . -0.60
0.35
$ Ile 371 . . B B . . . -0.860.71 * * . -0.60
0.23
Ile 372 . . B B . . . -0.820.83 * * , -0.60
0.11
Ser 373 . A B . . . . -0.520.83 * . . -0.60
0.23
Phe 374 A A . . . . . -0.570.04 * * . -0.30
0.54
Ala 375 A A . . . . . -0.46-0.64. . . 0.751.35
1~ Glu 376 A A . . . . . 0.09 -0.83* . . 0.751.01
Asp 377 A A ; . . . . 0.98 -0.79* . F 0.901.16
Glu 378 A A . . . . . 0.47 -1.57. . F 0.901.99
Ala 379 A A . . . . . 0.92 -1.39. . F 0.75
0.95
Gly 380 A A . . . . . 0.81 -0.63. . F 0.75
0.89
Glu 381 A A . B . . . 0.00 0.16 . . . -0.30
0.44
Leu 382 A A . B . . . -O.S90.84 . . . -0.60
0.36
Tyr 383 A A . B . . . -0.900.84 . . . -0.60
0.37
Phe 384 A A . B . . . -0.610.90 . . . -0.60
0.31
Leu 385 . A B B . . . -0.511.29 . . . -0.60
0.50
Ala 386 . A B B . . . -0.721.36 . . . -0.60
0.50
Thr 387 . A B B . . . -0.211.03 . . . -0.60
0.89
Ser 388 . A . . . . C -0.560.63 . . F -0.10
1.45
Tyr 389 . . . . . T C -0.100.44 . . F 0.301.45
Pro 390 . . . . T T . 0.12 0.70 . . F 0.501.58
25 Ser 391 . . . . T T . 0.50 0.71 . . . 0.351.19
Ala 392 . . B . . T . 0.92 0.76 . . . 0.081.17
Tyr 393 . . B . . . . 0.88 0.00 . . . 0.911.49
AIa 394 . . B . . T . 0.82 0.00 . * . 1.241.10
Pro 395 . . B . . T . 0.14 0.00 . * F 1.52
- 1.46
Arg 396 . . . . T T . 0.20 0.19 . . F I .30
0.65
Gly 397 . . 8 . . T . 0.83 0.19 . . F 0.921.01
Ser 398 . . B B . . . 0.38 -0.31. . F 0.991.31
Ile 399 . . B B . . . 0.11 0.04 * . . -0.04
O.S8
Tyr 400 . . B B . . . 0.32 0.69 * * . -0.47
0.43
35 Lys 401 . . B B . . . 0.00 0.26 * * . -0.30
0.54
Phe 402 . . B B . . . 0.04 0.30 * . . 0.191.19
Val 403 . . B B . . . 0.46 0.00 * . F 1.281.02
Asp 404 . . B . . T . 1.46 -0.76* . F 2.171.00
Pro 405 . . B . . T . 1.11 -0.76* . F 2.66
2.26
4flSer 406 . . . . T T . 0.86 -1.04* . F 3.40
3.07
Arg 407 . . . . T T . 1.34 -1.26* . F 3.06
2.85
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC'f/US99/25031
215
Arg 408 . . . . T . . 1.86 -0.83. . F 2.86
2.85
Ala 409 . . . . . . C 1.90 -0.83. . F 2.66
. 2.10
Pro 410 . . . . . T C 1:44 -1.21* . F 2.86
2.15
Pro 411 . . . . T T . 1.79 -0.64* * F 2.910.59
Gly 412 . . . . T T . 1.43 -0.64. * F 3.401.16
Lys 413 . . . . T T . 1.37 -0.39. * F 2.761.18
Cys 414 . . . . T T . 1.74 -0.81. * F 2.721.52
Lys 415 . . B . . T . 1.10 -0.81. * F 1.98
2.38
Tyr 416 . . B . . T . 1.10 -0.60. * F 1.49
0.88
1~ Lys 417 . . B . . T . O.S9 -0.17. * F L00
2.55
Pro 418 . . B B . . . 0.66 -0.10. * F 0.45
0.95
Val 419 . . B B . . . 1.01 -0.10. * F 0.601.18
Pro 420 . . B B . . . 1.01 -0.37. * F 0.79
0.85
Val 421 . . B B . . . 0.96 -0.37. * F 1.281.10
i5 Arg 422 . . B B . . . 0.96 -0.41. * F 1.621.99
Thr 423 . . B . . T . I -1.06* * F 2.66
.28 2.58
Lys 424 . . . . T T . 1?4 -1.49* * F 3.40
6.80
Ser 425 . . . . T T . 1.24 -1.44* * F 3.06
2.43
Lys 426 . . . . T T . 1.40 -1.01* * F 2.72
2.61
Arg 427 . . B . . . . 1.40 -0.71. * F 1.781.13
Ile 428 . . B . . . . 1.50 -0.71* * F 1.441.65
Pro 429 . . B . . . . 0.64 -0.67* * . 0.951.28
Phe 430 . . B . . . . 0.36 0.01 * * . -0.10
0.54
Arg 431 . A B . . . . 0.36 0.51 * * . -0.60Ø?7
25 Pro 432 . A B . . . . -0.07-0.17* * F 0.601.00
Leu 433 A A . . . . . -0.03-0.11* * F 0.60
L.67
Ala 434 A A . . . . . -0.63-0.26* * F 0.45
0.63
Lys 435 A A . . . . . 0.07 0.43 * * F -0.45
0.34
Thr 436 A A . . . . . -0.860.00 * * . 0.30
. 0.68
Val 437 A A . . . . . -1.460.00 * . . 0.30
0.56
Leu 438 A A . . . . . -0.600.19 * . . -0.30
0.23
Asp 439 A A . . . . . -0.01O.19 * . . -0.30
0.32
Leu 440 A A . . . . . -0.06-0.30* . . 0.30
0.74
Leu 441 A A . . . . . -0.04-0.54* . F 0.901.56
35 Lys 442 A A . . . . . 0.81 -0.84* . F 0.901.25
Glu 443 A A . . . . . 1.67 -0.84* . F 0.90
2.63
Gln 444 A A . . . . . 1.08 -1.53* . F . 0.90
6.38
Ser 445 A A . . . . . 1.30 -I * . F 0.90
.71 3?2
Glu 446 A A . . . . . 2.22 -1:11* . F 0.901.88
Lys 447 A A . . . . . ?.22 -I?I * , F 0.902.13
Ala 448 A A . . . . . 1.92 -1.61* . F 0.90
3.17
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
216
Ala 449 A A . . . . . 1.62-1.61* , 0.90
F 2.4b
Arg 450 A A . . . . . 1.62-1.23* . 0.90
. F 1.65
Lys 451 A A . . . . . 1.03-0.84* . 0.90
F 2.18
Ser 452 A . . . . T . 0.68-0.84* . 1.30
F 2.18
Ser 453 A . . . T . 0.46'-0.86. . 1.301.61
F
Ser 454 . . B . . T . 0.46-0.17. . 0.85
F 0.66
Ala 455 . . B . . T . 0.040.33 . . 0.25
F 0.50
Thr 456 . . B . . . . -0.340.33 . . -0.10
. 0.50
Leu 457 . . B . . '. . -0.260.37 . . -0.10
. 0.37
1~ Ala 458 . . B . . T . -0.540.41 . . -0.05
F 0.57
Ser 459 . . B . . T . -0.240.41 . . -0.05
F 0.40
Gly 460 . . . . . T C 0.000.33 . . 0.45
. F 0.83
Pro 461 . . . . . T C -0.500.07 * . 0.45
F 0.81
Ala~ 462 . . . , ' C 0.010.26 * . 0.25
. 'F 0.50
15 Gln 463 A . . . . . . 0.600.26 . . 0.05
F 0.68
Gly 464 . . B . . . . 0.94-0.17. . 0.65
F 0.76
Leu 465 . . B . . . . 0.94-0.60. . 1.101.50
F
Ser 466 A . . . . . . 0.86-0.67* . 0.95
F 0.86
Glu 467 A . . . . . . 1.14-0.69. * 1.101.16
F
Lys 468 A . . . . . . . -0.73. . 1.10
l t F 1.89
9
Gly 469 A . . . T T . 1.58-1.41. . 1.70
F 2.82
Ser 470 A . . . . T . 1.58-1.80. . 1.30
F 3.26
Ser 471 A . . . . T . 1.29-1.11. . 1.301.34
F
Lys 472 A . . . . T . 0.99-0.61. . 1.301.3?
F
2$ Lys 473 . . B . . . . 0.73-0.66. . 1.101.37
F
Leu 474 . . B . . . . 0.7?-0.61. . 1.101.58
F
Ala 475 . . B . . . . 0.77-0.51* . 1.401.14
F
Ser 47b . . B . . T . 0.77-0.13. . 1.45
F 0.77
Pro 477 . . B . . T . 0.770.26 . . 1.30
' F 1.24
Thr 478 . . . . T T . 0.72-0.43. . 2.60
F 2.46
Ser 479 . . . . . T C 1.22-0.53. . 3.00
F 2.95
Ser 480 . . . . T T . 1.00-0.43* * 2.60
F 2.76
Lys 481 . . B . . T . 1.41-0.17* * 1.901.58
F
Asn 482 . . B . . T . 1.28-0.66* * 1.90
F 2.30
35 Thr 483 . . B . . T . 1.38-0.61* * 1.941.70
F
Leu 484 . . B . . . . 1.33-0.57* * 1.781.32
F
Arg 4$5 . . B . . . . 1.32-0.14* * 1.67
F 0.81
Gly 486 . . B . . T . 1.32-0.06. * 2.210.81
F
Pro 487 . . . . T T . 1.37-0.54. * 3.401.96
F
Gly 488 . . . . T T . 1.72-1.23. * 3.06
F 2.00
Thr 489 . . , . . T C I -1:?3. * 2.52
.94 F 4.05
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
217
Lys 490 . A B . . . 1.94 -1.16. * F 1.58
. 2.65
Lys 491 . A B . . . 1.43 -1.59* * F 1.24
_ . 5.24
Lys 492 . A B . . . x.30 -1.37* * F 0.90
. 2.69
Ala 493 . A B . . . 1.43.-1.43* * F 0.901.33
.
Arg 494 . A B . . . 1.71 -1.00* * F 0.901.03
.
Val- 495 . A B . . . 0.81 -0.50* * F 0.75
. 0.70
Gly 496 . . B . T . 0.88 0.14* * F 0.25
~ . O.S2
Pro 497 . . B . T , 0.83 -0.36* * F 0.85
. O.S2
His 498 . . B . T . 1.08 0.04* * F 0.741.20
.
1 V 499 . . B . , T . 1.01 -0.17* * F 1.68
~ al 1.20
Arg S00 . . B . . T . 1.98 -0.60* * F 2.321.SS
Gln SO1 . . B . . T . 2.43 -1.03* . F 2.66
2.24
Gly S02 . . . . T T . 2.69 -1.53* . F 3.40
5.90
Lys S03 A . . . . T . 2.42 -2.I7. . F 2.66
. . 6.03
IS Arg S04 A . . . . . . 2.47 -1.79. * F 2.124.66
Arg SOS . . B . . . . 2.40 -1.50. . F 1.78
3.89
Lys 506 . B . . . . 2.10 -1.93. * F 1.44
3.89
Ser S07 . . B . . . . 2.41 -1.54. . F 1.44
2.66
Leu S08 . . B . . . . 2.07 -1.04. . F 1.781.85
20 Lys S09 , . B , . . . 1.61 -0.66. . F 2.121.24
Ser Si0 . . . . . . C 1.61 -0.23* * F 2.210.91
His S11 . . . . T T . 0.97 -0.61* * F 3.40
2.17
Ser 512 . . . . . T C 1.38 -0.69. * F 2.861.07
Giy S13 . . . . T T . 1..98-0.69. * F 3.021.57
25 Arg S14 . . . . T T . 1.63 -0.64. * F 2.981.78
Met SIS . . . . . . C 1.34 -0.76. * F 2.541.78
Arg S 16 . . . . . T C 1.38 -0.64. * F 2.70
1.82
Pro S 17 . . . : . T C 1.68 -1.07. * F 3.00
1.61
Ser 518 A . , . . T . 2.07 -0.67. * F 2.50
~ 2.82.
Ala S19 A . . . . T . 2.07 -1.29. * F 2.20
2.88
Glu S20 A A . . . . . 2.08 -1.29* * F 1.50
3.65
Gln 521 A A . . . . . 1.62 --1.21* * F 1.512.75
Lys S22 A A . . . . . 1.94 -1.17* . F 1.52
2.69
,
Arg 523 A A . . . . . 1.94 -1.67* . F 1.83
3.04
35 ~Ala S24 . A . . T . . 1.72 -1.29* . F 2.54
2.36
Gly S2S . . . . T T . 1.51 -1.00* . F 3.10
0.97
Arg S26 . . . . T T . 1.12 -O.S7* . F 2.79
0.77
Ser S27 . . . . . T C 0.69 -0.14* . F 1.98
0.97
Leu S28 . . . . . T C 0.19 -0.21* . . 1.671.25
Pro S29 . . B . . . . 0.39 -0.21* . . 0.810.8?
Ter 530 . . . - T . . 0.34 0.21* . . 0.30
. 0.78
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
218
PAGE INTENTIONALLY LEFT BLANK
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
219
Table II
Res I II III IV V VI VIIVIIIIX X XIXIIXIII
Position XIV
Met I . . . . . . C 0.69-0.24. * . 1.191.74
. .
Arg 2 . . . . . . C 0.38-0.24. * . 1.531.34
3 ~ ~ . . . T C 0.880.11. . . 1.32
0.91
Pro 4 . . . . T T . 1.27-0.31. . . 2.611.80
Gly 5 . . : . T T . 0.96-0.53. . F 3.401.48
Phe 6 . . . . T T . 0.740.26. . F 2.010.83
1 Arg 7 . A B . . . . -0.1$0.51. . . 0.42
~ 0.44
Asn 8 . A B . . . . -0.780.77* . . 0.08
0.37
Phe 9 . A B .. . . . -1.161.03* . . -0.26
0.35
Leu 10 . A B . . . . -1.110.74* . . -0.60
0.18
Leu 11 . A . . . . C -0.711.13* . . -0.40
0.15
1 Leu 12 . A . . . . C -1.631.11* . . -0.40
'Jr 0.23
Ala 13 . A . . . . C -2.441.01. . . -0.40
0.23
Ser ~ . A . . . . C -2.441.01. . . -0.40
14 0.23
Ser 15 . A . . . . C -2.221.11. . . -0.40
0.24
Leu 16 . A B . . . . -1.760.93. . . -0.60
0.24
Leu 17 . A B . . . . -1.760.86. . . -0.60
0.18
Phe 18 . A B . . . . -1.471.16. . . -0.60
0.11
Ala 19 . A . . . . C -1.761.16. . . -0.40
0.18
Gly 20 . A . . . . C -2.310.97. . . -0.40
0.22
Leu 21 . A . . . . C -1.710.93* . . -0.40
0.19
2$ Ser 22 . A . . . . C -0.900.57* . . -0.40
0.29
Ala 23 . A . . . . C -0.500.47* . . -0.40
0.51
Val 24 . A . . . C -0.610.43* . . -0.40
0.83
Pro 25 . . . . . T C -0.570.53* . F 0.15
0.53
Gln 26 . . . . T T . 0.030.53* . F 0.35
0.71
Ser 27 . . . . T T . 0.030.46* . F 0.501.4$
Phe 28 . . . . . T C -0.190.20* * F 0.60
i.28
Ser 29 . . . . . T C 0.780.46* * F 0.15
0.61
Pro 30 . . . . . T C 0.690.06* * F 0.45
0.89
Ser 31 . . . . T T . 0.400.06* * F 0.801.38
3$ Leu 32 . . . . T T . 0.490.19* * F 0.801.08
Arg 33 . . . . T . . 0.840.23* * F 0.601.08
Ser 34 . . . . T . . 0.560.23* * F 0.45
0.80
Trp 35 . . . . . T C 0.180.34* * F 0.45
0.98
Pro 36 . . . . . T C -0.190.16* * F 0.45
0.50
44 Gly 37 . . . . T T . 0.730.73* * . 0.20
0.34
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
220
Ala 38 . . . . T T . -0.190.34 * * . 0.50
0.38
Ala 39 . . , . . . G -0.190.1 * . . 0.10
. I 0.20
Cys 40 . B . T . . 0.210.07 * . . 0.30
. 0.27
Arg 41 . A B . . . . -0.17-0.36'* . . 0.30
0.53
Leu 42 . A . . . C 0.18-0.36* . . 0.50
0.53
Ser 43 . A . . . . C 0.47-0.86* * . 0.951.70
Arg 44 . A . . . . C 1.06-1.04* . F 1.10
l.lb
Ala 45 . A . . . . C 1.83-1.04. * F 1.10
2.44
Glu 46 . A . . T . . 1.83-1.73. * F 1.30
3.57
1~ Ser 47 . A . . T . . 1.98-Z.I . * F 1.30
l 3.57
Glu 48 . A . . T . . 2.39-1.54. * F 1.301.89
Arg 49 . A . . T . . 1.69-2.04. * F 1.30
2.14
Arg 50 . A . . T . . 2.0?-1.54* * F 1.581.62
Cys 51 . A . . T . . 1.72-1.50* * . 1.711.44
1 Arg 52 . A . . T . . 2.02-1.07* * F 1.99
'Jr 0.73
Ala 53 . . . . . T G 1.81-0.67* * F 2.47
0.64
Pro 54 . . . . T T . 1.49-0.24* * F 2.801.86
Gly 55 . . . . T T . 1.03-0.39. * F 2.521.47
Gln 56 . . . . . T C 1.110.04 * * F 1.441.44
Pro 57 . . . . . T C 0.410.04 * * F 1.010.94
Pro 58 . . . . T T . 0.190.11 . . F 0.93
0.96
Gly 59 . . . . T T . -0.270.37 . . F 0.65
0.46
Ala 60 . . B . . T . 0.040.54 . . . -0.20
0.16
Ala 61 . . B . . . . -0.300.61 . * . -0.40
0.14
25 L.eu 62 . . B . . . . 0.020.61 . * . -0.40
0.14
Cys 63 . . . . T . . -O.I10.19 . * . 0.610.27
His 64 . . . . T T . 0:340.11 . * . 1.12
0.26
Gly 65 . . . . T T . 0.2?-0.39. * F 2.18
0.63
Arg 66 . . . . T T . 0.86-0.50. * F 2.49
~ 0.63
3flGly 67 . . . . T T . 1.00-1.07. * F 3.10
0.77
Arg 68 ~ . . . T . . 1.32-1.00. * F 2.59
. 0.42
Cys 69 . . . . T T . 0.50-1.00. * . 2.33
0.21
Asp 70 . . . . T T . 0.18-0.36. * . 1.72
~ 0.16
Cys 71 . . . . T T . -0.82-0.21. * . 1.410.04
35 Gly 72 . . . . T T . -1.140.47 . * . 0.20
0.06
Val 73 . . . B T . . -1.290.47 . * . -0.20
' 0.02
Cys 74 . . B B . . . -1.480.97 . . . -0.60
0.05
Ile 75 . . B B . . . -1.791.04 * . . -0.60
0.03
Cys 76 . . B B . . . -1.121.10 . . . -0.60
0.07
4~ His 77 . . B B . . . -0.990.46 . . . -0.60
0.22
Val 78 . . . B T . . -0.48. . . . 0.10
0.31 0.48
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99/25031
221
Thr 79 . . B . . C -0.410.06. . 0.05
. F 0.89
Glu 80 . . . . T C -0.220.10* . 0.45
. F 0.64
Pro 81 . . . T T . -0.260.39. . 0.65
. F 0.75
Gly 82 . . . T T . -0.570.53. . 0.20
. 0.45
Met 83 . . . T T . 0.080.47* . 0.20
. . 0.2b
Phe 84 . . . T . . -0.420.90. . 0.00
. . 0.26
Phe 85 . . . T . . -1.091.16. . 0.00
. . 0.21
Gly 86 . . . . T C -0.881.30. . 0.00
. . 0.12
Pro 87 . . . . . T C -1.200.69. . 0.00
. 0.23
1 Leu 88 . . . . T T . -0.630.47* , 0.20
~ . 0.14
Cys 89 . . . . T T . 0.070.19* . 0.50
. 0.20
Glu 90 . A . . T . . 0.48-0.24* . 0.70
. 0.22
Cys 91 . A . . T . . -0.03. . . 0.10
0.24 . 0.28
His 92 . A . . T . . -0.490.20* . 0.10
. 0.39
15 Glu 93 . A . . T . . 0.320.20* . 0.10
. 0.12
Trp 94 . A . . T . . 0.680.20* . 0.10
. 0.39
Va1 95 . A . . T . . 0.430.11* . 0.10
. 0.42
Cys 96 . A . . T . . 1.100.37* . 0.38
. 0.38
Glu 97 . A . . T . . 0.790.37* . 0.66
. 0.60
Thr 98 . A . . T . . 0.49-0.11* . 1.69,0.80
F
Tyr 99 . . . . T T . 0.47-0.37. . 2.521.99
. F
Asp 100 . . . T T . 0.66-0,46. . 2.801.66
. F
Gly 101 . . . T T . 0.730.11. . 1.77
. F 0.62
Ser 102 . . . T T . 0.390.13. . 1.49
. F 0.40
25 Thr 103 . . . T . . 0.67-0.20. . 1.610.24
. F
Cys 104 . . . T ' . 0.570.30. * 0.78
. T . 0.32
Ala 105 . . . T T . 0.610.30. * 0.50
. . 0.24
Gly 106 . . . T T . 0.29-0.09. * 1.10
. . 0.33
His 107 . . . T. T . 0.590.00. * 0.50
. . 0.33
Gly 108 . . . T . . 0.23-0.57. * 1.35
. F 0.55
Lys 109 . . . T . . 0.56-0.50. * 1.36
. F 0.30
Cys 110 . :. . T ~ T . 1.19-0.50. . 1.72
. . 0.22
Asp 11 I . . . T T . 0.87-1.00. * 2.33
. . 0.44
Cys 112 . . . T T . 0.94-0.86. * 2.64
. . 0.12
3$ Gly I 13 . . . T T . 0.62-0.86. * 3.10
. F 0.44
Lys 114 . . . T . . 0.58-0.86. * 2.59
. F 0.14
Cys 115 . . . T . . 1.24-0.86. * 2.28
. F 0.44
Lys 116 . . . T . . 0.90-1.03. * 1.97
. F 0.76
Cys 1 t7 . . , T . . 1.28-1.03. * 1.94
. F 0.38
40 Asp 118 . . . T T . 1.38-0.11. * 1.810.74
. F
Gln 119 . . . T T . 0.990.07. * 1.49
. F 0.58
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
222
Gly 120 . . . . T T . 1.66 0.50 . * F 1.621.07
Trp 121 . . . . T T . 1.02 -0.07. * F 2.801.07
Tyr 122 . . . . T . . 1.02 0.43 . . . 1.12
0.62
Gly i23 . . . . T . . 1.02 0.60 . . . 0.84
0.34
Asp 124 . . . . T . . 0.78 0.57 . . . 0.56
0.56
Ala 125 . . . . T . . 0:91 0.41 . . . 0.28
0.56
Cys 126 . . . . T . . 0.89 0.09 * . . 0.30
0.87
Gln 127 . . . . T . . 1.13 0.14 * . . 0.30
0.75
Tyr 128 . . . . . . C 0.81 0.54 . . . -0.05
1.20
1 Pro 129 . . . . T T . 0.81 0.61 . * F 0.50
~ 1.20
Thr 130 . . . . T T . 0..590.04 . * F 0.801.15
Asn 13l . . . . T T . 0.94 0.33 . * F 0.65
0.61
Cys 132 . . . . T T . 0.99 0.06 . * . O.SO
0.57
Asp 133 . . . . T . . 1.28 -0.37. . . 0.90
0.79
IS Leu 134 . . . . T ~ . 1.53 -0.86. . F i.69
. 0.98
Thr 135 . . . . T . . 1.54 -1.26. . F 2.18
3.64
Lys 136 ~ . . . T . . 1.54 -1.44. . F 2.52
. 2.92
Lys 137 . . . . T . . 2.21 -1.04* . F 2.86
5.70
Lys 138 . . . . T T . 1.61 -1.33* . F 3.40
6.84
Ser 139 . . . . T T . 1.76 -1.20* . F 3.06
3.39
Asn 140 . . . . T T . 2. -0.63* . F 2.57
I 1 0.91
Gln 141 . . . . T T . 2.07 -0.63* . F 2.57
0.91
Met 142 . . . . T . . 1.72 -0.23* . . 2.071.09
Cys 143 . . . . T "' . 1.68 -0.23* . . 2.12
T 0.91
25 Lys 144 . . . . T T . 1.98 -0.23* . F 2.610.91
Asn 145 . . . . T T . 1.09 -0.63* . F 3.401.53
Ser 146 . . . . T T . 0.20 -0.56* . F 3.06
2.00
Gln 147 . . . B T . . 0.13 -0.44* . F 1.87
0.70
Asp 148 . . . B T~ . . 0.50 0.13 * . F 0.93
0.23
Ile 149 . . B B . . . 0.46 0.11 * . . 0.04
0.23
Ite 150 . . B B . . . -0.130.13 . . . -0.30
0.22
Cys ISI . . B . . T . -0.180.23 . . . 0.10
0.13
Ser 152 . . . . T T . -0.490.66 . . . 0.20
0.19
Asn 153 . . . . T T . -1.160.46 . . F 0.35
0.38
35 AIa 154 . . . . T T . -0.300.34 . . F 0.65
0.38
Gly ISS . . , . T . . -0.080.27 . . F 0.45
0.39
Thr 156 . . . . T . . 0.24 0.46 . . . 0.00
0.13
Cys 157 . . . . T T . 0.6b 0.49 . . . 0.20
0.13
His 1 S8 . . . . T T . -0.01-0.01. * . 1.10
0.25
Cys 159 . . . . T T . 0.62 0.13 . * . 0.50
0.09
Gly 160 . . . . T T . 0.30 -0.36. * . I .
t0
0.35
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/Z5031
223
Arg 161 . . . . T . . 0.61 -0.36. * . I .24
0.14
Cys 162 . . . . T T . 1.28 -0.86. * F 2.23
0.43
Lys 163 . ~ . . T T . 1.01 -1.03, * F 2.57
. 0.69
Cys 164 . . . . T T . 1.68 -1.07. * F 2.910.47
S Asp 165 . . . . T T . 1.68 -1.07. * F 3.401.48
Asn 166 . . . . T T . 1.27 -1.21. * F 2.910.73
Ser 167 . . . . T T . 1.59 -0.83. . F 2.721.83
Asp 168 . . . . T T . 0.73 -0.97. . F 2.381.08
Gly 169 . . : . T T . 0.54 -0.29. . F 1.59
0.56
1~ Ser 170 . . . B T . . 0.30 -0.04. . F 0.85
0.31
Gly 171 . . . B T . . -0.040.33 . * F 0.25
0.29
Leu 172 . . B B . . . 0.30 0.76 . * F -0.45
0.29
Val 173 . . B B . . . -0.400.33 . * . -0.30
0.43
Tyt 174 ~ . . B T . . -0.720.73 . * . -0.20
. 0.38
1$ Gly 175 . . . . T T . -0.420.87 . . . 0.20
0.24
Lys 176 . . . . T T . -0.740.19 . . . 0.50
0.57
Phe 177 . . . . T T . 0.07 0.11 . . . 0.84
0.20
Cys 178 . . . . T T . 0.92 -0.64* * . 2.08
0.33
Glu 179 . . . . T . . 1.28 -1.07* . . 2.22
0.28
20 Cys 180 . . . . T T . 1.62 -1.07* . . 2.76
0.62
Asp 181 . . . . T T . 0.91 -1.86' * F 3.40
2.01
Asp 182 . . . . T T . 0.72 -1.86* * F 2.910.62
Arg 183 . . . . T T . 1.39 -1.17. * F 2.88
0.81
Glu 184 . . . . T . . 1.39 -1.74. * . 2.50
0.81
2$ Cys 185 . . . . T . . 2.06 -1.74. * . 2.47
0.81
Ile 186 . . . . T . . 1.74 -1.74* * . 2.44
0.72
Asp 187 . . . . T T . 1.74 -1.26. * F 3.10
0.60
Asp 188 . . . . . T C 1.63 -1.26* * F 2.741.94
G1u 189 A . . . . T . 0.74 -1.83* . F 2.23
, 4.79
30 Thr 190 A . . . . T . 0.74 -1.83* . F 1.92
2.01
GIu 191 A . . . . . . 1.29 -1.26* . F 1.26
0.65
Glu 192 A . . . . . . 0.94 -0.83. . F 0.95
0.37
11e 193 . . . . T . . 0.91 -0.40. . . 1.15
0.25
Cys 194 . . . . T T . 0.57 -0.39. . . 1.60
0.20
3$ Giy 195 . . . . T T . 0.92 0.04 . . . 1.25
0.11
Gly 196 . . . . T T . 0.26 0.04 * . F 1.65
0.32
His 197 . . . . T T . 0:01 -0.07. . F 2.50
0.32
Gly 198 . . . . T T . 0.23 0.11 . . F 1.65
0.51
Lys 199 . . . . T T . 0.56 0.26 . . . 1.25
0.28
40 Cys 200 . . . . T T . 0.90 0.26 . . . 1.00
0.20
Tyr 201 . . . . T T . 0.58 0.16 . . . 0.75
0.33
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00129435 PCT/US99/25031
224
Cys 202 . . . T T . 0.370.30. . . 0.50
. 0.09
Gly 203 . . . T T . 0.041.06. * . O:LO
. . 0.26
Asn 204 . . . T T . 0.041.06. * . 0.20
. 0.09
Cys 205 . . . T T . 0.120.30* * . 0.50
. 0.33
Tyr 206 . . . T . . 0.020.23. * . 0.30
. 0.34
Cys 207 . . . T T . 0.400.23* * . 0.50
. 0.21
Lys 208 . . . T T . 0.710.74* * . 0.20
. 0.40
Ala 209 . . . T T . 0.370.67* * . 0.20
. 0.35
Gly 210 . . . T T . 1.030.34* * . 0.810.65
.
1 Trp 211 . . . T . . 1.32-0.23* * . 1.52
~ . 0.54
His 212 . . . . T C 1.32-0.23* * . 1.981.07
.
Gly 213 . . . T ~ T . 1.28-0.16. * F 2.49
. 0.58
Asp 214 . . . T T . 1.17-0.59. * F 3.10
. 0.96
Lys 215 . . . T T . .51 -0.71. * F 2.79
. 1 0.61
Cys 216 A . . T . . 1.13-0.81. * . 2.081.07
. ~
Glu 217 A . ~ . T . . 1.17-0.67. * . 1.62
. 0.34
Phe 218 A . . T . . 0.62-0.67. * . 1.310.29
.
Gln 219 A . . T . . 0.310.01. * . 0.10
. . 0.37
Cys 220 A . . T . . 0.06-0.07. * . 0.70
. 0.31
2U Asp 221 A . . T . . 0.430.36. * . 0.10
. 0.56
lle 222 A . . . . C 0.430.49. * . -0.06
. 0.34
Thr 223 . . . . T C 0.830.09. * F 1.281.09
.
Pro 224 , . . . T T . 0.88-0.10. . F 2.27
. . 0.88
Trp 225 . . . T T . 1.66-0.10. * F 2.76
. 2.50
25 Glu 226 . . . T T . 1.77-0.79. * F 3.40
. 3.39
Ser 227 . . . T T . 1.99-1.27. . F 3.06
. 4.29
Lys 228 . . . T T . 1.99-1.13* * F 2.72
. 2.19
Arg 229 . . . T T . 1.90-1.56* * F 2.381.82
.
Arg 230 . . . T ' T . 1.98-1.17. * F 2.38
. 1.$2
30 Cys 231 . . . T . . 1.98-1.13. . F 2.181.41
.
Thr 232 . . . T . . 1.93-1.13. * F 2.521.20
.
Ser 233 . . . . T C 1.93-0.70* * F 2.710.61
.
Pro 234 , . . T T . 0.93-0.70* * F 3.40
. 2.27
Asp 235 . . . T T . 0.16-0.59* * F 3.061.10
.
35 Gly 236 . . . T T . 0.52-0.50. * F 2.58
. 0.44
Lys 237 . . . T . . 0.83-0.50. * F 2.35
. 0.38
Ile 238 . , . T . . 1 -0.53. * . 2.47
. ~4 0.37
Cys 239 . . . T T . 1.11-0.53. * . 2.64
. ~ 0.73
Ser 240 . . . T T . 0.80-0.53. * F 3.10
. 0.36
Asn 241 . . . T T . 0.48-0.04. . F 2.49
. 0.74
Arg 242 . . . T T . -0.42-O.I6. . F 2.18
. 0.74
SUBSTITUTE SHEET (RULE 2~
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
225
Gly 243 . . . B T . . -0.20 -0.09. . F 1.47
0.41
Thr 244 . . . B T . . 0.12 0.10* . F 0.56
. 0.14
Cys 245 . . . B T . . 0.42 0.13* . . 0.10
0.07
Val 246 . . . B T . . -0.24 0.13* . . 0.10
0.12
Cys 247 . . . . T T . -0.67 0.27* * . 0.50
0.04
Gly 248 . . . . T T . -0.99 0.27. . . 0.50
0.12
Glu 249 . . . . T T . -0.71 0.27. . . 0.50
0.09
Cys 250 . . . . T T . -0.04 0.13. . . 0.50
0.22
Thr 251 . . . . T . . -0.04 -0.44. * . 0.90
' 0.37
1 Cys 252 . . . . T . . 0.62 -0.23. . . 0.90
~ 0.16
His 253 . . . . T . 0.76 -0.23. . . 1.24
0.50
Asp 254 . . . . T . . 0.44 -0.37. * . 1.58
0.54
Val 255 . . . . T. . . 0,77 -0.37. * . 2.071.44
Asp 256 . . . . . T C 1,08 -0.51. * F 2.861.05
15 Pro 257 . . . . T T . 1.46 -1.01* * F 3.401.05
Thr 258 . . . . T T . 1.14 -0.10* * F 2.76148
Gly 259 . . . . T T . 1.14 -0.31. * F 2.27
0.88
Asp 260 . . . . T . . 1. -0.31. * F 1.73
I 1 0.95
Trp 261 . . . . T . . 1.08 -0.06. * F 1.39
0.46
2~ Gly 262 . . . . . . C 0.94 -0.04. * F 0.85
0.63
Asp 263 . . . . T . . 1.26 -0.04. * F 1.05
0.38
Ile 264 . . . . T . . 1.29 -0.04. * . 0.90
0.60
His 265 . . . . T T . O.b2 -0.47* . . L 10
0.87
Gly 266 . . . . T T . 0.91 -0.33* * F 1.25
0.28
25 Asp 267 . . . . T T . 0.59 -0.33. * F 1.56
0.69
Thr 268 . . . . T T . 0.59 -0.44. * F 1.87
0.27
Cys 269 . . . . T T . 1.48 -0.94* * . 2.33
0.46
Glu 270 . . . . T T . 1.62 -1.37. . . 2.64
0.48
Cys 271 . . . . T T . 1.97 -1.37* . F 3.10
~ 0.65
Asp 272 . . . . T T . 1.30 -1.8b* . F 2.94
2.01
Glu 273 . . . . T . . 1.72 -1.86* * F 2.28
0.62
Arg 274 . . . . T T . 1.80 -1.86* . F 2.32
2:?8
Asp 275 . . . . T T . 0.94 -1.93* . F 2.011.38
Cys 276 . . . . T T . 1.37 -1.29* . , 1.40
0.59
35 Arg 277 . . . . T T . 1.37 -0.53* . . I.40
0.47
Ala 278 . , B B . . . 1.48 -0.53* . . 0.60
0.47
Val 279 . . B B . . . 1.12 -0.53* . . 1.091.73
~
Tyr 280 . . . B T . . 0.82 -0.34* * . 1.531.38
Asp 281 . . . . T T . 1.49 0.04* . . 1.671.83
40 Arg 282 . . . . T T . 1.38 -0.46* * F 2.76
4.12
Tyr 283 . . . . T T . 1:27 -1.i0* * F 3.404.39
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
226
Ser 284 . . . T T . 1.46-1.07* * F 3.06
. 2.28
Asp 285 . . . T . . 1.40-0.50* . F 2.07
~ . 0.62
Asp 286 . . . T . . 1.06-0.11* . F 1.73
. 0.53
Phe 287 . . . T . . 0.91-0.44* * . 1.24
. 0.39
$ Cys 288 . . . T T . 0.81-0.33. . . 1.10
. 0.32
Ser 289 . . . T T . 1.110.10 . . . 0.50
. 0.19
Gly 290 . . . T T . 0.440.50 . * F 0.35
. 0.38
His 291 . . . T T . 0.440.29 . * F 0.87
. 0.38
Gly 292 . . . T . . 0.480.11 . * F 0.89
. 0.46
Gln 293 . . . T . . 0.800.30 * * . 0.96
. 0.25
Cys 294 . . . T T . 1.210.30 * * . 1.38
. 0.18
Asn 295 . . . T T . 0.89-0.20. * . 2.20
. . 0.36
Cys 296 . . . T T . 0,92-0.06. * . 1.98
. 0.11
Gly 297 . . . T T . 0.60-0.46* * _ 2.04
. 0.34
1$ Arg 298 . . . T . . 0.64-0.46* * . 1.90
. 0.11
Cys 299 . . . . T T . 0,72-0.86* * . 2.46
0.43
Asp 300 . . . . T T . 0.38-0.93* * . 2.52
0.44
Cys 301 . . . . T T . 0.76-0.93* * . 2.80
0.22
Lys 302 . . . . T T . 0.86-0.01* * . 2.22
0.43
Ala 303 . . . . T . . 0.400.17 * * . 1.14
0.40
Gly 304 . . . . T . . I. 0.60 . * . 0.56
t 0.75
1
Trp 305 . . . . T . . 1.160.03 . * . 0.92
0.75
Tyr 306 . . . . T . . 1.160.03 . * ..1.131.48
Gly 307 . . . . T T . 1.110.10 * . F 1.67
0.80
2$ Lys 308 . . . . T T . 1.67-0.33* . F 2.761.32
Lys 309 . . . . T T . 1.80-0.74. . F 3.401.15
Cys 310 . . . . T T . 2.09-1.07. . F 3.061.79
Glu 31 t . . . : T . . 2.03-1.10. . F 2.52
1.55
His 312 . . . . . T C 1.71-0.71. . F 2.181.04
-
Pro 313 . . . , T T . 1.36-0.14. . F 1.741.04
.
Gln 314 . . _ . T 1' . 0.50-0.23. . F 1.25
0.87
Ser 315 . . . . T T . 0.870.46 . . F 0.35
0.52
Cys 316 . . . B T . . 0.280.34 . . F 0.25
0.45
Thr 317 . . . B . . C 0.310.41 . . . -0.40
0.27
3$ Leu 318 . . . B . . C 0.520.01 . . . -0.10
0.34
Ser 319 . . . B . . C 0.22-0.37. * . 0.651.11
Ala 320 A A . . . . . =0.37-0.56* * F 0.901.03
Glu 321 A A . . . . . 0.41-0.36* * F 0.45
0.87
Glu 322 A A
0.77-1.04* * F 0.90
I ~8
Ser 323 . A . . T . . 0.91-1.43* * F 1.64
2.53
lle 324 . A . . T . . 1.21-1.36* * F 1.83
0.78
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
227
Arg 325 A . . T . . 1.46 -0.96* . F 2.17
. 0.78
Lys 326 A . . T . . 1.16 -O.S3* . F 2.S10.S8
.
Cys 327 . . . T T . 0.86 -O.S3* . F 3.401.11
.
Gln 328 . . . T T . 1.16 -0.83* * F 2.910.76
.
$ Gly 329 . . . T T . 1.23 -0.83* * F 2.57
. 0.63
Ser 330 . . . T T . 0.91 -0.14* * F 1.93
. 0.97
Ser 33I . . . T . . 0.20 -0.29. * F 1.39
. 0.87
Asp 332 . , . T . . O.S7 -0.1 * * F LOS
. I 0.47
Leu 333 . . . . . C 0.22 -0.16* * F 1.16
. 0.47
Pro 334 . . . T . . 0.68 -0.11* * F 1.67
. 0.35
Cys 33S . . . T T . 0.63 -O.SO. * F 2.18
. 0.41
Ser 336 . . . T T . 0.98 -0.07. * F 2.49
. 0.49
Gly 337 . . . T T . 0.31 -0.76. * F 3.10
. 0.63
Arg 338 . . . T T . 1.12 -0.61. * F 2.79
. 0.63
Gly 339 . . . T . . 0.67 -1.19. * F 2.56
. 0.82
Lys 340 . . . T . . 0.99 -L00 * * F 2.53
. 0.44
Cys 341 . . , T T . 1.33 -L00 * * F 2.70
. 0.22
Glu 342 . . . T T . 1.01 -1.00* * . 2.52
. 0.45
Cys 343 . . . T T . 0.59 -0.86* * . 2.80
. 0.12
Gly 344 . . . T T . 0.27 -0.37. . . 2.22
. 0.33
Lys 34S . . . T . . -0.02-0.37. . . 1.74
. 0.10
Cys 346 . . . T . . 0.43 0.39 . . . 0.86
. 0.29
Thr 347 . . . T . . 0.22 0.24 . . . O.S8
. 0.46
Cys 348 . . . T . . 0.54 0.24 . * . 0.64
. 0.36
Tyr 349 . B . . . . 0.89 0.67 . * . 0.28
. 0.66
Pro 3S0 . . . . T C 0.96 0.10 . . F 1.47
. 0.76
Pro 351 . . . T T . 1.73 -0.39* . F 2.76
. 2.78
Gly 3S2 . , . T T . 1.19 -0.96* . F 3.40
. 3.47
Asp 3S3 . . . , T~ T . 1.61 -1.07* . F 3.06
~ . 1.67
3~ Arg 3S4 . . . T . . 1.51 -0.74* * F 2.521.69
.
Arg 3S5 . . . T . . 1.77 -0.74* * F 2.181.69
.
Val 356 . . . T . . 1.67 -1.17* * . 1.69
. 2.02
Tyr 357 . , . T . . 1.34 -0.69* * . 1.351.49
.
Gly 358 , . . T T . 1.34 -0.11* * F 1.25
. 0.41
Lys 3S9 . . . T T . O.S7 -0.11* . F 1.25
. 0.95
Thr 360 . . . T T . 0.46 -0.19* * F 1.59
. 0.33
Cys 361 . , . T T . 1.31 -0.94* * F 2.23
. O.SS
Glu 362 . . . T . . 1.67 -1.37* . . 2.22
. 0.46
Cys 363 . . . T T . 2.13 -1.37* . . 2.76
. 0.62
Asp 364 . . . T T . 1.41 -1.86* . F 3.40
. 2.28
Asp 36S . . . T T . 1.72 -1.86* . F 2.910.70
.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
228
Arg 366 . . . . T T . 2.39 -1.86* F 3.03
. 2.28
Arg 367 . _ . . . T . . 1..58-2.43* F 2.80
. 2 ~8
Cys 368 . . . . T . . 2.24 -1.74. F 2.771.12
.
Glu 369 . . . . T . . 1.90 -1.74. F 2.59
. 0.96
Asp 370 . . . . T T . 1.04 -1.31* F 3.10
. 0.48
Leu 37i . . . . T T . 0.08 -0.67* F 2.79
. 0.67
Asp 372 . . . . T T . -0.70-0.60. F 2.48
. 0.29
Gly 373 . . . . T T . -0.38-0.03* . 1.72
. 0.09
Val 374 . . B ' , . . . -0.720.40 * . 0.210.11
.
1~ Val 375 . . B . . . . -0.76O.I4 . . -0.10
* 0.07
Cys 376 . . . . T T . -0.290.64 . . 0.20
~ . 0.09
Gly 377 . . . . T T . -0.600.64 . . 0.20
. 0.12
Gly 378 . . . . T T . -0.920.49 . F 0.35
. 0.23
His 379 . . . T T . -0.370.41 . F 0.35
. . 0.23
1$ Gly 380 . . . T . . -0.180.23 . F 0.45
. . 0.32
Thr 381 . . . T . . 0.14 0.37 * F 0.45
. . 0.17
Cys 382 . . . T T . 0.60 0.37 * . 0.50
. . 0.12
Ser 383 . . . T T . 0.28 -0.13* . 1.28
. . 0.25
Cys 384 . . . T T . -0.540.01 . . 0.86
. 0.09
20 Gly 385 . . . T T . -0.870.17 * . i .04
. . 0.13
Arg 386 . . . T . . -O.S60.17 * . 1.02
. . 0.05
Cys 387 . B . T . . 0.22 -0.21* . 1.80
. . 0.16
Val 388 . B . . . . 0.18 -0.79* . 1.52
. . 0.32
Cys 389 . B . . . . 0.56 -0.79* . 1.34
. * 0.16
25 Giu 390 . . . T T . 0.20 0.13 * . 0.86
. . 0.32
Arg 391 . . . T T . -0.260.34 . . 0.68
. . 0.38
Gly 392 . . . T T . 0.46 0.13 . . 0.50
. . 0.69
Trp 393 . . . T T . 0.50 -0.44. . 1. l0
. . 0.80
Phe 394 . . , T - . . 0.50 0.24 * . 0.30
. . 0.34
Gly 395 . . . T . . O.SO 0.81 * . 0.00
. ' . 0.18
Lys 396 . . . T . . 0.36 0.79 * . 0.00
. . 0.30
Leu 397 . . . T . . 0.49 0.37 * . 0.64
. * 0.47
Cys 398 . . . T . . 0.89 0.01 * . 0.98
. * 0.74
.
Gln 399 . . . T . . 1.63 -0.41* . 1.92
. . 0.72
3$ His 400 . . . . T C 1.31 -0.41* . 2.411.75
. *
Pro 401 . . . T T . 1.27 -0.53* F 3.401.75
. *
Arg 402 . . . T T . 1.48 -0.70* F 3.061.63
. .
Lys 403 . . . T T . I -0.49. F 2.42
. .83 . 1.
i 8
Cys 404 . . . T . . 1.83 -0.50* . 2.031.11
. .
Asn 405 A . . . . C I -0.93. . I .14
. .87 . 0.98
Met 406 A . , , . C 2.08 -0.93* F 0.95
. . 0.85
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
229
Thr 407 . A . . . . C 1.67 -0.53* . F 1.44
2.73
Glu 408 A A . . . . . 1.67 -0.71. * F 1.58
2.28
Glu 409 A A . . . . . 2.33 -i.l* . F 1.92
l 4.61
Gln 410 . A . . T . . 1.52 -1.33* . F 2.66
5.13
Ser 411 . . . . T T . 1.46 -1.13* . F 3.40
2.44
Lys 412 . . . T T . 1.77 -0.56* . F 2.910.76
Asn 413 . . . . T C 1.47 -0.56* . F 2.62
0.76
Leu 414 . . . . . T C 0.88 -0.57* . . 2.38
0.76
Cys 415 . . . . T . . 0.88 -0.46* . . 1.99
0.38
1~ Glu 416 . . . . T . . 0.83 -0.46* . F 2.05
0.40
Ser 417 . . . . T T . -0.10-0.43* . F 2.50
0.48
Aia 418 . . . . T T . -0.91-0.43* . F 2.25
0.62
Asp 419 . . . . T T . -0.77-0.31* . F 2.00
0.30
Gly 420 . . . . T T . -0.400.26* . . i.00
0.12
Ile 421 . . B . . . . -0.740.26* . . 0.15
0.16
Leu 422 . . B . . . . -0.400.19* * . 0.
I
S
0.09
Cys 423 . . . . T T . -U.I 0.19* * . 1.00
6 0.19
Ser 424 . . . . T T . -0.460.19* * F 1.40
0.27
Gly 425 . . . . T T . -0.78-0.11. * F 2.25
0.43
2~ Lys 426 . . ~ . . T T . 0.08 -0.23. * F 2.50
0.43
Gly 427 . . . . T . . 0.22 -0.30. * F 2.05
0.44
Ser 428 . . . . T . . 0.54 -0.11* * F 1.80
0.24
Cys 429 . . . . T . . 0.89 -0.11' * . I .40
0.12
His 430 . . . . T T . 0.57 -0.11* . . 1.35
0.24
25 Cys 431 . . . . T T . -0.370.03* . . 0.50
0.10
Gly 432 . . . . T T . -0.690.33* . . 0.50
0.12
Lys 433 . . . . T T . -0.690.33* . . 0.50
0.05
Cys 434 . . . . T . . -0.610.21* . . 0.30
0.12
Ilc 435 . A . . T . . -0.580. * . . 0.10
. t4 0.13
3~ Cys 436 . A B . . . . 0.09 -0.29* . . 0.30
0.11
Ser 437 . A . . . . C 0.14 -0.29* . . 0.50
0.35
Ala 438 . A . . . . C -0.140.06* . . -0.10
0.52
Glu 439 . A . . T . . -0.370.13. . . 0.251.53.
Glu 440 . A . B T . . 0.22 0.24. . . 0.10
0.80
35 Trp 441 . A . B T . . 0.54 0.24. * . 0.251.06
Tyr 442 . A . B T . . 0.84 0.17. * . 0.10
0.61
Ile 443 . . . B T . . 0.73 0.17. * . 0.10
0.61
Ser 444 . . . B T . . 0.07 0.96. * . -0.20
0.50
Gly 445 . . . . T . . 0.07 0.61. * F 0.15
0.17
Glu 446 . . . . T . . -0.31-0.14. * . 0.90
0.41
Phe 447 . . . . T . . -0.07-0.26* . . 1 ?4
0.16
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
230
Cys 448 . . . T T . 0.82 -0.64* . 2.08
. * 0.28
Asp 449 _ . .~ . T T . 1.23 -1.07* . 2.42
. . 0.27
Cys 450 . . . T T . 1.58 -1.07* . 2.76
. . 0.60
Asp 451 . . . T T . 0.91 -1.86* F 3.401.87
. .
Asp 452 . . . T T . 1.61 -1.86* F 2.910.60
. .
Arg 453 . . . T T . 2.32 -1.86* F 2.721.87
. *
Asp 454 . . . T T . 2.29 -2.43* F 2.72
. * 2.24
Cys 455 . . . T T . 2.96 -1.93. F 2.721.83
. .
Asp 456 . . . T . . 2.61 -1.93. F 2.521.56
. .
1~ Lys 457 . . . T . . 1.80 -1.50* F 2.710.92
. .
His 458 . . . T T . 0.80 -0.81* F 3.401.42
. .
Asp 459 . . T T . 0.13 -0.70. F 2.910.60
. .
Gly 460 . . . T T . 0.49 -0.13. . 2.12
. . 0.16
Leu 461 . B . . T . 0.14 0.36. . 0.78
. . 0.17
lle 462 . B . . . . 0.10 0.29. . 0.24
. . 0.10
Cys 463 . . . T T . -0.210.69* . 0.20
. . 0.16
Thr 4b4 . . . T T . -1.100.69* F 0.35
. . 0.20
Gly 465 . . . T T . -1.420.69* F 0.35
. . 0.20
Asn 466 . . . T T . -0.910.57* F 0.35
. . 0.20
Gly 467 . . . T . . -0.690.39. F 0.45
. . 0:18
Ile 468 . . . T . . -0.370.47* . 0.00
. . 0.10
Cys 469 . . . T T . -0.060.47* . 0.42
. . 0.06
Ser 470 . . . T T . -0.380.47* . 0.64
. . 0.10
Cys 471 . . . T T . -0.380.61. . 0.86
. . 0.08
2$ Gly 472 . . . T T . -0.70-0.07. . 1.98
. . 0.24
Asn 473 . . . T T . -O.IO-0.07. . 2.20
. . 0.10
Cys 474 . . . T T . 0.57 0.46. . 1.08
. . 0.19
Glu 475 . . . T T . 0.52 -0.11. . 1.76
. . 0.32
Cys 476 . . . T T . 0.90 -0.11. . 1.54
. . 0.20
Trp 477 . . . T T . 1.24 0.40. . 0.42
. . 0.39
Asp 478 . . . T T . 0.90 0.23. . 0.50
. . . 0.36
Gly 479 . . . T T . 1.57 0.66. F 0.35
. . 0.67
.
Trp 480 . . . T T . 0.98 0.49. F 0.501.02
. .
Asn 481 . . . . T C 0.98 0.07. F 0.45
. . 0.62
35 Gly 482 . . . . T C 1.27 0.64* F O.15
. . 0.33
Asn 483 . . . . T C 0.38 0.21* . 0.30
. . 0.55
.
Ala 484 . . . . T C 0.43 -0.01. . 0.90
. . 0.24
Cys 485 A . . T . . -0.090.50. . -0.20
. . 0.25
Glu 486 A B . . . . -0.430.76. . -0.60
. . 0.13
11e 487 A . . T . . -0.390.79. . -0.20
. . 0.13
Trp 488 A . . T . . -0.390.67. . -0?0
. . 0.32
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
231
Leu 489 . A . . . . C -0.040.10 . . . -0.10
0.32
Gly 490 . . . . T T . 0.41 0.86 . * F 0.56
0.72
Ser 491 . . . . . T C 0.02 0.60 . . F 0.721.05
Glu 492 . . . . . T C 052 0.11 . . F 1.231.63
Tyr 493 . . . . . T C 0.42 -0.14. . . 1.89
2. I I
Pro 494 . . . T . . 0.84 -0.14. . . 2.10
2.01
Ter 495 . . . . T . . 0.80 -0.10. . . 1.891.4$
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
232
Table III
Res i II III IV V VI VIi IX X XI XiIXIII
Position VIII XIV
Met 1 A A . . . . . 0.10 -0.19. . . 0.30
0.92
Glu 2 A A . . . . . -0.32-0.1 * * . 0.30
~ I 0.72
Thr 3 A A . . . . . 0.18 0.14 * . . -0.30
0.47
Gly 4 A A . . . . . 0.68 -0.29* . . 0.30
0.93
Ala 5 A A . . . . . 0.86 -0.90* . F 0.901.05
1~ Leu 6 A A . . . . . 1.46 -0.47. . F 0.601.12
Arg 7 . A B . . . . 0.64 -0.56. . F 0.901.96
Arg 8 . . B . . . . 0.14 -0.30* . F 0.801.60
Pro 9 . A B . . . . 0.28 -0.11. . F 0.601.60
Gln 10 . A B . . . . 0.06 -0.37. . F 0.601.26
1$ Leu 11 . A B . . . . 0.06 0.31 * . . -0.30
0.53
Leu 12 . A B . . . . -0.871.00 . . . -0.60
0.28
Pro 13 . A B . . . . -1.791.26 . * . -0.60
0.14
Leu 14 . A B . . . . -2.391.54 . . . -0.60
0.14
Leu 15 . A B . . . . -3.061.54 . . . -0.60
0.14
Leu 16 , A B . . . . -2.591.43 . . . -0.60
0.05
Leu 17 . A B . . . . -2.121.43 . . . -0.60
0.06
Leu 18 . A B . . . . -2.581.17 . . . -0.60
0.07
Cys 19 . . B . . T . -1.981.06 * * . -0.20
0.04
Gly 20 . . . . T T . -1.060.80 * * . 0.20
0.08
25 Gly 21 . . . . T T . -0.830.11 . * F 0.65
0.20
Cys 22 . . B . . ~ . -0.37-0.07. * F 0.85
T 0.37
Pro 23 . . B . . . . 0.10 -0.21* * F 0.96
0.37
Arg 24 . . . . T T . 0.10 -0.21. * F 1.87
. 0.37
Ala 25 . . . . T T . 0.44 -0.07. * F 2.18
0.37
Gly 26 . . . . T T . 0.79 -0.24. * F 2.49
0.38
Gly 27 . . , . T T . 1.14 -0.67. * F 3.10
0.34
.
Cys 28 . . . . T . . 1.01 -0.19. * F 2.29
0.48
Asn 29 . . . . . T C 0.30 -0.26. * F 1.98
0.48
Glu 30 . . B . . T . 0.08 -0.07. . F 1.47
0.48
35 Thr 31 . . B . . T . 0.42 0.19 * . F 0.56
0.74
Gly 32 . . B . . T . 0.88 -0.39* . F 0.85
0.80
Met 33 A A . . . . . 0.73 -0.79* . . 0.60
0.91
Leu 34 A A . . . . . 0.52 -0.10* * . 0.30
0.52
Glu 35 A A . . . . . -0.29-0.16. * . 0.30
0.81
4~ Arg 36 A A . . . . . -0.640.10 * * . -0.30
0.67
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
233
Leu 37 A A . . . . . -0.64 0.06 * * . -0.30
, 0.44
Pro 38 A A . . . . . 0.00 -0.20* * . 0.30
~ 0.25
Leu 39 A A . . . . . 0.22 -0.20* * . 0.30
0.26
Cys 40 A A . . . . . -0.48 0.30 * * . -0.30
0.31
Gly 41 A A . . . . . -1.18 0.40 * * . -0.30
0.18
Lys 42 A A . . . . . -0.37 0.47
-0.60
0.21
Ala 43 A A . . . . . -0.76 -0.21* * . 0.30
0.67
Phe 44 A A . . . . . -0.54 -0.17* * . 0.30
0.67
Ala 45 A A . . . . . -0.22 0.01 * * . -0.30
0.33
1 Asp 46 A A . . 0 44 * *
~ 17 0
. . . . . -0.60
. 0.32
Met 47 A A . . . . . -0.73 -0.06* * . 0.30
0.75
Met 48 A A . . . . . -0.14 -0.20* * . 0.30
0.55
Gly 49 A A . . . . . -0.30 -0.70* * . 0.60
0.55
Lys 50 A . . B . . . 0.00 -0.06. * . 0.30
0.41
IS Val 51 A . . B 0 24 *
04 0
. . . . . . -0.30
. 0.44
Asp 52 A . . B . . . 0.36 -0.37. * . 0.30
0.89
Val 53 A . . B . . . 0.29 O.II . * . -0.30
0.47
Trp 54 A . . B . . . 0.63 0.69 *
-0.60
0.34
Lys 55 A . , g _ ,
-022 0.44 . * . -0.60
0.32
Trp 56 A . . B . . . 0.33 1.13 . . . -0.60
0.36
Cys 57 A . , B ,
0.33 ~ 0.87 . . . -0.60
0.46
Asn 58 . . . B . . C 0.49 -0.04* . . 0.50
0.40
Leu 59 . . . B . . C -0.11 0.74 * . . -0.40
0.33
Ser 60 . . . B . . C -1.01 0.51 * . . -0.40
0.43
25 Glu 61 . . B B . . . -0.97 0.59 * . . -0.60
0.20
Phe 62 . . B B . . . -0.54 0.94 . . . -0.60
0.38
Ile 63 . . B B . . . -0.54 1.01 * .~. -0.60
0.44
64 . . B B . . . -0.03 0.63 * . . -0.60
0.44
Tyr 65 . . $ B . , . -0.43 1.01 . . . -0.60
- 0.68
Tyr 66 . . B B . . . -0.74 1.01 * . . -0.60
0.84
Glu b7 . . . B T . . -0.04 0.8I * . . -0.05
1.63
Ser 68 . . . B T . . 0.18 0.57 . . . -0.05
1.68
Phe 69 . . . . T T . 0.72 0.39 * . . 0.50
0.57
Thr 70 , . . . T T . 0.97 0.11 * . F 0.65
0.48
35 Asn 71 . , . . , T C 0.61 0.11 . . F 0.45
0.62
Cys 72 A . . . . T . 0.61 0.34 . * F 0.25
0.71
Thr 73 A A . . . . . 0.32 -0.44. * F 0.45
0.85
Giu 74 A A . . . . . 1.02 -0.43* * . 0.30
0.53
Met 75 A A . . . . . 0.48 -0.43. * . 0.451.60
Giu 76 A A . . . . . -0.38 -0.36. * . 0.30
0.82
Ala 77 A A . . . . . -0.06 -0.20. * . 0.30
0.35
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCTNS99125031
234
Asn 78 A A . . . . . -0.410.23. * . -0.30
0.35
Val 79 . A B . . . . -0.660.19. * . -0.30
. 0.11
Val 80 . B . . . . -0.340.94. * . -0.60
A 0.17
Gly 81 . A B . . . . -0.561.36. * . -0.60
0.11
Cys 82 . . . . T . . 0.031.39* . . 0.00
0.23
Tyr 83 . . . . T . . -0.181.14* . . 0.00
0.50
Trp 84 . . B . . T . -0.130.93. . . -0.20
0.78
Pro 85 . . . . . T C 0.131.19* . F 0.301.20
Asn 86 . . . . . T C 0.481.11* . F 0.15
0.77
1 Pro 87 . . . . . T C 0.800.76* . F 0.30
~ 1.27
I-eu 88 . . . . . . C 0.340.27* . F 0.25
0.81
Ala 89 . . . . . . C -0.260.63* . F -0.05
0.44
Gln 90 . . B B . . . -0.360.91* . . -0.60
0.20
Gly 91 . . B B . . . -0.700.97* . . -0.60
0.35
15 Phe 92 . . B B . . . -1.380.71* . . -0.60
. 0.34
Ile 93 . . B B . . . -0.600.90* . . Ø60
O.14
Thr 94 . . B B . . . 0.101.00* . . -0.60
0.19
Gly 95 . . B B . . . 0.100.57* . . -0.60
~ 0.43
Ile 96 . . B B . . . -0.260.19* . . -0.15
1.06
His 97 . . B B . . . -0.260.29* . . -0.30
0.64
Arg 98 . . . B T . . 0.330.59* . . -0.20
0.56
Gln 99 . . . B T . . 0.640.54* . . -0.05
1.06
Phe 100 . . . B T . . 0.320.26* . . 0.251.26
Phe 101 . . . . T T . 0.900,33* . . 0.50
0.34
25 Ser 102 . . . . T T . 0.080.81. * . 0.20
0.29
Asn 103 . . . . T T . -0.031.06. . . 0.20
0.25
Cys 104 . . . . T T . 0.080.27. * . 0.50
0.47
Thr 105 . . . . T . . -0.08-0.51. . . 1.20
0.69
Val 106 . A . . T . . 0.59-0.26. * . 0.70
0.32
Asp 107 . A B . . . . 0.08-0.16. * . 0.30
0.81
Arg 108 . A B . . . . 0.08-0.04. * . 0.30
0.46
V 109 . A B . . . . 0.74-0.53. * . 0.75
al 1.08
His 110 . A B . . . . 0.84-1.17. * . 0.751.08
L,eu 111 . A . . . . C 1.49-0.74. * . 0.80
0.85
3$ Glu 112 . A . . . . C 1.49-0.31. * F 0.801.78
Asp I . A . . . . C 1.38-0.96* * F 1.10
13 2.18
Pro 114 . , . . . T C 1.38-1.46* * F 1.50
4.58
Pro 115 . . . . T T . 0.60-1.50* . F 1.701.96
Asp 116 A . . . . T . 0.52-0.81* . F I.15
0.97
Glu 117 A . . . . T . 0.31-0.13* * . 0.70
0.44
Val 118 A . . B . . . -0.50-0.13* . . 0.30
0.44
SUBSTITUTE SHEET (R.ULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
23$
Leu 1 . . B B . . . -1.180.13. . -0.30
i9 . 0.22
Ile 120 . . B 8 . . . -1.820.81
. . . -0.60
0.09
Pro 121 . . B B . . . -2.711.46. . -0.60
. 0.09
Leu 122 . . B B . . . -2.921.50. . -0.60
* 0.07
$ Ile 123 . . B B . . . -2.921.24. . -0.60
. , . 0.16
Val 124 . . B B . . . -2.971.20. . -0.60
. 0.08
Ile 125 . . B B . . . -2.891.41. . -0.60
. 0.07
Pro 126 . . B B . . . -2.991.41. . -0.60
* 0.08
Val i27 . . 8 B . . . -3.031.21. . -0.60
. 0.16
1~ Val 128 . B B . . . -2.731.21. . -0.60
* 0.17
Leu 129 . . B B . . . -2.481.03. . -0.60
. 0.11
Thr 130 . . B B . . . -2.181.21
-0.60
0.15
Val 131 . . B B . . . -2.311.07. . -0.60
. . 0.20
Ala 132 A . . B . . . -2.270.86. . -0.60
. 0.25
1$ Met 133 A . . B . . . -2.270.86. . -0.60
. 0.14
Ala 134 A . . B . . . _2.311.01. . -0.60
. 0.14
GIy 135 A . . B . . . -2.291.01* . -0.60
* 0.10
Leu 136 A . . B . . . -1.321.43* . -0.60
* 0.11
Val 137 A . . B . . . -1.030.81. . -0.60
* 0.21
Val 138 A . . B . . . -0.390.70* . -0.26
. 0.29
Trp 139 . . B B . . . 0.31 0.27* . 0.38
. 0.70
Arg 140 . . B B . . . 0.34 -0.41. F 1.621.84
.
Ser I41 . . B , . T . L -0.57. F 2.66
16 . 3.58
Lys 142 . . . . T T . 1.70 -1.21. F 3.40
* 5.68
2$ Arg 143 . . . . T T . 1.74 -1.64* F 3.06
. 4.I9
T~ 1 - - . . T T . I -0.96. F 2.72
~ .22 * 2.58
Asp 145 . A . . T . . 0.72 -0.66. F 1.981.06
.
Thr 146 . A B : . . . 0.63 -0.23* F 0.79
. 0.69
Leu I47 . A B . . . . 0.20 0.20* . -0.30
- . 0.61
Leu 148 . A B . . . . -0.300.14. . -0.30
* 0.47
Ter 149 . A B . . . . -0.380.57. . -0.60
. 0.42
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
wo oon9a3s
PCT/US99/2s031
236
Table IV
Res I II III IV V VI VII IX X XI XII
Position VIII X
III XIV
Met I A A . . . . . -0.760.27. * . -0.30
0.49
Arg 2 A A . . . . . -x.070.34* * . -0.30
0.39
Leu 3 A A . . . . . -1.490.70* * . -0.60
0.26
Leu 4 A A . . . . . -1.400.96. * . -0.60
0.22
Ala 5 A A , , . . . -1.820.73. * -0.60
0.15
1 Phe 6 A A
~
. . . . . -2.03l * * . -0.60
.41 0.15
Leu 7 A A . . . . . -2.731.41. * . -0.60
0.15
Ser 8 A A . . . . . -2.731.23. . . -0.60
0.15
Leu 9 A A . . . . . -2.781.41. . . -0.60
0.14
Leu 10 A A . . . . . . -3.001.27* . . -0.60
0.13
15 Ala 11 A A
. . . . . -2.301.27* . . -0.60
0.08
Leu 12 A A . . . . . -1.49i.29. . . -0.60
0.17
Val 13 A A . . . . . -1.500.60. . . -0.60
0.35
Leu 14 A A . . . . . -1.030.40. . . -0.02
0.50
Cln 15 A A B . . . . -0.530.33. . F 0.410.60
Glu 16 A . . . . T . -0.530.13. . F 1.241.I7
Thr 17 A . . . . T . -0.02-0.01. * F 2.121.43
Gly 18 . . . . T T . 0.02 -0.31. . F 2.801.11
Thr 19 A . . . . T . 0.62 -0.03* * F 1.97 0.53
Ala 20 A . . . . . . 0.73 0.40. . F 0.89 0.57
25 Ser 21
. . . . . . C 0.78 -0.09. . F 1.561.12
Leu 22 . A . . . . C 1.09 -0.51* . F 1.381.55
Pro 23 A A . . . . . I -1.00* . F 0.90 2.66
.54
Arg 24 A A . . . ' . . 1.90 -I.SO* * F 0.90 3.88
Lys 25 A A . . . . . 2.60 -1.89. . F 0.90 9.42
Glu 26 A A . . . . . 3.01 -2.57. . F 0.9011.93
Arg 27 A A . . . . . 3.82 -3.00. . F 0.9011.93.
Lys 28 A A . . . . . 4.03 -3.00. . F 0.9010.33
Arg 29 A A . . . . . 3.92 -3.00. . F 0.9010.33
Arg 30 A A . . . . . 3.28 -2.60. * F 0.90 9.13
35 Glu 31 A A . , . . . 3.07 -1.99* . F 0.90 4.52
Glu 32 A A . . . . . 3.07 -1.56. . F 1.24 3.57
Gln 33 A A . . . . . 3.02 -1.56* . F 1.58 3.57
Met 34 . A , . . . C 2.57 -1.56* . F 2.12 3.57
Pro 35 A . . . . T . 2.46 -1.13* . F 2.66 2.04
Arg 36 . . . . T T . 2.16 -1.13" . F 3.401.97
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00129435 PCT/US99/25031
237
GIu 37 A . . . . T . 1.46 -1.14* F 2.66
. 2.66
Gly 38 . _ . . . T T . 1.46 -0.97* F 2.721.49
*
Asp 39 A . . . . . . 1.20 -1.40* F 1.781.32
.
Ser 40 A . . . . . . 0.60 -0.76* F 1.29
0.57
$ Phe 41 . B
. , . . . 0.28 -0.07. . 0.50
. 0.47
G1u 42 . . B . . . . -0.53-0.07. . 0.50
. 0.44
Val 43 . . B . . . . -0.080.61. . -0.40
. 0.27
Leu 44 . . B , . . . -0.080.23. . -0.10
* 0.61
Pro 45 A . . . . . . 0.22 -0.16* 0.50
0
56
1 Leu 46 A . T .
~
. . . . 0.07 -0.16. . 0.85
* 1.27
Arg 47 A . , . . T . -0.74-0.16. F 1.001.14
*
Asn 48 . . B . T T . 0.11 -0.16. F 1.25
* 0.61
Asp 49 . . B . . T . 0.71 -0.19. F 1.00
* L 19
Val 50 . . 8 . . . . 0.92 -0.44* F 0.65
0
94
1$ Leu 51 . B .
. . . . . 1.73 -0.44. F 0.95
* 0.97
Asn 52 . . B . . T . 1.38 -0.44. F 1.45
. 0.94
Pro 53 . . . . . T C 1.03 0.3.1. F 1.501.98
.
Asp 54 . . . . T T . 1.03 0.10. F 2.00
* 2.37
Asn 55 . . . . . T C 1.03 -0.59. F 3.00
. 2.56
Tyr 56 . B B
. . . . 0.96 -0.34. F 1.801.23
*
Gly 57 . . B B . . . 0..96-0.09. . 1.20
. 0.52
Glu 58 . . B B . . . 0.36 -0.09* . 0.90
. 0.53
Val 59 . . B B . . . 0.06 0.20
0.00
0.28
Ile 60 . . B B . . . 0.06 -O.I7. 0.30
0.38
2$ Asp 61 . B B
. . . . 0.06 -0.20. . 0.30
. 0.35
Leu 62 . . B . . T . 0.40 0.56. . -0.20
. 0.75
Ser 63 . . . . . T C 0.40 -0.09. . 1.051.85
.
Asn 64 . . , . . T C 0.44 -0.77. F 1.501.9I
.
Tyr 65 A . . . . T . 1.02 -0.09. F 1.341.91
~ *
Glu 66 A
. . . . . . 1.02 -0.29. F 1.48
. 2.06
Giu 67 A . . . . . . 1.59 -0.67* F 2.12
. 2.14
Leu 68 . . B . . . . 1.54 -0.31* F 2.16
. 2.14
.
Thr 69 . . . . T T . 1.54 -0.64* F 3.401.22
.
Asp 70 . . . , T T . 1.79 -0.64* F 3.061.18
.
3$ Tyr 71 . . T T
. . . 0.98 -0.24* F 2.42
. 2.48
Gly 72 . . . . T T . 0.77 -0.24* F 2.081.42
.
Asp 73 A . . . . . , 1.58 -0.30* F 1.231.31
.
Gln 74 A . . . . . . 1.03 -0.30* F 0.981.45
*
Leu 75 . . B . . . . 1.08 -0.41. F 1.071.09
*
Pro 76 . B
. . . . . 0.47 -0.84. F 1.461.30
*
Giu 77 . . B B . . . 0.50 -0.20. F 0.90
* 0.56
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
238
Val 78 . . B B . . . 0.20 -O.ll. F 0.810.98
*
Lys 79 . - B B . , . -0.61-0.41. F 0.72
. * 0.85
80 ' ' B B ~ . . -0.39-0.16. F 0.63
* 0.40
Thr 81 ' ' B B . . . -0.390.34. F -0.06
* O
SS
$ Ser $2 . B .
. . . . . -0.980.13. F 0.05
* 0.42
Leu 83 , . B
.
-0.430.63. . -0.40
* 0.58
Ala 84 . , B -
- . . -0.7$0.47. . -0.40
* 0.58
Pro 8S A
. . . . . . -0.810.37. . -0.10
. 0.58
Ala 86 . . B B . . . -0.800 F
67
. . -0.45
1 Th . 0.49
~
r 87 . . B B . . . -0.710.37. F -0.1
. S 0.65
Ser ' . . B B . . . -0.490 F
88 30
. . 0.13
Ile $9 . . B B . . . 0.14 0.37. F 0.65
. 0.410.65
.
Ser 90 . . B . . T . 0.06 -0.13. F 1.59
. 0.90
Pro 91 . . . . . T C 0.33 -0.23. F 2
. 17 0
90
Ala 92 . . . T T .
.
. . 0.33 -0.13. F 2.801.86
.
Lys 93 . . B . . T . 0.04 -0.33. F 2.12
. 2.00
Ser 94 . . B , . . . 0.72 -0.21. F 1.641.31
.
Thr 95 ., B . . . . 0.68 -0.21. F 1.36
. . 2.00
Thr 96 . . $ . . . . O.SB -0.29. F 0.93
. 0
99
Ala 97 . B .
. . . . . 0.96 0.20. F 0.201.07
.
Pro 98 ' . B . . . . 0.61 0.24. F 0.481.14
.
Gly 99 . . . . T . . 0.61 0.14. F 1.161.06
.
Thr 100 . . . . . T C 0.92 0.04. F 1.441.41
.
Pro 101 . . . . . T C 1.02 -0.06. F 2.321
. 46
25 Ser 102 . . T T .
. . . 1.30 -0.06. F 2.80
. 2.28
Ser 103 . . . . . T C 0.91 0.00. F 2.32
. 2.28
Asn 104 . . . . . T C 0.94 0.13. F 1.441.46
.
Pro 105 . . . . . T C 1.37 0.19. F 1.361.57
.
Thr 106 . . . . T T . 1.37 -0.20. F 2.08
. 2
30
Met 107 . B .
. . . T . 1.36 -0.16. F 1.60
. 2.21
Thr 108 . . B . . . . 1.34 -0.07. F 1.60
. 2.07
Arg 109 . . B . . T . 0.76 -0.01. F 2.00
. 2.07
Pro 110 . . B . . T . 0.62 0.00* F 1.80
. 2.11
Thr 111 . . B . . T . 0.12 -0.19. F 1
. 601
45
35 Thr 112 . B .
.
. . . T . -0.090.01. F 0.65
. 0.61
Ala 113 . A B . . . . -0.590.?0. F -0.25
. 0.32
Gly 114 . A B . . . . -1.000.96. . -0.60
. 0.19
Leu 115 . A B . . . . -1.490.86. . -0.60
. 0.17
Leu 116 . A B . . . . -0.780.76. -0.60
0
23
Leu 117 . A B .
. . . . -0.680.66. F -0.45
* 0.40
Ser 118 . A B . . . . -0.090.66. F -0.29
. 0.75
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC1'/US99/25031
239
Ser 119 . B . . . . 0.22 0.37. F O.S2
. . L46
Gln 120 . B . . T . 0.69 0.19. F 0.$8
_ . 2.41
. .
Pro 121 . . . T T . 0.69 -0.07. F 2.041.78
. .
Asn 122 . . . T T . 1.29 0.23. F 1.601.10
. *
His 123 . . . T T . 1.28 0.27. F 1.29
. . 0.98
Gly 124 . . . T . . 0.91 0.36. . 0.78
. . 0.91
Leu 125 . . . . T C 0.10 0.50. . 0.32
. . 0.30
Pro 126 . . . T T . -0.54 0.79. . 0.36
. . 0.18
Thr 127 . . . T T . -1.21 0.93. . 0.20
. . 0.14
1 Cys 128 . B . . T -2 1
~ . 03 07
. . . . -0.20
. . 0.09
Leu 129 . B B . . . -2.36 1.03. . -0.60'
. . 0.04
Val 130 . B B . . . -2.3b 1.17. . -0.60
. . 0.02
Cys 131 . B B . . . -2.49 1.37. . -0.60
. . 0.02
Val 132 . B B . . . -2.48 1.23. . -0.60
. . 0.03
15 Cys 133 . B B 2 0
. 11 93
. . . - . . . -0.60
. . 0.05
Leu l34 . B B . . . -2.16 0.67. . -0.60
. . 0.13
Gly 13S . . . T T . -1.54 0.74. F 0.35
. * 0.13
Ser 136 . . . T T . -1.54 0.86. F 0.35
. * 0.39
Ser 137 . B . . T . -0.69 0.86. F -0.05
. . 0.25
Val 138 . B . . T . -0.02 0.17. . 0.10
, . 0.43
Tyr 139 . B . . . . -0. -0.26. . 0.50
. i 0 . 0.53
Cys 140 . B . . T . 0.24 0.04. . 0.10
. * 0.28
Asp 141 . B . . T . -0.27 -0.34. . 0.70
. * 0.63
Asp 142 . B . . T . 0.03 -0.30. F 0.85
. - * 0.33
25 Ile 143 . B . . T . 0.89 -1.06. F 1.301.07
. .
Asp 144 A B . . . . 0.24 -1.63. F 0.901.07
. .
Leu 14S A B . . . . 0.70 -0.94. F 0.75
. . 0.45
Glu 146 A B : . . . 0.49 -0.51. F 0.75
. * 0.99
Asp 147 A B . . . . -0.32 -0.77. F 0.99
. ~ * 0.92
Ile 148 A B . . . . 0.36 -0.09* F 0.93
. * 0.92
Pro 149 . . . . . C 0.47 -0.34* F 1.57
. . 0.82
Pro 150 . . . . . C 1.39 -0.34* F 1.810.96
. .
Leu 151 . . . . T C 1.08 -0.34* F 2.40
. . 2.68
Pro 152 . B . . T . 0.49 -0.54* F 2.26
. . 2.50
35 Arg 153 . . . T T . 1.13 -0.47* F 2.121.63
. .
Arg 154 . B . . T . 0.53 -0.14* F 1.48
.~ . 3.11
Thr 1 SS . B B . . . 0.50 -0.14* . 0.69
. . 1.66
Ala 156 . B B . . . 0.72 0.19* . -0.15
. 1.33
Tyr 157 . B B . . . 1.04 0.69* . -0.60
. * 0.68
Leu 158 . B B . . . 0.23 0.69* . -0.60
. * 0.93
Tyr 159 . B B . . . 0.12 0.99* . -0.60
. ~' 0.80
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PC1'/US99125031
240
Ala 160 . . B B . . . 0.54 0.89 * * . -0.60
0.82
Arg 161 . _ B B . . . 0.24 0.13 * * . -0.15
. 1.94
Phe 162 . . B B . . . 0.19 0.13 * * . Ø30
0.87
Asn 163 . . B B . . . I.II -0.24* * . 0.451.15
Arg 164 . . B B . . . 0.47 -0.74. * F 1.081.15
Ile 165 . . B B . . . 1.17 -0.06. * F 0.810.93
Ser 166 . . . B . . C 0.47 -0.84* * F 1.641.13
Arg 167 . . B B . . . 1.17 -0.74* * F 1.47
0.59
Ile 168 . . B B . . 1.17 -0.74* * F 1.801.45
.
1~ Arg 169 . . B B . . 0.36 -1.43* . . 1.471.80
.
Ala 170 A A . . . . 1.29 -1.03* * F 1.29
. 0.80
Glu 171 A A . . . . 1.24 -1.03. * F 1.26
. 2.27
Asp 172 A A . . . . 0.32 -1.29. * F 1.08
. 1,
i S
Phe 173 A A . . . . 0.90 -0.60. * F 0.75
. 0.94
15 Lys 174 A A . . . . 0.83 -0.61. * F 0.75
. 0.78
Gly 175 A A . . . . 0.61 -0.61* * F 0.75
. 0.94
Leu 176 A A . . . . 0.66 0.07 * * F -0.15
. 0.89
Thr 177 A A . . . . 0..77-0.71* * F 0.75
. 0.89
Lys 178 A A . . . . 0.58 -0.71* * F 0.901.76
.
2~ Leu 179 A A . . . . 0.53 -0.46* * F 0.601.50
.
Lys 180 . A B . . . 0.07 -1.14* * F 0.901.73
.
Arg 181 : A B . . . 0.58 -0.94* * F 0.75
. 0.71
Ile 182 . A B . . . 0.89 -0.56. * F 0.901.16
.
Asp 183 . A B . . . 0.84 -0.84. * . 0.60
. 0.93
25 Leu 184 . . B . T . 0.84 -0.44* * F 0.85
. 0.77
Ser 185 . . B , T . -0.090.24 * * F 0.25
. 0.90
Asn 186 . . . . T C -0.500.24 . * F 0.45
. 0.38
Asn 187 . . . : T C 0.09 0.63 * * F 0.15
. 0.62
Leu 188 . . B . , . . -0.800.33 * * . -0.10
. 0.62
Ile 189 . . B . . . 0.01 0.63 * . . -0.40
. 0.27
Ser 190 . . B . . . 0.31 0.23 * . F 0.05
. 0.28
Ser 191 . . B . . . 0.31 0.23 * * F 0.05
. 0.54
Ile 192 . . B . . . -0.28-0.46* . F 0.80
. 1.29
,
Asp 193 . . B . T . -0.17-0.64* . F 1.15
. 0.98
35 Asn 194 A . . . T . 0.83 -0.24* * F 0.85
. 0.63
Asp 195 A . . . T . 0.32 -0.63* . F 1.301.76
. ~
Ala 196 A . . . T . -0.19-0.63* . . 1.00
. 0.87
Phe 197 A A . . . . 0.67 0.06 * . . -0.30
. 0.45
Arg 198 A A . . . . O.U8 0.16 * . . -0.30
. 0.36
40 Leu 199 A A . . . . -0.730.66 * * . -0.60
. 0.36
Leu 200 A A . . . . -0.730.84 * . . -0.60
. 0.35
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/2503I
241
His 201 A A . . . . -0.140.46* . -0.60
. * 0.31
Ala 202 A A , . . . -0.260.46* . -0.60
. . * 0.62
Leu 203 A A . . . . -x.260.46* . -0.60
. * 0.62'
Gln 204 A A . . . . -1.260.46* -0.60
. . 0.32
$ Asp 205 . A B . -0 0
. 66 64
. . . . . -0.60
. . 0.26
Leu 206 . A B . . . -0.620.57. . -0.60
. . 0.49
Ile 207 . A B . . . -0.03-0.1. . 0.30
. I . 0.49
Leu 208 . . B . T . 0.78 -0.11* F 0.85
. . 0.47
Pro 209 A . . . T . -0.030.29. F 0.25
. . 0.99
Glu 210 A . . . T . -0.030.29. F 0.401.16
. *
Asn 211 A . . . T . 0.19 -0.40. F L00 2.44
. .
Gln 212 A A . . . . 0.27 -0.59. F 0.901.60
. *
Leu 213 A A . . . . 0.87 -0.33. . 0.30
. . 0.76
Glu 214 A A . . . 0 0
. 22 10
. . . -0.30
1$ . . 0.73
Ala 215 . A B . . . -0.590.34. . -0.30
. . 0.31
Leu 216 . A B . . . -0.800.63. . -0.60
. . 0.31
Pro 217 . . B . . . -1.100.37. . -0.10
. . 0.28
Val 218 . . B . . . -0.630.76* . -0.40
. . 0.37
Leu 219 . . B . T . -1.520.69* F -0.05
. . 0,44
Pro 220 . . . . T C -0.930.69* F 0.15
. 0.20
Ser 221 . . . . T C -0.820.26* F 0.45
. . 0.47
Gly 222 . . B . T . -1.420.40* F 0.25
. . 0.49
Ile 223 . A 8 . . . -0.570.40* F -0.15
. . 0.26
Glu 224 . A B . . . -0.61-0.03. . 0.30
. * 0.33
Phe 225 . A B 0 0 *
. 29 23
. . . - . . . -0.30
. 0.25
Leu 226 . A B . . . -0.80-0.20. . 0.30
. * 0.69
Asp 227 A A . . . . -0.46-0.20* . 0.30
. * 0.33
~8 A !'~ ~ ~ . . 0.54 0.20* . -0.30
~ . 0.61
Arg 229 A A . . . . -0.27-0.59. . 0.75
. * 1.45
~
Leu 230 A A . . . . 0.43 -0.59. . 0.88
. * 0.71
Asn 23I A A . . . . 0.94 -0.19* . 1.011.67
. *
Arg 232 . A . T . . 0.64 -0.44* F 1.84
. * L 14
Leu 233 . A . T . . 1.16 -0.06* F 2.121.85
. .
Gln 234 . . .. T T . 0.16 -0.31* F 2.801.14
. .
3$ Ser 235 . . . T T . 0.97 -0.03* F 2.37
. . 0.41
Ser 236 . . . . T C 0.76 0.37* F 1 ~9
. * 0.86
Gly 237 . . . T T . 0.06 0.11* F 1.210.76
. *
Ile 238 . A B . . . 0.28 0.21. F 0.13
. . 0.58
Gln 239 . A B . . . Ø420.33. F -0.15
. . 0.43
4~ Pro 240 . A B . . . -0.010.73* F -0.45
. * 0.38
Ala 241 A A . . . . Ø300.30* . -0.15
. * 1.06
SUBSTITUTE SKEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
242
Ala 242 A A . . . . . -0.560.11* . . -0.30
0.62
Phe 243 A A . . . . . 0.33 0.33* * . -0.30
0.40
Arg 244 A A . . . . . 0.38 -0.10* * . 0.30
~ 0.68
Ala 245 A A . . . . . -0.22-0.60* * . 0.751.35
Met 246 A A . . . . . 0.37 -0.41* * . 0.451.28
Glu 247 A A . . . . 0.26 -0.80* * . 0.751.13
.
Lys 248 A A . . . . 0.14 -0.01* * . 0.30
. 0.97
Leu 249 A A . . . . -0.210.17* * . -0.30
. 0.81
Gln 250 A A . . . . -0.430.31. . . -0.30
. 0.73
1 Phe 251 A A . . . . -0.131.00. . . -0.60
~ . 0.30
Leu 252 . A B . . . -0.131.39. * . -0.60
. 0.49
Tyr 253 . . B . . . -0.180.70. * . -0.40
. 0.47
Leu 254. . . B . . . -0.180.70* . . -0.23
. 0.88
Ser 255 . . B . T . -0.990.60* . . 0.14
. 0.88
I Asp 256 . . . T T . -0.290.60* . . 0.71
S . . 0.46
Asn 257 . . . T T . 0.22 -0.16* . F 1.93
. 0.94
Leu 258 . . B . T . -0.42-0.46* . F 1.70
. 0.94
Leu 259 . . B . . . 0.18 -0.16* . F 1.33
. 0.39
Asp 260 . . B . . . 0.13 0.27* . F 0.56
. 0.38
Ser 261 . . B . . . -0.080.30* . F 0.39
. 0.45
Ile 262 . . B .. T . -0.890.04* . F 0.42
. 0.85
Pro 263 . . B . T . -0.290.04* . F 0.25
. 0.42
Gly 264 . . . . T C 0.31 0.47* . F 4.15
. 0.48
Pro 265 . . . . T C 0.01 0.51. * F 0.301.07
.
25 Leu 266 . . . . . C -0.500.21* * F 0.42
. 0.93
Pro 267 . . . . T C 0.50 0.47* * F 0.49
. 0.77
Pro 268 . . . T T . 0.41 0.04* * F I .16
. 0.98
Ser 269 . . B . T . -0.100.00* * F 1.681.59
.
Leu 270 . . B . , T . 0.08 -0.04* * F 1.70
. 0.76
Arg 271 . . B . . . 0.08 0.03* * F 0.73
. 0.67
Ser 272 . . B . . . 0.29 0.29. . . 0.410.41
.
Val 273 . . B . . . 0.50 0.30. * . 0.24
. 0.87
His 274 . . B . . . 0.80 0.01. * . 0.07
. 0.71
Leu 275 . . B . T . 0.80 0.41* . . -0.20
. 0.86
35 Gln 276 . . . . T C -0.200.71* . F 0.15
. 0.95
Asn 277 . . . . T C O.IO 0.76. * F 0.15
. 0.49
Asn 278 . . . . T C 0.64 0.26* * F 0.601.03
.
Leu 279 A A . . . . 0.08 0.06* . . -0.30
. 0.86
Ile 280 A A . . . . 0.89 0.27* * . -0.30
. 0.53
4~ Glu 281 . A B , . . 1.00 0.27* . . -0.30
. 0.57
Thr 282 A A . . . . 1.00 -O.I3* . . O.d51.35
.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
243
Met 283 . A B . . . . 0.14 -0.81* . F 0.90
3.21
Gln 284 . A B . . . . 0.26 -0.86* . F 0.901.38
_
Arg 285 . A B . . . . 0.48 -0.07* . F 0.45
0.$3
Asp 286 . A . . T . . 0.48 0.01 * . . 0.10
0.45
$ Vat 287 . A B . . . . 0.58 -0.60* . . 0.60
0.43
Phe 288 A A . . . . . 1.18 -0.57* . . 0.60
0.34
Cys 289 A A . . . . . 1.18 -0.57* . . 0.60
0.35
Asp 290 A A . . . . . 1.03 -0.57* . F 0.75
0.82
Pro 291 A A . . . . . 1.08 -0.71. . F 0.901.30
Glu 292 A A . . . . . 1.90 -1.50. . F 0.90
- 4.83
Glu 293 A A . . . . . 2.29 -1.57. . F 0.90
3.94
His 294 A A . . . . . 3.07 -1.09* . F 0.90
3.67
Lys 295 A A . . . . . 3.18 -1.51. . F 0.90
4.16
His 296 A A . . . . . 339 -I * . F 0.90
.51 4.70
1$ Thr 297 A A . . . . . 2.58 - * . F 0.90
L 5.98
11
Arg 298 A A . . . . . 2.58 -0.93* . F 0.90
2.47
Arg 299 A A . . . . . 2.61 -0.93* . F 0.90
3.14
Gin 300 A A . . . . . 1.68 -1.43* * F 0.90
3.63
Leu 301 A A . . . . . 1.82 -1.23* * F 0.901.30
Glu 302 . A B . . . . 1.32 -1.23* * F 0.901.30
Asp 303 . A B . . . . 1.21 -0.54* * F 0.75
0.62
Ile 304 . A B . . . . 0.76 -0.94* * F 1.111.25
Arg 305 . A B . . . . 0.76 -1.20. * F 1.17
0.72
Leu 306 . A B . . . . 1.36 -0.80* * F 1.38
0.69
2$ Asp 307 . . . . T T . 0.47 -0.37* * F 2.241.52
Gly 308 . . . . . T C 0.47 -0.37. * F 2.10
0.54
Asn 309 . . . . . T C 0.54 0.03 * * F 1.441.06
Pro 310 . . . . . T C 0.13 0.03 * * F 1.08
0.52
Ile 311 . . B . . . . 0.13 0.41 . . F 0.17
0.71
3~ Asn 3I2 . . B . . . . -0.570.67 . . . -0.19
0.36
Leu 313 . . B . . , . -0.431.06 . * . -0.40
0.20
Ser 314 . . B . . . . -0.73L06 . * . -0.40
0.45
Leu 315 . . B . . . . -1.110.76 . * . -0.40
0.37
Phe 316 . . B . . T . -0.4?0.86 . * . -0.20
0.46
3$ Pro 317 . . . . T T . -1.170.93 . * . 0.20
0.54
Ser 318 . . . . T T . -1.021.33 . * . 0.20
0.56
Ala 319 . . B . . T . -1.531.21 . . . -0.20
0.35
Tyr 320 . . B . . . . -0.931.11 * . . -0.40
0.19
Phe 321 . . B . . . . -0.121.11 * . . -0.40
0.21
40 Cys 322 B
. . . . . . -0.720.73 * . . -0.40
0.42
Leu 323 . . B . . . . -0.630.91 . * . -0.40
0?2
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
244
Pro 324 . . $ . . . . -0.93 0.59 . . -0.40
* 0.39
Arg 325 . . B B . . . -1.03 0.49 . . -0.60
. 0.51
Leu 326 . . B B . . . -0.22 0.34 . . -0.30
. 0.61
Pro 327 . . . B T . . -0.26 -0.34 . 0.70
. * 0.78
S Iie 328 . . . B T . . 0.24 0.01 . . 0.10
. 0.34
Gly 329 . . B B . . . 0.07 0.50 . F -0.60
* 0.60
Arg 330 . . B B . . . -0.43 0.24 . F -0.15
* 0.50
Phe 331 . . B B . . . -0.01 0.24 * . -0.30
. 0.91
Thr 332 . . B B . . . -0. -0.01 . 0.45
i 9 * * 1.17
1~ Ter 333 . . B B . . . 0.31 -0.01 . 0.30
' * * 0.76
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PGT/US99/25031
245
Table V
Res I II III IV V VI VII VIIIIX X XII
Position . A B . . . . -1.30 0.70XI Xlll
Met . XIV
I . .
-0.60
0.39
Leu 2 . A B . . . . -1.72 0.96. . . -0.60
0.25
Leu 3 . A B . . . . -2.14 1.21. . . -0.60
0.16
Pro 4 . A B . . . . -2.06 1.47. . . -0.60
0.14
Leu 5 . A B . . . . -1.97 1.24* -0.60
Leu 6 . A B . . . . -2.18 0.94. . . 0.22
-0.60
0.36
Leu 7 . A B . . . . -2.18 0.94. . . -0.60
0.19
Ser 8 . A B . . . . -L7I 1.20* . . -0.60
0.19
Ser 9 . . B B . . . -1.84 0.94. . F -0.45
0.23
Leu 10 . . B B , . . -1.33 0.69 F -0.45
1 Leu 11 . . . B . . C -0.52 0.39* . F 0.27
S 0.05 0.27
Gly 12 . . . . . T C -0.30 0.40. . F 0.45 0.35
Gly 13 . . . . . T C -0.60 0.51. . F 0.15 0.43
.
Ser 14 . . B . . T . -0.30 0.44. . F 0.12 0.52
Gln 15 . . B . . T . 0.17 -0.24. * F 1.19 0.88
20 Ala 16 . . B . . . . I .09 -0.24. * F I .16
0.88
Met 17 . . B . . T . 0.73 -0.67. * F 1.981.28
Asp 18 . . B . . T . 0.79 -0.27. * F 1.70 0.64
Gly 19 . . . . T T . 0.20 0.24* * F 1.33 0.67
Arg 20 . . . . T T . 0.31 0.43* * 0.710.47
2$ Phe 21 . . B B . . . 0.04 -0.19* * . 0.64 0.56
Trp 22 . . B B . . . 0.64 0.46* * . -0.43
0.42
Ile 23 . . B B . . . 0.64 0.43* * . -0.60
0.37
Arg 24 . . B B . , . 0.69 0.43* * . -0.60
~ 0.74
Va1 25 . . B B . . . -0.28 0.03* *
F -0.30
Gln 26 . . . $ . . C -0.18 -0.24* * 0.94
0.65 0.99
Glu 27 . . . B . . C -0.74 -0.31* * F 0.65 0.50
Ser 28 . . . B T . . -0.07 0.33
0.10 0.50
Val 29 . . B B . . . -0.18 0.11
-0.30
0.45
Met 30 . . B B . . . 0.09 -0.29 0.30 0.45
35 Val 31 . . B B . . . -0.58 0.21. . . -0.30
0.34
Pro 32 . . B B . . . -0.58 0.40. . . -0.30
0.24
Glu 33 . . B . . . . -1.17 -0.24. . . 0.50 0.41
Ala 34 . . . . T . . -0.61 -0.17. . . 0.90 0.39
Cys 35 . . B . . . . -0.87 -0.43* . . 0.50 0.34
Asp 36 . . . B T
-0.22 -0.21* . 0.70 0.14
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
246
Ile 37 . . B B . . . -0.680.21. . -0.30
. 0.22
Ser 38 . . B B
-0.980.29. . -0.30
* 0.22
Val 39 . . B . . T . -1.090.10. . 0.10
* 0.18
Pro 40 . . B . . T . -0.720.89. -0.20
* 0.22
S Cys 41 . . . . T T . -0.970.59. . 0.20
* 0.22
Ser 42 . . . . T T . -0.290.96. . 0.20
* 0.46
Phe 43 . . . . T . . 0.12 0.74* . 0.28
. 0.46
Ser 44 . . B . . . . , 0.31. . 0.61
0.98 . 1.69
Tyr 45 . . B . . T . 1.19 0.14. . 1.09
. 2.19
Pro 46 . . . . T T . 1.57 -0.24. F 2.52
. 4.22
Arg 47 . . . . T T . 1.56 -0.11. F 2.80
. 3.31
Gln 48 . . . . T T . 1.91 -0.01. F 2.52
. 3.05
Asp 49 . . . . T . . 1.91 -0.34. F 2.041.95
*
Trp 50 . . . . T T . 1.84 -0.39. F 1.961.33
*
IS Thr 51 . . . . . T C 1.84 0.10. F 0.$81.11
*
Gly 52 . . . . T T . 1.14 0.13. F 0.801.03
*
Ser 53 . . . . . T C 0.90 0.63. F O.15
. 0.99
Thr 54 . . . . . . C 0.56 0.47. F 0.101.07
.
Pro 55 . . . . . T C 0.60 0.41. F 0.301.07
.
Ala 56 . . . T T . 0.62 0.74. . 0.351.26
.
Tyr 57 . . . . T T . 0.27 1.27. . 0.20
. 0.91
Gly 58 . . . . T T . 0.61 1.57. : 0.20
. 0.51
Tyr 59 . . B B . . . 0.33 1.14* . Ø45
. 1.01
Trp 60 . . B B . . . -0.311.i4* . -0.60
. 0.65
ZJ' Phe 61 . B B
. . . . -0.031.03* . -0.60
. 0.49
Lys 62 . . B B . . . 0.21 1.09* . -0.60
. 0.45
Ala 63 . . B B . . . 0.24 0.33
-0.30
0.74
. . B B . . . 0.18 -0.10* . 0.791.24
.
Thr 65 . . B B . . . 0.51 -0.40* F 1.13
~ . 0.89
Glu 66 . . B B . . . 0.87 -0.40* F 1.621.77
.
Thr 67 ' . . B T . . 0.23 -0.47* F 2.36
. 2.36
Thr 68 . . . T T . O.b -0.61* F 3.40
l . I .65
Lys 69 . . . . T T . 0.61 -0.67* F 3.061.48
.
Gly 70 . . . . . T C 0.33 -0.03. F 2.07
. 0.76
35 Ala 71 . . . . . T C 0.02 -0.Ol* F 1.73
. 0.53
Pro 72 . . B . . . . 0.33 -0.01* . 0.84
. 0.38
Val 73 - . B . . . . 0.61 0.39. . -0.10
. 0.62
Ala 74 . . B . . . . 0.57 0.46. . -0.10
. 0.84
Thr 75 . . B . . . . 0.61 0.36* . 0.50
* 0.94
Asn 76
. . . . . . C 1.31 0.31. F 1.301.70
.
His 77 . . . . . T C 1.52 -0.33* F 2.40
. 3.29
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
247
Gln 78 . . . . T C 1.52 -0.83* . F 3.00
. 3.95
Ser 79 . . . . T C 2.11 -0.67* . F 2.701.82
. .
Arg 80 . $ . . T . 1.82 -1.07* . F 2.20
. 2.32
Glu $1 A B . . . . 1.52 -0.96* . F 1.501.33
.
$ Val 82 A B . . . . 1.24 -0.97* * F 1.541.33
.
Glu 83 A B . . . . 1.36 -0.87* * . 1.28
. 0.98
Met 84 A B . . . . 1.31 -0.87* * . 1.771.10
.
Ser 85 . . . . T C 1.31 -0.44* * F 2.561.47
.
Thr 86 . , . T T . 0,61 -1.09. * F 3.401.67
.
1 Arg 87 . . . T T . 1.47 -0.30. * F 2.76
~ . 1.46
Gly 88 . . . T T . 0,66 -0.51. * F 2.721.88
.
Arg 89 . B B . . . 0.94 -0.21. * F 1.281.08
.
Phe 90 . B B . . . 0.90 -0.21. * . 0.64
. 0.79
Gln 91 . B B . . . 1.21 0.21. * . -0.30
. ~ 0.79
Leu 92 . B B . . . 0.89 -0.21. * . 0.30
. 0.68
Thr 93 . B $ . . . 0.64 0.21. * F 0.341.21
.
Gly 94 . . B . . C 0.58 -0.07. * F 1.33
. 0.70
Asp 95 . . . . T C 0.93 -0.47* * F 2.221.71
.
Pro 96 . . . . T C 0.93 -0.73. * F 2.861.17
.
Ala 97 . . . T T . 1.08 -0.81. . F 3.401.90
.
Lys 98 . . . T T . 1.09 -0.67. * F 2.910.61
.
Gly 99 . . . T T . 0.62 -0.29* . F 2.27
. 0.53
Asn 100 . B . T T . -0.23-0.03. * F 1.93
. 0.43
Cys 101 . B . . T . -0.910.11* * . 0.44
. 0.16
25 Ser 102 . B . . T . -0.210.80* * . -0.20
. 0.11
Leu 103 A B B . . . -0.260.37* * . -0.30
. 0.14
Val 104 A B B . . . -0.50-0.03* * . 0.30
. 0.43
Ile 105 A B B . . . -0.50-0.10* . . 0.30
. 0.33
Arg 106 A B B . . . -0.43-0.09* . . 0.30
. 0.68
3~ Asp 107 A $ B . . . -0.13-0.16* . . 0.30
. 0.91
Ala 108 A $ . . . . 0.68 -0.40* . . 0.45
. 2.25
Gln 109 A B . . . . 1.53 -1.09* . . 1.031.92
.
Met 110 A . . . . C 2.12 -1.09. . . 1.511.99
.
Gln 11 A B . . . .' 2.01 -0.70. . F 1.74
I 2.64
.
.
Asp 112 . . . T T . 1.77 -0.80. * F 2.82
. 2.64
Glu 113 . . . T T . 1.66 -0.44* . F 2.80
. 4.18
Ser 114 . . . T T . 0.96 -0.27* * F 2.52
. 2.09
Gln 115 . . . T T . 1.67 0.11* * F 1.641.08
.
Tyr 116 . B B . . . 0.81 0.11* * . 0.41
. 1.22
40 Phe 117 . B B . . . 0.81 0.76* . . -0.32
. 0.68
Phe 1 I . B B . . . 0.92 0.37* * . 0.04
8 0.68
.
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
WO 00/29435 PCT/US99/25031
248
Arg I 19 . . B B . . . 0.88 -0.03* . . 0.98
0.85
Val 120 . . B B . . . O.S8 -0.36* . . 1.32
_ 0.97
Glu 121 . . . . T T . O.S8 -0.76* . F 3.061.50
Arg 122 . . . . T T . 0.42 -0.79* . F 3.401.20
Gly 123 . . . . T T . 1.23 -0.14* * F 2.76
1.20
Ser 124 . . . . T T . 0.88 -0.79* * F 2.721.36
Tyr 12S . . B . . . . 1.73 -O.b3. * . 1.331.09
Val 126 . . B . . . . 1.03 0.37 . * . 0.391.76
Arg 127 . . B . . . . 0.32 0.73 . . . -0.25
1.14
1~ Tyr 128 . . B . . . . 0.67 0.96 . * . -0.40
0.72
Asn 129 . . B . . . 0.97 0.60 . * . -0.25
LS6
Phe 130 . . B . . . . 0.87 -0.04 * 0.651.33
Met 131 . . B . . . . 1.02 0.39 . * . -0.10
0.84
Asn 132 . . . . T T . 0.21 0.41 . * . 0.20
0.45
1$ Asp 133 . . . . T T . -0.360.80 . . . 0.20
0.45
Gly i34 . . . . T T . -0.310.70 . * . 0.20
0.38
Phe 13S . . B . . T . -0.470.09 . . . 0.10
0.47
Phe 136 . . B B . . . -0. 0.33 . * . -0.30
i 8 0.21
Leu 137 . . B B . . . -1.030.81 . . . -0.60
0.30
20 Lys 138 . . B B . . . -1.841.03 . . . -0.60
0.26
Val 139 . . B B . . . -1.800.93 . . . -0.60
0.25
Thr 140 . . B B . . . -1.80O.S3 . * . -0.60
0.40
Val 141 . . B B . . . -1.410.63 . . . -0.60
0.17
Leu. i42 . . B B . . . -0.811.11 . * . -0.60
0.34
25 Ser 143 . . B B . , . -0.740.90 . * . -0.60
0.36
Phe 144 , , B B . . . -0.100.41 * * . -0.26
0.96
Thr 14S . . . . . T C 0.21 0.20 * * F 1.281.80
Pro 146 . . . . . T C 1.07 -0.09* * F 2.22
2.32
Arg 147 . . . . . T C 1.84 -0.47. * F 2.56
~ 4.48
Pro 148 . . . . T T . 2.14 -0.76. * F 3.40
4.22
Gin 149 . . . . T . . 2.53 -0.84* * F 2.86
4.39
Asp ISO . . . . T . . 2.84 -0.79* . F 2.52
3.24
His 1 S 1 . . . T . .. 2.24-0.79* . F 2.18
. 3.50
Asn 1S2 . . . . T T . 1.82 -O.S3* * F 2.04
1.67
3 Thr 1 S3 . . . . T T . 1.37 -0.44. . F 1.40
J' 1.44
Asp 154 . . , . T T . 1.33 0.13 . * F 0.65
O.S7
Leu 1 SS . . B , . T . 0.48 0.13 * * . 0.10
0.48
Thr 1S6 . . B B . . . O.S1 0.37 . * . -0.30
0.25
Cys 157 . . B B . . . -0.19-0.11. * . 0.49
0.25
40 His 1S8 . . B B , . . -0.180.67 * * . -0.22
0.26
Val 1S9 . . B 8 . . . -0.070.37 * * . 0.27
0.24
SUBSTITUTE SHEET (RULE 26)
CA 02348824 2001-04-27
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PART1E DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME / DE
NOTE: ~ Pour (es tames additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPL1CATIONS/PATENTS
THIS SECTION OF THE APPL1CATIONIPATE~NT CONTAINS MORE
THAN ONE VOLUME
THiS lS VOLUME ~ OF
NOTE: For additional volumes please contact the Canadian Patent Office
